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SUMMARY
The purpose of this series of investigations was to elucidate
the endogenous control mechanisms active at primary afferent
terminals of nociceptive origin in the dorsal laminae of the spinal
cord grey matter. Such studies may enable the researcher to make
certain conclusions about endogenous mechanisms of pain control in
vivo. Furthermore, these studies may help to identify novel areas for
the development of analgesic drugs or protocols of therapeutic value
in both human and veterinary pain management.
Experiments were centred on one particular family of
neuropeptides, the tachykinin peptides, and their release in response
to peripheral noxious stimulation as determined by the antibody
microprobe technique. A review of the anatomy and physiology of
tachykinins in the spinal cord is presented at the start of this
thesis. The antibody microprobe technique itself is also fully
described.
Various means of modulating tachykinin release pharma¬
cologically were tested and are presented in this thesis. The results
presented here relate to studies on 1) morphine, 2) noradrenaline and
the imidazoline derivative drug, medetomidine, 3) neuropeptide Y.
A short review on the pharmacological actions of each of these
drugs is included. All the results presented are derived from
experiments on barbiturate anaesthetised, spinalised cats.
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1.1 A BRIEF HISTORY OF TACHYKININS.
In 1931, while testing alcohol extracts of various equine tissues for
acetylcholine activity, von Euler and Gaddum (1931) noted that some
extracts, particularly those taken from intestine and brain, showed
hypotensive and gut spasmogenic actions. This activity could not be
attributed to choline or acetylcholine as it was not altered to any
significant extent by the application of atropine. The active
component was named substance P (P for 'preparation'). Although this
was the first reference to a tachykinin peptide, further advances in
the study of tachykinins were slow, as complete purification of
substance P (SP) proved difficult to achieve.
Indeed it was a non-mammalian tachykinin, eledoisin, taken from
the Mediterranean octopus Eledone moschata which was the first to be
successfully purified and sequenced (Erspamer and Anastasi, 1962a,b).
Eledoisin and SP extracts were shown to share many pharmacological
activities and protease sensitivities, but they could also be readily
distinguished by their respective potencies in a variety of mammalian
systems including rabbit large intestine, guinea-pig ileum and dog
cardiovascular preparations. By 1971 two amphibian tachykinins,
physalaemin and phyllomedusin, had also been isolated (Erspamer,
1971) . As the physiological actions of all members of this peptide
group were notably faster than bradykinin and bradykinin-like
peptides, especially on gut preparations, it was at this point that
the term 'tachy-kinin' was adopted to describe this family of
peptides.
A few years prior to this establishment of tachykinins as a
peptide group in their own right, SP had been rediscovered in
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extracts of bovine and rat hypothalamic tissue (Leeman and
Hammerschlag, 1967). The, as then, unidentified peptide was shown to
stimulate salivation in rats, and this activity was not blocked by
cholinergic or adrenergic drugs. Within a few years this sialogogic
peptide had been purified (Chang and Leeman, 1970), and identified as
being the same peptide as that named by von Euler and Gaddum in 1931.
Forty years after its initial discovery SP was finally sequenced and
synthesised (Chang et al, 1971, Tregear et al, 1971).
Other non-mammalian tachykinins continued to be isolated and
sequenced: uperolein (Anastasi et al, 1975), kassinin (Anastasi et
al, 1977), pro-kassinin and hyalambatin (Yasuhara et al, 1981). The
existence of these non-mammalian peptides proved to be of less
interest, however, than the search for more mammalian peptides
sharing the now well established canonical carboxyl-terminal amino
acid sequence for tachykinins; -Phe~X-Gly-Leu-Met-NH2 where X is
either an aromatic (Phe, Tyr) or branched aliphatic (Val , lie)
amino acid residue.
It was proposed (Erspamer, 1981) that the amino acid sequence of
SP was older, in evolutionary terms, than those of the non-mammalian
tachykinins. Erspamer also suggested that the then current conviction
that SP was the only mammalian tachykinin and that the different
tachykinins were subject to phyllogenetic barriers with regard to
their distribution would eventually be proved incorrect. Of great
significance (as we shall later see), Erspamer also pointed out that
the developing techniques of immunocytochemistry and radioimmunoassay
were only valid in the study of SP if highly specific antisera were
used.
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In 1983 as a result of testing porcine spinal cord extracts for
a tachykinin-like effect on guinea-pig ileum contractility, a novel
mammalian tachykinin, named neuromedin K, was isolated and sequenced
second new tachykinin, named neuromedin L (Minamino et al, 1984). At
the same time other groups were also successful in isolating what
proved to be the same peptides, resulting in these two new mammalian
tachykinins being given several different names (Kimura et al, 1983,
Maggio et al, 1983, Nawa et al, 1984) . Attempts have been made to
standardise the naming of these two tachykinins, neurokinin A (NKA)
and neurokinin B (NKB) now being the most favoured names.
NKA = substance K, neurokinin alpha, neuromedin L.
NKB = neurokinin beta, neuromedin K.
In 1985 an N-terminally extended form of NKA was isolated from
porcine brain extracts (Tatemoto et al, 1985), which showed enough
biological activity to preclude it from being merely a precursor form
of NKA. This tachykinin was named neuropeptide K (NPK). More recently
a fifth mammalian tachykinin, neuropeptide gamma (NPy) , was isolated
from rabbit intestine (Dam et al, 1990b, Kage et al, 1988) . The
amino-acid sequences of these five mammalian tachykinins are
illustrated in figure 1.
Despite these recent additions to the tachykinin peptide family
(new non-mammalian tachykinins also continue to be identified) , most
work to date has focused on the 'oldest' member of the group, SP, and
to a lesser extent on NKA and NKB. The numerous review articles
dealing with tachykinin structure, synthesis and functions (Duggan
(Kangawa et al, 1983). Subsequently the same technique
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FIGURE 1. Amino acid sequences of the five established mammalian
tachykinin peptides; substance P, neurokinin A, neurokinin B,
neuropeptide K, and neuropeptide gamma (y) . The highly conserved
canonical C-terminal amino acid sequence is underlined. Note also










































and Weihe, 1991, Erspamer, 1971, Helke et al, 1990, Maggio, 1988,
Nakanishi, 1991, Nicoll et al, 1980, Otsuka and Yoshioka, 1993,
Pernow, 1953,1983, Regoli et al, 1990, Wilcox, 1991) continue to
become incomplete as the volume of work and the number of techniques
employed to study these peptides increases.
1.2 MOLECULAR BIOLOGY OF TACHYKININS
The stages involved in the neuronal synthesis of tachykinins and
of other groups of neuropeptides, from gene transcription to post-
translational processing are now well understood. Unlike classical
neurotransmitters such as noradrenaline, which are synthesised in
nerve terminals by a variety of enzymatic reactions, neuropeptides
are initially synthesised in ribosomes, within the neuronal cell
body, as larger precursor forms within which the neuropeptide
resides. The translation of genetic information in the cell nucleus
into messenger ribonucleic acid (mRNA), and the translation of that
mRNA, within ribosomes, into precursor proteins follows standard
peptide synthesis mechanisms (see Sherman et al, 1989) and will not
be discussed further here. Beyond this stage, however, notable
specialisations in neuropeptide synthesis exist. The first product of
mRNA transcription is a pre-propeptide, which contains a signal
peptide facilitating movement of the precursor molecule into the
rough endoplasmic reticulum (RER). Within the RER the signal peptide
is cleaved off the molecule to form a propeptide, which is then
transported to the Golgi apparatus where it is packaged into granules
and vesicles before transport to the nerve terminal. Various enzymes
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are also contained in these granules and these act to 'release' the
neuropeptide from the propeptide molecule and further modify it as
the granule passes from cell body to nerve terminal. These final
stages m neuropeptide synthesis (whsbe are discussed more fully at a
later point) are collectively termed "post-translational processing".
The above overview (illustrated in figure 2) applies generally
to neuropeptides, of which the tachykinin family form only a small
proportion. This pattern applies to pro-dynorphin, pro-enkephalin and
pro-opiomelanocortin related peptides, and also to pituitary
peptides, releasing factors and release-inhibiting factors. More (or
less) information is available about the biosynthesis of each
specific group, and a more detailed consideration of tachykinin
synthesis follows.
Two genes are currently considered to be involved in the coding
of tachykinin precursor molecules. The pre-protachykinin (PPT) I or A
gene contains the nucleotide sequences responsible for the synthesis
of SP, NKA, NPK and NPy precursor peptides (Nawa et al, 1983) . A
separate gene, the PPT II or B gene, encodes the mRNA responsible for
the production of NKB precursor peptide (Kotani et al, 1986).
Although the PPTB gene is very similar to the PPTA gene in terms of
its DNA sequence it has not yet been shown to encode any other
tachykinin precursor molecules.
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FIGURE 2. An overview of the cellular pathways involved in peptide
synthesis, as applicable to tachykinin neuropeptides. The figure
represents a highly simplified neurone with cell body and short axon.
1) DNA is transcribed in the nucleus to form messenger RNA
2) Messenger RNA is translated by ribosomes on the surface of
the rough endoplasmic reticulum (RER) to form a pre-propeptide; this
incorporates a signal protein which facilitates the movement of the
pre-propeptide into the lumen of the RER itself.
3) Inside the RER the signal protein is cleaved off to form a
propeptide molecule.
4) The propeptide is transported to the Golgi apparatus where
it is packaged into granules and vesicles.
5) Vesicles are released into the cell body and are transported
to the nerve terminal by axoplasmic transport.
6) During this axoplasmic transport, various enzymes (also
contained in the packaged granules) act on the propeptide, converting
it into the final tachykinin sequence. This is termed post
translational processing.
7) Following an appropriate stimulus, vesicles filled with the
now functional peptide release their contents into the synaptic cleft
by exocytosis.
FIGURE 2
OVERVIEW OF NEUROPEPTIDE SYNTHESIS
It was initially shown that two (Nawa et al, 1983) and then that
three (Krause et al, 1987) pre-protachykinin mRNAs could be produced
from the PPTA gene by alternative splicing of the individual exons of
the gene:
alpha PPT mRNA from exons 1,2,3,4,5 and 7
beta PPT mRNA from exons 1,2,3,4,5,6 and 7
gamma PPT mRNA from exons 1,2,3,5,6 and 7
Thus the differences between these three mRNAs involve only
exons 4,5 and 6 of the PPTA gene. (See also figure 3). How
alternative splicing of the transcripts of these exons is controlled
is not known. The different proportions of the three mRNAs seen not
only between species but also between different tissues within one
species (Kimura et al, 1984, Krause et al, 1987) do, however, suggest
that some form of control may exist at this level. For example, the
ratios of alpha:beta PPT mRNA in rat and bovine central nervous
system (CNS) tissue are <1:20 and 3:1 respectively, despite marked
homology in the structure of the PPTA gene between the species. In
the bovine, although alpha PPT mRNA was the predominant mRNA form in
CNS tissues, levels of beta PPT mRNA were greater in gut and thyroid
tissues (Carter and Krause, 1990).
Although the proportions of alpha, beta and gamma PPT mRNAs have
not been demonstrably altered by any exogenous factor, numerous
factors do seem to alter both PPTA gene expression and the overall
rate of tachykinin synthesis. Dopamine agonists (stimulatory) and
antagonists (inhibitory) have been shown to have such an effect in
rat striatum (Bannon et al, 1987, Haverstick and Bannon, 1989,
Lindefors et al, 1989) suggesting that interactions with other
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intrinsic messenger systems may account for variations in tachykinin
gene expression. Roles for nerve growth factor (stimulatory) in
cultured dorsal root ganglion cells (Lindsay et al, 1989) and
oestrogen in the hypothalamus (stimulatory) and pituitary
(inhibitory) (Brown et al, 1990) have also been suggested.
The pre-protachykinins are large peptides (alpha PPTA = 112
amino acids, beta PPTA = 130, gamma PPTA = 115, PPTB = 126),
certainly when compared to the tachykinins themselves (SP = 11 amino
acids, NKA = 10, NPK = 36, NPy = 21, NKB = 10). It seems likely that
several enzymes may be responsible for the post-translational
processing of the pre-protachykinin molecules. Sites which could be
utilised by both endoproteases and aminopeptidases have been
identified (Krause et al, 1987, MacDonald et al, 1989), and petidyl-
glycine-a-amidating mono-oxygenase (PAM) has been proposed as the
enzyme responsible for the C-terminal amidation of SP and NKA (Graham
and Gallop, 1989).
Antibodies raised to N-terminally extended tachykinins and to
tachykinin fragments have been used to identify these forms in
nervous tissue (Kream et al, 1985). Whether or not these peptides
represent novel tachykinins, as in the case of NPK, or simply
intermediates in post translational processing and metabolites
produced during tachykinin breakdown is open to question. The status
of one such tachykinin fragment, NKA (3-10), which could be produced
from both beta and gamma pre-protachykinin, is currently under
debate.
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FIGURE 3. Alternative splicing of the PPTA gene results in the
formation of three different preprotachykinin messenger RNAs (a, P
and y mRNA), depending on the sequence of exons included during DNA
transcription. Each type of mRNA has the potential to encode a































































I.PERIPHERAL AND CNS DISTRIBUTION
The information presented in this section is summarised in table 1.
Prior to the purification and sequencing of SP in the early
1970's, distribution studies on SP relied simply on its extraction
from the various body tissues, either by alcohol extraction (von
Euler and Gaddum, 1931,) or a salting out procedure with ammonium
sulphate (Pernow, 1953). These extracts were then tested either for a
stimulating effect on isolated smooth-muscle preparations such as
guinea-pig ileum or rabbit jejunum, or alternatively for their
hypotensive effect in the rabbit, von Euler and Gaddum (1931) had
noted in the first report of SP that, in the horse, its activity was
greatest in alcohol extracts of intestine or whole brain. Pernow
(1953) performed an exhaustive study of SP distribution in various
tissues from several species, (a few more recent studies on
tachykinin distribution in peripheral tissues might also be noted,
Brodin and Nilsson, 1981, Bucsics et al, 1983, Ekstrom et al, 1988).
In the horse, dog, guinea-pig and rat, SP was shown to be present in
the jejunum, although other areas of the gastrointestinal tract were
not studied in these species. In the monkey, cow, sheep, pig and cat
all areas of the digestive tract, including the stomach and
oesophagus, were shown to contain SP with the levels being generally
greatest in the jejunum and ileum. In the dog many other tissues were
also studied. SP activity was identified in all areas of the CNS
examined, in the spinal cord (grey and white matter combined) and in
a variety of peripheral ganglia and nerves, where a high level of SP
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activity was noted in the dorsal roots. The urinary bladder, ureters,
non-gravid uterus, gall bladder, diaphragmatic skeletal muscle,
lungs, heart, liver, spleen, kidneys, pancreas, thyroid and parotid
salivary glands were all shown to contain SP, albeit in much smaller
amounts than that found in nervous tissue.
The extracts obtained in these early studies were almost
certainly impure, and much of the activity attributed to SP is likely
to have been due, in part at least, to the presence of other
tachykinin peptides or unrelated compounds. Although this by no means
makes the findings of such studies invalid, care must be taken not to
overinterpret the results. The other clear limitation of simple
extraction/bioassay investigations is the inability to identify, at a
cellular level, which cell types and cell structures contain
tachykinins. After the sequencing of SP (and later of the other
tachykinins) a more detailed understanding of tachykinin distribution
could be achieved using radioimmunological and immunohistological
techniques. A vast amount of work has been carried out with these
techniques, and discussion of such studies will be limited
principally to those involving the nervous system, in keeping with
the topic of this thesis.
SP-like immunoreactivity (SPLI) in the brainstem has been
extensively mapped in the rat (Brownstein et al, 1976, Douglas et al,
1982, Kanazawa et al, 1984, Kanazawa and Jessell, 1976), cat (Lovick
and Hunt, 1983) and in man (Cooper et al, 1981, Emson et al, 1980,
Gale et al, 1978). SPLI is present in a large number of sites within
the brainstem, with notably high levels seen in the caudate nucleus
and the zona reticularis of the substantia nigra.
22
Early immunohistochemical studies revealed the presence of SPLI
in 20-25% of cell bodies in rat spinal and trigeminal ganglia, and in
nerve fibres within rat, cat and human spinal cord (Cuello et al,
1976, Hokfelt et al, 1975a,b, Nilsson et al, 1974) . Bioassays with,
now purer, SP extracts had identified high levels of SP-like activity
in bovine dorsal-root tissue (Takahashi et al, 1974), suggesting a
link between SP and sensory systems. Later studies, in rat, cat,
primate and man, confirmed this and further suggested that SP was
particularly associated with smaller diameter C- or A-delta type
sensory neurones carrying inputs from peripheral nociceptors. (Barber
et al, 1978, Bisby and Keen, 1986, Chan-Palay and Palay, 1977a,b,
Cuello and Kanazawa, 1978, Difiglia et al, 1982, Gibson et al, 1988,
Hokfelt et al, 1977, Hunt et al, 1981, Kawatani et al, 1985, Lamotte
and Shapiro, 1991, Ljungdhal et al, 1978, Maggio and Hunter, 1984,
Pickel et al, 1977, Villar et al, 1991). SPLI within the spinal cord
is associated with neuronal cell bodies (intrinsic neurones) only in
the dorsal horn of the grey matter. SPLI-containing fibres are found
throughout the whole of the grey matter and occasionally extending
into the white matter. The density of these SPLI fibres is, however,
greatest in laminae I and II of the superficial dorsal horn, and
around the central canal, the major site of somatic and visceral
primary afferent fibre termination (Kuo et al, 1983, Kuo and de
Groat, 1985, Light and Perl, 1977, Rethelyi et al, 1979) . In the
dorsal horn such fibres are seen to make axodendritic contacts with
intrinsic dorsal horn neurones.
It must be emphasised that not all SPLI in the dorsal spinal
cord is associated with primary afferent terminals, as much as 40-50%
may be associated with intrinsic neurones of the spinal cord or with
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bulbo-spinal projections (Ljungdhal et al, 1978). Moderately high
numbers of fibres showing SPLI are seen in lamina V of the dorsal
horn. The localisation of SPLI to dense-cored vesicles within
synaptic terminals has also been described (Cuello et al, 1977,
Cuello and Kanazawa, 1978, Merighi et al, 1989, Pelletier et al,
1977).
Larger peripheral nerves such as the vagus nerve show SPLI in
approximately 10% of their fibres, and again these seem to be
predominantly smaller unmyelinated neurones (Gamse et al, 1979b).The
detection of SP in peripheral tissues can largely be accounted for by
its presence in nerve fibres within those tissues. For example, the
gastrointestinal tracts of various species have an extensive
population of intrinsic neurones showing SPLI (Franco et al, 1979,
Malmfors et al, 1981, Nilsson et al, 1975a, Pearse and Polak,
1975),and also an extrinsic neuronal supply involving fibres showing
SPLI (Costa et al, 1980, Hayashi et al, 1982, Lundberg et al, 1978).
In peripheral tissues these SP immunoreactive terminals may be
associated with epithelial or secretory components, but are also
frequently seen to contact the walls of blood vessels (Anggard et al,
1979, Brodin et al, 1981, Dalsgaard et al, 1983, Ichikawa et al,
1990). Free SP immunoreactive material can also be detected in blood
(Gamse et al, 1978, Nilsson et al, 1975b, Yanaihara et al, 1976) and
this may derive from the SP innervation of vascular beds in
peripheral tissues such as the gut (Gamse et al, 1978) . Occasionally,
for example in tooth pulp, free nerve terminals showing SPLI are
identified (Brodin et al, 1981).
In the majority of the above studies the antibodies used were
polyclonally derived and directed at the C-terminal sequence of SP.
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Although SP is the most abundant tachykinin in mammalian tissues
(Arai and Emson, 1986), all currently identified members of the
mammalian tachykinin peptide family share a common C-terminal
sequence. Care must then be taken in immunochemical studies to avoid
using antisera with a high degree of cross-reactivity between two or
more members of the tachykinin family. The possibility exists that,
prior to the discovery of neurokinin A in 1983, some of the antisera
used were not fully specific for SP, and the distributions of SPLI
reported represent those of the tachykinin group as a whole rather
than just that of SP. It might be noted that although the combination
of high pressure liquid chromatography (HPLC) with radioimmunoassay
has been of great value in the detection and identification of
tachykinins (Aria and Emson, 1986, Lee,J-M. et al, 1986, Ogawa et al,
1985), such precise chemical identification cannot be directly
incorporated into immunocytochemical studies, which give a much more
detailed picture of peptide distribution. In more recent years,
however, antibodies showing very low cross-reactivities between
tachykinins or raised not against the peptides themselves but to the
PPTA or PPTB mRNAs have allowed yet further clarification of the
patterns of tachykinin distribution.
The overall distribution of SP, NKA, NKB and NPK throughout the
various tissues of the mammalian body appears to be similar (Arai and
Emson, 1986, Valentino et al, 1986). The proportions of the different
tachykinins does, however, vary from tissue to tissue (Brodin et al,
1986, Nagashima et al, 1989, Ogawa et al, 1985, Takano et al, 1988,
Tateishi et al, 1989,1990) suggesting the existence of some mechanism
or mechanisms regulating alternative gene splicing and/or post-
translational processing as outlined in the previous chapter.
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Hybridisation histochemistry studies, usi
PPTA mRNA or PPTB mRNA, have shown that in some CNS areas such as the
rat habendula or caudate putamen (Burgunder and Young, 1989a,b)
although both PPT genes are present throughout the area, individual
cells express only one of the two genes. In other areas, such as the
raphe nuclei and the nucleus of the lateral olfactory tract all cells
express one identical gene type, PPTA and PPTB respectively (Warden
and Young, 1988) . (It must be noted that the presence of PPT mRNA
within a neurone may not be equivocal with the release of tachykinins
from the terminals of that neurone).
Some observations may have significance in elaborating the
functional roles of the different members of the tachykinin family in
the spinal processing of nociceptive inputs. The distribution of
immunoreactive (ir)SP within the spinal cord has already been
described; a low density of immunoreactive fibres throughout the
spinal cord with a much higher density seen in laminae I and II of
the superficial dorsal horn, the main area of termination for primary
afferent fibres and in lamina X surrounding the central canal. The
distribution of PPTA mRNA in the spinal cord is similar to that seen
for irSP, and PPTA mRNA is also found in sensory neurones of dorsal
root ganglia. Furthermore, PPT-derived mRNAs are elevated in the
spinal cord following maintained, noxious, peripheral insult (Minami
et al, 1989, Noguchi and Ruda, 1992).
PPTB mRNA containing cells predominate in lamina III of the
dorsal grey matter and appear to be absent from dorsal root ganglion
cells (Warden and Young, 1988). Studies with a selective antibody for
NKB confirmed its preferential location to lamina III of the dorsal
spinal cord, and also showed that irNKB levels within the spinal cord
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were unaffected by dorsal rhizotomy, whereas this procedure led to a
marked drop in spinal cord irSP (Ogawa et al, 1985). Collectively
this data suggests a close association between the PPTA related
tachykinins; SP, NKA and possibly also NPK and NPy , and primary
afferent transmission in the dorsal spinal cord. This association
does not appear to exist for the PPTB related member off the
tachykinin family, NKB.
In peripheral tissues also, recent studies have suggested that
some sites, such as the guinea-pig ileum and urinary bladder, which
stain for irNKA and irSP, do not immunoreact with an NKB-specific
antiserum (Too et al, 1989a,b). Clearly, despite their marked
structural similarities, the products of the two tachykinin encoding
genes do have different distributions, although these distributions
overlap in some areas, particularly in the CNS. Functional
differences may, therefore, also exist.
A small number of studies have investigated tachykinin
distribution in non-mammalian species; chicken spinal cord (Sakamoto
and Atsumi, 1989), chicken spinal ganglia (Schultzberg et al, 1978),
lamprey CNS (van Dongen et al, 1986). As in mammals a close
association between irSP and sensory transmission in the spinal cord
is observed, and irSP staining is again heaviest in the superficial
dorsal horn.
The ontogeny of tachykinin expression in cat and rat CNS has
also been studied (Boylan et al, 1990, Diez-Guerra et al, 1989). The
results of these studies indicate that tachykinin expression in the
CNS of these species develops not only throughout gestation but also
continues for several weeks after birth. This may have significance
in the interpretation of some of the studies on tachykinin release
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and function which employ a preparation of neonatal spinal cord such
as that of Otsuka and Konishi (1976) . The findings of such studies
will be discussed in a later section. A requirement for nerve growth
factor in the development of tachykinin-containing sensory nerve
fibres has been reported (Mayer et al, 1982, Otten et al, 1980).
1.4 TACHYKININ DISTRIBUTION.
II. COEXISTENCE BETWEEN TACHYKININS OR WITH UNRELATED
PEPTIDES IN THE CENTRAL NERVOUS SYSTEM.
Immunocytochemical studies employing N-terminally directed (and
therefore more selective) antisera to individual tachykinins have
identified populations of primary afferent fibres staining for SP
alone, SP and either NKA or NPK or SP, NKA and NPK. (Dalsgaard et al,
1985, Ogawa et al, 1985, rat) . These variations may relate to the
three different mRNAs which can be derived from the PPTA gene (see
earlier section) each of which has the ability to encode a different
combination of tachykinin peptides.
Use of multiple antibodies can also detect coexistence with
other classes of neurotransmitter within individual neurones, and
this topic was reviewed by Dalsgaard, 1988. The specificity of
antisera used in these studies, however, generally precludes the
differentiation of the individual tachykinin(s) involved. Thus in
afferent fibres tachykinins are seen in 50-100% of neurones showing
immunoreactivity for calcitonin gene-related peptide (CGRP),
representing neuronal input derived from all peripheral tissues
(Sharkey et al, 1989, rat) . Some of the afferents from cutaneous
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receptors additionally stain for cholecystokinin (CCK) and pro-
dynorphin, whilst afferents arising from skeletal muscle vasculature
contain tachykinins, CGRP and CCK (Gibbins et al, 1987, guinea-pig).
Somatostatin coexists with tachykinins and CGRP in somatic afferent
fibres and a sub-population of these fibres also contains galanin,
but the specific origin of such fibres has not been determined (Garry
et al, 1989, cat) . The excitatory amino acid, glutamate, has been
shown to coexist with SP in primary afferent structures of the spinal
cord (Battaglia and Rustioni, 1988, rat and primate, de Biasi and
Rustioni, 1988, rat). Other peptides, such as endothelin (Giad et al,
1989, man), enkephalin-like peptides (Senba et al, 1989, rat) and
mammalian bombesin-like peptides (Cameron et al, 1988, cat) have also
been demonstrated to coexist with tachykinins in primary sensory
structures. As for other CNS sites, acetylcholine in the pons of the
rat (Vincent et al, 1983) and serotonin (5HT) in the medulla of both
rat and cat (Lovick and Hunt, 1983) have been shown to coexist with
tachykinins.
Overall the pattern of neurotransmitter/peptide coexistence in
the CNS is being increasingly revealed as extremely complex in
nature. The functional significance of peptide multiplicity within
individual neuronal structures is still unclear, but an interesting
interaction between CGRP and SP has recently been reported (Schaible
et al, 1992). Microinjection of CGRP into the superficial dorsal horn
of the cat was shown to facilitate the spread of SP away from sites
of release in the same area. The altered pattern of irSP detection
following CGRP application was almost identical to that seen
following antagonism of the peptidases responsible for SP degradation
in vivo (Duggan et al, 1992, as illustrated in figure 10, section 2),
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suggesting that following co-release of SP and CGRP the role of CGRP
might be to block such metabolism of SP, thus altering the area of
spinal cord over which it could have an effect on neuronal
structures. The potentiation of SP mediated effects at the spinal
level by CGRP in the rat has also been reported in
electrophysiological (Biella et al, 1991, Woolf and Wiesenfeld-
Hallin, 1986) and behavioural studies (Oku et al, 1987, Wiesenfeld-
Hallin et al, 1984). Thus interactions between co-released compounds
may not be confined to their direct effects on pre- or post-synaptic
elements.
1.5 TACHYKININ RECEPTORS.
Observations that the rank order of potencies for SP and non-
mammalian tachykinins, or derivatives of these compounds, varied
quite subtly in various bioassays utilising mammalian tissue (Buck
et al, 1984, Hunter and Maggio, 1984, Lee,C-M. et al, 1982, Maggi et
al, 1986, Piercey et al, 1985, Rosell et al, 1983, Szeli et al, 1977,
Watson et al, 1983) led to the suggestion that subtypes of mammalian
tachykinin receptor might exist. The specificity of receptor subtypes
for the different tachykinins was thought to relate to the N-terminal
amino acid sequences of the different peptides. The general range of
biological activities exhibited by the tachykinins seemed to be
dependant on the integrity of the common C-terminal amino acid
sequence, and also related to whether the residue X in the C-terminal
sequence PHE-X-GLY-LEU-MET-NH2 was an aromatic or aliphatic amino
acid. Substitution of single N-terminal amino acid residues on the
other hand could have only slight effects on biological activity,
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TABLE 1. Distribution of tachykinins in selected areas of the central
nervous system and selected peripheral tissues. Levels of tachykinins
_ "I
from different studies have been standardised to pmol g x tissue.
Data is derived from references cited in text.
TABLE 1.
DISTRIBUTION OF TACHYKININS IN CNS
AND PERIPHERAL TISSUES •
CNS SITE/PERIPHERAL TISSUE TACHYKININS pmol gzi
SP NKA NKB
Cerebral cortex 7.0 4 . 0 2.9
Striatum 312.2 26.2 1.2
Globus pallidus 114 . 7 68. 9 8.3
Substantia nigra 1154.2 115. 0 2.8
Ventral tegmental area 115. 4 68. 9 17.2
Nucleus accumbens 122.9 70.4 -
Hippocampus 4 .1 3.0 1.1
Hypothalamus (lateral nucleus) 201.4 171.3 31.4
Habenula 406. 0 240.2 -
Interpeduncular nucleus 474 . 6 168.3 -
Cerebellum 4 . 7 1.6 1.6
Solitary nucleus 459. 0 389.2 21.7
Raphe nuclei 275. 0 83. 0 -
Medulla oblongata 226. 4 71.1 7.2
Spinal cord
Dorsal horn (substantia gelatinosa) 503.7 65.9 9.1
Intermediolateral nucleus 121. 6 126. 0 31.6
Ventral horn 117.4 16.1 2.0
Ileum 47. 8 23.9 0.44
Colon 20.1 16.1 0. 67
Parotid salivary gland 16.2 0.4 0.4
Submandibular salivary gland 12.5 5.0 0.5
Heart 0.4 0.2 0.3
Urinary bladder 1.7 3.6 0.3
Adrenal gland 1.2 0.8 1.0
Skin 2.5 - -
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TABLE 2. Distribution of tachykinin receptors in selected areas of
the central nervous system and selected peripheral tissues (the same
locations as used in table 1) . As emphasised at the foot of the
table, these studies employed two methods, autoradiographic mapping
using radiolabelled ligands and hybridisation histochemistry studies
mapping the expression of messenger RNA encoding the various
receptors. The two techniques have, as described, produced differing
results. Data is derived from references cited in text.
TABLE 2.
DISTRIBUTION OF TACHYKININ BINDING SITES
IN CNS AND PERIPHERAL TISSUES.








































































































ranked positive identification of binding
sites or receptor mRNA.
negative result, ie. receptors not present,
no available data.
radiolabelled NKA binding demonstrated at
these sites, but NK2 receptor mRNA not
detected.
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although presumably altering the affinity of the peptide for the
different receptor subtypes (Couture et al, 1979, Erspamer, 1981,
Regoli et al, 1989) .
Prior to the discovery and sequencing of NKA and NKB in the mid
1980's, only two tachykinin receptor subtypes had been proposed :
SP-E (for eledoisin) and SP-P (for physalaemin) , based on the rank
order of potency in various smooth muscle preparations of SP and
other structurally related non-mammalian tachykinins. When NKA and
NKB were isolated in a pure form it was found that SP was the
preferred ligand for the SP-P receptor, NKA for the SP-E receptor and
NKB for a previously unidentified receptor subtype, SP-N, at that
stage identified in guinea-pig ileum (Laufer et al, 1985, Lee,C.-M.
et al, 1986). One study worthy of note, in part because the technique
for receptor differentiation is rather unusual is that of Vaught et
al (1986). Phenoxybenzamine, at varying doses was used as a multi-
affinity receptor antagonist to produce a competitive block of
kassinin-, physalaemin-, SP-, NKA-, and NKB-induced contractions of
guinea-pig ileum in vitro. From the pA2 values, three tachykinin
receptor subtypes were identified. The same tachykinins were also
injected intrathecally in mice, producing a characteristic hind-limb
scratching reflex (see later section), and phenoxybenzamine was again
employed to block the reflex. In the CNS two distinct tachykinin
receptor subtypes were quite clearly revealed, one of which showed
selectivity for NKB. The pA2 values for blockade of NKB effects in
the CNS were, however, very different from those seen in the guinea-
pig ileum. It is tempting to over-extrapolate the results of the
above study. Quite clearly it indicates tachykinin receptor
multiplicity in both peripheral and CNS tissues, but it also seems to
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indicate tissue or species differences in the NKB or NK3 receptor.
This latter conclusion should not be drawn from the data presented,
principally from the fact that the peripheral and CNS preparations
are very different in themselves, leading to variation in the
accessibility of receptor sites to the drugs tested. The variation in
experimental conditions relating to the different bioassay
preparations used in early studies on tachykinin receptor
multiplicity did indeed result in a great deal of confusion. The
results of more recent studies, such as that of Guard et al (1990)
measuring the binding of radiolabelled and highly selective NK3
ligands, suggest that NK3 receptors in ileum and CNS are
pharmacologically identical.
It is now accepted that three tachykinin receptor subtypes
exist, almost certainly in both the periphery and the CNS, and no
distinction is made between the receptor subtypes for the two areas.
NK*l, NK2 and NK3 (for neurokinin) are now the most widely accepted
terms for the three subtypes, with the receptors showing the highest
affinity for SP, NKA and NKB respectively. Neuropeptide gamma has
recently been reported as binding preferentially to the NK2 receptor
(Dam et al, 1990b) . The ranked affinities of endogenous tachykinins





Much work has been undertaken to develop specific (as opposed to
selective) ligands, both agonists and antagonists, for the receptors.
Many of these are analogues of the tachykinins themselves, for
example [ Sar 9,Met (02 ) ^ ]-SP (septide), [Nle10]-NKA (4-10) and
[MePhe"']-NKB, selective agonists for NK^, NK2 and NK3 receptors
respectively. Success has predominantly been achieved in developing
receptor agonists with high selectivity (Drapeau et al, 1987a,b,
Laufer et al, 1986, Regoli et al, 1987, 1988, Rovero et al, 1989,
Watson et al, 1983, Wormser et al, 1986 ). Of the antagonist
compounds available, [D-Arg^, D-Trp''' Leu-*--*-]-SP (spantide), which was
one of the earlier antagonists to be developed (Featherstone et al,
1986, Mizrahi et al, 1983), has been the most widely used despite
being only partially selective for the NK-j_ receptor. Recent drug
development has centred on the development of receptor antagonists
with better receptor selectivity, many of which are of a non-peptide
nature (Advenier et al, 1992, McElroy et al, 1992, Morimoto et al,
1992, Nagahisa et al , 1992, Poncelet et al, 1993, Rovero et al,
1990, Sakuruda et al, 1992).
Studies on tachykinin receptor distribution have primarily
relied on the binding of [^H] or [l^I] labelled forms of
tachykinins, tachykinin fragments or tachykinin analogues. Early
autoradiographic studies confirmed the heterogeneity of tachykinin
binding sites in CNS and peripheral tissues (Beaujouan et al, 1986,
Burcher et al, 1984, Mantyh et al, 1984b) and established that, in
the spinal cord, receptors binding SP were located post-synaptically
to sensory terminals in the dorsal horn and also at other sites such
as on somatic motor neurones in the ventral horn and on sympathetic
pre-ganglionic fibres in the intermediolateral cell column. Later,
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more refined investigations, in some cases using agonists with a high
selectivity for tachykinin receptor subtypes to displace bound
radiolabelled ligand, allowed a more detailed 'map' of receptor
distribution to be determined for brain ( Beaujouan et al, 1986, Buck
et al, 1986, Cascieri et al, 1985, Dam et al, 1990a, Dam and Quirion,
1986, Danks et al, 1986, Mantyh et al, 1984a,b, 1989 ), spinal cord
(Hunter et al, 1987, Yashpal et al, 1990,1991) and peripheral tissues
(Bergstrom et al, 1987, Mantyh et al, 1988,1989). Studies on
peripheral tissues have dealt almost exclusively with the gastro¬
intestinal tract.
The amino acid sequences of the individual tachykinin receptors
have also recently been determined, and the distribution of mRNAs
encoding the receptors has been mapped in hybridisation
histochemistry studies (Hershey and Krause, 1990, Sasai and
Nakanishi, 1989, Shigemoto et al, 1990, Tsuchida et al, 1990). The
structural characteristics of the three receptor subtypes conferring
their differing selectivities for the various tachykinins is now
being evaluated, but this work is still at an early stage. It has
been suggested that the extracellular domains of the receptors are
the most important sequences with regard to binding affinities (Fong
et al, 1992a,b,c).
NK^ receptors are found in both CNS and peripheral tissues, NK2
receptors predominantly in peripheral tissues and NK3 receptors
mainly in the CNS. Within the brain the density of the different
subtypes varies from region to region, with each receptor subtype
having a distinct pattern of distribution. In some cases there is a
marked mismatch between the presence of tachykinin receptor subtypes
and their putative endogenous tachykinin ligand. For example the
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substantia nigra contains a large number of irSP containing nerve
terminals, as described earlier, but very few NK-^ receptors (Buck et
al, 1986, Mantyh et al, 1989). The significance of such mismatches is
unclear.
In the spinal cord, the density of NK]_ receptors is highest in
laminae I, II and X of the grey matter, and in the intermediolateral
cell column, with a much lower presence in the ventral horn. This
corresponds closely with the spinal cord distribution of SP. NK2
receptors (when identified: see below and notes with table 2) and NK3
receptors in the spinal cord are restricted to the dorsal grey
matter, and are most likely associated with afferent pathways. In the
CNS as a whole, the densities of NK2 and NK3 receptors are generally
lower than that of the NK3 subtype. Peripheral tissues generally
express both NK^ and NK2 receptors, with some tissues (eg. rat
myenteric plexus or portal vein smooth muscle) also showing the
presence of NK3 receptors. NK2 receptors are present in much higher
numbers in peripheral tissues than in the CNS; the converse applies
to NK3 receptors.
Some recent studies have failed to detect NK2 (and in a few
cases NK3) receptors or mRNA in vertebrate CNS (Beaujouan et al,
1991, Dietl et al, 1991) which disagrees with earlier
autoradiographic studies where multiple tachykinin receptors were
identified in many areas of the CNS. This has led to the hypothesis
that the localisation of low numbers of NK2 receptors in brain and
spinal cord was due to poor specificity of the radioligands used in
these early studies and that NK2 receptors may indeed be absent from
the CNS. The same argument could be applied to the low levels of NK3
receptors seen in peripheral tissues. This hypothesis is not
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supported by some studies on receptor function at these sites (see
later). Tachykinin receptor distribution is summarised in table 2.
Tachykinin receptor distribution is clearly complex and the
functional roles of the different receptor subtypes have not yet been
well established. One note of caution concerns the assumption that
each receptor is closely associated with one endogenous tachykinin
ligand. NK^, NK2 and NK3 receptors are sometimes referred to as SP,
NKA and NKB receptors respectively, although all three tachykinins
show some affinity for each receptor subtype. The receptor/ligand
mismatches evident in some areas of the brain such as the substantia
nigra, where SP is abundant despite the lack of NK]_ receptors, and
the observation that NPK and NP gamma both have a higher affinity for
the NK2 receptor than NKA itself, suggest that this association may
not be physiologically accurate in many cases.
1.6 TACHYKININ FUNCTIONS AT A CELLULAR LEVEL.
Tachykinin effects at a cellular level can be broadly divided
into two categories; 1) elevation of intracellular Ca++ concentration
and 2)membrane depolarisation, both of which are closely
linked to smooth muscle contraction, secretory mechanisms and
neurotransmission.
The three receptor subtypes are structurally similar and all
show amino acid sequences similar to those found in G-protein coupled
receptors such as p-adrenergic or muscarinic receptors. There is much
evidence to support the coupling of tachykinin receptors to inositol
phospholipid hydrolysis by these G-proteins (Beaujouan et al, 1990,
Bristow et al, 1987, Guard et al, 1987, Hanley et al, 1980, Watson,
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1984) . This would indicate that activation of tachykinin receptors
brings about an elevation in intracellular Ca++ levels, either by
inositol 1,4,5-triphosphate mediated release of Ca++ from
intracellular stores, or diacylglycerol activation of protein kinase
C and the resultant opening of voltage gated Ca++ channels (Mayer et
al, 1990, Murase et al, 1989).
The principal mechanism of tachykinin induced membrane
depolarisation seems to be a reduction in K+ conductance (Fujisawa
and Ito, 1982, Katayama et al, 1979, Nowak and MacDonald, 1982). A
variety of membrane effects of tachykinins have, however, been
reported. These include inhibition of muscarine-sensitive K+ current
(Adams et al, 1983), inhibition of Ca++-activated K+ current (Akasu
and Tokimasa, 1989) and activation of other, non-K+, cation currents
(Minota et al, 1981, Reiser et al, 1982) . The increases in
intracellular Ca++ levels outlined above are also reported to enhance
Ca++-activated K+ conductance (Mayer et al, 1990, Murase et al,
1989), which may have some function in balancing the other,
depolarising, membrane actions of tachykinins.
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1.7 TACHYKININ FUNCTIONS IN PERIPHERAL TISSUES.
As discussed in the earlier section on tachykinin distribution,
many peripheral tissues contain nerve fibres or terminals showing
immunoreactivity for tachykinins. Such nerve fibres may be of a
sensory nature passing directly or indirectly from the peripheral
tissue to the CNS, whilst others are intrinsic to the tissue itself
or of extrinsic origin, fulfilling an efferent function. Some of
these nerve fibres form synaptic contacts within nerve plexi, whilst
others contact smooth muscle, secretory tissue, blood vessels or less
frequently exist as apparently free nerve endings. The range of
tissues in which tachykinins play a functional role is too large to
be considered in detail within the scope of this thesis, but the
major functions mediated by these peptides in peripheral structures
will be outlined with examples of locations at which they operate.
1)Sensory transmission. Tachykinin containing nerve fibres of
primary afferent origin can be found in many tissues; eg. skin
(Hokfelt et al, 1975a), peri-articular tissues (Pereira da Silva and
Carmo-Fonseca, 1990), dental pulp (Olgart et al, 1977),
gastrointestinal tract (Domoto et al, 1983, Hayashi et al, 1982),
and respiratory tract (Lundberg et al, 1984, Stjarne et al, 1989) and
pelvic structures (de Groat, 1987). These fibres are predominantly of
the A-delta or C-type, and in many cases have been shown to contain
both tachykinins and CGRP, or to be capsaicin sensitive
substantiating their classification as primary afferent fibres. These
fibres are associated with the transmission of noxious inputs such as
chemical or mechanical stimulation, to the CNS.
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2)Inflammation. Tachykinins are contained in nerve terminals in
the walls of blood vessels where their release brings about plasma
extravasation and vasodilation (Markle et al, 1990). Dilation of
blood vessels by tachykinins may be indirect and involve the
formation of nitric oxide (Whittle et al, 1989). Tachykinin release,
in response to noxious stimulation, from the peripheral terminals of
primary afferent fibres or in some cases from free nerve endings also
contributes to this response, which has been demonstrated in the skin
(Yonehara et al, 1987), joints (Lam and Ferrell, 1991,1993) eye
(Bill, 1991), dental pulp (Olgart et al, 1977) and lung (Saria et al,
1988). Tachykinins also stimulate the release of histamine from mast
cells and act as trophic factors for leucocyte infiltration (Coulson
and Holden, 1990) and further sensitise peripheral tissues to the
inflammatory effects of other compounds such as prostaglandin E2 and
prostacyclin (Nakamura-Craig and Smith, 1989). This sensitisation
results in further build up of inflammatory fluid, promotes more
release of tachykinins from peripheral nerve endings and also lowers
the threshold of these peripheral nociceptors, resulting in the pain
which is frequently associated with inflammatory change. Tachykinin
containing fibres may also be closely associated with antibody
production in response to antigenic challenge in the immune system
(Eglezos et al, 1991)
3)Secretion. Tachykinins have been shown to both stimulate and
inhibit secretion. Indeed SP was first identified by its sialogogic
nature. In salivary glands in the rat and ferret, SP has been shown
to be involved with endogenous stimulation of salivary glands.
41
Overall control of salivary output also seems to involve
acetylcholine, however, as atropine is required in addition to
tachykinin antagonists to completely abolish the outflow of saliva
produced by nerve stimulation in both the sub-mandibular and parotid
glands (Ekstrom et al, 1988, 1989, Hanley et al, 1980) . In the rat
pancreas SP inhibits fluid secretion from duct cells (Ashton et al,
1990) but stimulates amylase secretion from acinar cells (Katoh et
al, 1984) . SP also stimulates mucus secretion in the respiratory
tract (Coles et al, 1984).
4)Cardiovascular system. Vasodilatation and plasma extravasation
produced by tachykinins have been discussed above. It has been
suggested that at some sites such as heart (Weihe et al, 1981) ,
skeletal muscle (Ohlen et al, 1987) and in the gastro-intestinal
tract (Donnerer et al, 1984), SP may be involved in autoregulation of
blood flow. Changes in mean arterial blood pressure, heart rate and
peripheral vascular permeability have all been seen following
intrathecal or systemic administration of tachykinins (Eimerl et al,
1985, Hassessian et al, 1987,1988). These effects are most likely
mediated via spinal NKq receptors located on parasympathetic
preganglionic fibres although the effector mechanisms were not
determined in these studies.
5)Smooth muscle. In the respiratory system, tachykinins are
potent constrictors of smooth muscle in the major airways , where NKA
seems to be the most important of the endogenous tachykinins (Saria
et al, 1988) . The gastrointestinal tract, in addition to large
numbers of sensory fibres or fibres of extrinsic origin showing
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immunoreactivity for tachykinins (Costa et al, 1980, Hayashi et al,
1982, Lundberg et al, 1978), also contains the peptides in many
intrinsic fibres of the myenteric and submucous plexi (Franco et al,
1979, Malmfors et al, 1981, Nilsson et al, 1975a, Pearse and Polak,
1975) . Exogenously applied tachykinins clearly have an effect on
motility patterns in the smooth muscle of the gut wall (Kuwahara and
Yanaihara, 1987) and populations of tachykinin containing fibres may
play an important part in regulating gut motility, although both NKB
and NK3 receptors may be of lesser significance at this site than the
other tachykinins and receptor subtypes.Tachykinin functions in these
and other peripheral tissues are summarised in table 3.
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TABLE 3. Some postulated roles for tachykinins in peripheral tissues.
The (ubiquitous) association of tachykinins with primary afferent
pathways has been separated. Although not specified in the table,
most studies have been on the functions of substance P.
TABLE 3.
SOME POSTULATED ROLES FOR TACHYKININS
IN PERIPHERAL TISSUES.
GENERAL neurotransmitters of afferent pathways (often associated
with small diameter fibres conveying ?nociceptive input.)
EYE afferent pathways from cornea, miosis, retinal function.
TEETH vasodilation in dental pulp.
SALIVARY GLANDS increase secretion.
GASTRO-INTESTINAL TRACT control of smooth muscle contraction, local
regulation of blood flow, neurotransmitters of enteric
nervous system , antiulcerogenic.
GALL BLADDER control gall bladder contraction/rate of bile
secretion by hepatocytes.
PANCREAS stimulate amylase secretion in acini, inhibit fluid
secretion in duct cells.
RESPIRATORY SYSTEM cause bronchoconstriction, mucus secretion,
increased mucociliary response, vasodilation.
CARDIOVASCULAR SYSTEM involved in regulation of coronary blood flow,
vasodilation, plasma extravasation, hypoxic response of
carotid body.
URINARY SYSTEM associated with vasodilation, diuresis, natriuresis,
contraction of urinary bladder smooth muscle, afferent
pathways triggering micturition reflex.
ADRENAL GLANDS modulate of catecholamine release.
SKELETAL MUSCLE involved in regulation of local blood flow.
BONES and JOINTS important mediators of inflammation in periarticular
structures.
SKIN associated with control of blood flow, sweat glands.
INFLAMMATORY RESPONSES vasodilation, plasma extravasation, flare and
wheal (triple response), activation of white blood cells.
IMMUNE SYSTEM proliferation of lymphocytes, increase in
immunoglobulin A and M synthesis, increase in lymph flow
from peripheral lymph nodes.
HEALING ? proliferation of endothelial cells, ? increased rate of DNA
synthesis.
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1.8 TACHYKININ FUNCTIONS IN THE
CENTRAL NERVOUS SYSTEM.
I.SITES OUTWITH THE SPINAL CORD/AUTONOMIC NERVOUS SYSTEM.
As with tachykinin functions in peripheral tissues, the roles of
tachykinins in CNS sites outwith the spinal cord are too complex to
be discussed at length within the scope of this thesis, although they
have recently been reviewed by Otsuka and Yoshioka (1993). Key
observations will, however, be made.
1) Control of dopamine release. Both SP and NKA increase the
release of dopamine from neurones arising in the substantia nigra and
ventral tegmental area (A10). (Kelley et al, 1979, Reid et al, 1988).
The dopaminergic neurones from these sites target many areas of the
CNS including the striatum and are closely associated, in man at
least, with motor control. Nigral SP levels have been shown to be
reduced in cases of Parkinson's disease in man (Mauborgne et al,
1983). It has already been noted that despite the high levels of irSP
present in the substantia nigra (Brownstein et al, 1976, Cooper et
al, 1981, Douglas et al, 1982, Emson et al, 1980, Gale et al, 1978,
Kanazawa and Jessell, 1976, Lovick and Hunt, 1983), there are few
tachykinin binding sites in this area (Buck et al, 1986, Mantyh et
al, 1989) . This mismatch cannot currently be explained. In the
nucleus accumbens, SP and NKA have both been shown to enhance the
actions of endogenous dopaminergic neurones (Elliot et al, 1986, Van
den Bos et al, 1990) . It is again worth noting that dopaminergic
systems have been implicated in the modulation of the rate of PPTA
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gene transcription (Bannon et al, 1987, Lindefors et al, 1989),
suggesting some form of reciprocal control between the two systems.
2)Noradrenergic neurones of the locus coeruleus. Nerve terminals
containing SPLI make synaptic contact with noradrenaline-containing
neurones of the locus coeruleus, one of the major sites of origin of
catecholaminergic neurones in the brain, (Pickel et al, 1979). These
neurones, many of which pass into the spinal cord as descending
inhibitory fibres (Westlund et al, 1981), are excited by direct
application of SP (Guyenet and Aghajanian, 1977) .
3)Centres of respiratory and cardiovascular control. Like the
substantia nigra, the nuclei of the solitary tract contain high
levels of tachykinins, especially SP (see references in paragraph 1
above) . This area of the brain controls the transmission of many
respiratory and cardiovascular reflexes. Tachykinin containing
terminals in the solitary nuclei constitute fibres arising from other
areas of the brain, such as the raphe nuclei and ventral medulla
(Thor and Helke, 1987) and also represent primary afferent fibres
running in cranial nerves V, IX and X (Helke et al, 1980) . Some of
these afferent fibres may arise from chemoreceptors or baroreceptors
in, for example, the carotid sinus. Microinjection of SP into this
area causes a brief drop in blood pressure and slowing of the heart
rate (Hall et al, 1989) and also increases respiratory tidal volume
and frequency (Chen et al, 1990) .
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4)Autonomic nervous system. Neural elements showing tachykinin
immunoreactivity can be found in the dorsal nucleus of the vagus in
the brainstem, and also in the intermediolateral and sacral
parasympathetic nuclei in the spinal cord (Cuello and Kanazawa, 1978,
Hancock and Peveto, 1979) . These are all parasympathetic
preganglionic nuclei. Application of SP to individual parasympathetic
preganglionic fibres tends to cause their depolarisation (Dun and Mo,
1988). The functions of tachykinins in this system may be illustrated
by the changes in mean arterial blood pressure, heart rate and
peripheral vascular permeability which have been seen following
intrathecal administration of tachykinins (Hassessian et al,
1987, 1988) .
1.9 TACHYKININ FUNCTIONS IN THE
CENTRAL NERVOUS SYSTEM.
II. SPINAL CORD NOCICEPTIVE PROCESSING.
The evidence to support a role of tachykinins in spinal
processing of nociceptive inputs is overwhelming. SP, NKA and NKB all
elicit a characteristic grooming or scratching reflex when
administered intrathecally in rodents (Gamse and Saria, 1986, Wilcox,
1988), thought to relate to the perception of pain. Intrathecal
administration of SP or NKA also decreases the latency of the rat
tail-flick reflex (Cridland and Henry, 1986), whereas tachykinin
depletion by capsaicin pretreatment in the same species brings about
a thermal analgesia (Yaksh et al, 1979). Capsaicin is thought to have
a selective effect on primary afferent structures. Capsaicin
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application initially stimulates the release of, and subsequently
depletes, not only tachykinins but other peptides which exist in
primary afferent structures, such as CGRP and somatostatin (Hua et
al, 1986, Saria et al, 1986, Yaksh et al, 1979) . As only
approximately 20% of dorsal root ganglion neurones show tachykinin
immunoreactivity (Hokfelt et al, 1976), the behavioural effects of
capsaicin may clearly relate to its effects on other systems apart
from those involving tachykinins.
If the tachykinins function as neurotransmitters in pain
pathways then they should fulfil the basic criteria for
neurotransmitters in general; both the peptides and their receptors
should be present at appropriate sites, their release should be
demonstrated following appropriate stimuli, some effect on post
synaptic structures should be evident and some mechanism to limit
their action should exist.
1)Peptide/receptor distribution. These topics have been
discussed in earlier subsections. It might again be noted that
tachykinins have been identified in synaptic vesicles in nerve
terminals within the spinal cord (Cuello, 1977, Cuello and Kanazawa,
1978, Merighi et al, 1989, Pelletier et al, 1977), and that
tachykinin immunoreactivity in the spinal cord is largely associated
with fibres of primary afferent origin. In the spinal cord, unlike
some areas of the brain such as the substantia nigra, there is a good
correlation between tachykinin peptide distribution and tachykinin
receptor distribution.
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2)Tachykinin release. Superfusion studies have been used to
detect release of SPLI from spinal cord preparations in the rat,
guinea pig and cat, both in vivo and in vitro (Hua et al, 1986,
Linderoth and Brodin, 1989, Ono et al, 1991, Otsuka and Konishi,
1976, Pang and Vasko, 1986, Saria et al, 1986, Theriault et al, 1979,
Yaksh et al, 1979,1980). These studies initially demonstrated raised
levels of SPLI in the superfusate only in response to capsaicin or
veratridine application and to high levels of K+. Release of SPLI in
response to high K+ levels was Ca++ dependant, being abolished by low
Ca++/high Mg++, (such Ca++ dependant release of tachykinins can also
been demonstrated in various brain regions in vitro, Lindefors et al,
1985). Electrical stimulation of dorsal roots or peripheral nerves at
A-delta or C-fibre strength was inconsistent in producing raised
levels of SPLI (stimulation of larger fibres was ineffective) and
peripheral noxious stimuli, whether mechanical, thermal or chemical
produced no detectable changes.
The findings of such studies must be interpreted with some
caution on two counts. Firstly the sensitivity of simple tissue
perfusion techniques may be too low to detect small increases in
tachykinin levels following 'natural' peripheral stimuli such as
pinching or heating of the skin. Thus only relatively harsh stimuli,
such as capsaicin application or electrical stimulation, affecting
large populations of neurones produce detectable changes in levels of
released tachykinins. It would then be premature to conclude that
discrete peripheral stimuli in vivo are physiologically ineffective
in eliciting tachykinin release in the spinal cord. Secondly,
elevation of extracellular K+ levels will stimulate all neurones in
spinal cord slice or similar preparations. It has already been
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pointed out, in the section dealing with tachykinin distribution,
that approximately 50% of nerve terminals showing tachykinin
immunoreactivity in the spinal cord may be of intrinsic or supra¬
spinal origin. Release of tachykinins in the spinal cord following
elevation of K+ or similar 'blanket' stimuli cannot then be
attributed solely to release from primary afferent terminals.
Modifications of the superfusion technique, namely the push-pull
cannula in the rabbit and rat (Kuraishi et al, 1983,1985a, Oku et al,
1987, Tiseo et al, 1990) and microdialysis in the cat (Brodin et al,
1987), have been used to detect raised levels of tachykinin
immunoreactivity in the spinal cord in response to peripheral noxious
mechanical and thermal stimuli, inflammation of peripheral tissues
and to peripheral C-fibre stimulation. These techniques have a better
sensitivity for peptide detection than simple superfusion, presumably
accounting for their success in detecting elevated levels of
tachykinin release in response to physiological noxious peripheral
stimuli. Their anatomical resolution is not, however, sufficient to
allow detailed evaluation of sites of release in vivo (resolution is
in the order of 200|rm) . Evoked tachykinin release in these studies
could still be derived from intrinsic neurones of the spinal cord
rather than from primary afferent terminals.
In recent years a technique for peptide detection in vivo, the
antibody microprobe technique, has been developed by Duggan and co¬
workers (Duggan et al, 1988a, Duggan and Hendry, 1988, Hendry et al,
1988) . This was the technique used in the experiments detailed in
this thesis and the methodology will be discussed at length in a
later subsection. It is, however, worth noting at this point that
antibody microprobes have very high spatial resolution (<100|tm) and
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sensitivity for peptide detection (in the order of lO--^ moles
peptide per microprobe). In a variety of studies antibody microprobes
have demonstrated release of SP and NKA in cat spinal cord in
response to a variety of peripheral noxious stimuli; thermal,
mechanical, and chemical (arthritic) stimulation of cutaneous or
articular structures and electrical stimulation of afferent fibres of
nociceptive origin. (Duggan et al, 1988b,1989,1990,1991,1992, Hope et
al, 1990b,c, Lang et al, 1991,1994, Morton et al, 1990,1991, Schaible
et al, 1990,1992). Non-noxious peripheral stimuli were ineffective in
evoking spinal release of tachykinins. By merit of their high spatial
resolution, antibody microprobes further demonstrated that noxious
stimulus-evoked release of tachykinins is centred on the substantia
gelatinosa, laminae I and II of the superficial dorsal horn, the
major site of primary afferent fibre termination in the spinal cord.
This supports the hypothesis that tachykinins are released from the
central terminals of fibres of nociceptive origin.
3)Effects of tachykinins on spinal cord structures. The cellular
mechanisms underlying the effects of tachykinins on neuronal
structures have already been discussed.
The earliest observations on SP function in spinal cord was
simply that it excited neurones in spinal cord in vivo (Tulloch and
Zieglgansberger, 1978) which in some cases were shown to be activated
by peripheral noxious stimuli (Randic and Miletec, 1976, Sastry,
1979b). SP applied to cultured spinal neurones produces a slow
depolarisation, lasting many seconds (Nowak and MacDonald, 1982).
Similar long lasting excitatory post-synaptic potentials (EPSPs) are
seen in neurones of the cat spinal cord neurones following cutaneous
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noxious stimulation, and such EPSPs can be blocked by systemic
administration of tachykinin antagonists (De Koninck and Henry,
1991). In an isolated spinal cord/tail/hindlimb preparation from
newborn rat, the tachykinin antagonist spantide blocks similar long
lasting depolarisations recorded in neurones of the ventral horn in
response to electrical C-fibre stimulation in the dorsal horn or to
peripheral capsaicin application (Nussbaumer et al, 1989, Otsuka and
Yanagisawa, 1988). NKA application produces similar electrophysio¬
logical changes in spinal neurones to those seen with SP (Yanagisawa
and Otsuka, 1990).
It is interesting to note that a proportion of tachykinin
containing primary afferent terminals in the spinal cord also contain
the fast acting excitatory neurotransmitter, glutamate (Battaglia and
Rustioni, 1988, de Biasi and Rustioni, 1988). Stimulation of such
terminals should then result in both slow and fast post-synaptic
potentials, the significance of which will be discussed at the end of
this subsection. Within the spinal cord tachykinins have, then, been
shown to function as excitatory transmitters in primary afferent
pathways of pain transmission (in addition to their roles in other
systems such as autonomic preganglionic pathways). Is the role of
tachykinins in primary afferent pathways limited to fibres of
nociceptive origin?
Henry (1976) initially reported that SP only excited dorsal horn
neurones which responded to noxious cutaneous thermal stimuli, and
more recently Duggan et al (1988b,1990) have shown that noxious
mechanical, thermal and chemical stimuli are all effective in evoking
spinal release of both SP and NKA, whereas innocuous stimuli do not
evoke such release. Such a nocispecific role for tachykinins in
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primary afferent transmission is supported by reports that dorsal
horn neurones with strong nociceptive input show significantly higher
numbers of tachykinin immunoreactive contacts in the spinal cord than
other neurone types (De Koninck et al, 1992) . The hypothesis is,
however, not supported by the findings of Leah et al (1985), who
reported no correlation between sensory function of electro-
physiologically characterised primary afferent fibres and SP-
immunoreactivity. Many fibres in this study did not respond to any
form of cutaneous stimulation; these may have been silent nociceptor
fibres, which under normal conditions do not respond to defined
peripheral stimuli but only become sensitive to noxious stimulation
under inflammatory conditions (Handwerker et al, 1991). Duggan and
co-workers have shown that spinal release of SP and NKA in response
to peripheral noxious stimuli is enhanced during inflammation (Hope
et al, 1990b, Schaible et al, 1990) . This enhanced release may be
derived from such silent nociceptors and may in part explain the
findings reported by Leah and co-workers.
As with other systems, the specific roles of the different
tachykinins and their receptors in spinal afferent processing have
not yet been well established. Two recent studies are, however, worth
noting. An antinociceptive effect of intrathecally applied NKB on the
rat tail-flick reflex has been reported (Laneauville et al, 1988)
leading to the suggestion that NKg receptors might mediate
antinociceptive functions in the spinal cord. The same group,
however, reported a variable effect of SP, both algesic and
analgesic, in the same preparation and the observation must therefore
be approached with some caution. The lack of an NKg mediated
component in the tachykinin facilitation of thermal nociception (but
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not antinociception per se) in the rat has also been reported
(Fleetwood-Walker et al, 1988) .
4 Tachykinin metabolism/reuptake mechanisms. Although an uptake
mechanism has been demonstrated in CNS for the tachykinin fragment
SP (5-11) (Nakata et al, 1981), a similar mechanism does not appear
to exist for the whole SP (Segawa et al, 1977) . Indeed no selective
reuptake mechanism has been identified for any of the mammalian
tachykinins (McKelvey and Blumberg, 1986). Another way in which
tachykinin function in vivo could be limited is by enzymatic
degradation.
In vitro, SP and NKA are degraded by a number of enzymes
including angiotensin converting enzyme (ACE), aminopeptidases,
carboxypeptidases and enkephalinase (EC 3.4.24.11) (Littlewood et al,
1988, Turner and Hooper, 1987, Wang et al, 1991) .
Acetylcholinesterase will also degrade SP in vitro (Chubb et al,
1980) but this effect has not be demonstrated under in vivo
conditions. Inhibition of enkephalinase activity has been shown to
potentiate the detection of SP release from slices of rat substantia
nigra and guinea-pig spinal cord in vitro (Geppetti et al, 1989,
Mauborgne et al, 1987a) and to facilitate the effects of exogenously
applied SP or NKA in peripheral tissues such as the ferret trachea
(Sekizawa et al, 1987).
Several peptidases can be detected in mammalian nervous tissue
or cerebrospinal fluid (Barnes et al, 1991, Healy and Orlowski, 1992,
Nyberg et al, 1984). Although the exact identity of the enzyme(s)
responsible for actual tachykinin degradation in vivo has not been
established, Duggan et al (1992) reported that kelatorphan, an
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inhibitor of aminopeptidases, dipeptidyl-aminopeptidases and
enkephalinase, facilitated the spread of SP in the cat dorsal horn
following noxious stimulus-evoked release and that this facilitation
was not further increased by the application of captopril, an
inhibitor of ACE. It was postulated that the marked spread of NKA
seen following its release under normal conditions (Duggan et al,
1990) might relate to its resistance to proteolytic degradation in
vitro, which is greater than that seen for SP (Bishop et al, 1986,
Theodorsson-Norheim et al, 1985) . NKA has a half-life, in vitro, in
the order of 30 minutes, whereas that of SP is only about 2 minutes.
The distribution of enkephalinase immunoreactivity in the rat
CNS correlates well with the distribution of irSP in many (but not
all) areas, including the superficial laminae of the spinal cord
(Pollard et al, 1989) . Of the potential mechanisms of tachykinin
degradation, a role for enkephalinase in vivo is currently the best
substantiated.
5)Conclusions. The role of tachykinins as neurotransmitters is
well supported by the results of the investigations outlined above.
These peptides fulfil all of the necessary criteria for their
classification as neurotransmitters; presence, presence of their
receptors, evident release and function at both cellular and system
levels. These criteria have been demonstrated most comprehensively in
the dorsal spinal cord, where their role in primary afferent
transmission has been conclusively established. Within spinal
afferent pathways both SP and NKA can be linked very selectively to
primary afferent pathways of nociceptive origin, although the
physiological role of NKB is perhaps not so clear.
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The one area, however, where SP and NKA do not conform to the
pattern of a classical neurotransmitter is in their durations of
action and the probable mechanisms and rates of their breakdown in
vivo: this is especially true of NKA. Glutamate, which may be co-
released with the tachykinins from a proportion of primary afferent
terminals produces 'fast' signalling from one neurone to another and
is removed rapidly from the site of its release (Johnston, 1978).
NKA, and to a much lesser extent SP, persist beyond the duration of
the stimuli evoking their release and spread away from the initial
area of that release. In this respect they may represent a second
form of neurotransmission, which has been termed "volume
transmission" (Fuxe and Agnati, 1991). Released tachykinins may,
then, reach receptor sites distant from the initial area of release,
and their effects may continue for some time following that release.
The ligand/receptor mismatch described in the substantia nigra may be
evidence for such a mechanism. Physiologically, NKA acting at
tachykinin receptors in the rat spinal cord has been shown to
potentiate the flexor withdrawal reflex for more than one hour
following its release (Wiesenfeld-Hallin et al, 1991).
One recent study (Schaible et al, 1992) demonstrated that
microinjection of CGRP, itself contained in primary afferent
terminals of nociceptive origin, directly into the superficial dorsal
horn of the cat spinal cord produced similar increases in spread and
persistence of released SP as those seen following peptidase
inhibition. This lends more support to the hypothesis of volume
transmission, as it may indicate that such a mechanism of
neurotransmission could also be under some form of physiological
control in vivo.
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The observations that SP and NKA in the spinal cord may not act
focally and rapidly do not detract from their close association with
nociceptive primary afferent transmission. It might be, however, that
these peptides would be better described as neuromodulators, altering
spinal cord function over a comparatively wide area and for
comparatively protracted periods, as opposed to classical
neurotransmitters such as glutamate.
1.10 ANTIBODY MICROPROBES
I.PRINCIPLES OF THE TECHNIQUE.
Antibody microprobes were developed (Duggan and Hendry, 1988,
Duggan et al, 1988a)
"as a means of getting better spatial resolution in determining
sites of release of neuropeptides in the central nervous system and
to do so with minimal disturbance to the structures giving release"
(Duggan,1992).
The technique has enabled the release of tachykinins (Duggan et
al, 1988b, 1989, 1990, 1991a, b, 1992, Hope et al, 1990b,c, Lang et
al, 1991, 1994, Lang and Hope, 1994, Morton et al, 1990, Schaible et
al, 1990,1992,1993), and of other peptides such as CGRP (Morton et
al, 1990), somatostatin and nerve growth factor (Duggan et al, 1989,
Morton et al, 1988), galanin (Hope et al, 1994), and dynorphin (Riley
et al, current study) in response to a variety of peripheral stimuli,
to be evaluated in the spinal cord of either the cat or the rat in
vivo. The technique has also been used in the rat to measure (3-
endorphin release in the periaqueductal grey, (Duggan et al, 1993),
thyrotrophin releasing hormone in the lateral septum and septo-
hypothalamic nucleus (Waterfall et al, 1993) and SP release in the
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nucleus accumbens and striatum (Furmidge et al, 1993,1994a,b). In the
cat brain, antibody microprobes have been used to measure enkephalin,
neuropeptide Y (NPY) and SP release in the periaqueductal grey and
(SP only) ventrolateral medulla (Williams et al, 1992,1993,1994).
The preparation and use of antibody microprobes will be
discussed fully in the section on experimental methods. Briefly,
antibody microprobes are glass microelectrodes, of similar dimensions
to those used for extracellular recording in electrophysiological
studies, evenly coated with antibodies raised against a particular
peptide. Microprobes are inserted, with stepping motor
micromanipulators, sequentially into the tissue of interest with the
concurrent application of defined peripheral stimuli. Released
peptide will then bind to antibodies on the area of the microprobe
surface adjacent to the site of release. Such binding of endogenous
ligand can then be detected by the subsequent failure of the
microprobe to bind an exogenous, radiolabelled form of the peptide.
The distribution of the radiolabelled ligand is measured with a
computer aided image analysis system as the optical density of
autoradiographs obtained by incubating the radiolabelled microprobes
on x-ray film. Individual microprobe analyses are grouped together
according to stimulus/experimental parameters, and pairs of such
grouped or 'mean' image analyses can be compared statistically. The
release pattern of endogenous ligand detected on the antibody
microprobes can then be related back to the individual laminae of the
spinal cord, or other discrete CNS structures. The principles of the
antibody microprobe technique are illustrated in figures 4-7.
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FIGURE 4. A. Reaction of the glass surfaces of antibody microprobes
with y-Aminopropyltriethoxysilane to produce alkylamine (siloxane
coated) glass microprobes.
B. The sequence of reagents used to couple immunoglobulins

























































FIGURE 5. Principles of neuropeptide detection in vivo using antibody









































































FIGURE 6. Conversion of single autoradiographic images into grey
scale plots and their grouping into mean image analyses with means











































FIGURE 7. Statistical comparison between two mean image analyses and

































































Although not a truly quantitative technique, increases or
decreases in the total amount of peptide released over a period of
time can be visualised, as the non-damaging nature of the microprobes
means that many individual probes can be placed, one after another,
in the same area of tissue. Thus, antibody microprobes have been used
to demonstrate the altered release pattern of noxious stimulus-evoked
SP release in cat spinal cord, following local administration of
peptidase inhibitors or calcitonin gene-related peptide (Duggan et
al, 1992, Schaible et al, 1992) or following the development of an
acute experimental arthritis (Schaible et al, 1990) . The antibody
microprobe is currently the most sensitive and least damaging
technique available for the in vivo detection of peptide release.
Antibody microprobes might be described as a semi-quantitative, semi-
dynamic means of evaluating neuropeptide release in vivo, and are
ideally suited to the aims of the investigations presented in this
thesis, as outlined at the end of this section.
1.11 ANTIBODY MICROPROBES
2)PATTERNS OF TACHYKININ RELEASE
IN CAT SPINAL CORD.
Antibody microprobes have been used to investigate the stimulus-
evoked release of both SP and NKA in the dorsal spinal cord of the
cat (Duggan et al, 1988b,1989,1990,1991a,b,1992, Hope et al, 1990b,c,
Lang et al, 1991, 1994, Lang and Hope, 1994, Morton et al, 1990,
Schaible et al, 1990,1992,1993). Noxious peripheral thermal,
mechanical and electrical (C-fibre strength) stimuli are all
effective in evoking the release of both peptides, the normal release
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patterns of which are illustrated in figures 8 and 9. Innocuous
peripheral stimuli are normally ineffective in evoking spinal release
of tachykinins although, in a model of acute arthritis, flexion of
the arthritic joint to a degree non-noxious in the normal animal did
evoke release of both NKA (Hope et al, 1990b) and SP (Schaible et al,
1990). Furthermore, the pattern of irSP detection in the spinal cord
in response to flexion of an arthritic joint was different to that
seen in the normal animal, but similar to the pattern of SP release
seen following intraspinal application of peptidase inhibitors
(Duggan et al, 1992) or CGRP (Schaible et al, 1992) (see below and
figure 10).
The characteristics of stimulus-evoked SP and NKA release in the
cat spinal cord are outlined in the following pages.
Stimulation of normal peripheral tissues.
NKA. 1)Release in the spinal cord is evoked by noxious peripheral
mechanical, thermal and electrical stimulation.
2)irNKA is detected along the entire length of the antibody
microprobe following its stimulus evoked release. This detection
extends both ventrally (measured as deep as lamina V) and dorsally
(as far as the spinal cord surface) from the substantia gelatinosa
(SG) of the spinal dorsal horn, the major site of primary afferent
fibre termination. As irNKA is detected in the white matter dorsal to
the SG, where there are very few, if any, NKA containing nerve
terminals, it has been proposed that this pattern of post stimulus
irNKA detection represents an initial focal release in the
superficial laminae of the dorsal horn followed by the subsequent
diffusion of the peptide away from the initial area of release.
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3) Basal levels of irNKA are detected in the spinal cord, at all
depths, in the absence of any prior peripheral noxious stimulation.
4) Following its stimulus-evoked release, irNKA persists in the
spinal cord, and significantly elevated levels of the peptide can be
detected for between 30 minutes and 1 hour following the cessation of
the stimulus.
SP, 1) Release in the spinal cord is evoked by noxious thermal,
mechanical and electrical stimulation. Early work suggested that
relatively harsh noxious stimuli (compared to those employed in irNKA
studies) were required to elicit spinal cord release of irSP (Duggan
et al, 1988b) . This may relate to the sensitivity of the antibody
microprobes, or rather to the antisera used, in these early studies.
Broadly speaking, the stimulus parameters required to evoke irSP and
irNKA release in the spinal cord are the same.
2) Stimulus evoked release of irSP is much more focal than that
seen with irNKA. irSP release is primarily focused on the SG, laminae
I and II, of the superficial dorsal horn. A smaller area of release
is located approximately 0.5mm deep to this in laminae III/V. In some
individual animals, at some spinal cord sites, very small (100-200|rm)
foci of irSP release are detected in the deep dorsal horn (personal
observation, unpublished). irSP detection on the surface of the
spinal cord is also encountered in some individuals but it is unclear
whether this relates to the applied peripheral noxious stimuli or
simply to inflammation of the surrounding pial structures (Schaible
et al, 1990) .
65
FIGURE 8. Typical pattern of stimulus-evoked immunoreactive
substance P release.
A. compares two mean image analyses for groups of
microprobes. Microprobes were inserted 3mm into the dorsal spinal
cord for 10 minutes during either electrical stimulation of the
ipsilateral tibial at C-fibre strength ('Stim. control', n=18) or in
the absence of peripheral stimulation ('Air control', n=17). The mean
grey scale plot for each group is illustrated, with the + and -
standard errors, respectively for the two groups, calculated at 30pm
intervals.
B. Plot of the results of a Student's t-test performed
between paired data points from the two groups at 30pm intervals.
Points at which the difference attained statistical significance
(t>2, P<0.05) are shaded in grey and referred to a diagram showing
the locations of the different laminae of the dorsal horn. The
typical pattern of stimulus-evoked substance P detection is revealed,
ie. highly significant levels of substance P in a confined band
centred on the substantia gelatinosa, laminae II and III, with a less
well defined band in the deeper laminae, IV and V, of the dorsal
horn.
FIGURE 8.
























Depth within the spinal cord (mm)
r 4
L 2
Ventral horn VI V IV m II I Dorsal columns
66
FIGURE 9. Typical pattern of stimulus-evoked immunoreactive
neurokinin A release.
A. compares two mean image analyses for groups of
microprobes. Microprobes were inserted 3mm into the dorsal spinal
cord for 30 minutes during either electrical stimulation of the
ipsilateral tibial at C-fibre strength ('Stim. control', n=7) or in
the absence of peripheral stimulation ('Air control', n=ll). The mean
grey scale plot for each group is illustrated with the positive and
negative standard errors, for the two groups respectively, calculated
at 30|rm intervals.
B. Plot of the results of a Student's t-test performed
between paired data points from the two groups at 30fxm intervals.
Points at which the difference attained statistical significance
(t>2, P<0.05) are shaded in grey and referred to a diagram showing
the locations of the different laminae of the dorsal horn. The
typical pattern of stimulus-evoked neurokinin A detection is
revealed, ie. highly significant levels of neurokinin A throughout
the entire dorsal horn of the grey matter and also extending dorsally
into the white matter.
FIGURE 9.
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FIGURE 10. Effect of the microinjection of synthetic peptidase
inhibitors (kelatorphan and enalaprilat) at 2500, 2000, 1500 and
1000|im below spinal cord surface (and in the area of subsequent
antibody microprobe insertion) on stimulus-evoked levels of
immunoreactive substance P in the barbiturate anaesthetised cat.
Microprobes were inserted into the spinal cord for 10 minutes in all
cases. Groups of antibody microprobes illustrated are: 'No stim.' (in
all figures, n=16) a group of microprobes inserted in the absence of
any concurrent noxious stimulus, 'Noxious pinch' groups of antibody
microprobes inserted during concurrent noxious pinching of the
glaborous skin and interdigital areas of the ipsilateral hind paw
either A. prior to (n=ll), B. 35-40 minutes after (n=14) or C. 50-60
minutes after (n=9) microinjection of peptidase inhibitors into the
dorsal spinal cord. The stimulus evoked pattern of substance P
detection clearly changes, in a time dependant manner, following
peptidase administration and after one hour resembles the
distribution normally seen for stimulus-evoked levels of neurokinin
A. Microinjection of CGRP into the dorsal spinal cord has a similar
effect on the pattern of substance P detection in the spinal cord

















OF PEPTIDASE ADMINISTRATION ON THE
OF SUBSTANCE P DETECTION.
A
B
Noxious pinch 35 - 45 min
post peptidase inhibitors
C
Noxious pinch 50 - 60 min
4 3 2 1 0
Depth within spinal cord (mm)
68
3) irSP persistance following the cessation of an adequate
peripheral stimulus has not been systematically investigated , but it
appears to be less than that seen with irNKA.
4) Basal levels of irSP in the absence of prior peripheral
noxious stimulation are not consistently observed, and where present
are much lower than those seen for irNKA.
Stimulation of arthritic joints.
NKA. Following injection of the stifle joint with kaolin/carrageenan,
irNKA detection was immediately increased in the spinal cord
following flexion of, or application of pressure to, the treated
joint at levels which in the untreated animal would be non-noxious.
The pattern of irNKA detection was similar to that seen with other
forms of stimulation in the normal animal.
SP■ Following joint injection with kaolin/carrageenan, joint flexion
or application of pressure to the joint at previously innocuous
levels, evoked irSP release only after a delay of 6-7 hours. When
irSP release was evoked the pattern of detection was different to
that seen when applying conventional peripheral noxious stimuli to
the normal animal. Stimulation of an arthritic joint resulted in a
comparatively broad zone of irSP detection extending ventral to the
substantia gelatinosa and dorsally as far as the cord surface. A
similar change in the pattern of irSP detection has been reported
following intraspinal injection of peptidase inhibitors or calcitonin
gene-related peptide (Duggan et al, 1992, Schaible et al, 1992).
These observations may be related; developing arthritis may promote
the central protection of SP from enzymatic degradation.
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1.12 MODULATION OF TACHYKININ RELEASE
FROM PRIMARY AFFERENT TERMINALS.
STUDIES WITH ANTIBODY MICROPROBES.
An inhibition of neurotransmitter release from the central
terminals of nociceptors (presynaptic inhibition) has been suggested
as being important in several mechanisms of analgesia. Melzak and
Wall (1965) proposed a segmental presynaptic inhibitory mechanism
activated by impulses in larger diameter (non-nociceptive) primary
afferent fibres. Jessell and Iversen (1977) suggested that endogenous
compounds, such as metenkephalin, known to be analgesic at the level
of the spinal cord, might act by presynaptically inhibiting primary
afferent transmitter release in the spinal dorsal horn. A similar
mechanism has been proposed for the supraspinal control of
nociceptive processing in the spinal cord, either directly via
descending inhibitory fibres or indirectly via activation of
segmental inhibitory fibres (Duggan, 1985) .
The spinal analgesic effects of certain groups of drugs,
including the opiates and the a2 adrenoceptor agonists, are
frequently explained by their proposed activation of such pre¬
synaptic inhibitory mechanisms operating at primary afferent
terminals of nociceptive origin. As outlined in this section, the
tachykinin peptides SP and NKA are closely associated with this type
of primary afferent terminal, and the pattern of their release in the
spinal cord in response to defined peripheral noxious stimuli can now
be visualised using the antibody microprobe technique. The work
presented in this thesis was performed with the purpose of
establishing what contribution, if any, presynaptic inhibition of SP
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or NKA release makes to the spinal analgesia produced by various
compounds. Drugs already in clinical use (morphine, noradrenaline,
and medetomidine an imidazoline derivative a2 adrenoceptor agonist)
and also the neuropeptide NPY were evaluated in this way. The results
for each drug will be presented in a separate section.
1.13 INHIBITION OF TRANSMITTER RELEASE
FROM PRIMARY AFFERENT TERMINALS:
GENERAL CONCEPTS.
There are several mechanisms (see also figure 11) by which a
systemically or topically administered compound might bring about a
reduction in neurotransmitter release from primary afferent terminals
in the spinal cord;
1) activation of fibres of supraspinal origin constituting
descending inhibitory controls on spinal cord functions.
2) direct activation of inhibitory systems within the spinal
cord itself.
3) a direct inhibitory effect on peripheral receptors or
afferent nerve fibres.
1)Supraspinal inhibitory pathways. Electrical or chemical stimulation
of many areas of the brainstem results in inhibition of transmission
of impulses in neurones of the spinal cord (Carstens et al, 1980,
Gernart et al, 1980, Hall et al, 1982, McCreery et al, 1979). A wide
variety of neuroactive compounds are contained in these descending
inhibitory pathways, including noradrenaline, 5HT, dopamine, SP,
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thyroid releasing hormone, cholecystokinin, galanin, NPY, beta-
endorphin and enkephalin (see Duggan and Weihe, 1991, for a full
review). Similarly, the anatomical organisation of these systems is
complex. For example noradrenergic descending inhibitory fibres arise
largely from the Kolliker-Fuse nucleus (Stevens et al, 1982) but also
from the A6 cell group of the nucleus locus coeruleus, the A7 cell
group of the subcoeruleus, parabrachial nucleus and the A5 cell group
lateral to the inferior olive (Kwiat and Basbaum, 1992, Westlund et
al, 1984). To quote from this last study:
" Our present lack of understanding may be partially explained
by the as yet unknown microanatomical relationships of noradrenergic
neurones to other classes of cells. Based on anatomical
considerations alone, conflicting physiological and pharmacological
data can be attributed to the influence of non-noradrenergic systems
or to the coactivation or inhibition of two noradrenergic systems
which influence areas of contradictory function."
This is a rather protracted way of saying that the mechanisms by
which these descending fibres exert their effects in the spinal cord,
and the ways in which the different descending inhibitory systems
interact are not understood. Despite having been made over ten years
ago, the statement still holds true. Descending inhibitory fibres may
directly contact neurones involved in primary afferent transmission,
or they may contact intrinsic neurones of the spinal cord which in
turn influence afferent (or efferent) transmission (see below). In
fact both mechanisms could be active. This gap in the understanding
of descending inhibitory pathways is unimportant in regard to the
present studies, with two exceptions.
The first exception is when a drug is administered in such a way
as to stimulate both descending inhibitory pathways and intrinsic
spinal mechanisms simultaneously. This could theoretically apply to
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the study of the effects of systemically applied morphine on NKA
release from primary afferent terminals. Morphine applied
intracerebro-ventricularly has been proposed as activating descending
serotonergic and noradrenergic pathways inhibiting the transmission
of nociceptive impulses in the spinal cord (Suh and Tseng, 1990,
Yaksh, 1985). Morphine is also analgesic when administered at the
level of the spinal cord (as will be fully discussed in section 3) .
Systemic administration of morphine to spinally intact animals may
activate both mechanisms of analgesia (Yeung and Rudy, 1980) making
the contribution of opioid receptor activation in the spinal cord
itself difficult to determine. This is one of the reasons why the
animals used in the present studies were spinalised at the spino-
thoracic level; to interrupt any descending inhibitory pathways.
The second problem arises from the tonic inhibition of spinal
cord function (this may be a general phenomenon, rather than
selective for particular forms of afferent transmission) mediated by
descending inhibitory pathways during surgical anaesthesia (Hall et
al, 1981,1982). This is again obviated by spinal cord transection. It
is, however, worth noting that the results of one study suggest that
there is no tonic descending inhibitory control of irSP release in
the anaesthetised cat (Duggan et al, 1988c).
2)Activation of intrinsic spinal cord mechanisms. It might first be
noted that in the present studies it is not possible to relate the
effects of the drugs used to a particular endogenous control system.
Thus, if a spinally-administered compound were to reduce the amount
of a particular peptide released from primary afferent terminals as
detected by antibody microprobes, it might bring about that reduction
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either by a direct action on those primary afferent terminals or by
activation of segmental inhibitory neurones of the spinal cord.
As already discussed, receptors located on the central terminals
of nociceptive afferents might be contacted in vivo by processes of
either descending inhibitory fibres or by intrinsic neurones of the
spinal cord. Descending inhibitory fibres have already been
discussed. Intrinsic neurones of the spinal cord contain literally
dozens of potential neurotransmitters (see Duggan and Weihe, 1991),
most of which have not been functionally evaluated. Gamma-
aminobutyric acid (Duggan and Foong, 1985) and endogenous opioid
peptides (Catley et al, 1983, Duggan et al, 1985) are classically
associated with segmental inhibitory systems in the spinal cord, but
their exact mechanism of action in blocking primary afferent
transmission is not yet known.
The organisation of inhibitory mechanisms within the spinal cord
is probably very complex and interactions between more than one
system can be observed. For example, in spinally intact rabbits, an
interaction between segmental opioid and descending noradrenergic
inhibition of an electrically evoked sural nerve reflex has been
revealed (Clarke et al, 1988,1989). This type of interaction between
opiate and noradrenergic inhibitory systems can also be demonstrated
in a number of experimental models involving rodents and the cat
(Hylden et al, 1991, Omote et al, 1991, Ossipov et al, 1989,
1990a,b,c, Roerig et al, 1992, Sullivan et al, 1987, Taiwo et al,
1985, Wilcox et al, 1987). Development of cross-tolerance between the
two systems has also been shown (Kalso et al, 1993, Solomon and
Gebhart, 1988a). However, as with the various descending inhibitory
pathways, the functional significance of the various segmental
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controls in the spinal cord has not yet been clarified. The actual
existence of presynaptic contacts to primary afferent terminals has
been established in only a very few cases, and the histological
evidence to support a presynaptic mechanism for the inhibition of
transmitter release by particular compounds from such sites will be
discussed separately for each study.
3)Peripheral effects. At very high doses (much higher than those
used in the present study) morphine may block the propagation of
action potentials in primary afferent fibres (Jurna and Grossman,
1977). The sensitisation of peripheral receptors during the processes
of tissue damage and inflammation has previously been discussed.
There is some evidence that peripheral (in many cases articular)
opiate receptors may in part mediate the analgesia produced by
morphine in such inflammatory states (Khoury et al, 1990, Parsons et
al, 1990, Russell et al, 1987, Stein, 1993, Stein et al, 1990a,b).
Other drugs such as aspirin (Grubb et al, 1991, Guilbaud and Iggo,
1985, Heppelmann et al, 1986, Monkada et al, 1975) and serotonin
(Birrell et al, 1990) have been shown to desensitise articular
receptors in experimental models of arthritis, and such
desensitisation will presumably lead to a reduction in the amount of
neurotransmitter released from the central projections of such
receptors under these conditions.
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FIGURE 11. Possible sites of action for drugs leading to altered
spinal processing at the first afferent synapse.
Drugs may activate descending or segmental inhibitory fibres
at their source (A) or may mimic the effects of the endogenous
neurotransmitters which such fibres release: either postsynaptically
(B) on second order neurones in the spinal cord or presynaptically
(C) on the synaptic terminals of primary afferent fibres. This effect
may not be direct but may mimic the effects of neurotransmitters
released by spinal interneurones activated by such
descending/segmental pathways (D,E). Alternatively drugs may have
direct effects on primary afferent terminals or their synaptic
contacts unrelated to endogenous control mechanisms (F,G) or modulate
pre- or postjunctional effects at the synapses between
descending/segmental fibres and spinal interneurones (H,I). Lastly
drugs may alter the transmission of nociceptive information in the
primary afferent fibres themselves (J) or alter transduction
mechanisms in receptors located in peripheral tissues (K).
FIGURE 11.
POSSIBLE SITES OF ACTION FOR DRUGS PRODUCING






2.1 STORAGE OF PEPTIDES AND OTHER ORGANIC COMPOUNDS.
A large number of chemicals are used in the preparation and use
of antibody microprobes. Most of these are inorganic and their
handling and storage is straightforward. The organic compounds are
not so robust and certain precautions were taken in their use.
Antibodies.
All antibodies were purchased commercially, and were delivered
as freeze-dried lyophylates. In some cases this lyophylate was stored
at -20°C for several weeks prior to reconstitution, without any
apparent loss in the integrity of the antibody. These lyophylates
already contain buffering salts and bovine serum albumin (BSA)
resulting in the addition of a minimum volume of diluent being
required to fully dissolve them completely. In practice it was found
that all of the antibodies used could be reconstituted at double the
manufacturers suggested concentration for radioimmunoassay (RIA).
Lyophylates were reconstituted in distilled and Millipore filtered
water and the resulting solution was immediately divided into 0.5ml
aliquots in capped, polythene Eppendorf tubes. These aliquots were
then stored at -20°C (in later studies at -70°C) until use. As with
all organic solutions, the unused portion of any thawed aliquot of
antibody was discarded, as re-freezing promotes the breakdown of such
compounds.
The absolute number of antibody molecules in a given volume of
solution is not determinable when purchasing such commercial antisera
designed for use in RIA studies. However, one batch of antisera was
sufficient for 15 to 25 antibody microprobe experiments, and the
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concentration of antibody used
Furthermore, the suitability of ea
microprobe experiments was tested
will later be described
in any one study was constant,
ch new batch of antisera for use in
by a variety of in vitro tests, as
Unlabelled peptides.
These were purchased in freeze-dried form and reconstituted
according to the suppliers recommendations with the appropriate
diluent. Peptides were initially reconstituted to various
concentrations and stored as lOOpl aliquots in capped Eppendorf tubes
at -20°C. The bulk of the peptide was stored as a 10~^M solution,
which was later used to make up batches of 10~®, 10~^ and 10~®M
aliquots, these then being stored in a similar fashion.
Radiolabelled peptides.
Commercially -^^I-labelled SP and NKA were purchased from
Amersham, UK in batches, each containing a total of 10)xCi of
radioactive material. Each 10(a.Ci batch was reconstituted immediately
on delivery with the recommended diluent to a total volume of 100p.l
and then divided into 20 x 5)0.1 aliquots. These aliquots were stored
in a dedicated, lead screened freezer at -20°C until required.
Following thawing, single aliquots were diluted in a solution of
phosphate buffered saline (PBS)/azide containing 0.5% BSA to give a
solution with a gamma emission of 2000 counts minute--'-(cpm) (j.1— .
This final dilution was made only on the day of use, and the solution
was then stored on ice (but not frozen) until required. 125j ^as a
half life of 60 days, and unused aliquots of radiolabelled peptide
were discarded 6 weeks after their specified activity date.
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2.2 ANTIBODY MICROPROBE PREPARATION.
I.SILOXANE POLYMER COATING.
The technology of antibody microprobe production is not static,
that is to say that refinements in the process are constantly being
tested and applied. Consequently, the preparation of antibody
microprobes has changed in various subtle ways since the work
presented in this thesis was initiated. What is presented here is the
current method of antibody microprobe production. The techniques have
most recently been reviewed by Duggan, 1992. The processes involved
in antibody coupling to the glass were illustrated earlier in figures
4 and 5.
Preparation of glass.
Hollow Pyrex glass tubing (outer diameter 3mm, inner diameter
2mm, non-filament) of the type commonly used to make
electrophysiological recording electrodes was used to manufacture the
antibody microprobes. The glass was drawn out by heating it in the
coil of a microelectrode puller (Clarke), with the settings adjusted
to give an even taper from tip to shank (see figures 12A and 12B) .
Both ends of the microprobe were then heat sealed; the wide, unpulled
end in a gas flame and the tip by touching it briefly against a
heated coil, controlled by a micromanipulator and placed under a
binocular microscope to allow accurate sealing. Approximately 100|om
of the tip was sealed by this method. The resultant glass microprobe
is very flexible and resistant to accidental breakage, both factors
being requisite for their subsequent use. The microprobes were then
80
FIGURE 12. A. Outline of mechanism for pulling glass microprobes. A
hollow tube of pyrex glass is suspended between two holders, running
through a heated metal coil at midlength. The lower holder is
attached to a metal weight. As the glass is heated it stretches and
the lower holder drops, until, at a particular distance a switch is
activated, which triggers a strong electromagnetic field, rapidly
pulling the weight down and drawing the molten glass out to a point.
All factors (heat of coil, drop until pull triggered and pull force)
are variable allowing fine adjustment of microprobe shape.
B. Typical dimensions of antibody microprobes. Electrodes
for physiological recording (i) tend to have an abrupt taper towards
the end. Antibody microprobes (ii) have a more even taper with the
dimensions shown. Antibody microprobes are stored with the tips heat
sealed (iii) and these sealed tips must be broken off before in vivo








placed in glass carrying buckets in groups of approximately twenty
for ease of handling. Microprobes, in buckets, were immersed in 10%
nitric acid for 30 minutes and then given 3 x 10 minute washes in
Millipore filtered distilled water. The buckets of probes were then
dried in a clean oven at 200°C for at least 2 hours, or until further
use. This process resulted in clean, dry microprobes with some degree
of surface etching on which subsequent chemical reactions could
proceed.
Preparation of reagents.
Glass carrying buckets of the same type used to hold the
microprobes were filled with molecular sieves (Aldrich 4A, 4-8 mesh)
and heat dried at 200°C for 2 hours. Clean Pyrex-glass boiling tubes
(Quickfit 24/29) were heated to 200°C and then allowed to cool.
Whilst still warm they were placed in a fume cupboard and filled with
10ml aliquots of gamma-aminopropyltriethoxysilane (APTES) (Aldrich)
taken from a freshly opened 100ml bottle (it was usual to prepare 8
such tubes in each session of microprobe production). Unused APTES is
discarded. To each boiling tube 40ml of reagent grade toluene
(Aldrich) was then added, and the tubes were stoppered with polythene
caps. The buckets of molecular sieves were removed from the oven and
allowed to cool slightly. One bucket of sieves was then added to each
tube of APTES/toluene mixture. The tubes were transferred to a
humidity cabinet saturated with water vapour at room temperature and
left for 1 hour. The purpose of the molecular sieves was to remove as
much water as possible from the APTES/toluene mixture, as excessive
water in the solution will interfere with the even build up of
siloxane polymer on the surface of the microprobes.
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2.Exposure of glass to reagents.
The buckets of glass microprobes were carefully removed from the
oven with metal forceps and suspended in the humidity cabinet for 1
minute, allowing a fine layer of water vapour to adsorb to their
surface. The presence of at least a small amount of absorbed water on
the surface of the glass was required for the initiation of the
formation of siloxane polymer. As quickly as possible the boiling
tubes were then opened, the buckets of molecular sieves removed and
the buckets of microprobes lowered into the APTES/toluene mixture.
Each tube of reagent, now containing a bucket of microprobes was then
restoppered and removed from the humidity cabinet. Boiling tubes were
then placed in a centrifuge and spun at 6°C, 2000rpm for 1 hour. This
centrifugation resulted in a more even build up of siloxane polymer
on the surface of the microprobes. This may have been due either to
centrifugation of free water away from the tips of the microprobes or
to the removal of small particles of debris from the solution around
the tips which may act as foci for the polymerisation reaction. The
stoppered tubes were then removed from the centrifuge and left at
room temperature for 12 hours. The buckets of microprobes were then
removed from the boiling tubes in a fume cupboard and washed by brief
immersion in toluene, after which they were allowed to dry at room
temperature before being placed in an oven at 200°C for 24 hours to
cure the siloxane polymer. The APTES/toluene mixture was then
discarded.
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FIGURE 13. Scanning electron micrographs of A. the surface of an
uncoated glass microprobe and B. the surface of a siloxane coated
microprobe. (Both x20,000).
FIGURE 13.
ELECTRON MICROGRAPHS OF SILOXANE-COATED AND
UNCOATED MICROPROBES.
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3.Assessment of siloxane coating.
Scanning electron micrographs of the surfaces of both uncoated
and siloxane coated microprobes are illustrated in figure 13. It can
be seen that the polymer coating not only provides a chemical base
for the subsequent immobilisation of antibodies to the microprobe but
also vastly increases its surface area. A good polymer coat on the
surface of the microprobes will appear, under x40 magnification using
incident light, as a milky deposit on the surface of the microprobes;
white prior to heat curing and yellowish afterwards. The microprobes
were subsequently used to detect peptide binding at a resolution of
50-100jrm, and consequently assessment of polymer coating in this way
was not sufficiently accurate. Following curing, individual
microprobes were placed in a micromanipulator mounted under a
binocular microscope and examined at xl25 magnification using
transmitted. This allowed the siloxane coating to be examined in
great detail.
It was important to identify microprobes with uneven or patchy
distribution of siloxane coating, which were discarded, and also to
identify microprobes with small focal aggregations of polymer. In
some cases these 'lumpy' microprobes could be made usable by wiping
the tip vigorously with soft tissue; this tends to remove irregular
lumps of siloxane polymer whilst leaving the underlying layers
intact. Up to 60% of microprobes were routinely discarded at this
stage, leaving only those with a very even coating of siloxane
polymer. Microprobes designated adequate for in vivo use were then
stored horizontally in specially prepared grooved metal racks, inside
covered boxes, until required. Microprobes were sorted into three
groups; those with light, medium and heavy siloxane polymer coatings.
85
Although the analysis of microprobe images (see later section) is
performed in such a way as to minimise the effects of coat density on
the final result, it was felt that each experiment should utilise
microprobes with similar densities of siloxane, and consequently of
antibody, coating.
2.3 ANTIBODY MICROPROBE PREPARATION.
II.ANTIBODY COUPLING.
The binding of antibodies to siloxane coated microprobes takes
from 3-5 days and the use of the antibody microprobes must be timed
to prevent their wastage. Siloxane coated microprobes can be stored
indefinitely, but once organic molecules have been linked to the
microprobe coating they have a relatively short lifespan. Unpublished
in vitro work suggests that, following completion of antibody
coupling, the microprobes will lose approximately 25% of their
binding affinity for the relevant peptide every 7 days. Microprobes
were, therefore, used within 24 hours of their preparation.
There are three stages in the coupling of antibodies to the
siloxane coated microprobes, each stage being designed to maximise
both the specificity and affinity of the finished microprobes for the
peptide of interest.
1.Glutaraldehyde
Aldehyde groups are utilised for the subsequent immobilisation
of proteins to the siloxane polymer. Siloxane coated probes were
selected (and their coatings given a final check under the
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microscope) in the desired numbers for the proposed experiments.
Microprobes were placed in groups of 20 in the handling buckets
previously mentioned and immersed in a 2.5% solution of
glutaraldehyde in distilled water for 30 minutes. The buckets of
probes were then washed for 3 x 10 minute washes in distilled water
before proceeding immediately to stage 2.
2.Glutaraldehyde/Protein A coupling.
Protein A is derived from culture of Staphylococcus aureus and
has a high selectivity for binding immunoglobulins of the IgG class.
Protein A (Sigma) was diluted in PBS containing 0.1% sodium azide, to
a final concentration of 0. lmg ml--'-. 5p.l glass microcapillaries were
filled with the protein A solution. Under a dissecting microscope,
the tip of each glutaraldehyde treated microprobe was then placed
into one of the protein A filled capillaries. In any case where the
sealed tip of an antibody microprobe was broken at this stage, that
microprobe was discarded. Each microprobe with its tip inside a
capillary was then placed horizontally on a perspex rack. The rack
was placed in a covered plastic tray containing, in its base, tissue
paper soaked in PBS/azide. This fluid was to prevent loss of the
protein A solution from the capillaries by evaporation during the
subsequent incubation. The covered racks were then placed in a cold
room at 4°C for 24 hours.
3.Protein A/Antibody coupling.
Following incubation in protein A, microprobes were removed from
their capillaries and placed in petri dishes containing sodium
borohydride 2.5% w/v in borate buffer. The ensuing reaction, which
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produces free hydrogen, reduces the Schiff bases which may form by
aldehyde coupling of amino groups on the protein A. The microprobes
were then replaced in the handling buckets and given 3 x 10 minute
washes in PBS/azide solution. Commercially obtained polyclonally
derived antisera to either SP or NKA (Peninsula Laboratories) was
diluted to twice the manufacturers recommended dilution for
radioimmunoassay. (Ideally antibody would have been used in an even
more concentrated form. Commercially prepared antisera such as these
are supplied, however, as a lyophylate which already contains
buffering salts and antibacterial agents making its reconstitution in
more concentrated form impossible.) 5jj.1 glass capillaries were filled
with the required antibody solution and the tip of each microprobe
was inserted into a capillary as previously described. The
microprobes were again placed on perspex racks in covered boxes and
incubated at 4°C for 24-48 hours.
A few hours before their use in vivo, the capillaries were
removed from the antibody coated microprobes which were then placed
in glass handling buckets, and stored ready for use immersed in
PBS/azide solution.
2.4 IN VITRO TESTING OF ANTIBODY MICROPROBES.
Before use in vivo, antibody microprobes were subjected to
numerous in vitro tests of their selectivity and affinity for the
ligand being studied. This in vitro testing was carried out in two
stages 1)extensive in vitro checking of antibody microprobes prepared
with a newly purchased batch of antibody, prior to planning any in
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vivo work with that antibody and 2) a more intensive check of
microprobe function concurrent with each in vivo experiment.
When purchasing a new antibody attention was paid to the
manufacturers claims regarding the cross-reactivity of the antibody
with other peptides. Thus, for the C-terminally directed antibody to
SP used in two of these studies, Peninsula Laboratories stated that
the antibody cross-reacted with fragments of SP containing at least
the last 5 amino acid residues, but showed negligible cross
reactivity with NKA and NKB. The C-terminally directed NKA antibody,
again from Peninsula Laboratories, was stated as having 100% cross-
reactivity for NPK (the N-terminal extended form of NKA.) , 70-80%
cross reactivity with NKB and negligible cross reactivity with SP.
This was the most selective NKA antibody commercially available at
that time. Given that SP and NKA are released in the same area of the
spinal cord and in response to the same forms of peripheral stimuli,
it was important to verify the manufacturers claims for antisera
specificity prior to commencing in vivo work.
1)Newly purchased antibody.
A number of antibody coated microprobes were prepared as
previously described. These were divided into groups of approximately
six and marked with indelible marker pen to allow their subsequent
identification. These microprobes were then inserted into 5(j.l
capillaries filled with various peptide solutions, and incubated for
30 minutes at 37°C in a humidified box (to prevent evaporation of the
peptide solutions from the capillaries). Taking microprobes coated
with antibody to SP as an example, the solutions used might optimally
be as follows;
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Group 1 no incubation n=6
Group 2 10-6m SP n=6
Group 3 io-7m SP n=6
Group 4 io-8m SP n=6
Group 5 io-7m NKA n=6
Group 6 io-7m Dynorphin (1-8) n=6
Following their incubation in peptide the microprobes were
mounted in a holder and lowered into a chilled solution of PBS
containing 0.1% Tween, stirred magnetically. The tips of the
microprobes were left in this solution for 15 minutes to remove any
unbound peptide from their surfaces. After washing, the tips of the
microprobes were place in 5^.1 capillaries filled with a solution of
Bolton-Hunter labelled l^I-SP, diluted in PBS/azide containing 0.5%
BSA to give 2000 counts minute--'- p.l--'-. BSA was added at this stage to
block non-specific tracer binding to the microprobe surface. The
microprobes were then incubated in the capillaries filled with tracer
solution for 24 hours at 4°C.
Following incubation in the radiolabelled tracer solution the
microprobes were removed from the capillaries and each microprobe had
both sealed ends removed; the thick end with a glass saw and the tip
with watchmakers forceps under a dissecting microscope. As short a
length of the tip as possible was removed in this way. The probes
were again washed for 15 minutes in chilled PBS/Tween. This time,
however, the thick ends of the microprobes were mounted in a sealed
perspex block which was in turn connected to a vacuum pump. Probes
were washed under suction at this stage to suck the washing solution
through the inside of the microprobes, thus removing any
90
radiolabelled peptide which might have been drawn in during the
preceding incubation.
The tips of the microprobes were then broken off, between a
thumb and forefinger, to a uniform length of approximately 1.5 cm.
The tips were then fixed to narrow strips of cardboard with a small
amount of liquid paper (Tipex) applied to the thick end. The strips
of card were numbered to allow subsequent identification of the
individual microprobe tips. These strips of card were then placed in
Beckmann RIA gamma-counter tubes, and the amount of radioactivity, in
counts minute-^, was determined for each tube. (An example of typical
counts obtained in this way, but for a less extensive in vitro test,
is illustrated in table 4) . Lastly, the strips of card bearing the
microprobe tips were fixed to a sheet of cartridge paper with Tipex.
This sheet of paper was placed in a standard (non-screen) x-ray film
cassette with a sheet of monoemulsion x-ray film (Kodak NMB) and left
for several days to produce autoradiographic images of the
microprobes. The protocol for testing anti-NKA coated microprobes in
vitro is essentially the same, but obviously using radiolabelled NKA
and with the substitution of NKA solutions for SP solutions and vice
versa.
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TABLE 4. The results of a typical in vitro test of antibody
microprobe function. The table is, in fact, the printout from a
Beckmann RIA gamma counter, used to measure the ^^I-substance P
binding of antibody (substance P) microprobes after incubation in a
variety of solutions.
Tubes, 1,2,3, Saline (controls) No suppression of binding.
Tubes, 4,5,6, Substance P (10~®M) >75% suppression.
Tubes, 7,8,9,10,11 Galanin (10_®M) No statistically
significant suppression.
Tubes, 12,13,14,15,16,Substance P (10~^M) >50% suppression.
TABLE 4.
TYPICAL RESULT OF AN IN VITRO TEST OF ANTIBODY
MICROPROBE FUNCTION.
PARAMETERS 01
01 ID : 1-125 -»
02 TIME-S (SEC) 0060 -»
03 TIME-U (SEC) 0060 —»
04 IS (1-125) 01 ->
05 METHOD 06 —>
06 REPLICATES 01 ->
07 PRINTOUTS
08 FACTOR 1 +1 . 000E+02 ->
09 FACTOR 2 +6 . 000E+01 ->
10 FIRST PAT.NO 0000
11 FIRST PAT.NO 0001 —»
12 POS-CODE 0000- —>
PAT DET POS TIME COUNTS1 COR.CPM1 MEAN
0 1 1 60 1932 1899.4}
0 1 2 60 2097 2065.4} 2019.4
0 1 3 60 2125 2093.5}
0 1 4 60 437 396.2}
0 1 5 60 453 412 .3} 351. 6
0 2 6 60 272 246.2}
0 2 7 60 2703 2709.8}
0 2 8 60 1348 1336.6}
0 2 9 60 1725 1718.7} 1643.0
0 2 10 60 619 597.9}
0 3 11 60 1851 1852.4}
0 3 12 60 445 419.0}
0 3 13 60 717 696.3}
0 3 14 60 791 771.7} 687.2
0 3 15 60 1012 997.0}
0 3 16 60 627 552.0}
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Several conclusions can be drawn from the results of such an
assay, the different groups giving different information as follows.
Group 1: the amount of bound tracer on these microprobes gives
an indication of the affinity of the microprobe for the given ligand.
This may be influenced by the actual amount of antibody bound to the
probe surface or by the binding affinity of the particular antibody
used, and this may vary slightly from batch to batch. Anti-SP coated
microprobes generally gave unsupressed radioligand binding in the
range of 1500-2000 cpm, anti-NKA coated microprobes tended to show a
slightly lower level of radioligand binding, in the region of 1000
cpm.
Groups 2-4: these groups give an indication of the sensitivity
of the microprobe assay and its suitability for in vivo application.
Prior incubation in an unlabelled peptide, for which the antibody
shows affinity, reduces the number of antibody binding sites
available for subsequent radioligand binding. The total amount of
tracer binding is, therefore, suppressed. The exact relationship
between the in vitro sensitivity and in vivo sensitivity of a
microprobe cannot be determined, as the concentrations of peptide at
the sites of release in the spinal cord are not determinable. All
previous microprobe studies on tachykinin release in the dorsal horn
of the spinal cord have, however, shown that where radiolabelled
tracer binding is suppressed by 50% or more by prior incubation in a
_ n
10 'M solution of unlabelled ligand, microprobes will be effective in
detecting release in vivo. In all studies presented here, the
_ n
suppression of tracer binding by 10 'M ligand was in this range. In
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fact, in some tests, suppression by the 10 peptide solution was
greater than 50%.
Groups b and. 6: These groups give an indication of the
selectivity of the antibody microprobes for the selected peptide.
Prior incubation in a structurally related peptide (Group 5),
verifies the manufacturers claim that the SP antisera shows no cross-
reactivity for NKA and vice versa. If this is the case, then no
suppression of radiolabelling should occur, and indeed this was the
case with all antisera used in these studies. The inclusion of
microprobes pre-incubated in a completely non-related peptide (Group
6) strengthens the identification of the antisera as selective for
the peptide being studied. Such pre-incubation should not, and in no
case did, suppress subsequent radioligand binding.
Autoradiographs. The tips of the in vitro antibody microprobes
are evenly exposed to the radiolabelled peptide, so the
autoradiographs of the microprobe tips should show an even
distribution of tracer binding. Study of these autoradiographs allows
a very sensitive assessment of the evenness of the distribution of
antibody on the microprobe surface. The siloxane polymer can itself
be visualised under the microscope, but the examination of
autoradiographs is the only way to monitor the even application of
the organic layers to the antibody microprobes. On the rare occasions
where the autoradiographic images of in vitro probes had a lumpy or
uneven distribution of radiolabelling, a few antibody coated
microprobes were incubated in a l^I-labelled antibody raised against
the FAb region of the peptide antisera being used. In no instance
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were the autoradiographs of microprobes labelled in this way uneven.
Where in vitro microprobes produced poor quality images this was,
therefore, attributed to a degeneration of the radiolabelled peptide
solution which was replaced.
2) In vitro tests concurrent with in vivo experimentation.
During each in vivo experiment, a small number of the prepared
antibody microprobes were selected for use in a small in vitro test
of antibody microprobe quality. These were divided into two groups
and treated in the way described for groups 1 and 3 of the larger in
vitro study described earlier in this section, ie. no suppression of
tracer binding, and suppression with 10~^M unlabelled peptide. This
test was performed to confirm that the microprobe affinities and
sensitivities were still as expected from the earlier in vitro
investigations. An additional benefit was that the radioactivity
counts from the unsuppressed group of in vitro microprobes gave some
indication of how long the in vivo microprobes should be left on x-
ray film to produce usable autoradiographs.
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2.5 ANIMAL PREPARATION.
Barbiturate anaesthetised cats were used in all experiments.
Male and female cats in a weight range of 2.4 to 3.2kg, bred
specifically for research purposes, were purchased from authorised
suppliers (BS+S/Hillgrove). Animals were typically housed for at
»
least one week prior to their use in order to minimise any stress-
induced alterations in their physiology which might be brought about
by transportation and change of environment.
Induction of anaesthesia was by intraperitoneal injection of
sodium pentobarbitone (Nembutal, CEVA Ltd) , 35mg kg--*-, 35mg ml--'- in
physiological saline. Throughout surgery, anaesthesia was maintained
by bolus injection of the same drug at 10 mg ml-"- into one or other
cephalic vein. Following the completion of surgery a continuous
intravenous infusion of sodium pentobarbitone at 6mg ml-"- at a rate
sufficient to maintain clinical anaesthesia was administered via
cannulation of a cephalic vein for the duration of the experiment.
Following induction of anaesthesia cats were given a subcutaneous
injection of ampicillin (Norobrittin, Norbrook Laboratories Ltd) ,
25mg kg-"-, which was repeated 10 hours later. This injection of
antibiotic was to help maximise the sterility of the experimental
preparation, particularly with regard to the subsequent exposure of
the spinal cord. Throughout surgery and experimentation the cat was
placed on an electrically heated blanket to maintain body temperature
at 37.4°C. This was controlled via a rectal temperature probe
connected to the blanket control box.
Initial surgery involved the cannulation of 1) a cephalic vein
in the foreleg to allow subsequent anaesthetic/drug administration
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2) one carotid artery which was then used to continuously monitor
systemic blood pressure and 3) the trachea, allowing artificial
positive pressure ventilation where required and continuous
monitoring of end tidal CO2 levels (maintained at 4%).
The animal was then placed in ventral recumbency, laterally
supported with sandbags, and the skin over the dorsum was incised
rostrocaudally by electro-cautery. The connective tissue overlying
the muscles of the transversospinalis muscle group was then cut
longitudinally either side of the dorsal vertebral processes from the
sacro-iliac joint rostrally as far as the third lumbar vertebra.
Transversospinalis and longissimus muscles were then retracted
laterally from the dorsal surface of the vertebrae by blunt
dissection, and held clear by retractors. Any bleeding from muscle
capillaries at this stage was stopped by cauterisation.
The dorsal surface of the spinal cord was then removed with
rongeurs, from the sacroiliac joint to approximately 1cm rostral to
the lumbar enlargement of the spinal cord and the exposed spinal cord
temporarily covered with cotton-wool soaked in sterile Ringer's
solution. The transversalis muscles on either side of the laminectomy
were then removed. Lastly, a second, much smaller dorsal laminectomy
was made in the region of the thoraco-lumbar junction. The exposed
spinal cord at this site was injected with 0.1ml of a 2% solution of
lignocaine (Xylocaine, Astra) and after a few minutes cut with a pair
of fine pointed scissors. A small cotton-wool ball soaked in sterile
Ringer's solution was then placed over the site of cord transection.
The cat was then transferred to a stereotaxic frame. The
preparation was held in place by 1) ear bars, 2) 3 spinal swan-necked
clamps placed under the vertebral transverse processes on each side
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of the backbone in the area of the spinal lumbar enlargement, 3) a
clamp around the vertebral body immediately caudal to the site of
spinal cord transection, 4) a clamp placed over the dorsal processes
of the sacrum and 5) hip pins placed in the region of the iliac
crests. These clamps not only supported the animal in the frame, but
also provided excellent spinal cord stability. The cotton-wool
covering the exposed cord was removed and, under a dissecting
microscope, the edges of the laminectomy were packed with a sterile
haemostatic gauze (Sterispon) to prevent subsequent bleeding. The
dura mater was then cut with sterile iris scissors and retracted
laterally. The exposed cord was finally covered with a thin layer of
a sterile solution of agar in Ringer's solution.
At proposed sites of antibody microprobe insertion, a small area
of agar was removed with sterile watchmakers forceps to expose the
spinal cord. This pool was then continually irrigated with sterile
Ringer's solution at 37°C to prevent drying of the cord surface.
Watchmakers forceps were also used to remove very small areas of pia
arachnoid within the pool, such patches being necessary for
subsequent antibody microprobe insertion into the spinal cord.
In experiments in which peripheral nerve stimulation was used,
both hind legs were elevated and supported by clamps and the skin
overlying the gastrocnemius muscles was cut and stitched to a pool-
maker. The tibial nerves were exposed between the muscles of the calf
which were retracted laterally. The exposed nerves were mounted
(untransected) on platinum stimulating electrodes and the pools were
flooded with liquid paraffin. In experiments where electrical nerve
stimulation was used, or where artificial ventilation was necessary,
animals were given the neuromuscular blocker gallamine triethiodide
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(Flaxedil) 4mg kg--*- hr-l by injection into the cannulated cephalic
vein. Thresholds for nerve stimulation were determined before
neuromuscular blockade, and in all cases the effects of gallamine
were allowed to wear off periodically to allow verification that the
level of barbiturate anaesthesia was unaltered.
At the end of each experiment the animal, still anaesthetised,
was killed by means of intravenous injection of a concentrated
solution of sodium pentobarbitone (Euthesate, Willows Francis
Veterinary), which resulted in cardiac arrest within a few seconds.
2.6 IN VIVO USE OF ANTIBODY MICROPROBES.
Prior to the insertion of antibody microprobes into the spinal
cord, a NaCl filled extracellular recording electrode placed in the
superficial dorsal horn or a silver ball recording electrode placed
on the cord surface were used to record field potentials elicited by
innocuous cutaneous stimulation of the hind paws. These field
potentials were displayed on a cathode ray oscilloscope. Gentle
pressure applied to the toes or brushing of the skin of the foot were
commonly employed. This recording was made to ensure that the
proposed site of microprobe insertion did receive a substantial
primary afferent input from the ipsilateral hind paw.
Microprobes, prepared as described earlier, were removed from
the PBS/azide solution in which they were stored immediately prior to
use and both sealed ends were removed, the thick end with a glass saw
and the tip by gently bumping it against the surface of a metal coil
under a binocular microscope. The microprobes were examined under
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xl25 magnification to check the diameter of the broken tip (between 5
and 2 0|rm) , and the evenness of the siloxane coating. Microprobes were
numbered using a coded system of coloured rings, and filled with a
solution of 2% pontamine sky blue in sodium acetate. This filling of
the microprobes with dye was performed to facilitate microprobe
visualisation in subsequent procedures.
One microprobe was then placed in each of two stepping motor
micromanipulators, one orientated vertically and the other 10° from
vertical. The manipulators were then moved down by hand until they
were close to the spinal cord surface. Spinal cord irrigation was
temporarily stopped and excess Ringer on the surface of the cord
removed by suction. Under xl5 magnification, the tips of the two
microprobes were moved in the horizontal plane until both overlay the
patch which had earlier been made in the pia mater at the proposed
site of insertion. Paired microprobes were positioned as close
together as possible. The microprobes were then lowered with the
micromanipulators until the tips were just touching the surface of
the spinal cord. The micromanipulators were zeroed and then used to
insert the microprobes into the dorsal spinal cord to a depth of 3.0
or 4.0mm from cord surface (depending on the study) . In the case of
the micromanipulator angled at 10° from the vertical this meant
moving it down to a slightly greater reading eg. 4.25mm.
Once the microprobes were in situ the Ringer irrigation system
was turned on again. The length of time that individual microprobes
remained in situ, and the peripheral stimuli applied during that
time, varied according to the experimental protocol, and will be
outlined separately in the methods section for each study. Following
exposure to the spinal cord, microprobes were treated in the same as
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that earlier described for in vitro tests; washing in PBS/Tween, 24
hour incubation in radiolabelled tracer and a final wash in PBS/Tween
with suction. The tips of the in vivo microprobes were not mounted on
strips of card, but were stuck directly onto a sheet of cartridge
paper with Tipex before this was itself placed in a cassette with
monoemulsion x-ray film. The previously assigned microprobe number
corresponding to each tip was written on the paper just above it. The
exposure time necessary to produce autoradiographs of microprobes
suitable for analysis varied from 3 days to 4 weeks. The required
time for exposure was estimated by taking into account the amount of
unsuppressed radioligand binding on in vitro microprobes. Such in
vitro testing was performed concurrently, as previously described,
with each in vivo experiment.
At the end of each experiment a dye filled microprobe was used
to ionophoretically expel a small quantity of pontamine sky blue dye
at several sites. The spinal cord in this area was then removed,
fixed in formaldehyde and subsequently sectioned to provide
anatomical verification of microprobe placement. An example^ of one
such section is shown in figure 14.
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FIGURE 14. Histological section of cat spinal cord removed following
an in vivo antibody microprobe experiment. Pontamine sky blue was
injected in areas of preceding microprobe insertion at a depth of
1.1mm below cord surface (substantia gelatinosa). The location of dye
staining in the section has been shaded in the area indicated by the
arrow. In this experiment both the site of dye ejection in the
substantia gelatinosa and the tract of micropipette insertion have
been stained (the latter simply due to dye being forced back up the
outside of the micropipette by the pressure produced at the site of
ejection). This method was routinely used to verify the placement of
microprobes.
FIGURE 14.





The results presented in this thesis are all derived from
experiments in which electrical stimulation at C-fibre strength of a
peripheral nerve (the tibial nerve) was employed to elicit tachykinin
release in the spinal cord. There were several reasons for this
choice of stimulus.
Previous antibody microprobe studies have largely sought to
identify the release of particular peptides in the CNS in response to
defined, cutaneous stimuli; noxious mechanical, thermal and arthritic
challenges have all been employed. The use of a range of stimulus
types has two main benefits. Firstly, it increases the likelihood
that peptide release will be detected in instances where the exact
physiological role of that peptide has not been established.
Secondly, it allows some evaluation of what that physiological role
is by comparing the efficacy of the different stimulus types in
evoking peptide release. The aim of the present studies was different
in that we wished to investigate the pharmacological modulation of SP
and NKA release in the spinal cord. The stimuli required to evoke
release, and the patterns of that release, had already been
established for these tachykinins, as discussed in the previous
section.
In order to assess whether or not any change in peptide release
was truly a pharmacological event, as opposed to the result of
physiological variability, we needed a stimulus which would not only
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evoke release of tachykinin in the spinal cord, but additionally
would not vary with repeated application. Noxious cutaneous stimuli,
such as heat and pinch, tend to promote inflammation of the
surrounding tissues. This sensitises the peripheral endings of
nociceptors (as described in the subsection dealing with tachykinin
functions) to subsequent stimulation and thus the central release of
neurotransmitter from those nociceptive fibres may increase with
time. Nerve stimulation does not normally promote peripheral
inflammation and events at the central terminals of nociceptive
fibres stimulated electrically should remain constant with repeated
stimulation. Electrical stimulation must of course be intermittent to
prevent depletion of central release mechanisms.
Nerve stimulation has other advantages. It is much more easily
quantified than heat or pinch; the voltage applied to the nerve or
the current running through it can be measured very accurately, and
monitored throughout the course of the experiment. Electrical
stimulation may also evoke release of neuropeptides from 'silent
nociceptors ' which would not be seen with cutaneous stimuli in the
normal animal, and the release of tachykinins from this class of
nociceptor may be important in certain inflammatory states (Hope et
al, 1990b, Schaible et al, 1990) .
In the two studies on pharmacological manipulation of evoked SP
release presented here, nerve stimulation was the only stimulus type
used. It was chosen for the reasons detailed above. The third study,
the earliest work presented, measured the effects of morphine
application on the stimulus evoked release of NKA, and employed both
noxious mechanical stimulation of the hind paw and nerve stimulation.
Because of the persistence of NKA in the spinal cord seen following
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its release, it will be evident when comparing the studies that the
experimental protocol used was very different from that employed for
SP. Because of the nature of this protocol, the stimulus type in the
NKA study is of a lesser significance.
2) Protocol for nerve stimulation.
Electrical stimulation of the ipsilateral tibial nerve was
employed as a stimulus in all studies reported here. Prior to
administration of the neuromuscular blocker, gallamine, the threshold
for tibial nerve stimulation was measured. This was taken to be the
lowest applied voltage which caused visible twitching of the toe
muscles in the hind paw. Experimental stimulation was at 20V, which
in all cases exceeded the stimulation threshold by greater than 100
times. Stimuli were delivered as 0.3-0.5ms square wave pulses (singly
or in groups of three at 330Hz), at 10-30Hz. These ranges apply to
all experiments, but in each individual experiment stimulus
parameters were held constant. Stimulation of the tibial nerve at
this strength and frequency will activate both unmyelinated (C) and
myelinated (A-delta) fibres.
3)Protocol for noxious mechanical stimulation.
Noxious mechanical pinching of the ipsilateral hind paw was
employed as a stimulus only in the study on morphine and NKA release.
Five 'crocodile' clips were applied to the pads and interdigital skin
of the ipsilateral hind paw in a cycle of 3 minutes on, 2 minutes off
for the duration of the stimulus (30 minutes total). This pattern of
stimulation and the frequency with which it was employed resulted in
no visible inflammation of the hind paw.
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2.8 ANALYSIS OF ANTIBODY MICROPROBE AUTORADIOGRAPHS.
The techniques employed in the analysis of microprobe images
were based on those described by Hendry et al (1988). A satisfactory
x-ray film exposure was considered to be one with unblurred, dark
images for all microprobes. In some instances, following examination
of the initial x-ray film, it was necessary to expose a second film
to the microprobes for a different time from that used for the first
exposure. Occasionally, single antibody microprobe images would be
blurred due to poor apposition of the microprobe to the film and in
this case a minor repositioning of the affected microprobe was made
prior to repeated exposure. Examples of x-ray film images are
included in figure 15. The film selected for analysis was then
labelled with indelible marker pen, each image being identified by
the number assigned to that microprobe prior to its use in vivo. The
film was cut up into small sections, each section containing one or
two complete microprobe images. Surface dust and grease was removed
from each piece of x-ray film by wiping with lens tissue.
Microprobe images were analysed with a computerised image
analysis system utilising an Image Technology PC Vision frame grabber
board operating in a Data Control Systems 286e(AT) computer. Single
microprobe x-ray film images were placed on a standard microscope
stage in a light proof box, and illuminated from beneath through a
narrow slit only just larger than the microprobe image itself. The
film was scanned with a Panasonic charge coupled device camera,
producing a 512 x 512 pixel 'map' of the microprobe x-ray film image.
The amount of light reaching the camera was kept constant from one x-
ray film image to the next by means of varying the current passing to
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the light source. The magnification of the system used in these
studies was such that the scanned image corresponded to only the last
5mm of the microprobe tip. The system is illustrated in figure 15.
Following subtraction of background values, calculated by
scanning blank areas of the x-ray film, the scanned images were
individually integrated by the computer with respect to darkness for
each vertical column of pixels. This resulted in a plot of greyness
of the image vs distance along the length of the probe tip with a
resolution of 10pm between integrals. The principle was illustrated
in figure 6A. The integrals for each scanned microprobe image were
stored on hard disk together with 35 coded values representing
various details corresponding to the experimental parameters
pertaining to that image. These coded values are outlined in table 5.
Despite all the checks of microprobe quality performed in siloxane
polymer coating and antibody binding procedures, or during in vitro
studies, a small proportion of microprobe x-ray film images were
found to be unsuitable for further analysis and were discarded at
this stage. Such images most often showed focal intensities of
radioligand binding which could not be attributed to any
physiological event. Subsequently a data sorting program was used to
group together microprobe images fulfilling stated experimental
criteria. Mean image analyses were then produced for each group, (as
illustrated in figure 6B), representing mean grey scale value for the
group at each 10pm point along microprobe length.
For further mathematical analysis of microprobe images, the
integral mean grey scale values were pooled into groups of 3,
reducing the spatial resolution of the technique to 30pm. Thus
standard errors of means could be produced for each group of three
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points in the mean grey scale plots, and pairs of mean image
analyses, representing different experimental manipulations, could be
compared statistically.
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FIGURE 15. Microprobe image analysis system. (A) Individual x-ray
film images of the type shown are placed on a microscope stage, with
a sub-stage lighting source, placed in a blacked out cabinet, and
scanned by a Panasonic charge-coupled device camera. (B) A direct
image of the x-ray film (the last 5mm of the tip) is displayed on a
monitor to allow placement and film quality to be assessed. (C) The
512x512 pixel scan is relayed to an Image Technology PC Vision frame
grabber board and converted into a data file. (D) A Data Control
Systems 286e(AT) computer not only runs the image capture programme,
but also subtracts background (blank film) values from each image
data file and integrates columns of the 512x512 pixel image into a
plot of 1 greyness' at lOjim intervals along the length of the
autoradiograph. The computer stores these grey scale plots, and by
running other programmes can be used to search through files of
individual images and produce plots of mean grey scale values for
groups of microprobes meeting stated experimental criteria. (E) These
final images can then be printed out in a form similar to that









TABLE 5. Examples of coding values applied to individual antibody
microprobes. These values allow the subsequent sorting of microprobe
images into groups conforming to stated experimental criteria. Some
factors (code numbers 1-15) apply to all microprobes in each
experiment, whereas others (code numbers 16-35) vary for each
individual microprobe. The actual variables for each code are too
extensive to list here, but an example (Code 33, drug type and dose)
is illustrated.
TABLE 5.







4 X-ray film cassette type
5 X-ray film type
6 Hours exposure of film




11 +/- paralysed (gallamine)
12 Antibody used (type and
manufacturer)
13 Antibody dilution
14 Concentration of peptide for
in vitro test






18 Individual probe number (in
experiment)
19 Time in cord
20 Depth of insertion into cord
21 Estimated depth in cord
22 Estimated depth in
substantia gelatinosa
23 Estimated depth in lamina V
24 Tracer ligand
25 Type of wash after in vivo
use
26 Incubation time in
radiolabelled ligand
27 Film faults
28 Total prior noxious stimulus
for animal
29 Total prior noxious stimulus
for patch
30 Age of patch
31 Probe order in patch (1st,
2nd etc)
32 Antibody type on paired
probe
33 Drug type and dose
34 Time since first dose of
active drug
35 Extra comments (mark for
deletion etc.)
EXAMPLE VALUES
Code number 33, Drug type
and dose. From morphine
study (section 3)
Morphine 0-5mg/kg i.v. 10
Morphine 5.1-10 mg/kg i.v. 11
Morphine >10mg/kg i.v. 12
Naloxone (after morphine) 13
0-0.5mg/kg i.v. 14
Naloxone (after morphine) 15
0.51-lmg/kg i.v. 16
Nalox. only 0-0.5mg/kg i.v. 17
Nalox. only 0.51-lmg/kg i.v. 18
Nalox. only >1.0mg/kg i.v. 19
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SECTION 3.
THE EFFECTS OF MORPHINE
ON NEUROKININ A RELEASE.
The results presented in this section have previously been published
as :
"Analgesic doses of morphine do not reduce noxious stimulus-
evoked release of immunoreactive neurokinins in the dorsal horn of
the spinal cat." C.W.Lang, A.W.Duggan & P.J.Hope.
British Journal of Pharmacology (1991) volume 103, pp 1871-1876.
These experiments were the first series during the course of my
studies in which I was the principal investigator.
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3.1 INTRODUCTION.
Opiate drugs are used in both veterinary and, more widely, in
human medicine, where they are of particular use as analgesics, and
are notably effective when administered epidurally (see Benedetti et
al, 1990 for review of current therapeutic techniques). Despite this
clinically proven efficacy in alleviating the transmission and
perception of pain, the mechanisms by which opiate drugs bring about
such effects have not yet been fully established.
Substance P (SP) and neurokinin A (NKA), two members of the
tachykinin family of neuropeptides, extensively coexist in the small
diameter dorsal root ganglion cells of the rat (Dalsgaard et al,
1985, Dalsgaard, 1988). Both of these peptides have been proposed as
being important in the transmission of information from nociceptive
afferents to spinal or brainstem neurones (Otsuka and Yanagisawa,
1988, Fleetwood-Walker et al, 1990) . Studies of the release of these
compounds in the spinal cord of the cat with antibody microprobes
have shown that both SP and NKA are released in response to a similar
range of peripheral noxious stimuli (Duggan et al, 1988b,1990, Hope
et al, 1990b, Schaible et al, 1990), including noxious thermal and
mechanical challenge. The findings of these studies suggested that
higher grade noxious stimuli which produced actual tissue damage, as
opposed to non-damaging noxious stimuli, might be more effective in
releasing immunoreactive (ir) SP. irNKA detection on the other hand
was not increased by tissue damage. One important difference between
the release patterns of the two peptides was, however, in their
persistence in the spinal cord following noxious stimulus-evoked
release. Relative to SP, NKA spread widely in the spinal cord
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following its release, and could be detected for a considerable
period of time (up to one hour) in the absence of continued
stimulation. This led to the hypothesis that NKA may not function as
a classical neurotransmitter, but might instead have a long term
modulatory role on spinal cord systems.
Opioid binding sites (unclassified: Atweh and Kuhar, 1977, rat,
Pert et al, 1975, rat, Lamotte et al, 1976, primate, mu: Morris and
Herz, 1987, rat, Gouarderes et al, 1985, rat and guinea-pig, delta:
Dashwood et al, 1986, rat, Traynor et al, 1990, rat, mouse, hamster,
mouse, kappa: Allerton et al, 1989, rat, Hunter et al, 1989, dog) and
endogenous opioid peptides such as dynorphin and enkephalins
(Botticelli et al, 1981, rat and rabbit, Lamotte et al, 1991,
primate, Senba et al, 1989, rat) have been demonstrated in the spinal
cord, and are largely associated with the superficial laminae of the
dorsal horn. Systemic morphine administration in spinal cats
(Einsphar and Piercey, 1980, Le Bars et al, 1976a,b) spinal rats
(Jurna and Heinz, 1979) and paraplegic man (Wilier and Bussel, 1979)
reduces the responses of neurones in the superficial and deep laminae
of the dorsal horn to noxious thermal, noxious mechanical and C/A
delta fibre stimulation. The effects of electrical stimulation of
larger diameter nerve fibres was unaffected as were spinal neurones
identified as having a purely non-noxious input, suggesting that the
inhibitory effects of morphine might be specific to nociceptive
afferent pathways. Ionophoretic application of morphine (Duggan et
al, 1977) and the |r opioid agonist [D-Ala^ Me-Phe4,Gly-ol^]
enkephalin (DAMGO) (Fleetwood-Walker et al, 1988) in the region of
the substantia gelatinosa (SG) of the cat selectively suppressed the
transmission of impulses from nociceptive afferents to deeper
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neurones of the dorsal horn. The SG is the major site of termination
of unmyelinated cutaneous afferent fibres (Light and Perl, 1977).
Since administration of naloxone into the SG completely blocked the
effects of analgesic doses of systemically administered morphine on
deep neurones of the dorsal horn of the cat (Johnson and Duggan,
1981), it is likely that opiate receptors in the SG are the major
ones mediating the analgesic actions of morphine at the spinal level,
whether administered systemically or intrathecally.
A variety of mu and delta opiate receptor agonists, when applied
topically, produce inhibition of spinal cord responses to
electrically-evoked C-fibre input (Dickenson et al, 1986,1987,1988,
Sullivan et al, 1989). Results of such studies are valuable in
confirming the importance of these receptor subtypes in spinal
processing of nociceptive input, but cannot identify which sites
within the dorsal horn are involved.
Met^-enkephalin (a delta agonist), morphine and metorphamide (a
mu and partial kappa agonist) microinjected into the SG all depressed
the responses of neurones in laminae IV and V to peripheral noxious
thermal and C/A-fibre stimulation, but only met^-enkephalin showed
this effect when microinjected directly into laminae IV/V (Duggan et
al, 1981, Morton et al, 1987, Zhao et al, 1986) . These results
suggest that both mu and delta opioid receptor-mediated inhibitory
mechanisms may exist in the substantia gelatinosa and that,
additionally, delta opioid inhibitory mechanisms exist in direct
association with neuronal structures in the deeper laminae of the
spinal dorsal horn. The effects of [D-Ala^,D-Leu^]-enkephalin (DADL),
a highly selective delta opioid agonist, also support the existence
of a delta opioid system mediating the inhibition of spinal
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nociceptive afferent transmission (Onofrio and Yaksh, 1983, Tung and
Yaksh, 1982, Yaksh, 1983). Kappa opioid agonists such as
ethylketocyclazocine, bremazocine and U-50,48811 (a benzeneacetamide
derivative), when administered intrathecally in the rat were shown to
inhibit behavioural responses to noxious visceral chemical stimuli
but not to noxious cutaneous thermal stimuli (Schmauss and Yaksh,
1984) . Intrathecal administration of mu agonists in the rat also
inhibit the typical grooming/scratching response to intrathecal
neurokinin administration (Wilcox, 1988). One recent study has
suggested that kappa opioid receptors exert their antinociceptive
effects predominantly in the deeper laminae of the dorsal horn
(Fleetwood-Walker et al, 1988). The same study failed to detect any
antinociceptive effect, in either the SG or in the deeper laminae of
the dorsal horn, of delta opioid agonists against noxious cutaneous
thermal or mechanical stimulation. This same research group also
reported antinociceptive effects of delta ligands and, to a lesser
extent of mu ligands, in lamina I of the rat dorsal horn (Fleetwood-
Walker et al, 1988, Hope et al, 1990a).
The functional distribution of opioid receptor types in the
spinal dorsal horn is clearly complex and is not yet fully resolved.
It seems likely however that with respect to the processing of
nociceptive inputs in the rat, delta, mu and kappa receptors are of
primary importance in laminae I-II, II-III (the SG) and laminae III-V
respectively (Duggan and Fleetwood-Walker, 1993). The relative
contributions of each receptor type may, however, change with
different pain states. For example, Stanfa et al (1992) reported that
during carrageenan-induced peripheral inflammation in the rat the
potencies of intrathecally applied mu, delta and kappa opioid
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receptor agonists for the depression of spinal cord neuronal activity
were all increased. The potency of the mu agonist, morphine, was
enhanced to a far greater extent (30 times normal) than the other
agonists, suggesting that mu opioid receptor mediated inhibition may
be predominantly important in the processing of nociceptive input
from inflamed tissues. The role of opioid peptides and related drugs
in spinal sensory processing has recently been reviewed (Duggan and
Fleetwood-Walker, 1993).
One mechanism by which morphine could produce analgesia is by a
presynaptic inhibition of neurotransmitter release from nociceptive
primary afferent terminals. An early observation in support of this
hypothesis was that the endogenous opioid peptide, enkephalin,
inhibited the release of SP from cultured sensory neurones (Mudge et
al, 1979). Morphine, in high concentrations, when added to the
superfusate of either a slice of upper spinal dorsal horn (Mauborgne
et al, 1987b, Pang and Vasko, 1986) , or of the spinal cord in vivo
(Go and Yaksh, 1987, Hirota et al, 1985, Yaksh et al, 1980) has been
shown to reduce stimulus evoked release of irSP. However,
systemically administered morphine at analgesic doses has failed to
reduce release of irSP evoked by noxious stimulation (Kuraishi et al,
1983, Morton et al, 1990) .
With the recognition that a peripheral noxious stimulus results
in the central release of a number of neuroactive compounds including
amino acids (Kangrga and Randic, 1990) and peptides (Duggan et al,
1988b,1990), a complete study of opiates and release from primary
afferents is clearly a complex task. There is evidence that the
arrival of impulses in nociceptive afferents produces not only fast
transmission to fibres ascending to the brain, but also long lasting
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events such as prolonged facilitation of flexor reflexes (Cervero et
al, Cook et al, 1987, Hoheisel and Mense, 1989, Hylden et al, 1989
1988, Neugebauer and Schaible, 1988, Woolf, 1983, Woolf and Wall,
1986a) . It has been proposed that NKA (rather than SP) is more
important in these prolonged spinal events as, following release of
irNKA, this peptide (or an extended form such as neuropeptide K
(NPK)) diffuses widely away from the initial sites of release and
also persists in the spinal cord (Hope et al, 1990b, c) . Of note is
the finding that, in the rat, low doses of morphine suppressed the
prolonged facilitation of spinal reflexes produced by nociceptive
input, whereas higher doses were required to suppress fast
transmission as measured by an unfacilitated nociceptive reflex
(Woolf and Wall, 1986b). Such considerations indicate the need for a
study of opiates and the central release of NKA. In the present study
therefore, the effects of analgesic doses of systemically
administered morphine on the noxious stimulus-evoked release of NKA
were examined in the spinal cords of barbiturate anaesthetised,
spinalised cats.
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3.2 ANTIBODY MICROPROBE PREPARATION.
Antibody microprobes were prepared as previously described. A
polyclonal antiserum, raised against the carboxyl terminus of NKA was
used (Peninsula). Information supplied by the manufacturer indicated
that this antiserum showed 100% cross-reactivity for the N-terminal
extended form of NKA, NPK, and 70-80% cross-reactivity with
neurokinin B (NKB), but negligible cross reactivity with SP. This was
verified by in vitro tests as described earlier.
3.3 ANIMAL PREPARATION/MICROPROBE ANALYSIS.
Experiments were performed on 8 cats, anaesthetised and subsequently
prepared as described under the section on general methodology. All
microprobes were inserted 3mm into the dorsal spinal cord, which in
this species places their tips in the upper ventral horn. All
microprobes remained in the spinal cord for 30 minutes. The analysis
of antibody microprobes subsequent to their use in vivo and in vitro
also followed the methods outlined earlier.
3.4 STIMULUS PARAMETERS.
Peripheral noxious stimulation throughout a 30 minute period of
antibody microprobe insertion was provided either l)by applying
'crocodile' clips to the pads and interdigital skin of the
ipsilateral hind paw in a cycle of 3 minutes on, 2 minutes off or
2)by electrical stimulation of the ipsilateral tibial nerve (groups
of three 0.5ms pulses at 330Hz, repeated at 10Hz, amplitude 20V).
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3.5 DRUG ADMINISTRATION AND EXPERIMENTAL REGIMES.
The drugs used were administered via an intravenous catheter
placed in the right cephalic vein. Morphine was administered as a
lOmg ml--'- solution in physiological saline, naloxone as lmg ml-"- in
physiological saline.
As previously demonstrated (Duggan et al, 1990, Hope et al,
1990c), the elevation of irNKA levels in the dorsal spinal cord
following a limited peripheral noxious stimulus, persists for up to 1
hour. Such persistence creates difficulties when testing a compound
which may block release, as a series of pre-drug measurements of
stimulus-evoked release may result in a build up of irNKA in the
dorsal horn. In this situation any subsequent reduction in neurokinin
release brought about by drug administration may not be detectable.
For this reason, these experiments examined the basal levels of irNKA
present in the dorsal horn in the absence of any prior noxious
stimulation and then administered morphine before measuring the
stimulus evoked release of these compounds. Several groups have
shown that, in the spinal cat, doses of morphine ranging from 0.3 to
4. Omg kg-"- iv. reduced the synaptic activation of dorsal horn
neurones by peripheral noxious stimuli (Duggan et al, 1980, Johnson
and Duggan, 1981, Le Bars et al, 1976a,b). The present experiments
used morphine at doses just above the upper limit of this range
(5.Omg kg-1iv.) as, with the protocol used, a complete inhibition of
noxious stimulus-evoked irNKA release would be much more readily
detected than a partial reduction. A more significant test of the
effect of morphine on irNKA release came from the effects of
subsequent naloxone administration. If stimulus-evoked release of
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irNKA was increased when naloxone is administered after morphine,
this would indicate that morphine had reduced, even if only
partially, the release of these compounds.
The above protocol is not optimal if morphine increases the
release of irNKA. A series of experiments were therefore included in
which the effects of both morphine and/or naloxone on basal levels of
irNKA were evaluated and comparisons were also made with earlier
studies (Hope et al, 1990b,c) on the patterns of stimulus-evoked
irNKA release in the absence of pharmacological manipulation.
3.6 RESULTS.
A total of 97 microprobes coated with antibodies to NKA were
inserted into the dorsal spinal cord. Additionally, 64 microprobes
were used for concurrent in vitro tests performed as previously
described. These in vitro tests consistently demonstrated suppression
of the binding of 125j_nka by greater than 50% following prior
incubation in a solution of lO-"^ mol 1~^ unlabelled NKA.
35 antibody microprobes were inserted 3mm into the spinal cord
and left in situ for 30 minutes without stimulation of either hind
paw or the concurrent administration of any drug. These 'control'
microprobes formed the basis for assessing possible effects of
morphine or naloxone on the basal levels of irNKA. The remaining 62
probes were inserted into the spinal cord in the presence of
peripheral stimuli and/or drug administration as detailed in the
following pages.
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3.6.1 EFFECTS OF MORPHINE AND NALOXONE
ON BASAL LEVELS OF IMMUNOREACTIVE NEUROKININS.
In 4 experiments morphine was the first drug administered, and
in the remaining experiments naloxone was administered first.
7 probes were inserted into the spinal cord in the absence of
prior or concurrent noxious stimulation, and within 1 minute of
morphine administration (5mg kg--*- iv. ) . In the case of these
microprobes, this dose of morphine represented the first drug
administration. The mean image analysis of these microprobes is
illustrated in the upper trace ('morphine') of figure 16. When this
group is compared with the mean image analysis of microprobes
inserted into the spinal cord in the absence of any prior stimulation
or drug application and in the same experiments (lower trace figure
16, 'controls', n=ll), no significant differences are present, as
illustrated in figure 16 in the plot of the t-statistics derived from
the differences between these two mean image analyses.
13 microprobes were inserted into the dorsal spinal cord in the
absence of prior or concurrent noxious stimulation and within 1
minute of naloxone administration (0. 5mg kg~l iv. ) . In the case of
these microprobes, there had been no prior morphine administration.
The mean image analyses of this group of microprobes ('naloxone') and
of their corresponding control group ('controls', n=23) are
illustrated in figure 17 together with a plot of the t-statistics
derived from their differences. This plot of t-values shows that no
significant differences exist between the two groups.
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An additional 10 microprobes were inserted into the spinal cord
in the absence of any prior or concurrent noxious stimulation and
within 1 minute of morphine application (5mg kg--*- iv. ), but in this
case morphine administration immediately followed the application of
naloxone (0. 5mg kg--'- iv. ) . Again, when compared with the relevant
control group, no statistically significant differences were found
(figure 18).
Summary. Neither morphine (5mg kg~^ iv. ) nor naloxone (0. 5mg kg--*-
iv.), administered in the absence of peripheral noxious stimulation,
produced significant changes in the detectable basal levels of irNKA
in the dorsal spinal cord. A combination of the two drugs at the same
dosages also failed to significantly alter basal levels of irNKA in
the dorsal horn.
3.6.2 EFFECT OF MORPHINE ON STIMULUS-EVOKED
IMMUNOREACTIVE NEUROKININ RELEASE.
17 microprobes were inserted into the dorsal spinal cord within
90 minutes of morphine administration (5mg kg--1- iv. ) and with
concurrent noxious stimulation of the ipsilateral hind paw or tibial
nerve. Noxious pinch and electrical stimulation of unmyelinated
primary afferent fibres have previously been shown to be adequate
stimuli for releasing irNKA in the dorsal spinal cord (Duggan et al,
1990, Hope et al, 1990c) . In the series of experiments illustrated
here, following morphine administration, noxious stimulus-evoked
irNKA release was observed in a zone extending from the spinal cord
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surface to approximately 1.3mm into the dorsal grey matter. This is
illustrated in figure 19. Although these increases in the levels of
irNKA in the dorsal horn produced by peripheral noxious stimulation
appear similar to those produced by comparable stimuli in other
studies in which drugs were not administered (Duggan et al, 1990,
Hope et al, 1990b,c) a small inhibition of release by morphine could
only be assessed by the subsequent administration of naloxone.
11 microprobes were inserted into the dorsal spinal cord within
1 minute of naloxone administration (0.5mg kg--'- iv. ) given after
morphine application and with concurrent peripheral noxious
stimulation. These microprobes were inserted immediately following
those illustrated in figure 19, immediately after the period of
peripheral stimulation following morphine administration. Figure 20
compares the mean image analyses of the two groups and shows that
naloxone administration had no significant effect on the levels of
noxious stimulus-evoked irNKA detection in the spinal dorsal horn
seen in the presence of systemic morphine. This lack of change
following naloxone administration suggests that prior morphine
application had in no way altered noxious stimulus-evoked irNKA
release.
Summary. Morphine application (5mg kg-"- iv. ) did not result in a
complete inhibition of noxious stimulus-evoked irNKA release.
Furthermore, the pattern of irNKA detection seen following subsequent
naloxone administration (0. 5mg kg-"- iv. ) suggests that morphine had
not produced a partial reduction in stimulus-evoked irNKA release.
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FIGURE 16. The effects of systemic morphine administration on resting
levels of immunoreactive neurokinin A in the dorsal horn. 'Controls',
the mean image analysis of microprobes (n=ll) inserted into the
dorsal spinal cord with no prior or concurrent drug administration
and no prior or concurrent peripheral stimulation. 'Morphine', the
mean image analysis of microprobes (n=7) inserted into the dorsal
spinal cord immediately following morphine (5mg kg~l,i.v.)
administration and in the absence of prior or concurrent peripheral
stimulation. The analysis was performed with a resolution of lOjim and
with each group the continuous line has joined these points. The +
standard error of the mean (SEM) at each point is plotted for the
'morphine' group and the -SEM at each point is plotted for the
'control' group. The t-values (2t = PC0.05) derived from the



















FIGURE 17. The effects of systemic naloxone administration on resting
levels of immunoreactive neurokinin A in the dorsal horn. 'Controls',
the mean image analysis of microprobes (n=23) inserted into the
dorsal spinal cord with no prior or concurrent drug administration
and no prior or concurrent peripheral stimulation. 'Naloxone', the
mean image analysis of microprobes (n=13) inserted into the dorsal
spinal cord immediately following naloxone (0.5mg kg-^,i.v.)
administration and in the absence of prior or concurrent peripheral
stimulation. Standard errors of means for the two groups and t values



























































FIGURE 18. The effect of systemic morphine following systemic
naloxone on resting levels of immunoreactive neurokinin A in the
dorsal horn. 'Controls', the mean image analysis of microprobes
(n=ll) inserted into the dorsal spinal cord with no prior or
concurrent drug administration and no prior or concurrent peripheral
stimulation. 'Morphine following naloxone', the mean image analysis
of microprobes (n=10) inserted into the dorsal spinal cord following
morphine (5mg kg-l,i.v.) which immediately followed naloxone (0.5mg
kg-l,i.v.) administration and in the absence of prior or concurrent
peripheral stimulation. Standard errors of means for the two groups
and t values (2t=P<0.05) derived from the differences of the means

















































FIGURE 19. The effects of noxious stimulation of the ipsilateral hind
paw, following systemic morphine administration on immunoreactive
neurokinin A levels in the dorsal horn. 'Controls', the mean image
analysis of microprobes (n=ll) inserted into the dorsal spinal cord
with no prior or concurrent peripheral stimulation. 'Morphine
(stim.)', the mean image analysis of microprobes (n=17) inserted into
the dorsal spinal cord following morphine (5mg kg_^,i.v.)
administration and during noxious stimulation of the ipsilateral hind
paw. Standard errors of means for the two groups and t values



















































FIGURE 20. Effect of naloxone following morphine on noxious stimulus-
evoked immunoreactive neurokinin A release. 'Morphine (stim.)the
mean image analysis of microprobes (n=17) as described in figure 19.
'Naloxone following morphine (stim.)', the image analysis of
microprobes (n=10) inserted into the dorsal spinal cord immediately
following those illustrated in the 'Morphine (stim.)' group, and
after naloxone (0. 5mg kg~l,i.v.) administration during noxious
stimulation of the ipsilateral hind paw. Standard errors of means for
the two groups and t values (2t=P<0.05) derived from the differences












































































When the results of the present experiments are considered with
those of Kuraishi et al (1983) and Morton et al (1990), there is
little evidence that analgesic doses of opiates administered
systemically reduce tachykinin release (either SP or NKA) from the
central terminals of nociceptors. These results are, however, at
variance with those of studies examining the effects of topically
applied opiates on SP release, and these differences merit further
discussion.
Other studies on morphine and SP release.
Inhibition of SP release by opiates was first shown by Jessell
and Iversen (1977) in a slice preparation of rat trigeminal nucleus.
The stimulus used in this study was, however, 47mM K+ in the
perfusate. A similar effect on high K+ induced SP release has been
demonstrated with slices of rat spinal cord in vitro (Lembeck and
Donnerer, 1985, Mauborgne et al, 1987b, Pang and Vasko, 1986) . The
main problem with such studies is in the stimulus employed. Elevation
of K+ levels in the slice perfusate will depolarise virtually all
neuronal structures. SP is closely associated with primary afferent
terminals of nociceptive origin in the superficial laminae of the
dorsal horn, but as has previously been discussed a significant
proportion of neuronal elements in the spinal cord showing
immunoreactivity for SP represent the terminals of either descending
fibres of supraspinal origin or of intrinsic spinal neurones. Hence
the source of SP in the above studies is uncertain. Furthermore, the
concentration of morphine employed was high, 10_^-10~^M.
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Using the push-pull cannula technique on rabbit spinal cord in
vivo, Hirota et al (1985) demonstrated a reduction in the release of
SP following noxious cutaneous stimulation with 10~^M morphine in the
perfusate. Further support for the proposal that opiates impair SP
release from the central terminals of nociceptors came from the
experiments of Go and Yaksh (1987) and Yaksh et al (1980) in which
10~^M morphine added to a superfusate of cat spinal cord in vivo
reduced the release of SP into the perfusate following electrical
stimulation of unmyelinated primary afferent fibres.
The roles of mu, delta and kappa receptors in opiate spinal
analgesia.
The contributions of the different opiate receptor types to
inhibition of stimulus-evoked SP release have also been studied. The
group of Mauborgne et al (1987b) found that while the mu receptor
agonist [D-Ala^ , N-Me-Phe^,-Gly-ol]-enkephalin (DAMGO) (10~^M)
increased both high K+ and capsaicin induced release of SP from rat
dorsal horn slices, the delta-receptor agonist [D-Thr^]-Leu-
enkephalin-Thr (DTLET) (3.10~®M) reduced SP release in the same
preparation. Aimone and Yaksh (1989) found that both mu (morphine)
and delta (DAGO, or (D-Pen^,-Pen^]-enkephalin (DPLPE)) opioid
receptor agonists, all at 10~®-10-^M, were effective in inhibiting
capsaicin-evoked SP release from rat spinal cord in vivo. DTLET and
dermenkephalin, another delta agonist, have also been shown to
inhibit the basal release of SP into an intrathecal perfusate of rat
spinal cord in vivo (Collin et al, 1991). The same group demonstrated
an enhancing effect of the delta antagonist naltrindole on these
basal SP levels, suggesting the existence of a tonic delta opioid
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receptor mediated inhibition. A role for delta receptors in mediating
the inhibitory effects of opiates on neuronal activity in the spinal
cord has clearly been identified in many studies (Dickenson et al,
1986,1987,1988, Onofrio and Yaksh, 1983, Sullivan et al, 1989, Tung
and Yaksh, 1982, Yaksh, 1983). Kappa receptor agonists such as U-
50,488H (0.5 - 50.10-®M) have been shown to be without effect on the
release of SP from the spinal cord in a variety of in vitro and in
vivo preparations (Aimone and Yaksh, 1989, Hamon et al, 1988, Pohl et
al, 1989).
The effects of drug dose.
It might be noted that the concentrations of drugs used in all
of the above studies were high and that no group has found that
systemic analgesic doses of morphine reduce SP release in the spinal
cords of spinalised animals. Thus, Kuraishi et al (1983) using push-
pull cannulae in the dorsal horn of the spinal rabbit observed that
although systemic morphine at lOmg kg--*- iv reduced irSP release in
response to peripheral noxious mechanical stimulation, a lower dose
of lmg kg--'- iv was ineffective in producing such a change . Morton et
al (1990), using antibody microprobes, failed to observe any effect
of morphine in two dose ranges (l-6mg kg-"- and 10-20mg kg-"- iv. ) on
irSP release in the dorsal horn of the spinal cat following noxious
mechanical or thermal cutaneous stimulation.
Since studies which have observed effects on tachykinin release
have used relatively high concentrations of opiates, is the same true
of experiments which have administered opiates microionophoretically
in the substantia gelatinosa (SG) and hence may have over-emphasised
the importance of events near the first central synapse of
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nociceptors? Although tissue concentrations in microionophoretic
experiments are unknown, the finding that naloxone administered in
the SG decreased the effects of systemic morphine (4mg kg~"M on
deeper neurones of the spinal cord (Johnson and Duggan, 1981) does
support the importance of opiate receptors in the SG in mediating the
action of systemic morphine on spinal neurones. This still does not
identify a direct or indirect presynaptic action of opiates on the
central terminals of nociceptive afferent fibres, and the conflicting
evidence for and against such an effect comes principally from, in
some cases, more refined electrophysiological studies.
Cellular mechanisms for morphine analgesia, the evidence for pre- and
postsynaptic effects.
Support for a postsynaptic effect of opioids on intrinsic
neurones of the SG came from Yoshimura and North (1983) who observed
a hyperpolarisation (possibly mediated by an increased K
conductance) of such cells in a slice preparation, and Sastry and Goh
(1983) who found many to be excited in vivo by ionophoretically
administered morphine. These inconsistencies have not, however, been
explained.
Morphine has been shown to have a stimulatory effect on Na+/K+-
ATPase activity in homogenates of rat cerebral cortical synaptic
membrane or synaptosomal membrane (Nishikawa et al, 1990, Nishikawa
and Shimuzu, 1990) . This effect would support both presynaptic and
postsynaptic inhibitory mechanisms, but would be totally nonselective
within the neuronal population of the dorsal horn. Other studies have
associated the action of morphine with a specific receptor-linked G
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protein mediating K+ membrane conductance (Shen and Crain, 1990),
allowing—£xax—a tissiaa colootivo pootoynaptio offoot.
When gamma-aminobutyric acid (GABA) acts presynaptically on the
central terminals of large diameter muscle afferents, the resulting
depolarisation is associated with reduced transmitter release and an
increased excitability when tested with an adjacent stimulating
microelectrode (Curtis et al, 1980). Administering opioid peptides
near the central terminals of nociceptors in the SG has, however,
been shown to result in decreased electrical excitability (Carstens
et al, 1987, Sastry, 1980), a result not consistent with the well
established mechanism of GABA mediated presynaptic inhibition. A
different mechanism of reducing transmitter release from central
terminals might be if calcium entry with each invading impulse were
to be reduced through a shortening of action potential duration. Such
a shortening has been observed with micromolar concentrations of
opioids acting on cultured dorsal root ganglion neurones (Shen and
Crain, 1989, Werz and MacDonald, 1982), but lower, nanomolar,
concentrations had the opposite effect (Shen and Crain, 1989) .
Lombard and Besson (1989) tried to assess the relative
importance of pre- and postsynaptic actions of morphine by recording
the firing of dorsal horn neurones in decerebrate spinal rats with
intact dorsal roots (and an induced peripheral arthritis) and
comparable cells in non-arthritic animals with sectioned dorsal
roots. Morphine (2mg kg--'- iv. ) depressed the spontaneous firing of
neurones in both preparations but a greater effect was observed in
the arthritic animals with intact dorsal roots. Such a result
indicates an action by opiates on the pathway from primary afferent
terminals to the neurones studied but cannot distinguish between
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effects on terminals and effects on interneurones interposed between
such terminals and the neurones studied.
Histological studies.
Is there anatomical evidence for opiate mediated presynaptic
inhibition at primary afferent terminals? Capsaicin pretreatment in
newborn rats (Gamse et al, 1979a) and dorsal root transection in the
primate (Lamotte et al, 1976) were both shown to produce a small (10
2 0'u) decrease in the number of opiate binding sites in the SG. These
results might indicate the existence of opiate receptors located
presynaptically on a subpopulation of primary afferent terminals.
More recent ultrastructural analyses (Cho and Basbaum, 1988,1989)
failed to identify significant numbers of opioid peptide containing
axo-axonic contacts to primary afferent structures in the spinal
cord, thus failing to support the concept of a significant
presynaptic function of opiates at such sites. (It is interesting to
note that, in man, there is a marked reduction in morphine
requirement for analgesia with increasing age (Moore et al, 1990),
and thus the in vivo pattern of endogenous opiate function may be
different in neonates versus immature versus adult animals. Such
observations may underlie the inconsistencies outlined above).
Conclusion.
It has been the conclusion of studies which have observed
reductions in tachykinin release with high concentrations of opiates
that a presynaptic action on the central terminals of nociceptors is
an important component of opiate analgesia (Yaksh and Noueihed,
1985) . The results of the present experiments, considered with the
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earlier findings of Kuraishi et al (1983) and Morton et al (1990)
suggest that such an action does not occur significantly on the
subpopulation of primary afferent fibres releasing tachykinin
peptides. Primary afferent transmission mediated by the release of
other compounds such as glutamate (where it does not coexist in
primary afferent terminals with tachykinins, see Battaglia and
Rustioni, 1988, de Biasi and Rustioni, 198 8, p29) might, however, be
impaired by the action of morphine in the spinal cord. It should be
noted that the functional roles of the different opiate receptor
types are clearly complex and have not yet been well established;
this might have implications for the interpretation of results given
here.
One recent study which highlights the problems arising in the
interpretation of results obtained with ligands, such as morphine,
which act at more than one receptor type (Kosterlitz et al, 1985) is
that of Suarez-Roca et al (1992). This group reported a multiphasic
effect of morphine on SP release from slices of rat trigeminal
nucleus in vitro. Increasing doses of morphine in the bath solution,
(10~9,io~^,10~6, and 10~^ mM) respectively lowered, raised, lowered
and raised K+-evoked SP release. The simplest interpretation of this
result must be that varying proportions of the different opioid
receptor types; mu, delta and kappa, are activated with the different
doses of morphine used. Potentiation, by morphine, of basal SP
release from guinea-pig brain slices in vitro has also been reported
(Chahl, 1990). Further studies on the modulation of tachykinin
release from primary afferent terminals by receptor specific opioid
peptides may ultimately prove to be rewarding: this is discussed more
fully in the concluding section of this thesis.
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SECTION 4.
THE EFFECTS OF NORADRENALINE AND MEDETOMIDINE
ON NOXIOUS STIMULUS-EVOKED SUBSTANCE P RELEASE.
The results presented in this section have been published as:
"Microinjection of noradrenaline or medetomidine does not alter
the pattern of nerve stimulus-evoked release of substance P in the
spinal cord of the anaesthetised cat: a study with antibody
microprobes." C.W.Lang, P.J.Hope, B.D.Grubb & A.W.Duggan.
British Journal of Pharmacology (1994), vol. 112, pp951-957.
The results presented here represent a major part of my
studies, in which I was the principal investigator.
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4.1 INTRODUCTION.
Whereas opiate drugs are widely used in human therapy, a2
adrenoceptor agonists such as xylazine (Booth, 1988, Robertson and
Muir, 1983, Waterman et al, 1988), detomidine (Clarke and Taylor,
1986, Lindberg, 1986) and medetomidine (Clarke and England, 1989,
Jalanka, 1990, MacDonald et al, 1988, Vaha-Vahe, 1990, Vainio and
Vaha-Vahe, 1990) have been more widely used in veterinary medicine,
where their hypotensive effects are less marked (Nolan and Erhardt,
1990) and they are therefore safer to use than in man.
The history of a2 adrenoceptor agonists in the treatment of pain
is somewhat unusual in that interest in their clinical potential
initially centred on the use of the drug clonidine in man. Clonidine
has been administered to human patients in a variety of ways; orally,
transdermally and epidurally, as part of both analgesic and
preanaesthetic regimes (Bernard et al, 1991, Lilja et al, 1991, Ota
et al, 1992, Rostaing et al, 1991, Segal et al, 1991, Tamsen and
Gordh, 1984, Van Essen et al, 1991, Wright et al, 1990) but its
efficacy in such treatments in man seems to be highly variable and
given its hypotensive properties it has never become widely popular
in human therapy. Curiously, the use of clonidine was never adopted
by veterinary practitioners despite its reportedly greater potency
and duration of action than, for example xylazine, when used as an
epidural analgesic in domestic species such as the sheep (Nolan et
al, 1987).
In recent years a number of imidazoline-derivative a2-selective
agonist drugs have been developed. In order of their appearance these
are xylazine, detomidine and medetomidine, all of which are
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structurally related (see figure 21) , and have found wide popularity
in veterinary therapy principally as sedatives/analgesics (see above
references and also Hall and Clarke, 1991, for review of therapeutic
techniques), where one great advantage in their use is the
reversibility of their effects either by classical a2 adrenoceptor
antagonists such as yohimbine and idazoxan (Docherty et al, 1987, Hsu
et al, 1989) or by newer imidazoline derived compounds, notably
atipamezole (Jalanka, 1990, Vaha-Vahe, 1990, Vainio and Vaha-Vahe,
1990). These drugs are less hypotensive than older a2 agonists such
as clonidine, and the most recent drug in the group to be developed,
dexmedetomidine (simply the D-isomer of medetomidine) is now
beginning to receive increased attention as a potential therapeutic
agent in man (Aantaa et al, 1991, Aho et al, 1992, Karhuvaara et al,
1991, Sullivan et al, 1992, Scheinin et al, 1992). This has
stimulated renewed interest in the role of a2 adrenoceptor agonist
drugs in animal models of spinal nociceptive processing.
Although all of the a2 adrenoceptor agonist drugs used
clinically (including the imidazoline derivatives) also show some
agonist action at al adrenoceptors, the results of studies with
intrathecally applied receptor selective agonists and antagonists
(Fleetwood-Walker et al, 1985, Headley et al, 1978, Howe et al, 1983)
indicate that the antinociceptive properties of such drugs are
selectively mediated via the a2 receptor. The sedative properties of
these drugs, produced in the brainstem, has also been attributed
principally to their action at a2 adrenoceptors (Schaffer et al,
1986, Vainio and Vaha-Vahe, 1990).
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FIGURE 21. Molecular structure of five a2 adrenoceptor agonist drugs,
noradrenaline, clonidine and three structurally related imidazoline













A complication in studies on the actions of a.2 adrenoceptor
agonist drugs in neural tissues is the discovery that many of them,
especially the imidazoline derivatives, bind to a previously
unrecognised group of receptors (Convents et al, 1989, Kamisaki et
al, 1990, Michel et al, 1989). These receptors were originally
recognised as non-adrenergic idazoxan binding sites, or NAIBS, and
are now also termed 'imidazoline receptors' of which at least two,
and possibly three subtypes can be identified (Michel and Insel,
1989, Wikberg et al, 1991) . The contribution of spinal imidazoline
binding sites to the effects of some of the newer drugs may prove to
be quite dramatic: Savola and Savola (1992) reported that, as
evaluated by displacement studies, at least 50% of dexmedetomidine
binding in rat spinal cord could be attributed to NAIBS. It is
difficult to evaluate the functional significance of these receptors
as no truly specific agonists or antagonists for the imidazoline
receptors have yet been developed, and it is therefore only possible
to compare the effects of compounds with relatively higher or lower
affinities for this receptor group. The results of one such study of
this nature by Downie et al (1991) suggested that the effects of
clonidine on sacral spinal reflexes may involve only a2 adrenoceptors
and not the imidazoline binding sites, but beyond this our
understanding is still limited.
Although there is considerable data on the brainstem sites of
origin of descending pathways controlling spinal transmission of
nociceptive information, comparatively little is known about the
mechanisms operating at the spinal end of these pathways. A wealth of
evidence suggests that release of the monoamines, noradrenaline and
5-hydroxtryptamine (5HT), mediates in part the brainstem control of,
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and segmental mechanisms active on, spinal nociceptive transmission.
This evidence includes the effects of agonists (and antagonists)
applied, in a variety of experimental models, either systemically
(rat :Austin et al, 1976, Kayser et al, 1992, rabbit: Clarke et al,
1988, man: Nance et al, 1989), topically to the spinal cord (mouse:
Hylden and Wilcox, 1983, rat: Camarata and Yaksh, 1985, Danzebrink
and Gebhart, 1990, Fisher et al, 1991, Gordh et al, 1989, Hylden et
al, 1991, Kuraishi et al, 1985b, Reddy et al, 1980, Sagen and
Proudfit, 1984, Solomon and Gebhart, 1988a,b, Sullivan et al, 1987,
1992, Takano and Yaksh, 1991, Tjolsen et al, 1990, Tseng and Tang,
1989, Uhlen et al, 1990, cat: Collins et al, 1984, Nakagawa et al,
1990, sheep: Waterman et al, 1988) or near to single neurones in the
dorsal spinal cord (cat: Calvillo and Ghignone, 1986, Curtis et al,
1983, Davies, 1989, Davies and Quinlan, 1985, Fleetwood-Walker et al,
1985, Headley et al, 1978, Jeftinija et al, 1981, Zhao and Duggan,
1988) and the behavioural effects, or electrophysiological changes in
spinal cord neurones, produced by electrical stimulation of brain
stem areas exhibiting monoamine containing nerve fibres (rat:
Reynolds, 1969, cat: Gebhart et al, 1984, Mayer and Liebeskind, 1974,
Oliveras et al, 1974).
In addition, a dense plexus of catecholamine containing nerve
terminals (rat: Rajaofetra et al, 1992, Schroder and Skagerberg,
1985, cat: Doyle and Maxwell, 1991a,b, Lackner, 1980, primate: Chung
et al, 1989, Westlund et al, 1984) and a marked density of
catecholamine binding sites (rat: Giron et al, 1985, Jones et al,
1982, Unnerstall et al, 1984, Young and Kuhar, 1980, sheep:
Bouchenaffa and Livingstone, 1987, man: Unnerstall et al, 1984)
exists in the dorsal spinal cord, the main area of primary afferent
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transmission, thus providing an anatomical basis for their
involvement in the control of nociceptive transmission.
An attractive hypothesis for a mechanism of selective analgesia
at the spinal level is a presynaptic reduction in transmitter release
from primary afferent terminals of nociceptive origin. A body of work
already exists investigating this possibility with regard to several
analgesic compounds including noradrenaline. These include both in
vivo and in vitro transmitter release studies (Kuraishi et al, 1985a,
Ono et al, 1991, Pang and Vasko, 1986) and also electrophysiological
assessment of the responses of individual nerve terminals in the
dorsal spinal cord to drug application (Calvillo and Ghignone, 1986,
Curtis et al, 1983, Jeftinija et al, 1981). Much of this earlier work
produced controversial results, as will later be discussed, and the
spinal mechanism of monoamine analgesia remained unresolved.
The most direct method of investigating a possible presynaptic
reduction of neurotransmitter release by monoamines is to measure
neurotransmitter release in the dorsal spinal cord, in response to a
defined peripheral noxious stimulus, before and after monoamine
application at the sites of neurotransmitter release. The tachykinin
neuropeptide substance P (SP) is a neurotransmitter known to be
associated with primary afferent fibres of nociceptive origin. The
stimulus parameters for evoking the spinal release of SP have now
been adequately defined (Duggan et al, 1988b) to make it a suitable
transmitter for studies of this nature. The present series of
experiments have used antibody microprobes to measure the release of
immunoreactive (ir) SP in the superficial dorsal horn in response to
peripheral noxious stimulation. The effects of noradrenaline
microinjection from a micropipette with its tip positioned in the
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region of the substantia gelatinosa (SG) have been evaluated in terms
of any change in the pattern of stimulus evoked irSP detection.
Because of the considerable evidence that the relevant receptor
mediating the antinociceptive action of spinal noradrenaline is of
the a2 adrenoceptor type (Fleetwood-Walker et al, 1985, Headley et
al, 1978, Howe et al, 1983), the effects of the highly selective a2
adrenoceptor agonist medetomidine hydrochloride (supplied by Farmos,
Finland) were also studied.
4.2 ANTIBODY MICROPROBE PREPARATION.
Antibody microprobes were prepared as described in the earlier
section on general methodology. A polyclonal antiserum, raised
against the carboxyl terminus of SP was used (Peninsula). Information
supplied by the manufacturer indicated that this antiserum bound SP
and fragments of SP containing at least the last five C-terminal
amino acid residues (thus the major breakdown products of SP produced
by the action of endopeptidases in vivo were unlikely to be
detected) , but showed negligible cross reactivity with either
neurokinin A (NKA) or neurokinin B (NKB) . This was verified by in
vitro tests of the type outlined earlier.
4.3 ANIMAL PREPARATION/MICROPROBE ANALYSIS.
Experiments were performed on 7 cats, anaesthetised and
subsequently prepared as described under the section on general
methodology. All microprobes were inserted 4mm into the dorsal spinal
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cord, which in this species places their tips in the upper ventral
horn. All microprobes remained in the spinal cord for 10 minutes. The
analysis of antibody microprobes subsequent to their use in vivo and
in vitro also followed the methods outlined earlier.
4.4 STIMULUS PARAMETERS.
Peripheral noxious stimulation throughout a 10 minute period of
antibody microprobe insertion was provided by electrical stimulation
of the ipsilateral tibial nerve (groups of three 0.5ms pulses at
330Hz, repeated at 10Hz, amplitude 20V).
4.5 DRUG ADMINISTRATION AND EXPERIMENTAL REGIMES.
The technique of drug microinjection is illustrated in figure
22. Noradrenaline and medetomidine were microinjected (as 10~^M
solutions in sterile Ringer) into the dorsal horn from micropipettes
(tip diameter 20-40 (im) positioned with a micromanipulator at
subsequent depths of 1.0, 1.5, 2.0, and 2.5mm below the dorsal
spinal cord surface. Although the peak release of irSP evoked by
tibial nerve stimulation is in the superficial dorsal horn (1.1mm
below cord surface, Duggan et al, 1988b) there is significant release
in a zone extending approximately 0.5 to 1.0mm deep to this area.
Hence the reason for performing microinjections at sites deep to the
region of the substantia gelatinosa (SG).
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FIGURE 22. Techniques of drug microinjection into the spinal cord.
Drug solutions were pressure ejected from glass micropipettes of the
same dimensions as those used to make antibody microprobes. Two
general techniques were employed.
1) In the neuropeptide Y study (see section 5) some drug
administration into the substantia gelatinosa was performed whilst
single antibody microprobes were in situ. In this case two
micromanipulators were used A. to position the antibody microprobe,
held in a dorso-ventral plane and B. to position the drug filled
micropipette, held at 10° from the dorso-ventral plane. Drug ejection
was gradual, over a 10 minute period and was controlled by manually
compressing the air held in the barrel of a 10ml glass syringe
connected by tubing directly to the barrel of the drug filled
pipette. Due to the very small tip diameter (20-40pm) of this
micropipette, drug ejection could be performed in a very gradual
manner and was monitored by following, under magnification, the
meniscus of the drug solution moving between calibration marks placed
beforehand on its barrel.
2) In all other cases drugs were microinjected prior to
antibody microprobe insertion. This was performed as described above
but either manipulator could be used. Each drug administration was
typically of 0.2-0.5pl total volume, but divided into separate
smaller injections, either at each of four depths (1.0, 1.5, 12.0,
2.5mm below cord surface) or at the same depth (1.1mm) but at
multiple closely adjacent sites within the same pial patch.
FIGURE 22.
MICROINJECTION OF DRUG SOLUTIONS
INTO THE SPINAL CORD.
Individual micropipettes were calibrated by filling the shanks
with firstly 0.2(4.1 and then 0.4(4,1 distilled water. These volumes were
expelled from a Hamilton microlitre syringe onto a small piece of
sterile Parafilm and rapidly sucked up into the micropipette under
microscopic observation. Calibration marks were then drawn onto the
surface of the micropipette with a fine marker pen, the water
expelled under pressure and replaced in a similar manner with drug
solution. The total drug volume was 0.5|4.1, ie. 0.125 (4.1 at each site.
Previous experiments (Duggan et al, 1991a,1992, Schaible et al, 1992,
(see also section 5) have shown that microinjection of Ringers
solution or phosphate buffered saline (PBS) with comparable or larger
volumes had no effect on the stimulus evoked release of irSP in this
region of the spinal cord (see figures 31 and 32 in later section) .
In the spinal cord, drug solutions were microinjected by means of
pressure applied to the end of the micropipettes with a glass syringe
and rubber tubing. This arrangement allowed very fine control over
the ejection of solutions, which could be monitored under a binocular
microscope.
The timing of microinjections in relation to stimuli evoking
release of irSP is important in experiments of this type for several
reasons. Firstly, if a compound is inactivated quickly the
microinjection may need to be performed whilst a microprobe is
already in situ and a stimulus being delivered. Previous experiments
with neuropeptide Y (NPY) microinjection (Duggan et al, 1990, see
section 5) and inhibitors of endopeptidase 24.11 (Duggan et al, 1992)
showed that this was not necessary with these compounds. Secondly,
the injected compound may need to diffuse within the spinal cord for
an effect on irSP release to be detected; this implies a need to
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inject a short time prior to testing for inhibition of release. In
the experiments presented in this section injections of noradrenaline
or medetomidine were performed after control microprobes (either no
applied stimulus or nerve stimulus controls) had been removed from
the cord, and microinjections were then administered gradually over a
5 minute period. Subsequent pairs of microprobes were then inserted
as rapidly as possible into the cord and these were typically in situ
1-2 minutes following cessation of drug microinjection.
4.6 RESULTS.
4.6.1. STIMULUS-EVOKED RELEASE OF IMMUNOREACTIVE
SUBSTANCE P.
The mean image analyses of 13 microprobes inserted 4mm into the
spinal cord and left for 10 minutes in the absence of peripheral
nerve stimulation ('Air controls') and 24 microprobes inserted for
the same times and to the same depth but during electrical
stimulation of myelinated and unmyelinated primary afferents of the
ipsilateral tibial nerve ('Stim. controls') are illustrated in figure
23A. These microprobes are derived from the same individual
experiments. Significant differences between these mean image
analyses occur from 0.7 to 1.2 mm from the dorsal surface of the
spinal cord, and there is also a smaller zone of significance
approximately 1.5 mm below cord surface. The maximal difference
occurs at a depth of 1.0 mm (figure 23B) . This site of maximal
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release approximates to the SG and lamina I and agrees with the
findings of previous studies (Duggan et al, 1988b,1991a).
When dye is ejected from the tip of a single microprobe and its
position in the spinal cord subsequently determined in a spinal cord
section then sites of neuropeptide release can be inferred with great
accuracy. With mean image analyses, as presented here, the location
of sites of release is less precise. With microprobes placed a fixed
distance into the spinal cord (4 mm in this series of experiments)
the relationship of spinal laminae to distance from the tip will vary
between individual animals and also, from microprobe to microprobe,
with distance from the midline. When encoding the information
describing the position of a microprobe, a correction factor is
included when appropriate, but the referral of spinal laminae to a
mean image analysis should still be regarded as approximate.
Summary. The noxious stimulus-evoked release of irSP was as expected
from the findings of earlier studies employing the same techniques,
with the site of maximal irSP release being centred in the SG of the
spinal dorsal horn.
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4.6.2. THE EFFECT OF NORADRENALINE MICROINJECTION
ON NOXIOUS STIMULUS-EVOKED RELEASE OF
IMMUNOREACTIVE SUBSTANCE P.
The mean image analyses of 38 microprobes inserted 4mm into the
spinal cord for 10 minutes with concurrent electrical stimulation of
myelinated and unmyelinated afferents of the ipsilateral tibial nerve
('stim. controls') and 35 microprobes inserted under the same
_ O
conditions but immediately following the microinjection of 10 °M
noradrenaline at depths of 1.0, 1.5, 2.0 and 2.5mm below cord surface
in the area of subsequent microprobe insertion ('post NA') are
illustrated in figure 24. The two groups of microprobes are derived
from the same individual experiments. The two analyses are virtually
identical and at no point does the difference between their mean grey
scale values attain statistical significance.
Summary. The microinjection of 10~%1 noradrenaline directly into the
superficial dorsal horn of the spinal cord had no significant effect
on the subsequent noxious stimulus-evoked release of irSP.
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4.6.3.EFFECT OF MEDETOMIDINE MICROINJECTION ON NOXIOUS
STIMULUS-EVOKED RELEASE OF IMMUNOREACTIVE SUBSTANCE P.
The mean image analyses of 31 microprobes inserted 4mm into the
spinal cord for 10 minutes with concurrent electrical stimulation of
the myelinated and unmyelinated afferents of the ipsilateral tibial
nerve ('Stim. controls') and 20 microprobes inserted under the same
conditions but following the microinjection of 10_^M medetomidine at
depths of 1.0, 1.5, 2.0 and 2.5mm below cord surface in the area of
subsequent microprobe insertion ('post med. ' ) are illustrated in
figure 25A. These two groups are again derived from the same
individual experiments, ie. the 'stim. controls' groups illustrated
in figures 24A and 25A do not represent the same microprobes.
Although these two mean image analyses do not appear to be as
similar as those illustrated in figure 24A, there are again no
statistically significant differences between their mean grey scale
values at any point within the spinal cord (figure 25B). A small area
of increased irSP detection following medetomidine microinjection is
evident at the cord surface. This has been observed in previous
studies following microinjection of sterile PBS-azide into the spinal
cord (Duggan et al, 1991) . It is thought to represent developing
inflammation at the cord surface rather than a genuine
pharmacological action of medetomidine.
Summary. The microinjection of 10—-^M medetomidine directly into the
superficial dorsal horn of the spinal cord had no significant effect
on the subsequent pattern of noxious stimulus-evoked irSP release
within the spinal cord.
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FIGURE 23. Nerve stimulus-evoked release of immunoreactive
substance P in the superficial dorsal horn.
A. The mean image analysis of two groups of microprobes
are plotted. Those which remained in the spinal cord for 10 minutes
and without the application of a peripheral stimulus ('Air controls',
n=13) and those present in the spinal cord during electrical
stimulation of myelinated and unmyelinated afferents of the
ipsilateral tibial nerve ('Stim. controls', n=24). The mean grey
scale values of microprobes were calculated, as before, at 30|jm
intervals and a line joins these points. At each point the standard
error of the mean (SEM), + for 'Stim. controls' and - for 'Air
controls' is plotted.
B. A plot of the t-statistics derived from the
differences of the means for the two groups of microprobes
illustrated in A. This plot is superimposed on a diagram of a cross
section of the lumbar spinal cord of the cat and the shaded area






















FIGURE 24. Lack of effect of microinjection of noradrenaline into the
dorsal horn on the nerve stimulus-evoked release of immunoreactive
substance P. The mean image analyses of two groups of microprobes are
plotted: those present in the spinal cord for 10 minutes during
electrical stimulation of the ipsilateral tibial nerve at C-fibre
strength ('Stim. controls', n=38) and those with comparable
stimulation, but inserted after microinjection of noradrenaline
(10_^M) into the dorsal horn ('Post NA', n=35) . The format of the





















FIGURE 25. Lack of effect of microinjection of medetomidine into the
dorsal horn on the nerve stimulus-evoked release of immunoreactive
substance P.
A. The mean image analysis of microprobes present in the
spinal cord for 10 minutes during electrical stimulation of the
ipsilateral tibial nerve at C-fibre strength ('Stim. controls', n=31)
and those with comparable stimulation, but inserted after
microinjection of medetomidine (10_^M) into the dorsal horn ('Post
med. ', n=20) . The format of the plot is similar to that in figure
23A.
B. A plot of the t-statistics derived from the
differences of the means of the two groups shown in A. is
superimposed on a diagram of the lumbar spinal cord of the cat. The



















The present experiments have shown that microinjections of
noradrenaline (0.5p.l, 10_^M) or of the imidazoline derivative drug
medetomidine (0.5(j.l, lO--^) , which shows a high affinity for a2
adrenoceptors and imidazoline receptors, in the region of the SG of
the cat spinal dorsal horn had no detectable effect on the nerve-
stimulus evoked release of irSP.
Tachykinins and spinal nociceptive processing: interpretation of
results.
Although it is improbable that the tachykinin peptides account
for fast transmission from nociceptors (those impulses accurately
signalling the onset, offset and intensity of a noxious stimulus),
release of these compounds from the central terminals of nociceptors
is well established (Duggan et al, 1988b,1989,1990a,b,1991,1992, Hope
et al, 1990b,c, Lang et al, 1991,1994, Lang and Hope, 1994, Morton et
al, 1990,1991, Schaible et al,1990,1992), and potential controls of
such release require investigation.
Interpretation of the present results is largely based on the
belief that, in acutely spinalised cats, the irSP detected in the
spinal cord following peripheral nerve stimulation is largely of
primary afferent origin. A contribution from intrinsic spinal
neurones cannot be excluded, but release from fibres of supraspinal
origin cannot have occurred in a spinalised preparation. It is worth
noting that the distribution of irSP detection by antibody
microprobes, following peripheral nerve stimulation, in these
experiments is in accord with the findings of previous antibody
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microprobe studies (Duggan et al, 1988b,1991, Schaible et al, 1992).
Microinjection of noradrenaline directly into the SG had no
effect on the stimulus-evoked release of irSP. Administration of
drugs in this manner has previously been shown to be an effective way
of modulating stimulus evoked irSP release. Thus microinjection of
NPY was shown to reduce irSP detection following peripheral nerve
stimulation (Duggan et al, 1991, and see also section 5) whereas
microinjection of calcitonin gene-related peptide (CGRP) or of the
peptidase inhibitor drug, kelatorphan, enhanced post-stimulus
detection of irSP (Duggan et al, 1992, Schaible et al, 1992).
Noradrenaline may, following microinjection have been subject to
rapid reuptake and degradation in the spinal cord. Medetomidine
however, the other a2 adrenoceptor agonist drug tested in these
studies, does not appear to be subject to any reuptake mechanism
(Dr.R.Virtanen, Farmos, personal communication), but instead is
metabolised by hydroxylation in the liver (Salonen and Eloranta,
1990) . Medetomidine should, therefore, remain active for some time
following its injection into neuronal tissue, yet still failed to
show any effect on irSP release. Similar arguements can be used in
considering the ability of the drugs used to diffuse to appropriate
sites of action in the spinal cord: medetomidine is highly lipophilic
(Savola et al, 1986) and should readily spread throughout neuronal
tissue following microinjection.
Other studies on a2 adrenoceptor agonists and SP release.
The current observation that noradrenaline was ineffective in
reducing noxious stimulus evoked irSP release is in conflict with the
findings of some earlier studies. Ono et al (1991) demonstrated that
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clonidine (10~^M) and tizanidine (10~^M), both a2 adrenoceptor
agonist drugs, reduced the veratridine-induced release of SP from
slices of rat spinal cord in vitro. This effect was blocked by
yohimbine (10~^M) and also by prazosin (10~^M), leading Ono and co¬
workers to conclude that the reduction of SP release was mediated by
a2B adrenoceptors. Pang and Vasko (1986) reported that noradrenaline
(10~^M) inhibited the high K+-evoked release of SP from a similar
preparation of rat spinal cord, and this inhibition was reversed by
phentolamine (10~^M) indicating that the effect was mediated by
receptors in the a adrenoceptor group.
Veratridine application, or simple elevation of extracellular
K+ levels, do not represent stimuli which are selective to structures
of primary afferent origin, and perfusion of cord slices allows no
spatial resolution of the source of neurotransmitter release. SP is
also present in intrinsic neurones of the spinal cord and the SP
detected in these in vitro studies may be derived in part from such
structures: control mechanisms at spinal interneurones might be very
different from those at primary afferent terminals. Lastly, Kuraishi
et al (1985a) reported that noradrenaline (10~^M) added to the
perfusate of a push-pull cannula inserted into the upper dorsal horn
of rabbit spinal cord in vivo reduced the release of irSP in response
to a peripheral noxious mechanical stimulus. This effect was reversed
by both yohimbine (10~^M) and prazosin (10~^M). The low group numbers
in these experiments (n=5) and the very large variance in the release
of irSP following the addition of antagonist drugs to the perfusate
did, however, indicate the need to re-examine the effects of
noradrenaline on stimulus evoked irSP release in vivo.
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Cellular mechanisms of action of a.2 adrenoceptor agonists in
blocking spinal nociceptive transmission; electrophysiological and
histological studies.
These results are part of an extended study on possible
presynaptic controls of tachykinin release from the central terminals
of nociceptors. Presynaptic inhibition of transmitter release from
such terminals has been proposed as being important in several
mechanisms of analgesia, including that resulting from impulses
arriving in large diameter afferents (Melzak and Wall, 1965) and
analgesia resulting from electrical stimulation in the mid-brain
periaqueductal grey matter (Fields and Basbaum, 1978). There is,
however, relatively little data bearing directly on this question.
Both noradrenaline (Fleetwood-Walker et al, 1985, Headley et
al, 1978, Reddy and Yaksh, 1980) and medetomidine, or its D-isomer
form dexmedetomidine, (Fisher et al, 1991, Ossipov et al, 1990b,
Pertovaara et al, 1991) have been shown to block transmission of
nociceptive inputs in the rat and cat at the level of the spinal
cord, either by their actions when applied intrathecally, or by merit
of an observable antagonism of their effects by intrathecally applied
compounds. The actual mechanisms responsible for such inhibition of
spinal nociceptive processing have, however, remained largely
unresolved.
As in the previous section, the electrophysiological and
anatomical evidence to support a presynaptic action of these
compounds should be considered. Calvillo and Ghignone (1986) reported
that intravenous clonidine, an a2 adrenoceptor agonist, selectively
increased the electrical excitability of C-fibre primary afferent
terminals in cat spinal cord, and that this excitability was reversed
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by both yohimbine and phentolamine. Such primary afferent
depolarisation might lead to presynaptic inhibition; gamma-
aminobutyric acid (GABA) produces a similar, depolarising, action at
the central terminals of larger diameter (A-delta) primary afferent
terminals, the mechanism thought to underly its inhibitory effects at
such sites (Curtis and Lodge, 1982, Sastry, 1979a). However,
Jeftinija et al (1981) have previously reported that micro-
ionophoresed noradrenaline reduced electrical excitability in
approximately 2/3 of C-fibre central terminals, perhaps indicating a
novel, presynaptic inhibitory mechanism. In this earlier study the
effects of noradrenaline could not be reversed with either
phentolamine or yohimbine applied locally or systemically, and the
exact significance of these findings remains unclear.
It is of note that in recent immunocytochemical studies, Doyle
and Maxwell (1991a,b,1993b) failed to identify catecholamine-
containing axo-axonic contacts in cat SG, yet axo-dendritic and axo-
somatic contacts showing positive immunoreactivities for two of the
enzymes involved in noradrenaline synthesis, tyrosine hydroxylase and
dopamine-p-hydroxylase were readily identifiable. It is the former
axo-axonic type of contact which is thought to be involved in
presynaptic control at primary afferent terminals and these results
do not, therefore, provide anatomical evidence to support a
presynaptic action of noradrenaline at such sites. (The same group
have, however, identified axo-axonic contacts in the cat SG
containing NPY (Doyle and Maxwell, 1993a) which is of great
significance in relation to the results presented in the next
section). Wikberg and Hajos (1987) reported that primary afferent
terminal destruction by capsaicin treatment in neonatal mice did not
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alter the number of [3H]-clonidine binding sites in the spinal cord,
again suggesting that spinal a2 binding sites were located
postsynaptically to primary afferent terminals. The pattern of
catecholaminergic innervation in the spinal cord of another species
of rodent, the rat, has been shown to change over a considerable
period of time following birth (Commissiong, 1983) and the findings
of Wikberg and Hajos might, therefore, be viewed with a degree of
caution.
The roles of imidazoline receptors and of both al and a2
adrenoceptors in spinal cord processing.
Noradrenaline may have acted on more than one a adrenoceptor
subtype in the dorsal horn. It is not known if al adrenoceptors
exist on the central terminals of nociceptors, but al adrenoceptor-
mediated effects have been observed on neurones of the SG, the major
site of primary afferent fibre termination. Thus North and Yoshimura
(1984) observed a prazosin (al) reversible depolarisation of SG
neurones in a slice preparation of rat dorsal horn but also a
yohimbine (a2) reversible hyperpolarisation of these cells. If these
differing actions occurred simultaneously on nociceptive terminals
following noradrenaline microinjection, then no net effect on irSP
release might be detectable. Medetomidine is, however, a highly a2
adrenoceptor selective drug, approximately 1600 times higher affinity
for the a2 as compared to the al adrenoceptor subtype (Virtanen et
al, 1988), yet it also failed to alter irSP release. This suggests
that there is no a2 adrenoceptor mediated inhibition of stimulus
evoked irSP release from primary afferent terminals of nociceptive
origin.
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As discussed earlier, the physiology of imidazoline receptor-
mediated effects in the spinal cord is currently poorly understood,
largely due to the current lack of any imidazoline receptor-specific
agonist or antagonist drugs. As detailed earlier, it has recently
been suggested that at least 50% of the binding of labelled forms of
drugs like medetomidine in the spinal cord is accounted for by
binding at non-adrenergic sites (Savola and Savola, 1992, see also
concluding section of thesis). It is likely, therefore, that in the
present series of experiments medetomidine was active at a population
of imidazoline receptors in the cat spinal cord, in addition to its
effects on a2 adrenoceptors. The present finding, that medetomidine
was without effect in reducing noxious stimulus-evoked release of
irSP does not support a presynaptic inhibition of transmitter release
from primary afferent terminals mediated by either a2 adrenoceptors
or imidazoline receptors.
One criticism which might be levelled at the protocol used in
the current series of experiments is the lack of any antagonist drug
administration. This was quite deliberate. If an inhibition of
stimulus-evoked irSP release had been detected in response to
microinjection of either drug, further experiments would have been
performed in an attempt to block such inhibition with either the a2
antagonist yohimbine, or the imidazoline derivative atipamezole,
which is active as an antagonist at both a2 and imidazoline
receptors. Such extended studies would have allowed classification of
any effect as being either a2, or non-a2 adrenoceptor mediated. In
the case of medetomidine, but not of noradrenaline, producing
inhibition of irSP release, use of the anatagonists available would
have gone some way to determining whether this effect was due to the
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higher potency and selectivity of medetomidine for the a2 class of
adrenoceptor, or alternatively a consequence of its affinity for
imidazoline receptors. Given the results obtained, such extended
studies would have been of little value.
Conclusion.
In conclusion, the results presented in this section indicate
that the spinal analgesia produced by noradrenaline and medetomidine
is in neither case mediated via presynaptic inhibition of irSP
release from the central terminals of C- or A-delta primary afferent
fibres. In accord with the results of electrophysiological and
histological studies by other groups, my experiments suggest that the
well-documented effects of noradrenaline in the superficial dorsal
horn result from postsynaptic effects on intrinsic neurones of this
area. In the case of medetomidine this conclusion can be applied both
to its effects mediated via a2 adrenoceptors and its presumed, but as
yet unidentified, actions mediated via imidazoline receptors.
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SECTION 5.
THE EFFECT OF NEUROPEPTIDE Y ON
NOXIOUS STIMULUS-EVOKED SUBSTANCE P RELEASE.
These results have previously been published as:
"Microinjection of neuropeptide Y into the superficial dorsal horn
reduces the stimulus-evoked release of immunoreactive substance P in
the anaesthetised cat." A.W. Duggan, P.J. Hope & C.W. Lang.
Neuroscience (1991) volume 44, pp 733 - 740.
The results presented in this section are derived from experiments in
which I collaborated equally with the researchers named above.
162
5.1 INTRODUCTION.
Neuropeptide Y (NPY) is a 36 amino acid peptide found throughout the
central nervous system of many species. The superficial dorsal horn
of the spinal cord of several mammalian and non-mammalian species has
been shown to contain a dense network of NPY-containing fibres,
mainly of supraspinal origin (man: Allen et al, 1984, rabbit:
Blessing et al, 1987, elasmobranch: Cameron et al, 1990, rat:
Chronwell et al, 1985, Henschen et al, 1988, cat: Krukoff, 1987). NPY
is also present in the terminals of some primary afferent fibres
(Wakisaka et al, 1991, 1992), although not significantly in C-fibre
afferents. The superficial dorsal horn of the spinal cord is a site
of potential interaction of many neuroactive compounds. The
substantia gelatinosa (SG) is the major site of termination of
cutaneous unmyelinated primary afferents (Light and Perl, 1977), many
of which are nociceptors, and these fibres contain excitatory amino
acids and neuropeptides, either singly or in a complex series of
combinations (Duggan and Weihe, 1990). In addition, both intrinsic
neurones of the SG and the terminals of propriospinal and
supraspinally derived fibres contain amino acids, monoamines and
neuropeptides. To understand the interactions between such a large
number of compounds is clearly a complex task. One aspect which can
be investigated experimentally is whether any of the substances
contained within the SG act to reduce the release of compounds from
the central terminals of primary afferent fibres, in the manner which
has already been outlined in relation to <x2 adrenoceptor agonists and
opioids in the preceding sections. In this series of experiments,
however, the choice of compound, NPY, represents an agent which
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although known to be present throughout the peripheral (PNS) and
central nervous systems (CNS) (indeed it is one of the most
ubiquitous CNS peptides) has not yet been well defined in terms of
its physiological role. Consequently the potential of NPY, or of
agents acting at NPY receptors, as new analgesic agents has not yet
been fully investigated.
In both the PNS and the CNS there are several instances where
NPY has been shown to have effects on nerve terminals, in vivo and in
vitro, consistent with an impairment of transmitter release from
those terminals (hippocampal slice: Colmers et al, 1991, Hass et al,
1987, cardiac vagal fibres: Kilborn et al, 1985, peripheral nerve
terminals, Guiliani et al, 1989, Wahlestedt et al, 1985).
It has already been mentioned that an inhibition of transmitter
release from the central terminals of nociceptors has been used to
explain several mechanisms of analgesia. Examples include the 'Gate
Theory' of Melzak and Wall (1965), and the hypothesis of Jessell and
Iversen (1977) which evolved from their study of opiate effects on
substance P (SP) release from slices of rat trigeminal nucleus. (This
topic has already been discussed at some length, see pages 70 - 75,
and has been reviewed in part by both Basbaum and Fields, 1984, and
Duggan, 1985) . If NPY had such an action in the superficial dorsal
horn, and if the relevant receptors were located near the central
terminals of primary afferent fibres of nociceptive origin, then such
a mechanism could contribute to analgesia of both segmental and
supraspinal origin. Both mechanisms merit investigation following
reports of analgesic effects following the intrathecal administration
of NPY in the rat (Hua et al, 1991, Yaksh, 1990) .
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The series of experiments presented in this section were
performed in order to test the effects of NPY, microinjected directly
into the dorsal spinal cords of anaesthetised cats on the subsequent
release pattern of immunoreactive (ir)SP seen following electrical
stimulation of afferent fibres of presumed nociceptive origin. The
experimental protocol (outlined on the following pages) was similar
to that used in studies of noradrenaline/medetomidine modulation of
stimulus-evoked irSP release (presented in section 4), thus allowing
a direct comparison to be made between the two series of experiments.
5.2 ANTIBODY MICROPROBE PREPARATION.
Antibody microprobes were prepared as described in the earlier
section on general methodology, with the exception that the protein A
used to bind immunoglobulins onto the microprobe surfaces was
produced by Porton, not in this instance by Sigma. A polyclonal
antiserum, raised against the carboxyl terminus of SP was used
(Peninsula). This was the same antiserum as that subsequently used in
the series of experiments presented in section 4 (see page 143) .
Information supplied by the manufacturer indicated that this
antiserum bound SP and fragments of SP containing at least the last
five C-terminal amino acid residues, (thus the major breakdown
products of SP produced by the action of endopeptidases in vivo were
unlikely to be detected) , but showed negligible cross reactivity with
either neurokinin A (NKA) or neurokinin (NKB). This was verified by
in vitro tests as previously described.
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5.3 ANIMAL PREPARATION/MICROPROBE ANALYSIS.
Experiments were performed on seven cats, anaesthetised and
subsequently prepared as described under the section on general
methodology. All microprobes were inserted 3mm into the dorsal spinal
cord, which in this species places their tips in the upper ventral
horn. All microprobes remained in the spinal cord for 20 minutes. The
analysis of antibody microprobes subsequent to their use in vivo and
in vitro also followed the methods outlined earlier.
5.4 STIMULUS PARAMETERS.
Peripheral noxious stimulation throughout a 20 minute period of
antibody microprobe insertion was provided by electrical stimulation
of the ipsilateral tibial nerve (groups of three 0.5ms pulses at
330Hz, repeated at 10-30Hz (constant in each experiment), amplitude
2 0V) .
5.5 DRUG ADMINISTRATION AND EXPERIMENTAL REGIMES.
Microinjection (see figure 22) of NPY was performed in two ways.
In two experiments the tips of an antibody microprobe and a
micropipette containing 0.5(0.1 of NPY were positioned just above the
dorsal surface of the spinal cord. The microprobe was held vertically
in a micromanipulator and the micropipette was held in a separate
micromanipulator angled at 10° from vertical in an anteroposterior
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plane. The microprobe was inserted 3mm into the spinal cord. Using
basic trigonometry, the distance the micropipette needed to be moved
to position the tip 1.1mm below the dorsal surface of the spinal cord
was calculated (1.12mm). The micropipette was then inserted to this
distance, thus placing the tip approximately in the middle of the SG.
NPY was subsequently injected slowly throughout the entire 20 minute
period of microprobe insertion to a total volume of approximately 0.2
(Xl.
In the remaining five experiments, a series of two to three
microinjections, each of approximately 0.2|xl, was made around the
margins of an area of denuded pia mater (ie. at the edges of the pial
patches) and following this microinjection of NPY pairs of antibody
microprobes were inserted into the centre of the patches. NPY was
microinjected at a concentration of 10~^M in sterile phosphate
buffered saline (PBS) in one experiment and 10~^M in sterile PBS in
six experiments.
The method of calibrating and filling micropipettes was
discussed in section 4, as was consideration of the timing of drug
microinjection relevant to antibody microprobe insertion. The need
for vehicle/volume controls was also discussed in section 4, but it
was as part of this study on NPY microinjection that extensive
controls involving the microinjection of PBS alone into the dorsal




5,6.1 STIMULUS EVOKED RELEASE OF IMMUNOREACTIVE
SUBSTANCE P.
The mean image analysis of 16 microprobes inserted 3mm into the
spinal cord and left in situ for 20 minutes in the absence of any
form of applied peripheral stimulus ('Air controls') and 33
microprobes inserted for the same time and to the same depth but
during electrical stimulation of both the unmyelinated and the
myelinated afferent fibres of the ipsilateral tibial nerve ('Nerve
stim.') are illustrated in figure 26A. These microprobes were derived
from all seven experiments in this study.
Significant differences between these mean image analyses occur
from 0.6 to 1.4mm below the dorsal surface of the spinal cord with
the maximal difference at a depth of 1.0mm as shown in figure 26B.
This site of maximal irSP release approximates to the location of the
substantia gelatinosa (SG) and lamina I of the dorsal grey matter and
thus agrees with the findings of other studies (Duggan et al, 1988b,
1991a, Lang et al, 1994) . As with these other studies, and for the
same reasons, the referral of spinal laminae to such mean image
analyses should be considered approximate.
Summary. The noxious stimulus-evoked release of irSP was as expected
from the findings of earlier studies employing the same techniques,
with the site of maximal irSP release being centred in the SG of the
spinal dorsal horn.
168
5.6.2 THE EFFECT OF CONCURRENT NPY MICROINJECTION
ON NOXIOUS STIMULUS-EVOKED RELEASE OF
IMMUNOREACTIVE SUBSTANCE P.
The mean image analyses of 12 microprobes inserted 3mm into the
spinal cord for 20 minutes and with concurrent electrical stimulation
of the unmyelinated and myelinated afferents of the ipsilateral
tibial nerve ('Stim. controls') and 13 microprobes inserted under the
same conditions but with NPY (lO-"^ in one experiment, 10~^M yn one
other) being microinjected 1.1mm below the dorsal surface of the
spinal cord and approximately 100|im from the microprobe shaft
('During NPY ') are compared in figure 27. Although the mean image
analysis of microprobes inserted during NPY microinjection is
displaced below that of control microprobes (indicating reduced
stimulus-evoked release of irSP), this difference only marginally
attains statistical significance over a very restricted area
approximately 1.5mm below cord surface.
Summary. Injection of NPY concurrent with tibial nerve
stimulation/microprobe insertion resulted in only a marginal decrease
in the levels of irSP detected.
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5.6.3 THE EFFECT OF PRIOR NPY MICROINJECTION
ON NOXIOUS STIMULUS-EVOKED RELEASE OF
IMMUNOREACTIVE SUBSTANCE P.
The effectiveness of ipsilateral tibial nerve stimulation in
evoking release of irSP prior to and in the 20 minute period
following NPY microinjection (10~^M, five experiments) is compared in
figure 28. The mean image analysis for 20 microprobes inserted
following NPY microinjection ('0-20 min post NPY') is significantly
displaced below that of 33 stimulus control microprobes ('Stim.
controls') over an area beginning at 0.8mm below cord surface and
extending to a depth of 2.0mm. In the second 20 minute period of
tibial nerve stimulation after NPY microinjection the stimulus-evoked
release of irSP is still reduced (20 microprobes, '21-40 min post
NPY') but over a much more restricted area of the spinal cord. This
is illustrated in figure 29, which shows a significant reduction in
irSP detection (t>2) only in the region of laminae I and II of the
dorsal grey matter.
A small number of microprobes (n=5) were inserted during a third
period of nerve stimulation. The mean image analysis of these 5
microprobes, not illustrated, was observed not to differ
significantly from that of the pre-NPY microinjection control group.
Summary. Microinjection of 0.2-0. 6p.l of NPY (10~^M in PBS) inhibited
the subsequent nerve stimulus-evoked release of irSP. This effect was
time dependant, being maximal in the first 20 minutes following NPY
microinjection, and ceasing (within the sensitivity of the technique
used) by 41-60 minutes after drug administration.
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5.6.4 RELEASE OF IMMUNOREACTIVE SUBSTANCE P
FOLLOWING MICROINJECTION OF PHOSPHATE-BUFFERED SALINE
CONTAINING SODIUM AZIDE.
Figure 30 illustrates the mean image analyses of 25 microprobes
inserted into the spinal cord during ipsilateral tibial nerve
stimulation but prior to microinjection of PBS-azide in similar
volumes to those used for NPY microinjection ('Stim. controls') and
of 12 microprobes inserted with the same peripheral stimulus but in
the 0-20 minute period following microinjection ('0-20 min post
PBS') . There is a small zone of enhanced irSP detection at the
surface of the spinal cord following PBS microinjection, but within
the spinal cord the two mean image analyses are virtually identical.
(This zone of enhanced release of irSP on the spinal cord surface was
also seen following medetomidine microinjection, as detailed in
section 4 and, as in that study, is thought to represent a time-
dependant inflammatory effect rather than a drug-mediated change).
Figure 31 compares the mean image analysis of the preinjection
group of microprobes ('Stim. controls') with that of 7 microprobes
inserted during ipsilateral tibial nerve stimulation, but 21-40
minutes after PBS-azide microinjection ('21-40 min post PBS). Again
the two mean image analyses are virtually identical.
Summary Microinjection of PBS containing azide, in similar volumes as
those used for the microinjection of drug-containing solutions had no
detectable effect on the subsequent nerve stimulus-evoked pattern of
irSP release within the spinal cord.
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FIGURE 26. Stimulus-evoked release of immunoreactive substance P.
A. 'Air controls', the mean image analysis of microprobes
(n=16) inserted 3mm into the spinal cord for 20 minutes without any
peripheral stimulation, compared with a second group, 'Nerve stim.'
(n=33) present in the spinal cord for 20 minutes but during
electrical stimulation of the ipsilateral tibial nerve at C-fibre
strength. The mean grey scale values of microprobes were calculated,
as before, at 30|im intervals and a line joins these points. At each
point the standard error of the mean (SEM), + for 'Nerve stim.' and -
for 'Air controls' is plotted.
B. A plot of the t-statistics derived from the
differences of the means for the two groups of microprobes
illustrated in A. This plot is superimposed on a diagram of a cross
section of the lumbar spinal cord of the cat and the shaded area
indicates where these differences attain significance (t>2, P<0.05).
FIGURE 26.
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FIGURE 27. Marginally reduced release of immunoreactive substance P
during microinjection of neuropeptide Y (NPY) in the superficial
dorsal horn. 'Stim. controls', the mean image analysis of a group of
microprobes (n=12) inserted 3mm into the dorsal spinal cord during
electrical stimulation of the ipsilateral tibial nerve at C-fibre
strength but prior to NPY microinjection . 'During NPY', microprobes
(n=13) again present in the spinal cord for 20 minutes and during
tibial nerve stimulation, but in this case during the slow
microinjection of NPY (10_ '/lO^M, 0. 2|im) into the adjacent tissue at
a depth of 1.1mm. The format of the plot is similar to that in figure
26. A plot of the t-statistics derived from the differences of the
means of the two image analyses is shown with respect to distance






























FIGURE 28. Reduced stimulus-evoked release of immunoreactive
substance P in the period 0-20 minutes following microinjection of
neuropeptide Y (NPY). This figure compares the mean image analysis of
microprobes (n=33, 'Stim. controls')/ inserted 3mm into the dorsal
spinal cord during electrical stimulation of the ipsilateral tibial
nerve at C-fibre strength with that of microprobes (n=22, '0-20 min
post NPY'), present in the period 0-20 minutes after microinjection
of NPY (10~^M). The format of the plot is similar to that in figure
26. A plot of the t-statistics derived from the differences of the
means for the two groups of microprobes is also illustrated. The


























Figure 29. Reduced stimulus-evoked release of immunoreactive
substance P in the period 21-40 minutes following microinjection of
neuropeptide Y (NPY). This figure compares the mean image analysis of
the ' Stim. controls' group as described in figure 28, with that of
microprobes (n=20, '21-40 min post NPY'), present in the period 21-40
minutes after microinjection of NPY (10~5M) . The format of the plot
is similar to that in figure 26. A plot of the t-statistics derived
from the differences of the means for the two groups of microprobes
is also illustrated. The shaded areas on this plot indicate where





















FIGURE 30. Failure of microinjection of phosphate buffered saline
(PBS) in the superficial dorsal horn to reduce stimulus-evoked
release of immunoreactive substance P. 'Stim. controls', a group of
antibody microprobes (n=25) present in the spinal cord for 20 minutes
during electrical stimulation of the ipsilateral tibial nerve at C-
fibre strength. '0-20 min post PBS', microprobes (n=12) inserted
under similar conditions and in the same experiments , but in the
period 0-20 minutes after microinjection of PBS into the superficial
dorsal horn. The format of the plot is similar to that in figure 26.






















FIGURE 31. Failure of microinjection of phosphate buffered saline
(PBS) in the superficial dorsal horn to reduce stimulus-evoked
release of immunoreactive substance P. 'Stim. controls', the group of
microprobes illustrated in figure 30. '21-40 min post PBS',
microprobes (n=7) inserted under similar conditions and in the same
experimpfl688y but in the period 21-40 minutes after microinjection of
PBS into the superficial dorsal horn. The format of the plot is
similar to that in figure 26. There are no significant differences






















































The results of the experiments in this section have shown that
microinjection of 0.2)0.1 - 0.6(xl NPY (10~^M - 10_^M) , in the region of
the SG of the dorsal horn, reduces the nerve stimulus-evoked release
of irSP.
Microinjection of drugs into the spinal cord and interpretation of
results.
Interpretation of these results requires consideration of the
limitations imposed by microinjection. It was unknown at the time of
performing these experiments whether or not NPY would be inactivated
quickly or slowly within the spinal cord, and hence the initial
experiments microinjected the peptide continuously while microprobes
were actually present in the spinal cord. This technique had the
disadvantage that the neuropeptide-containing solution was
administered at one site only (although relatively close to part of
the microprobe shaft) and the time for diffusion away from the site
of ejection was restricted when compared with the method of
introducing microprobes after microinjection. The findings that
greater inhibition of the stimulus-evoked release of irSP was
produced by the latter method indicate its suitability for a compound
such as NPY. Microinjection probably introduces relatively large
amounts of a compound into the spinal cord when compared to the
levels achieved by synaptic release, and hence local inactivation
processes are likely to be saturated for some time after
microinjection. Even with a rapidly degraded compound (such as
noradrenaline as in the series of experiments detailed in section 4)
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introduction of microprobes after microinjection is probably the
method of choice in this type of study. It should, then, be
emphasised that the persistence of NPY's effects for up to 40
minutes, as seen in these experiments, may not represent a time
course applicable to the effects of NPY in vivo following synaptic
release.
It is probable that most of the increases in irSP seen following
peripheral nerve stimulation in these and the preceding experiments
were due to release from the central terminals of peripheral
nociceptors (Duggan and Hendry, 1986, Duggan et al, 1988b).
Significant inhibition of irSP release following NPY application
occurred over almost the whole of the dorsal grey matter in the first
20 minutes following microinjection but was restricted to laminae I
and II in the following 20 minute period. This suggests that the
initial 'controls' microprobes, illustrated in figure 26 were
detecting a basal presence of irSP in the deeper laminae of the
dorsal horn, that this was increased by nerve stimulation and that
microinjection of NPY reduced both basal and stimulus-evoked irSP
release. The basal presence of irSP in the deeper laminae of the
dorsal horn does, however, contradict the findings of earlier studies
performed by members of this same group using the same technique.
This issue is one which I will discuss fully in the concluding
section of this thesis but it does not, I feel, in any way invalidate
the findings of the experiments detailed here.
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Presynaptic action of NPY on nerve terminals: histological and
physiological studies.
An inhibition, by NPY, of stimulus-evoked irSP release from the
central terminals of unmyelinated primary afferent fibres would
explain the present results. At the time these results were published
the only fine structural study on the relationship between NPY-
containing elements and primary afferent pathways was in the lamprey
(Bongianni et al, 1990), where varicosities showing immunoreactivity
for NPY were found in close apposition to the ascending and
descending branches of primary afferent neurones. Since then, Doyle
and Maxwell (1993a) have identified axo-axonic contacts in the SG of
the cat containing NPY, thus providing an anatomical corroboration
for the findings of the present study.
In the periphery, several actions of NPY on nerve terminals have
been described. There is evidence that NPY released from sympathetic
nerve terminals contacting blood vessels acts as a negative feedback
mechanism, controlling not only its own release but also that of
noradenaline (Stjarne and Lundberg, 1986, Wahlestedt et al, 1986).
High intensity stimulation of cardiac sympathetic nerves results in
prolonged inhibition of the ability of the vagus to slow the heart.
This effect, which is mimicked by NPY application, is believed to
result from an inhibition of acetylcholine release from vagal endings
(Kilborn et al, 1985) . Little previous work can be cited on the
effects of NPY on tachykinin release, but Guiliani et al (1989) have
demonstrated an inhibition, by NPY, of tachykinin release from the
peripheral terminals of capsaicin-sensitive nerve fibres in the
airways of the guinea-pig.
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There is also electrophysiological evidence for presynaptic
actions of NPY in the CNS. Studies on cultured dorsal root ganglion,
hippocampal and sympathetic neurones (Bleakman et al, 1992, Toth et
al, 1993, and Walker et al, 1988) indicate that NPY inhibits calcium
influx across the membranes of these cells, possibly via the
secondary messenger protein kinase C (Ewald et al, 1988) . Inhibition
of depolarisation-evoked SP release has also been observed in
cultured dorsal root ganglion neurones (Walker et al, 1988) and these
two effects may be linked. In the hippocampus of the rat both Colmers
et al, (1985,1991) and Hass et al, (1987) demonstrated inhibition of
release of an excitatory transmitter, possibly L-glutamate, by NPY
(10~®M) added to the perfusate of a slice preparation. It is
important to emphasise that these latter effects were obtained in
slice preparations which lack a blood supply, since vascular effects
need to be considered when any compound is injected into or
superfused onto the brain or spinal cord under in vivo conditions.
NPY is known to contract blood vessels (Westfall et al, 1988), and so
a contribution by such an effect to the present results should not be
excluded. It is not, however, known if the small intrinsic vessels of
the spinal cord bear NPY receptors.
Possible interactions between NPY and other inhibitory systems.
NPY has been shown to coexist with the classical inhibitory
neurotransmitter GABA in neurones of the spinal cord (Rowan et al,
1993) and brain (Aoki, 1989,1990, Jones and Hendry, 1986). As a dense
plexus of both NPY-containing fibres (man: Allen et al, 1984, rabbit:
Blessing et al, 1987, elasmobranch: Cameron et al, 1990, rat:
Chronwell et al, 1985, Henschen et al, 1988, Hunt et al, 1981 cat:
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Krukoff, 1987) and noradrenaline-containing fibres (these being
largely of supraspinal origin) exist in the dorsal horn of several
species (rat: Rajaofetra et al, 1992, Schroder and Skagerberg, 1985,
cat: Doyle and Maxwell, 1991a,b,1993b, Lackner, 1980, primate:
Westlund et al, 1984), this might be taken as evidence to suggest a
coexistence of NPY with catecholamines in descending inhibitory
fibres of supraspinal origin. Although NPY does, indeed, coexist with
noradrenaline in a subpopulation of neurones in the locus coeruleus,
(Everitt et al, 1984, Holets et al, 1988), only 2% of such neurones
actually project to the ipsilateral spinal cord as opposed to other
areas of the CNS. As the locus coeruleus represents one of the major
CNS sites giving rise to the noradrenergic terminals seen in the
dorsal spinal cord, this would suggest that coexistence of NPY with
noradrenaline in fibres of the dorsal spinal cord is likely to be
limited at best.
The effects of NPY in the present experiments could act
synergistically to those of noradrenaline in the control of spinal
transmission of nociceptive information. NPY is present in intrinsic
spinal neurones (Krukoff, 1987, Sasek and Elde, 1985) and release
from such neurones might represent a mechanism by which NPY might
presynaptically alter release of neurotransmitters from primary
afferent terminals in vivo. As detailed in section 4, intrathecal
administration of noradrenaline inhibits spinal reflexes to
peripheral noxious stimuli, and microinophoretic administration of
noradrenaline in the region of the SG suppresses the transmission of
nociceptive information to deeper neurones. My own studies on
noradrenaline did not, however, support a presynaptic inhibition of
irSP release from primary afferent terminals in the SG underlying
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these effects. Noradrenaline has, however, been shown to
hyperpolarise neurones of the rat SG in vitro (North and Yoshimura,
1984) and thus a system whereby noradrenaline and NPY, asreleased
from terminals in the SG, might interact in the inhibition of primary
afferent signal propagation can be envisaged. In such a scheme NPY
acts presynaptically on the primary afferent terminal to reduce
stimulus-evoked transmitter release, while at the same time
noradrenaline reduces the excitability of postsynaptic structures. As
previously mentioned, Doyle and Maxwell (1993a) have identified axo¬
axonic contacts in the SG of the cat containing NPY, thus providing
an anatomical corroboration for such a hypothesis.
NPY receptor subtypes.
Inevitably, more than one type of NPY receptor is now recognised
I
(Aicher et al, 1991, Doods and Krause, 1991, Dumont et al, 1992,
Potter and McCloskey, 1992). Fuxe et al (1990) have suggested
differing functions for the 'high' and 'low' affinity types of NPY
receptor. Low affinity NPY (Y1 or postjunctional) receptors are
proposed as being localised to subsynaptic areas where high levels of
undegraded NPY are encountered. High affinity NPY (Y2 or
prejunctional) receptors are proposed to occur remotely from sites of
NPY release, their activation relying on diffusion of NPY from those
sites; this process has been termed 'volume transmission' (Fuxe and
Agnati, 1991), a concept which was discussed much earlier in relation
to tachykinin function. A proportion of released NPY molecules may be
degraded by peptidases in vivo and one product of this degradation,
the fragment NPY (13-36), can be used as a potent and selective
agonist for the Y2 receptor (Aicher et al, 1991) . This observation
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adds further support to the proposition of Fuxe et al that Y2
receptors might mediate the effects of NPY at sites remote from its
initial release. High affinity sites for NPY have been identified in
the SG of the rat trigeminal nucleus (Nakajima et al, 1986) and hence
if the hypothesis of Fuxe et al is correct then a somatotopically
diffuse inhibition of SP release may follow synaptic release of NPY.
Fortuitously, it is the Y2 receptor which has been implicated in the
aforementioned block, by NPY, of calcium currents in cultured dorsal
root ganglion neurones (Bleakman et al, 1991).
Conclusion.
The results presented in this section, taken in conjunction with
the recent histological findings of Doyle and Maxwell (1993a),
strongly support the existence of a presynaptic control of tachykinin
release from primary afferent terminals in the superficial dorsal
horn mediated by NPY. As discussed, it is most likely that this NPY
is derived, in vivo, from intrinsic neurones of the spinal cord
itself, but such an inhibitory mechanism might complement the actions






My primary intention in this section is not to present a
scientific discussion of my findings (this has already been done for
the three series of experiments presented in the preceding sections)
Rather I would wish to draw together my personal feelings about the
results obtained and the overall value of these studies.
The antibody microprobe technique has been applied to studies of
neurotransmitter release within several neural tissues. The studies
presented here relate more specifically to the investigation of how
particular classes of antinociceptive drugs might exert their effects
at the level of the spinal cord.
The spinal cord may be viewed as a highly complex system.
Synaptic events can be fast or slow, multiple transmitters may be
released at many synapses, (influencing the pre- and postsynaptic
effects of each other, limiting each others release and possibly even
modulating intrasynaptic events). We can, via hybridisation
histochemistry, measure the potential production rates of
neurotransmitters in vivo and these may be altered as part of
physiological control mechanisms. Similarly, cellular production of
enzymes and of the membrane substrates for reuptake mechanisms may be
up- or down-regulated in particular situations. Multiple receptors
exist for almost every identified neurotransmitter and multiple
second messenger systems exist within cells to mediate the effects of
receptor activation. A multitude of potential neurotransmitters exist
and in many cases their functions have not yet been elucidated (even
the tachykinins themselves cannot yet be fully classified
functionally) . The spinal cord is far from static in its physiology,
or in popular terms it shows a marked "plasticity". The consequences
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(both positive and negative) of this plasticity for clinical pain
management regimes are extensive (McQuay and Dickenson, 1990). Into
this complexity of mechanisms and interactions we inserted antibody
microprobes and tried to make a logical interpretation of our
findings. In order to do this we had to make several assumptions
regarding the ongoing physiology of the spinal cord.
1) That tachykinins were released in response to peripheral
noxious stimulation in a nocispecific manner. Furthermore, that this
release was over an anatomically defined area of the spinal cord and
was reproducible from one animal to another.
2) That the drugs studied were known to block the transmission
of nociceptive information at the level of the spinal cord.
3) That the hypothesis of Jessell and Iversen (1977) could
justifiably be applied to these drugs in terms of the known
distribution of endogenous neurotransmitters within cat spinal cord.
Studies by our own group and others have been cited throughout
this thesis in support of the above points. In relation to point 3)
above, however, the work of Doyle and Maxwell (1991a,b,1993a,b)
should again be emphasised. This group failed to identify any
catecholamine containing axo-axonic contacts in cat spinal dorsal
horn, although such contacts staining for neuropeptide Y (NPY) were
readily apparent. This work was concurrent with our own and so
supports our findings rather than suggesting that the
noradrenaline/medetomidine study was misconceived. Similar comments
apply to the findings of Cho and Basbaum (1988, 1989) on opioid
peptide containing contacts in spinal cord.
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The initial impetus was to study drugs of veterinary relevance.
Opiates and a2 adrenergic agonists were initially chosen as these
represent two classes of drugs used clinically to provide everything
from simple analgesia to deep sedation depending on dose. The
intention was to determine if these drugs were working, in part, by
means of a presynaptic inhibition of nociceptive afferent fibre
discharge in the spinal dorsal horn. What can we ultimately conclude
from the findings of these studies?
Morphine , at clinical doses, produces no net inhibition of NKA
release in vivo. As a finding in its own right I feel that this is of
significance. Such presynaptic inhibition has often been assumed to
be one of the main mechanisms of opiate spinal analgesia. Morphine is
a very potent analgesic in man and, if correctly administered,
equally effective in domestic species, despite the myths and
preconceptions which surround its use in species such as the cat
where misdosing may cause excitement rather than sedation. As with
most neuroactive drugs there are multiple receptors which may be
activated by opiate drugs. In the case of morphine most of its
analgesic effects will be mediated via mu receptors for which, almost
inevitably, subtypes are now being suggested. Morphine also shows
significant affinity for delta opioid receptors, and low but
detectable binding with the kappa receptor type (Kosterlitz et al,
1985) . The effects of morphine at these different receptors are
likely to be varied in terms of analgesia (either in terms of which
modalities of nociceptive input are blocked, with regard to which
part of the transmission pathway is involved, or even in terms of
contrasting algesic effects; see Duggan et al, 1981, Fleetwood-Walker
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et al, 1988,1990, Hope et al, 1990a, Morton et al, 1987, Onofrio and
Yaksh, 1983, Schmauss and Yaksh, 1983, Zhao et al, 1986) . Thus we
must say that morphine applied systemically has no net effect on
primary afferent release of NKA and that it is unlikely that such an
effect contributes to the clinical analgesia produced by the drug.
What about other opioid/opiate drugs in clinical usage? These have
different receptor specificities from morphine and different ranges
of effects. Pentazocine, for example is predominantly active at
kappa opioid receptors and is used for pain management in various
domestic species, although in man it is less popular due to a
relatively high incidence of dysphoria associated with its use.
Further studies on the effects of the different opiate
analgesics, or maybe more practically of opioid receptor specific
ligands, might show different effects on presynaptic inhibition of
tachykinin release. The principal problem in the late 1980's, when
the morphine study was started, was the relatively limited
availability of experimental opioid ligands showing activity in the
CNS when administered systemically. In addition to this it was
decided that NKA was not the ideal neurotransmitter on which to
perform inhibition studies, mainly due to its persistence following
release. As Morton et al were at that time studying the effects of
opiates on substance P (SP) release (Morton et al, 1990) we ourselves
did not perform follow-up experiments on the effects of opioid drugs
on tachykinin release. The technique of intra-spinal drug
administration was developed in the subsequent study on adrenergic
agonists.
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Noradrenaline/Medetomidine The effects of these compounds
(administered intraspinally) on stimulus-evoked SP release were
studied. Noradrenaline, the classical example of an endogenous a2
adrenergic receptor agonist, did not reduce stimulus evoked SP
release. The technique of spinal drug administration was a new one to
our group and rather than simply increasing the concentration of
noradrenaline used (which would have increased al receptor
activation) we opted to use the new imidazoline compound medetomidine
which has a much higher a2 selectivity. This was also without effect.
The results of this study are perhaps the most controversial of those
presented here. Noradrenaline has classically been associated with
descending and segmental inhibitory pathways in the spinal cord and
its actions have (as with opiate drugs) often been attributed to pre¬
synaptic inhibition at primary afferent terminals. The lack of effect
of medetomidine and the findings of Doyle and Maxwell (1991a,b,
1993a,b), do however strengthen our case. SP is a much better choice
of compound for these studies than NKA, being short-lived in vivo and
more restricted in its distribution following release. A more
interesting result would have been an inhibitory effect evident with
medetomidine but not with noradrenaline. Such an effect would have at
that time been attributed either to activation of imidazoline binding
sites by medetomidine or an antagonistic effect mediated by al
receptors activated (significantly) by noradrenaline only. Further
studies utilising available antagonists would then have been of great
interest; regrettably the necessity for these did not arise.
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Neuropeptide Y Studies on NPY ran in parallel with the
noradrenaline studies. The potential for an interaction, in
modulating primary afferent transmission, between NPY and
noradrenaline have already been discussed in section 5.
Microinjections of small volumes of NPY at concentrations of 10~^ to
10~^M did inhibit the noxious stimulus evoked release of SP. To date
this is the only compound which has been shown, with the antibody
microprobe technique, to inhibit tachykinin release from primary
afferent terminals. The support of our findings by the concurrent
anatomical studies of Doyle and Maxwell (1993a) has already been
emphasised.
What have these studies contributed to the field of
neuroscience? The morphine and a2 adrenoceptor agonist studies have,
at least, indicated that these drugs do not work by the presynaptic
mechanism often attributed to them (at least in terms of primary
afferent pathways utilising tachykinin peptides). This indicates a
possible area for the development of new analgesic drugs ie.
compounds which do target these sites of neurotransmitter release.
NPY appears to do just this, but NPY is a neuropeptide widely
distributed in the central nervous system (CNS), and difficulties
might arise with the use of drugs active at its receptors in a
clinical context. Systemic administration of such drugs might have
diverse effects in the whole animal, some of these effects being
detrimental to the animals well-being. Morphine, however, has become
popular and is effective as a systemically administered analgesic
drug despite having a similar 'whole-nervous system' effect. In the
case of morphine the clinical advantages of its use outweigh the
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disadvantages (respiratory depression, tolerance, addiction,
dysphoria etc). Drugs active at NPY receptors might prove to have a
similar positive balance of therapeutic value. The NPY study is also
of great value to our research group, however, providing evidence
that antibody microprobes can be used to detect quantitative changes
in immunoreactive SP release over a period of time.
Further studies. Incorporated in the end of this volume are
reprints of papers published from the results of the antibody
microprobe studies with which I have been involved during my period
of study in Edinburgh. Several different compounds have been
successfully measured in CNS structures, including NKA, SP, beta-
endorphin and galanin, and studies have been performed in both the
cat and rat. The antibody microprobe technique can be applied to the
detection of many peptides but it must be noted that not all studies
are successful. To date studies on endothelin and dynorphin release
have failed to yield consistent data, and a study on the effects of
intraspinal serotonin administration on SP release also presented
technical difficulties.
Antibody microprobes, in their present form, are best suited to
the detection of peptides in neural tissue on a simple yes/no basis.
It is not possible at the present time to make them truly
quantitative. Gross changes in peptide distribution following drug
administration are readily detected (eg. the effects of calcitonin
gene-related peptide (CGRP)/peptidase inhibitors on the pattern of
stimulus-evoked SP release), but more subtle changes may be beyond
the present limit of antibody microprobe sensitivity. Modifications
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of the technique may be possible in the future and I would divide
such changes into three areas:
1) Improvement of sensitivity. Maximisation of density and
affinity of ligand binding sites on microprobe surfaces. This may
involve the production of higher affinity antisera against the
peptides being studied or alternatively changes to the way in which
antibody molecules are chemically bound to the microprobes.
Comments have already been made about the subtle differences in
the pattern of stimulus-evoked SP release in the spinal cord between
early (Duggan and Hendry, 1986, Duggan et al, 1988b) and more recent
antibody microprobe studies (notably Duggan et al, 1991a, see also
section 5), and these may simply be due to improved antibody
microprobe sensitivity. Thus the original antibody microprobe papers
of Duggan and co-workers (1986,1988b) revealed a stimulus-evoked
pattern of irSP release confined to the superficial laminae of the
dorsal horn, and a basal presence which was not only an inconsistent
finding but which was in low levels when present and which was
certainly not detectable in the deeper laminae of the dorsal horn.
The existence of a basal presence of irSP has never been re-evaluated
per se, but subtle changes in the antibody microprobe technique over
the last five years may account for a basal presence of irSP now
being detectable, as illustrated in section 5.
2)Improvement of image analysis systems. Iodinated markers for
unoccupied antibody binding sites do provide a high resolution means
of imaging the distribution of peptide on microprobe surfaces. The
main drawback of this technique is the delay (in some cases of weeks)
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between the experiment and the visualisation of results. The
development of fluorescent, rather than radioactive, markers may
allow a more "instant" analysis of peptide distribution on
microprobes. Taking this one step further it may in the future be
possible to perform such analysis in situ ie. with the peptide
binding itself producing fluorescence and the light produced being
measured optically from within the microprobe barrel.
3)Application of the technique to different media and sites eg.
using antibodies bound to planar surfaces as opposed to conical
forms. Such modification (with suitable alterations in image analysis
technique) might allow the visualisation of peptide release from, for
example, meninges or structures of the gastrointestinal tract. The
basic principles of the antibody microprobe technique might also be
applied to cell culture media in order to monitor the peptide
production of growing cells.
These are changes which might be pursued in the antibody
technique itself. Different types of study would now also be of
interest with a view to extending the results obtained over the last
few years. It is clear that the afferent terminal is by no means the
only site at which analgesia can be produced. Even confining studies
to the first synapse, intra-synaptic events (again as in the case of
the CGRP/peptidase inhibitor studies) may be further manipulated with
the aim of producing analgesia. At the post-synaptic membrane the
many receptor subtypes may all mediate different effects. Receptor
specific antagonism as opposed to blockade of neurotransmitter
release may prove to be a more viable means of producing a defined
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analgesia without other functional deficits. The blockade of specific
second messenger systems may be of equal value, but before this can
be assessed the actual functions of these receptor/messenger subtypes
must be evaluated. Such studies are currently being undertaken by
various groups (Fleetwood-Walker et al, 1993, Parker et al, 1993,
Picard et al, 1993, Thompson et al, 1993, Wienrich et al, 1989).
Whole animal studies are also of interest, particularly if they
can be directly applied to clinical case material. I would propose
that it should now be possible (utilising some of the techniques used
in the studies presented here) to develop a biochemical assay for
"pain" in domestic species. Pain is of course a perceptual event, not
readily quantifiable in domestic species. What would really be
measured would be maintained nociceptive input from either somatic or
visceral structures to the CNS. Plasma levels of NKA may reflect such
ongoing input, and their evaluation by radioimmunoassay may provide a
useful diagnostic/prognostic tool in veterinary and human medicine.
Although SP has been measured in this fashion in human plasma,
cerebrospinal fluid, saliva and articular fluid (Marshal et al, 1990,
Parris et al, 1990, Tamsen et al, 1982) such work has provided no
clear correlation with pain perception and studies on NKA are
curiously limited. Measurement of dynorphin levels in a similar
fashion (perhaps in cerebrospinal fluid) may equally be of value in
the assessment of spinal cord injuries.
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With the advent of more refined analytical and experimental
techniques the apparent contributions that the tachykinin peptides
and their receptors make to spinal cord processing continue to
increase. As our understanding of the whole field of neuroscience
becomes more complete, it is clear that many, many opportunities for
the development of novel analgesics must exist but at the same time
our overall understanding of how the spinal cord actually functions
is in some ways getting more confused. The true picture of spinal
cord processing is a very large and very complex puzzle; we are still
taking the pieces out of the box. I hope that the work presented in
this thesis has helped to shape a couple of those pieces.
196
BIBLIOGRAPHY
1 Aantaa, A., Jaakola, M.-L., Kallio, A., Kanto, J., Scheinin, M.
and Vuorinen, J., A comparison of dexmedetomidine, an alpha2-
adrenoceptor agonist, and midazolam as i.m. premedication for minor
gynecological surgery, Br. J. Anaes., 67 (1991) p402-409.
2 Advenier, C., Rouissi, N., Nguyen, Q.T., Emonds-Alt, X.,
Breliere, J.-C., Neliat, G., Naline, E. and Regoli, D., Neurokinin A
(NK2) receptor revisited with SR 48968, a potent non-peptide
antagonist, Biochem. Biophys. Res. Comm., 184 (1992) pl418-1424.
3 Aho, M. , Erkola, 0., Kallio, A., Scheinin, H. and Korttila, K.,
Dexmedetomidine infusion for maintenance of anesthesia in patients
undergoing abdominal hysterectomy, Anesth. Analg., 75 (1992) p940-
94 6.
4 Aicher, S.A., Springston, M., Berger, S.B., Reis, D.J. and
Wahlestedt, C., Receptor-selective analogs demonstrate NPY/PYY
receptor heterogeneity in rat brain, Neurosci. Lett., 130 (1991) p32-
36.
5 Aimone, L.D. and Yaksh, T.L., Opioid modulation of capsaicin-
evoked release of substance P from rat spinal cord in vivo, Peptides,
10 (1989) pll27-1131.
6 Akasu, T. and Tokimasa, T., Potassium currents in submucous
neurones of guinea-pig caecum and their synaptic modification, J.
Physiol., 416 (1989) p571-588.
7 Allen, J.M., Gibson, S.J., Adrian, T.E., Polak, J.M. and Bloom,
S.R., Neuropeptide Y in human spinal cord, Brain Res., 308 (1984)
pl45-148.
8 Allerton, C.A., Smith, J.A.M., Hunter, J.C., Hill, R.G. and
Hughes, J., Correlation of ontogeny with function of [3H]U69593
labelled kappa opioid binding sites in the rat spinal cord, Brain
Res., 502 (1989) pl49-157.
9 Anastasi, A., Erspamer, V. and Endean, R. , Structure of
uperolein, a physalaemin-like endecapeptide occurring in the skin of
Uperoleia rugosa and Uperoleia marmarota, Experentia, 31 (1975) p394-
395.
10 Anastasi, A., Montecucchi, P., Erspamer, V. and Visser, J., Amino
acid composition and sequence of kassinin, a tachykinin dodecapeptide
from the skin of the African frog Kassina senegalensis, Experentia,
33 (1977) p857-858.
11 Anggard, A., Lundberg, J.M., Hokfelt, T., Nilsson, G.,
Fahrenkrug, I. and Said, S., Innervation of the cat nasal mucosa with
special reference to relations between peptidergic and cholinergic
neurons, Acta. Physiol. Scand., (Suppl.)473 (1979), p50.
12 Aoki, C. and Pickel, V.M., Neuropeptide Y in the cerebral cortex
and the caudate-putamen nuclei: ultrastructural basis for
interactions with GABAergic and non-GABAergic neurons, J. Neurosci.,
9 (1989) p4333-4354.
197
13 Aoki, C. and Pickel, V.M., Neuropeptide Y in cortex and striatum:
Ultrastructural distribution and coexistence with classical
neurotransmitters and neuropeptides, Ann. NY Acad. Sci., 611 (1990)
pl86-205.
14 Arai, H. and Emson, P.C., Regional distribution of neuropeptide K
and other tachykinins (neurokinin A, neurokinin B and substance P) in
rat central nervous system, Brain Res., 399 (1986) p240-249.
15 Ashton, N., Argent, B.E. and Green, R. , Effects of vasoactive
intestinal peptide, bombesin and substance P on fluid secretion by
isolated rat pancreatic ducts, J. Physiol., 427 (1990) p471-482.
16 Atweh, S.F. and Kuhar, M.L., Autoradiographic localization of
opiate receptors in rat brain: I. Spinal cord and lower medulla,
Brain Res., 124 (1977) p53-67.
17 Austin, J.H., Nygren, L.G. and Fuxe, K., A system for measuring
the noradrenaline receptor contribution to the flexor reflex, Med.
Biol., 54 (1976) p352-363.
18 Bannon, M.J., Elliot, P.J. and Bunney, E.B., Striatal tachykinin
biosynthesis, regulation of mRNA and peptide levels by dopamine
agonists and antagonists, Molec. Brain Res., 3 (1987) p31-37.
19 Barber, R.P., Vaughn, J.E., Slemmon, J.R., Salvaterra, P.M.,
Roberts, E. and Leeman, S.E., The origin, distribution and synaptic
relationships of substance P axons in rat spinal cord, J. Comp.
Neurol., 184 (1978) p33-55.
20 Barnes, K., Bourne, A., Cook, P.A., Turner, A.J. and Kenny, A. J.,
Membrane peptidases in the peripheral nervous system of the pig:
their localization by immunohistochemistry at light and electron
microscopic levels, Neuroscience, 44 (1991) p245-261.
21 Basbaum, A.I. and Fields, H.L., Endogenous pain control systems:
brainstem spinal pathways and endorphin circuitry, Ann. Rev.
Neurosci., 7 (1984) p309-338.
22 Battaglia, G. and Rustioni, A., Co-existence of glutamate and
substance P dorsal root ganglion neurones of the rat and monkey, J.
Comp. Neurol., 277 (1988) p302-312.
23 Beaujouan, J.-C., Teutsch, B., Saffroy, M. , Petitet, F., Torrens,
Y. and Glowinski, J., NK-1 receptors are the only class of tachykinin
receptors found on mouse cortical astrocytes, Peptides, 12 (1991)
p813-820.
24 Beaujouan, J.C., Daguet de Montety, M.C., Torrens, Y., Saffroy,
M. , Dietl, M. and Glowinski, J., Marked regional heterogeneity of
1251-Bolton Hunter substance P binding and substance P induced
activation of phospholipase in astrocyte cultures from the embryonic
or newborn rat, J. Neurochem., 54 (1990) p669-675.
25 Beaujouan, J.C., Torrens, Y., Saffroy, M. and Glowinski, J.,
Quantitative autoradiographic analysis of the distribution of binding
sites for 1251 Bolton Hunter derivatives of eledoisin and substance P
in the rat brain, Neuroscience, 18 (1986) p857-875.
198
26 Benedetti, C., Acute pain: A review of its effects and therapy
with systemic opioids, Advances in Pain Research and Therapy, 14
(1990) p367-424.
27 Bergstrom, L., Beaujouan, J.C., Torrens, Y., Saffroy, M.,
Glowinski, J., Lavielle, S., Chassaing, G., Marquet, A., D'Orleans-
Juste, P. and Dion, S., 3H-Neurokinin A labels a specific tachykinin-
binding site in the rat duodenal smooth muscle, Molec. Pharmacol., 32
(1987) p7 64-771.
28 Bernard, J.-M., Hommeril, J.-L., Passuti, N. and Pinaud, M.,
Postoperative analgesia by intravenous clonidine, Anesthesiology, 75
(1991) p577-582.
29 Biella, G., Panara, C., Pecile, A. and Sotgiu, M.L., Facilatatory
role of calcitonin gene-related peptide (CGRP) on excitation induced
by substance P (SP) and noxious stimuli in rat spinal dorsal horn
neurons. An iontophoretic study in vivo, Brain Res., 559 (1991) p352-
356.
30 Bill, A., Effects of some neuropeptides on the uvea, Exp. Eye
Res., 53 (1991) p3-ll.
31 Birrell, G.J., McQueen, D.S., Iggo, A. and Grubb, B.D., The
effect of 5-HT on articular sensory receptors in normal and arthritic
rats, Br. J. Pharmacol., 101 (1990) p715-721.
32 Bisby, M.A. and Keen,P., Regeneration of primary afferernt
neurons containing substance P-like immunoreactivity, Brain Res., 365
(1986) p85-95
33 Bishop, J.F., Moody, T.W. and O'Donohue, T.L., Peptide
transmitters of primary sensory neurons: similar actions of
tachykinins and bombesin-like peptides, Peptides, 7 (1986) p835-842.
34 Bleakman, D., Colmers, W.F., Fournier, F. and Miller, R.J.,
Neuropeptide Y inhibits Ca++ influx into cultured dorsal root
ganglion neurones of the rat via a Y2 receptor, Br. J. Pharmacol.,
103 (1991) pl781-1789.
35 Bleakman, D., Harrison, N.L., Colmers, W.F. and Miller, R.J.,
Investigations into neuropeptide Y-mediated presynaptic inhibition in
cultured hippocampal neurones of the rat, Br. J. Pharmacol., 107
(1992) p334-34 0.
36 Blessing, W.W., Oliver, J.R., Hodgson, A.H., Joh, T.H. and
Willoughby, J.O., Neuropeptide Y-like immunoreactive CA1 neurones in
the rostral ventrolateral medulla of the rabbit project to
sympathetic preganglionic neurones in the spinal cord, J. Auton.
Nerv. Syst., 8 (1987) pl21-129.
37 Bongianni, F., Christenson, J., Hokfelt, T. and Grillner, S.,
Neuropeptide Y-immunoreactive spinal neurons make close appositions
on axons of primary sensory afferents, Brain Res., 523 (1990) p337-
341.
38 Booth, N.H., Drugs acting on the central nervous system. In
Veterinary Pharmacology and Therapeutics, Vol. 6 , Iowa State
University Press, 1988.
199
39 Botticelli, L.J., Cox, B.M. and Goldstein, A., Immunoreactive
dynorphin in mammalian spinal cord and dorsal root ganglia, Proc.
Natl. Acad. Sci. (USA), 78 (1981) p7783-7786.
40 Bouchenafa, O. and Livingstone, A., Autoradiographic localisation
of alpha 2 adrenoceptor binding sites in the spinal cord of the
sheep, Res. Vet. Sci., 42 (1987) p382-386.
41 Boylan, M.K., Levine, M.S., Buchwald, N.A. and Fisher, R.S.,
Patterns of tachykinin expression and localization in developing
feline neostriatum, J. Comp. Neurol., 293 (1990) pl51-163.
42 Bristow, D.R., Curtis, N.R. and Suman Chauhan, N., Effects of
tachykinins on inositol phospholipid hydrolysis in slices of hamster
urinary bladder, Br. J. Pharmacol., 90 (1987) 211-217.
43 Brodin, E., Gazelius, B., Olgart, L. and Nilsson, G. , Tissue
concentration and release of substance P-like immunoreactivity in the
dental pulp, Acta. Physiol. Scand., Ill (1981) pl41-149.
44 Brodin, E., Lindefors, N., Dalsgaard, C.J., Theodorsson-Norheim,
E. and Rosell, S., Tachykinin multiplicity in rat central nervous
system as studied using antisera raised against substance P and
neurokinin A, Regul. Pept., 13 (1986) p253-272.
45 Brodin, E., Linderoth, B., Gazelius, B. and Ungerstedt, U., In
vivo release of substance P in cat dorsal horn studied with
microdialysis, Neurosci. Lett., 76 (1987) p357-362.
46 Brodin, E. and Nilsson, G., Concentration of substance P-like
immunoreactivity in tissues of dog, rat and mouse, Acta. Physiol.
Scand., 112 (1981) p305-312.
47 Brown, E.R., Haran, R.E. and Krause, J.E., Gonadal steroid
regulation of substance P (SP) and SP-encoding messenger ribonucleic
acids in the rat anterior pituitary and hypothalamus, Endocrinology,
126 (1990) p330-340.
48 Brownstein, M.J., Mroz, E.A., Kizer, J.S., Palkovitz, M. and
Leeman, S.E., Regional distribution of substance P in the brain of
the rat, Brain Res., 116 (1976) p299-305.
49 Buck, S.H., Burcher, E., Shults, C.W., Lovenberg, W. and
O'Donohue, T.L., Novel pharmacology of substance K-binding sites: a
third type of tachykinin receptor, Science, 226 (1984) p987-989.
50 Buck, S.H., Helke, C.J., Burcher, E., Shults, C.W. and O'Donohue,
T.L., Pharmacologic characterisation and autoradiographic
distribution of binding sites for iodinated tachykinins in the rat
central nervous system, Peptides, 7(6) (1986) pll09-1120.
51 Bucsics, A.P., Holzer, P. and Lembeck, F. , The substance P
content of peripheral tissues in several mammals, Peptides, 4 (1983)
p451-455
52 Burcher, E., Shults, C.W., Buck, S.H., Chase, T.N. and O'Donohue,
T.L., Autoradiographic distribution of substance K binding sites in
rat gastrointestinal tract: a comparison with substance P, Eur. J.
Pharmacol., 102 (1984) p561-562.
200
53 Burgunder, J.M. and Young, W.S.III., Neurokinin B and substance P
genes are co-expressed in a subset of neurons in the rat habendula,
Neuropeptides, 13 (1989a) pl65-169.
54 Burgunder, J.M. and Young, W.S.III., Distribution, projection and
dopaminergic regulation of the neurokinin B mRNA-containing neurons
of the rat caudate-putamen, Neuroscience, 32 (1989b) p323-335.
55 Calvillo, 0. and Ghignone, M., Presynaptic effect of clonidine on
unmyelinated afferent fibers in the spinal cord of the cat, Neurosci.
Lett., 64 (1986) p335-339.
56 Camarata, P.J. and Yaksh, T.L., Characterization of the spinal
adrenergic receptors mediating the spinal effects produced by
microinjection of morphine into the periaqueductal gray, Brain Res.,
336 (1985) pl33-142.
57 Cameron, A.A., Leah, J.D. and Snow, P.J., The coexistence of
neuropeptides in feline sensory neurons, Neuroscience, 27 (1988)
p969-97 9.
58 Cameron, A.A., Plenderleith, M.B. and Snow, P.J., Organization of
the spinal cord in four species of elasmobranch fish:
cytoarchitecture and distribution of serotonin and selected
neuropeptides, J Comp. Neurol., 297 (1990) p201-218.
59 Carstens, E., Gilly, H., Schreiber, H. and Zimmerman, M., Effects
of midbrain stimulation and iontophoretic application of serotonin,
noradrenaline, morphine and GABA on electrical thresholds of afferent
C- and A- fibre terminals in cat spinal cord, Neuroscience, 21 (1987)
p395-406.
60 Carstens, E., Klumpp, D. and Zimmermann, M., Differential
inhibitory effects of medial and lateral midbrain stimulation on
spinal neuronal discharges to noxious skin heating in the cat, J.
Neurophysiol., 43 (1980) p332-342.
61 Carter, M.S. and Krause, J.E., Structure, expression and some
regulatory mechanisms of the rat preprotachykinin gene encoding
substance P, neurokinin A, neuropeptide K and neuropeptide gamma, J.
Neurosci., 10 (1990) p2203-2214.
62 Cascieri, M.A., Chicchi, G.G. and Liang, T., Demonstration of two
distinct tachykinin receptors in rat brain cortex, J. Biol. Chem.,
260 (1985) pl501-1507.
63 Catley, D.M., Clarke, R.W. and Pascoe, J.E., Naloxone enhancement
of spinal reflexes in the rabbit, J. Physiol., 339 (1983) p61-73.
64 Cervero, F., Handwerker, H.O. and Laird, J., Prolonged noxious
mechanical stimulation of the rat's tail. Responses and encoding
properties of dorsal horn neurones, J. Physiol., 404 (1988) p419-436.
65 Chahl, L.A., Morphine produces release of substance P-like
immunoreactivity from guinea-pig central nervous system, Neurosci.
Lett., 118 (1990) p88-90.
201
66 Chan-Palay, V. and Palay, S.L., Immunocytochemical identification
of substance P cells and their processes in rat sensory ganglia and
their terminals in the spinal cord: light microscopic studies, Proc.
Natl. Acad. Sci. (USA), 74 (1977a) p3597-3601.
67 Chan-Palay, V. and Palay, S.L., Ultrastructural identification of
substance P cells and their processes in rat sensory ganglia and
their terminals in the spinal cord by immunocytochemistry, Proc.
Natl. Acad. Sci. (USA), 74 (1977b) p4050-4054.
68 Chang, M.M. and Leeman, S.E., Isolation of a sialogogic peptide
from bovine hypothalamic tissue and its characterisation as substance
P, J. Biol. Chem., 245(18) (1970) p4784-4790.
69 Chang, M.M., Leeman, S.E. and Niall, H.D., Amino acid sequence of
substance P, Nature New Biol., 232 (1971) p86-87.
70 Chen, Z., Hedner, J. and Hedner, T., Local effects of substance P
on respiratory regulation in the rat medulla oblongata, J. Appl.
Physiol., 68 (1990) p693-699.
71 Cho, H.J. and Basbaum, A.I., Increased staining of immunoreactive
dynorphin cell bodies in the deafferented spinal cord of the cat,
Neurosci. Lett., 84 (1988) pl25-130.
72 Cho, H.J. and Basbaum, A.I., Ultrastructural analysis of
dynorphin-B immunoreactive cells and terminals in the superficial
dorsal horn of the deafferented spinal cord of the rat, J. Comp.
Neurol., 281 (1989) pl93-205.
73 Chronwell, B.M., Di Maggio, D.A., Massari, V.J., Pickel, V.M.,
Ruggerio, D.A. and O'Donohue, T.L., The anatomy of neuropeptide Y-
containing neurones in rat brain, Neuroscience, 15 (1985) pll59-1181.
74 Chubb, I.W., Hodgson, A.J. and White, G.H., Acetylcholinesterase
hydrolyses substance P, Neuroscience, 5 (1980) p2065-2072.
75 Chung, K.S., Lee, W.T. and Westlund, K.N., Adrenergic fibers in
the spinal cord of the monkey: light and electron microscopic study,
J. Auton. Nerv. Syst., 28 (1989) p203-210.
76 Clarke, K.W. and England, G.C.W., Medetomidine, a new sedative-
analgesic for use in the dog and its reversal with atipamezole, J.
Small Animal Practice., 30 (1989) p343-348.
77 Clarke, K.W. and Paton, B.S., Combined use of detomidine with
opiates in the horse, Equine Vet. J., 20 (1987) p331-334.
78 Clarke, K.W. and Taylor, P.M., Detomidine, A new sedative for
horses, Equine Vet. J., 18 (1986) p366-370.
79 Clarke, R.W., Ford, T.W. and Taylor, J.S., Adrenergic and
opioidergic modulation of a spinal reflex in the decerebrated rabbit,
J. Physiol., 404 (1988) p407-417.
80 Clarke, R.W., Ford, T.W. and Taylor, J.S., Activation by high
intensity peripheral nerve stimulation of adrenergic and opioidergic
inhibition of a spinal reflex in the decerebrated rabbit, Brain Res.,
505 (1989) pl-6.
202
81 Coles, S.J., Neill, K.H. and Reid, L.M., Potent stimulation of
glycoprotein secretion in canine trachea by substance P, J. Appl.
Physiol., 57 (1984) pl323-1327.
82 Collin, E., Mauborgne, A., Bourgoin, S., Chantrel, D., Hamon, M.
and Cesselin, F., In vivo tonic inhibition of spinal substance P (-
like material) release by endogenous opioid(s) acting at delta
receptors, Neuroscience, 44 (1991) p725-731.
83 Collins, J.G., Kitihata, L.M., Matsumoto, M. , Homma, E. and
Suzukawa, M., Spinally administered epinephrine suppresses noxiously
evoked activity of WDR neurons in the dorsal horn of the spinal cord,
Anesthesiology, 60 (1984) p269-275.
84 Colmers, W.F., Klapstein, G.J., Fournier, A., St-Pierre, S. and
Treherne, K.A., Presynaptic inhibition by neuropeptide Y in rat
hippocampal slice in vitro is mediated by a Y2 receptor, Br. J.
Pharmacol., 102 (1991) p41-44.
85 Colmers, W.F., Lukowiak, K. and Pittman, Q., Neuropeptide Y
reduces orthodromically evoked population spike in rat hippocampal
CA1 by a possibly presynaptic mechanism, Brain Res., 346 (1985) p404-
408.
86 Commissiong, J.W., The development of catecholaminergic nerves in
the spinal cord of the rat. II. Regional development, Brain Res., 313
(1983) p75-92.
87 Convents, A., De Backer, J.-P., De Keyser, J. and Vauquelin, G.,
High affinity binding of 3H Rauwolscine and 3H RX781094 to alpha-2
adrenergic receptors and non-stereoselective sites in human and
rabbit brain cortex membranes, Biochem. Pharmacol., 38 (1989) p455-
463.
88 Cook, A.J., Woolf, C.J., Wall, P.D. and McMahon, S.B., Dynamic
receptive field plasticity in rat spinal cord dorsal horn following
C-primary afferent input, Nature, 325 (1987) pl51-153.
89 Cooper, P.E., Fernstrom, M.H., Rorstad, O.P., Leeman, S.E. and
Martin, J.B., The regional distribution of somatostatin, substance P
and neurotensin in human brain, Brain Res., 218 (1981) p219-232.
90 Costa, M. , Cuello, A.C., Furness, J.B. and Franco, R. ,
Distribution of enteric neurons showing immunoreactivity for
substance P in the guinea-pig ileum, Neuroscience, 5 (1980) p323-331.
91 Coulson, I. H. and Holden, C.A., Cutaneous reactions to substance
P in atopic dermatitis, Br. J. Dermatology, 122 (1990) p343-349.
92 Couraud, J.Y., Frobert, Y. , Conrath, M., Renzi, D., Grassi, J.,
Drapeau, G., Regoli, D. and Pradelles, P., Monoclonal antibodies to
substance P: production, characterisation of their fine
specificities, and use in immunocytochemistry, J. Neurochem., 49
(1987) pl708-1719.
93 Couture, R. , Escher, E. and Regoli, D., Effects of substance P
analogues in the rat tail-flick test, Eur. J. Pharmacol., 134 (1987)
p355-359.
203
94 Couture, R. , Fournier, A., Magnan, J., St-Pierre, S. and Regoli,
D., Structure-activity studies on substance P, Can. J. Physiol.
Pharmacol., 57 (1979) pl427-1436.
95 Cridland, R.A. and Henry, J.L., Comparison of the effects of
substance P, neurokinin A, physalaemin and eledoisin in facilitating
a nociceptive reflex in the rat, Brain Res., 381 (1986) p93-99.
96 Cuello, A.C., Jessell, T.M., Kanazawa, I. and Iversen, L.L.,
Substance P: localisation in synaptic vesicles in rat central nervous
system, J. Neurochem., 29 (1977) p747-751.
97 Cuello, A.C. and Kanazawa, I., The distribution of substance P
immunoreactive fibres in the rat central nervous system, J. Comp.
Neurol., 178 (1978) pl29-156.
98 Cuello, A.C., Polak, J.M. and Pearse, A.G., Substance P: a
naturally occurring transmitter in human spinal cord, Lancet, 2
(1976) pl054-1056.
99 Curtis, D.R., Bornstein, J.C. and Lodge, D., In vivo analysis of
GABA receptors on primary afferent terminations in the cat, Brain
Res., 194 (1980) p255-258.
100 Curtis, D.R., Leah, J.D. and Peet, M.J., Effects of noradrenaline
and 5-hydroxytryptamine on spinal la afferent terminations, Brain
Res., 258 (1983) p328-332.
101 Curtis, D.R. and Lodge, D., The depolarization of feline ventral
horn group la spinal afferent terminations by GABA, Exp. Brain Res.,
46 (1982) p215-233.
102 Dalsgaard, C.-J., Jonsson, C.-E., Hokfelt, T. and Cuello, A.C.,
Localization of substance P-immunoreactive nerve fibres in the human
digital skin, Experentia, 39 (1983) pl018-1020.
103 Dalsgaard, C.J., The sensory system. In A. Bjorklund, T. Hokfelt
and C. Owman (Eds.), Handbook of Chemical Neuroanatomy. Vol.6,
Elsevier, New York, 1988, p599-636.
104 Dalsgaard, C.J., Haegerstrand, E., Theodorsson-Norheim, E.,
Brodin, E. and Hokfelt, T., Neurokinin A-like immunoreactivity in rat
primary sensory neurons: co-existence with substance P,
Histochemistry, 83 (1985) p37-39.
105 Dam, T.-V., Escher, E. and Quirion, R., Visualization of
neurokinin-3 receptor sites in rat brain using the highly selective
ligand [3H]-senktide, Brain Res., 506 (1990a) pl75-179.
106 Dam, T.-V. and Quirion, R., Pharmacological characterization and
autoradiographic localization of substance P receptors in guinea pig
brain, Peptides, 7 (1986) p855-864.
107 Dam, T.-V., Takeda, Y., Krause, J.E., Escher, E. and Quirion, R. ,
Gamma-preprotachykinin-(72_92)-peptide amide: an endogenous
preprotachykinin I gene-derived peptide that preferentially binds to
neurokinin-2 receptors, Proc. Natl. Acad. Sci. (USA), 87 (1990b)
p246-250.
204
108 Danks, J.A., Rothman, R.B., Cascieri, M.A., Chicchi, G.G., Liang,
T. and Herkenham, M. , A comparative autoradiographic study of the
distributions of substance P and eledoisin binding sites in rat
brain, Brain Res., 385 (1986) p273-281.
109 Danzebrink, R.M. and Gebhart, G.F., Antinociceptive effects of
intrathecal adrenoceptor agonists in a rat model of visceral
nociception, J. Pharmacol. Exp. Therap., 253 (1990) p698-705.
110 Dashwood, M.R., Dickenson, A.H., Knox, R. , Roques, B.P.,
Sullivan, A.F., Mu and delta opiate receptors: location and
influences on nociceptive transmission in the rat spinal cord,
J.Physiol., 376 (1986) p57P.
111 Davies, J., Effects of tizanidine, eperisone and afloqualone on
feline dorsal horn neuronal responses to peripheral cutaneous noxious
and innocuous stimuli, Neuropharmacology, 28 (1989) pl357-1362.
112 Davies, J. and Quinlan, J.E., Selective inhibition of responses
of feline dorsal horn neurones to noxious cutaneous stimuli by
tizanidine (DS103-282) and noradrenaline: involvement of alpha 2-
adrenoceptors, Neuroscience, 16 (1985) p673-682.
113 De Biasi, S. and Rustioni, A., Glutamate and substance P co-exist
in primary afferent terminals in the superficial laminae of the
spinal cord, Proc. Natl. Acad. Sci. (USA), 85 (1988) p7820-7824.
114 De Groat, W.C., Neuropeptides in pelvic afferent pathways,
Experentia, 43(7) (1987) p801-813.
115 De Koninck, Y. and Henry, J.L., Substance P-mediated slow
excitatory postsynaptic potential elicited in dorsal horn neurons in
vivo by noxious stimulation, Proc. Natl. Acad. Sci. (USA), 88 (1991)
pll344-11348 .
116 De Koninck, Y., Ribeiro-da-Silva, A., Henry, J.L. and Cuello,
A.C., Spinal neurons exhibiting a specific nociceptive response
receive abundant substance P-containing synaptic contacts, Proc.
Natl. Acad. Sci. (USA), 89 (1992) p5073-5077.
117 Dickenson, A.H., Sullivan, A.F., Feeney, C., Fournie-Zaluski,
M.C. and Roques, B.P., Evidence that endogenous enkephalins produce
delta-opiate receptor mediated neuronal inhibitions in rat dorsal
horn, Neurosci. Lett., 72 (1986) pl79-182.
118 Dickenson, A.H., Sullivan, A.F., Knox, R. , Zajac, J.M. and
Roques, B.P., Opioid receptor subtypes in the rat spinal cord:
electrophysiological studies with mu- and delta-opioid receptor
agonists in the control of nociception, Brain Res., 413 (1987) p36-
44 .
119 Dickenson, A.H., Sullivan, A.F. and Roques, B.P., Evidence that
endogenous enkephalins and a delta opioid receptor agonist have a
common site of action in spinal antinociception, Eur. J. Pharmacol.,
148 (1988) p437-439.
120 Dietl, M.M. and Palacios, J.M., Phylogeny of tachykinin receptor
localization in the vertebrate central nervous system: Apparent
absence of neurokinin- 2 and neurokinin-3 binding sites in the human
brain, Brain Res., 539 (1991) p211-222.
205
121 Diez-Guerra, F.J., Veira, J.A., Augood, S. and Emson, P.C.,
Ontogeny of the novel tachykinins, neurokinin A, neurokinin B and
neuropeptide K in the rat central nervous system, Regul. Pept., 25
(1989) p87-97.
122 Difiglia, M. , Aronin, N. and Leeman, S.E., Light microscopic and
ultrastructural localization of immunoreactive substance P in the
dorsal horn of the monkey spinal cord, Neuroscience, 7 (1982) pll27-
1139.
123 Doherty, T.J., Ballinger, J.A., McDonell, W.N., Pascoe, P.J. and
Valliant, A.E., Antagonism of xylazine induced sedation by idazoxan
in calves, Can. J. Vet. Res., 51 (1987) p244-248.
124 Domoto, T., Gonda, T., Oki, M. and Yanaihara, N., Co-existence of
substance P and methionine-5-enkephalin-like immunoreactivity in
nerve cells of the myenteric ganglia in the cat ileum, Neurosci.
Lett., 47 (1984) p9-13.
125 Donnerer, J., Bartho, L., Holzer, P. and Lembeck, F. , Intestinal
peristalsis associated with release of immunoreactive substance P,
Neuroscience, 11 (1984) p913-918.
126 Doods, H.N. and Krause, J., Different neuropeptide Y receptor
subtypes in rat and rabbit vas deferens, Eur. J. Pharmacol., 204
(1991) pl01-103.
127 Douglas, F.L., Palkovits, M. and Brownstein, M.J., Regional
distribution of substance P-like immunoreactivity in the lower
brainstem of the rat, Brain Res., 245 (1982) p376-378.
128 Downie, J.W., Espey, M.J. and Gajewski, J.B., Alpha 2-
adrenoceptors not imidazole receptors mediate depression of a sacral
spinal reflex in the cat, Eur. J. Pharmacol., 195 (1991) p301-304.
129 Doyle, C.A. and Maxwell, D.J., Catecholaminergic innervation of
the spinal dorsal horn: a correlated light and electron microscopic
analysis of tyrosine hydroxylase-immunoreactive fibres in the cat,
Neuroscience, 45 (1991a) pl61-176.
130 Doyle, C.A. and Maxwell, D.J., Ultrastructural analysis of
noradrenergic nerve terminals in the cat lumbosacral spinal dorsal
horn: a dopamine-beta-hydroxylase immunocytochemical study, Brain
Res., 563 (1991b) p329-333.
131 Doyle, C.A. and Maxwell, D.J., Neuropeptide Y-immunoreactive
terminals form axo-axonic synaptic arrangements in the substantia
gelatinosa (lamina II) of the cat spinal dorsal horn, Brain Res., 603
(1993a) pl57-161.
132 Doyle, C.A. and Maxwell, D.J., Direct catecholaminergic
innervation of spinal dorsal horn neurones with axons ascending the
dorsal columns in cat, J. Comp. Neurol., 331 (1993b) p434-444.
133 Drapeau, G., D'Orleans-Juste, P., Dion, S., Rhaleb, N.-E.,
Rouissi, N. and Regoli, D., Selective agonists for substance P and
neurokinin receptors, Neuropeptides, 10 (1987a) p43-54.
134 Drapeau, G., D'Orleans-Juste, P., Rhaleb, N.-E., Dion, S. and
Regoli, D., Specific agonists for NKB receptors, Eur. J. Pharmacol.,
136 (1987b) p401-403.
206
135 Duggan, A.W., Pharmacology of descending control systems, Phil.
Trans. R. Soc. Bull., 308 (1985) p375-391.
136 Duggan, A.W., Detection of neuropeptide release in the central
nervous system with antibody microprobes, J. Neurosci. Methods, 34
(1990) p47-52.
137 Duggan, A.W., Antibody Microprobes. In J. Stamford (Ed.),
Monitoring Neuronal Activity: A Practical Approach, Oxford University
Press, Oxford, 1992, pl81-202.
138 Duggan, A.W. and Fleetwood-Walker, S.M., Opioids and sensory
processing in the central nervous system. In A. Herz (Ed.), Handbook
of Experimental Pharmacology, volume 104/1, Opioids I, Springer-
Verlag, Berlin, 1993, p731-771.
139 Duggan, A.W. and Foong, F.W., Bicuculline and spinal inhibition
produced by dorsal column stimulation in the cat, Pain, 22 (1985)
p249-259.
140 Duggan, A.W., Griersmith, B.T. and North, R.A., Morphine and
supraspinal inhibition of neurones: evidence that morphine decreases
tonic descending inhibition in the anaesthetized cat, Br. J.
Pharmacol., 69 (1980) p461-466.
141 Duggan, A.W., Hall, J.G., Foong, F.W. and Zhao, Z.Q., A
differential effect of naloxone on transmission of impulses in
primary afferents to ventral roots and ascending spinal tracts, Brain
Res., 344 (1985) p316-321.
142 Duggan, A.W., Hall, J.G. and Headley, P.M., Suppression of
transmission of nociceptive impulses by morphine: Selective effects
of morphine administered in the region of the substantia gelatinosa,
Br. J. Pharmacol., 61 (1977) p65-76.
143 Duggan, A.W. and Hendry, I., Immobilized antibodies: a newer
approach to measurement of released neuropeptides, N. I. P. S., 3
(1988) p44-46.
144 Duggan, A.W. and Hendry, I.A., Laminar localization of the sites
of release of immunoreactive substance P in the dorsal horn with
antibody coated microelectrodes, Neurosci. Lett., 68 (1986) pl34-140.
145 Duggan, A.W., Hendry, I.A., Green, J.L., Morton, C.R. and
Hutchison, W.D., The preparation and use of antibody microprobes, J.
Neurosci. Methods, 23 (1988a) p241-247.
146 Duggan, A.W., Hendry, I.A., Morton, C.R., Hutchison, W.D. and
Zhao, Z.Q., Cutaneous stimuli releasing immunoreactive substance P in
the dorsal horn of the cat, Brain Res., 451 (1988b) p261-273.
147 Duggan, A.W., Hope, P.J., Jarrott, B., Schaible, H.-G. and
Fleetwood-Walker, S.M., Release, spread and persistence of
immunoreactive neurokinin A in the dorsal horn of the cat following
noxious cutaneous stimulation. Studies with antibody microprobes,
Neuroscience, 35 (1990) pl95-202.
148 Duggan, A.W., Hope, P.J. and Lang, C.W., Microinjection of
neuropeptide Y into the superficial dorsal horn reduces stimulus
evoked release of immunoreactive substance P in the anaesthetized
cat, Neuroscience, 44 (1991a) p733-740.
207
149 Duggan, A.W., Hope, P.J., Lang, C.W. and Bjelke, B., Noxious
mechanical stimulation of the hind paws of the anaesthetized rat
fails to elicit release of immunoreactive beta-endorphin in the
periaqueductal grey matter, Neurosci. Lett., 149 (1993) p205-208.
150 Duggan, A.W., Hope, P.J., Lang, C.W. and Williams, C.A.,
Sustained isometric contraction of skeletal muscle results in release
of immunoreactive neurokinins in the spinal cord of the anaesthetized
cat, Neurosci. Lett., 122 (1991b) pl91-194.
151 Duggan, A.W., Johnson, S.M. and Morton, C.R., Differing
distributions of receptors for morphine and Met5-enkephalinamide in
the dorsal horn of the cat, Brain Res., 229 (1981) p379-387.
152 Duggan, A.W. and Morton, C.R., Tonic descending inhibition and
spinal nociceptive transmission. In H.L. Fields and J.M. Besson
(Eds.), Progress in Brain Research. Volume 77, Elsevier Science
Publishers B.V., 1988, pl93-207.
153 Duggan, A.W., Morton, C.R., Hendry, I.A. and Hutchison, W.D.,
Peripheral stimuli releasing neuropeptides in the dorsal horn of the
cat. In F. Cervero, G.J. Bennett and P.M. Headley (Eds.), Processing
of Sensory Information in the Superficial Dorsal Horn of the Spinal
Cord, Plenum Publishing Corporation, 1989, p347-363.
154 Duggan, A.W., Morton, C.R., Hutchison, W.D. and Hendry, I.A.,
Absence of tonic supraspinal control of substance P release in the
substantia gelatinosa of the anaesthetized cat, Exp. Brain Res., 71
(1988c) p597-602.
155 Duggan, A.W., Schaible, H-G., Hope, P.J. and Lang, C.W., Effect
of peptidase inhibition on the pattern of intraspinally released
immunoreactive substance P detected with antibody microprobes, Brain
Res., 579 (1992) p261-269.
156 Duggan, A.W. and Weihe, E., Central transmission of impulses in
nociceptors: events in the superficial dorsal horn. In A.I. Basbaum
and J.-M. Besson (Eds.), Towards a New Pharmacotherapy of Pain, John
Wiley & Sons, 1991, p35-67.
157 Dumont, Y., Martel, J.-C., Fournier, A., St-Pierre, S. and
Quirion, R. , Neuropeptide Y and neuropeptide Y receptor subtypes in
brain and peripheral tissues, Prog. Neurobiol., 38 (1992) pl25-167.
158 Dun, N.J. and Mo, N., In vitro effects of substance P on neonatal
rat sympathetic preganglionic neurones, J. Physiol., 399 (1988) p321-
333.
159 Eglezos, A., Andrews, P.V., Boyd, R.L. and Helme, R.D.,
Tachykinin mediated modulation of the primary antibody response in
rats: evidence for mediation by an NK2 receptor, J. Neuroimmunology,
32 (1991) pll-18.
160 Eimerl, J., Bayorh, M.A., Zukowska-Grojec, Z., Faden, A. I. , Ezra,
D. and Feuerstein, G., Substance K: vascular and cardiac effects in
rat and pig, Peptides, 6 S2(5) (1985) pl49-153.
161 Einsphar, F.J. and Piercey, M.F., Morphine depresses dorsal horn
neuron responses to controlled noxious and non-noxious cutaneous
stimulation, J. Pharmacol. Exp. Therap., 213(3) (1980) p456-461.
208
162 Ekstrom, J., Ekman, R., Hakanson, R. , Luts, A., Sundler, F. and
Tobin, G. , Effects of capsaicin pretreatment on neuropeptides and
salivary secretion of rat parotid glands, Br. J. Pharmacol., 97
(1989) pl031-1038.
163 Ekstrom, J., Mansson, B., Olgart, L. and Tobin, G., Nonadrenergic
noncholinergic salivary secretion in the ferret, Qu. J. Exp.
Physiol., 73 (1988) pl63-173.
164 Elliot, P.J., Nemeroff, C.B. and Kilts, C.D, Evidence for a tonic
facilatory influence of substance P on dopamine release in the
nucleus accumbens, Brain Res., 385 (1986) p379-382.
165 Emson, P.C., Arregui, A., Clement-Jones, V., Sandberg, B.E.B. and
Rossor, M. , Regional distribution of methionine-enkephalin and
substance P-like immunoreactivity in normal human brain and in
Huntington's disease, Brain Res., 199 (1980) pl47-160.
166 Erspamer, V. , Biogenic amines and active polypeptides of the
amphibian skin, Ann. Rev. Pharmacol., 11 (1971) p327-350.
167 Erspamer, V. , The tachykinin peptide family, T. I. N. S., 4
(1981) p267-269 .
168 Erspamer, V. and Anastasi, A., Structure and pharmacological
actions of eledoisin, the active endecapeptide of the posterior
salivary glands of Eledone, Experentia, 18 (1962a) p58-59.
169 Erspamer, V. and Anastasi, A., Synthesis of eledoisin,
Experentia, 18 (1962b) p59.
170 Everitt, B.J., Hokfelt, T., Terenius, L., Tatemoto, K., Mutt, V.
and Goldstein, M. , Differential co-existence of neuropeptide Y (NPY)-
like immunoreactivity with catecholamine in the central nervous
system of the rat, Neuroscience, 11 (1984) p443-462.
171 Ewald, D.A., Matthies, H.J.G., Perney, T.M., Walker, M.W. and
Miller, R.J., The effect of down regulation of protein kinase C on
the inhibitory modulation of dorsal root ganglion neuron Ca2+
currents by neuropeptide Y, J. Neurosci., 8 (1988) p2447-2451.
172 Featherstone, R.L., Fosbraey, P. and Morton, I.K.M., A comparison
of the effects of three substance P antagonists on tachykinin-
stimulated [3H]-acetylcholine release in the guinea-pig ileum, Br. J.
Pharmacol., 87 (1986) p73-77.
173 Fisher, B., Zornow, M.H., Yaksh, T.L. and Peterson, B.M.,
Antinociceptive properties of intrathecal dexmedetomidine in rats,
Eur. J. Pharmacol., 192 (1991) p221-225.
174 Fleetwood-Walker, S.M., Hope, P.J., Mitchell, R. , El-Yassir, N.
and Molony, V. , The influence of opioid receptor subtypes on the
processing of nociceptive inputs in the spinal dorsal horn of the
cat, Brain Res., 451 (1988) p213-226.
175 Fleetwood-Walker, S.M., Mitchell, R. , Hope, P.J., El-Yassir, N.,
Molony, V. and Bladon, C.M., The involvement of neurokinin receptor
subtypes in somatosensory processing in the superficial dorsal horn
of the cat, Brain Res., 519 (1990) pl69-182.
209
176 Fleetwood-Walker, S.M., Mitchell, R., Hope, P.J., Molony, V. and
Iggo, A. , An alpha-2 receptor mediates the selective inhibition by
noradrenaline of nociceptive responses of identified dorsal horn
neurones, Brain Res., 334 (1985) p243-254.
177 Fleetwood-Walker, S.M., Parker, R.M.C., Munro, F.E., Young, M.R.,
Hope, P.J. and Mitchell, R. , Evidence for a role of tachykinin NK2
receptors in mediating brief nociceptive inputs to rat dorsal horn
(laminae III- V) neurons, Eur. J. Pharmacol., 242 (1993) pl73-181.
178 Fong, T.M., Huang, R.-R.C. and Strader, C.D., Localization of
agonist and antagonist binding domains of the human neurokinin-1
receptor, J. Biol. Chem., 267 (1992a) p25664-25667.
179 Fong, T.M., Yu, H., Huang, R.-R.C. and Strader, C.D., The
extracellular domain of the neurokinin-1 receptor is required for
high-affinity binding of peptides, Biochemistry, 31 (1992b) pll806-
11811.
180 Fong, T.M., Yu, H. and Strader, C.D., The extracellular domain of
substance P (NK1) receptor comprises part of the ligand binding site,
Biophys. J., 62 (1992c) p59-60.
181 Franco, R. , Costa, M. and Furness, J.B., Evidence that axons
containing substance P in the guinea-pig ileum are of intrinsic
origin, Naunyn Schmeid. Arch. Pharmacol., 307 (1979) p57-63.
182 Fujisawa, K. and Ito, Y., The effects of substance P on smooth
muscle cells and on neuroeffector transmission in the guinea-pig
ileum, Br. J. Pharmacol., 76 (1982) p279-290.
183 Furmidge, L.J., Duggan, A.W. and Arbuthnott, G.W., Substance P
release from rat nucleus accumbens and striatum: an in vivo study
using antibody microprobes, Brain Res., 610 (1993) p234-241.
184 Furmidge, L.J., Duggan, A.W. and Arbuthnott, G.W., In vivo
detection of NKA release in rat substantia nigra, Neuropeptides,
26(SI) (1994a) p47.
185 Furmidge, L.J., Duggan, A.W. and Arbuthnott, G.W., Measurement of
neuropeptide release from rat brain using antibody microprobes,
Neuropeptides, 26 (1994b) p43-46.
186 Fuxe, K. and Agnati, L.F., Two principal modes of electrochemical
communication in the brain: volume versus wiring transmission. In K.
Fuxe (Ed.), Volume Transmission in the Brain, Raven Press, New York,
1991, pl-9.
187 Fuxe, K., Agnati, L.F., Harfstrand, A., Zoli, M. , Von Euler, G.,
Grimaldi, R., Merlo Pich, E., Bjelke, B., Eneroth, P., Benfenati, F.,
Cintra, A., Zini, I. and Martire, M. , On the role of neuropeptide Y
in information handling in the central nervous system in normal and
physiopathological states, Ann. N. Y. Acad Sci., 579 (1990) p28-67.
188 Gale, J.S., Bird, E.D., Spokes, E.G., Iversen, L.L. and Jessell,
T., Human brain substance P: Distribution in controls and
Huntington's chorea, J. Neurochem., 30 (1978) p633-634.
210
189 Gamse, R. , Holzer, P. and Lembeck, F. , Indirect evidence for
presynaptic location of opiate receptors on chemosensitive primary
sensory neurones, Naunyn Schmeid. Arch. Pharmacol., 308 (1979a) p281-
285.
190 Gamse, R., Lembeck, F. and Cuello, A.C., Substance P in the vagus
nerve. Immunochemical and immunohistochemical evidence for axoplasmic
transport, Naunyn Schmeid. Arch. Pharmacol., 306 (1979b) p37-44.
191 Gamse, R. , Mroz, E., Leeman, S.E. and Lembeck, F., The intestine
as a source of immunoreactive substance P in plasma of the cat,
Naunyn Schmeid. Arch. Pharmacol., 305 (1978) pl7-21.
192 Gamse, R. and Saria, A. , Nociceptive behavior after intrathecal
injections of substance P, neurokinin A and calcitonin-gene related
peptide in mice, Neurosci. Lett., 70 (1986) pl43-147.
193 Garry, M.G., Miller, K.E. and Seybold, V.S., Lumbar dorsal root
ganglia of the cat: a quantitative study of peptide immunoreactivity
and cell size, J. Comp. Neurol., 284 (1989) p36-47.
194 Gebhart, G.F., Sandkuhler, J., Thalhammer, J.G. and Zimmerman,
M. , Inhibition in spinal cord of nociceptive information by
electrical stimulation and morphine microinjection at identical sites
in midbrain of the cat, J. Neurophysiol., 51 (1984) p75-89.
195 Geppetti, P., Santicioli, P., Rubini, I., Spillantini, M.G.,
Maggi, C.A. and Sicuteri, F., Thiorphan increases capsaicin-evoked
release of substance P from slices of dorsal spinal cord of guinea-
pig, Neurosci. Lett., 103 (1989) p69-73.
196 Gernart, K.D., Wilcox, T.K., Chung, J.M. and Willis, W.D.,
Inhibition of nociceptive and non-nociceptive responses of primate
spinothalamic cells by stimulation in medial brain stem, J.
Neurophysiol., 45 (1980) 121-136.
197 Giad, A., Gibson, S.J., Ibrahim, N.B.N., Legon, S., Bloom, S.R.,
Yanagisawa, M. , Masaki, T., Varndell, I.M. and Polak, J.M.,
Endothelin 1, an endothelium-derived peptide, is expressed in neurons
of the human spinal cord and dorsal root ganglia, Proc. Natl. Acad.
Sci. (USA), 86 (1989) p7634-7638.
198 Gibbins, I.L., Furness, J.B. and Costa, M. , Pathway specific
patterns of the co-existence of substance P, calcitonin gene-related
peptide and dynorphin in neurons of the dorsal root ganglia of the
guinea pig, Cell Tissue Res., 248 (1987) p417-437.
199 Gibson, S.J., Polak, J.M., Katagiri, T., Su, H., Weller, R.O.,
Brownwell, D.B., Holland, S., Hughes, J.T., Kikuyama, S. and Ball,
J., A comparison of the distributions of eight peptides in spinal
cord from normal controls and cases of motor neurone disease with
special reference to Onuf's disease, Brain Res., 474 (1988) p255-278.
200 Giron, L.T.,Jr., McCann, S.A. and Crist Orlando, S.G.,
Pharmacological characterization and regional distribution of alpha-
noradrenergic binding sites of rat spinal cord, Eur. J. Pharmacol.,
115 (1985) p285-290.
201 Go, V.W.L. and Yaksh, T.L., Release of substance P from the cat
spinal cord, J. Physiol., 391 (1987) pl41-167.
211
202 Gordh, T.,Jr., Jansson, I., Hartvig, P., Gillberg, P.G. and Post,
C., Interactions between noradrenergic and cholinergic mechanisms
involved in spinal nociceptive processing, Acta. Anaesthesiol.
Scand., 33 (1989) p39-47.
203 Guarderes, C., Cros, J, Quirion, R., Autoradiographic
localisation of mu, delta and kappa opioid receptor binding sites in
rat and guinea-pig spinal cord, Neuropeptides, 6 (1985) p331-342.
204 Graham, L. and Gallop, P.M., Peptidylglycine alpha-amidating
monooxygenase activity in spinal cord, dorsal roots, and dorsal root
ganglia of Macaca fascicularis, Brain Res., 491 (1989) p371-373.
205 Grubb, B.D., Birrell, J., McQueen, D.S. and Iggo, A., The role of
PGE2 in the sensitization of mechanoreceptors in normal and inflamed
ankle joints of the rat, Exp. Brain Res., 84 (1991) p383-392.
206 Guard, S., Watling, K.J. and Watson, S.P., Neurokinin 3 receptors
are linked to inositol phospholipid hydrolysis in the guinea-pig
ileum longitudinal muscle-myenteric plexus preparation, Br. J.
Pharmacol., 94 (1988) pl48-154.
207 Guard, S., Watson, S.P., Maggio, J.E., Phon Too, H. and Watling,
K.J., Pharmacological analysis of [3H]-senktide binding to NK3
tachykinin receptors in guinea-pig ileum longitudinal muscle-
myenteric plexus and cerebral cortex membranes, Br. J. Pharmacol., 99
(1990) p767-773.
208 Guilbaud, G. and Iggo, A., The effect of acetylsalicylate on
joint mechanoreceptors in rats with polyarthritis, Exp. Brain Res.,
61 (1985) pl64-168.
209 Guiliani, S., Maggi, C.A. and Meli, A., Prejunctional modulatory
action of neuropeptide Y on peripheral terminals of capsaicin-
sensitive sensory nerves, Br. J. Pharmacol., 98 (1989) p407-412.
210 Guyenet, P.G. and Aghajanian, G.K., Excitation of neurons in the
nucleus locus coeruleus by substance P and related peptides, Brain
Res., 136 (1977) pl78-184.
211 Hall, J.G., Duggan, A.W., Johnson, S.M. and Morton, C.R.,
Medullary raphe lesions do not reduce descending inhibition of dorsal
horn neurones of the cat, Neurosci. Lett., 25 (1981) p25-29.
212 Hall, J.G., Duggan, A.W., Morton, C.R. and Johnson, S.M., The
location of brainstem neurones tonically inhibiting dorsal horn
neurones of the cat, Brain Res., 244 (1982) p215-222.
213 Hall, L.W. and Clarke, K.W., Principles of sedation, analgesia
and premedication. In L.W. Hall and K.W. Clarke (Eds.), Veterinary
Anaesthesia, Vol.9 , Balliere Tindall, 1991, p51-79.
214 Hall, M.E., Miley, F.B. and Stewart, J.M., Cardiovascular effects
of substance P peptides in the nucleus of the solitary tract, Brain
Res., 497 (1989) p280-290.
215 Halliday, G.M., Blumbergs, P.C., Cotton, R.G.H., Blessing, W.W.
and Geffen, L.B., Loss of brainstem serotonin- and substance P-
containing neurons in Parkinson's disease, Brain Res., 510 (1990)
pl04-107 .
212
216 Hamon, M. , Bourgoin, S., Le Bars, D. and Cesselin, F., In vivo
and in vitro release of central neurotransmitters in relation to pain
and analgesia. In H.L. Fields and J-M. Besson (Eds.), Pain
Modulation. Progress Brain Research, Vol.77 , Elsevier Science
Publishers,, Amsterdam, 1988, p431-444.
217 Hancock, M.B. and Peveto, C.A., Preganglionic neurons in the
sacral spinal cord of the rat: an HRP study, Neurosci. Lett., 11
(1979) pl-5.
218 Handwerker, H.O., Kilo, S. and Reeh, P.W., Unresponsive afferent
nerve fibres in the sural nerve of the rat, J. Physiol., 435 (1991)
p229-242 .
219 Hanley, M.R., Lee, C.M., Jones, L.M. and Michell, R.H., Similar
effects of substance P and related peptides on salivation and
phosphatidylinositol turnover in rat salivary glands, Molec.
Pharmacol., 18 (1980) p78-83.
220 Hass, H.L., Hermann, A., Greene, R.W. and Chan-Palay, V., Action
and location of neuropeptide tyrosine (Y) on hippocampal neurons of
the rat in slice preparations, J. Comp. Neurol., 257 (1987) p208-215.
221 Hassessian, H., Couture, R. and Jacques, L., Spinal action of
neurokinins in the rat: effects on mean arterial pressure, heart
rate, and vascular permeability, Can. J. Physiol. Pharmacol., 65
(1987) p2182-2187 .
222 Hassessian, H., Drapeau, G. and Couture, R. , Spinal action of
neurokinins producing cardiovascular responses in the conscious
freely moving rat: evidence for a NK-1 receptor mechanism, Naunyn
Schmeid. Arch. Pharmacol., 338 (1988) p649-654.
223 Haverstick, D.M. and Bannon, M.J., Evidence for dual mechanisms
involved in metamphetamine-induced increases in striatal
preprotachykinin mRNA, J. Biol. Chem., 264 (1989) pl3140-13144.
224 Hayashi, H., Ohsumi, K., Ueda, N., Fujiwara, M. and Mizuno, N.,
Effect of spinal ganglionectomy on substance P-like immunoreactivity
in the gastroduodenal tract of cats, Brain Res., 232 (1982) p227-230.
225 Headley, P.M., Duggan, A.W. and Griersmith, B.T., Selective
reduction by noradrenaline and 5-hydroxytryptamine of nociceptive
responses of cat dorsal horn neurones, Brain Res., 145 (1978) pl85-
189.
226 Healy, D.P. and Orlowski, M., Immunocytochemical localization of
endopeptidase 24.15 in the rat brain, Brain Res., 571 (1992) pl21-
128.
227 Helke, C.J., Charlton, C.G. and Wiley, R.G., Studies on the
cellular localization of spinal cord substance P receptors,
Neuroscience, 19 (1986) p523-533.
228 Helke, C.J., Krause, J.E., Mantyh, P.W., Couture, R. and Bannon,
M.J., Diversity in mammalian tachykinin peptidergic neurons: multiple
peptides, receptors and regulatory mechanisms, F. A. S. E. B., 4
(1990) pl606-1615.
213
229 Helke, C.J., O'Donohue, T.L. and Jacobowitz, D.M., Substance P as
a baro- and chemoreceptor afferent neurotransmitter:
immunocytochemical and neurochemical evidence in the rat, Peptides, 1
(1980) pl-9.
230 Hendry, I.A., Morton, C.R. and Duggan, A.W., Analysis of antibody
microprobe autoradiographs by computerized image processing, J.
Neurosci. Methods, 23 (1988) p249-256.
231 Henry, J.L., Effects of substance P on functionally identified
units in cat spinal cord, Brain Res., 114 (1976) p439-451.
232 Henschen, A., Hokfelt, T., Elde, R., Fahrenkrug, J., Frey, P.,
Terenius, L. and Olson, L., Expression of eight neuropeptides in
intraoccular spinal cord grafts: organotypical and disturbed patterns
as evidenced by immunohistochemistry, Neuroscience, 26 (1988) pl93-
213.
233 Heppelmann, B., Pfeffer, A., Schaible, H.-G. and Schmidt, R.F.,
Effects of acetylsalicylic acid and indomethacin on single groups III
and IV sensory units from acutely inflamed joints, Pain, 26 (1986)
p337-351.
234 Hershey, A.D. and Krause, J.E., Molecular characterization of a
functional cDNA encoding the rat substance P receptor, Science, 247
(1990) p958-962.
235 Hirota, N., Kuraishi, Y., Hino, Y., Sato, Y. and Takagi, H., Met-
enkephalin and morphine but not dynorphin inhibit noxious stimuli-
induced release of substance P from rabbit dorsal horn in situ,
Neuropharmacology, 24 (1985) p567-570.
236 Hoheisel, V. and Mense, S., Long term changes in discharge
behaviour of cat dorsal horn neurones following noxious stimulation
of deep tissues, Pain, 36 (1989) p239-256.
237 Hokfelt, T., Elde, R., Johansson, O., Luft, R. , Nilsson, G. and
Arimura, A., Immunohistochemical evidence for separate populations of
somatostatin-containing and substance P-containing primary afferent
neurons in the rat, Neuroscience, 1 (1976) pl31-136.
238 Hokfelt, T., Kellerth, J.O., Nilsson, G. and Pernow, B.,
Substance P: Localization in the central nervous system and in some
primary afferent neurons, Science, 190 (1975a) p889-890.
239 Hokfelt, T., Kellerth, J.O., Nilsson, G. and Pernow, B.,
Experimental immunohistochemical studies on the localization and
distribution of substance P in cat primary sensory neurons, Brain
Res., 100 (1975b) p235-252.
240 Hokfelt, T., Ljungdahl, A., Terenius, L., Elde, R. and Nilsson,
G., Immunohistochemical analysis of peptide pathways possibly related
to pain and analgesia: enkephalin and substance P, Proc. Natl. Acad.
Sci. (USA), 74 (1977) p3081-3085.
241 Holets, V.R., Hokfelt, T., Rokaeus, A., Terenius, L. and
Goldstein, M. , Locus coeruleus neurons in the rat containing
neuropeptide Y, tyrosine hydroxylase or galanin and their efferent
projections to the spinal cord, cerebral cortex and hypothalamus,
Neuroscience, 24 (1988) p893-906.
214
242 Homma, E., Collins, J.G., Kitihata, L.M., Matsumoto, M. and
Kawahara, M. , Suppression of noxiously evoked WDR dorsal horn
neuronal activity by spinally administered morphine, Anesthesiology,
58 (1983) p232-236.
243 Hope, P.J., Fleetwood-Walker, S.M. and Mitchell, R., Distinct
antinociceptive actions mediated by different opioid receptors in the
region of lamina I and laminae III-IV of the dorsal horn of the rat,
Br. J. Pharmacol., 101 (1990a) p477-483.
244 Hope, P.J., Jarrott, B., Schaible, H.-G., Clarke, R.W. and
Duggan, A.W., Release and spread of immunoreactive neurokinin A in
the cat spinal cord in a model of acute arthritis, Brain Res., 533
(1990b) p292-299.
245 Hope, P.J., Lang, C.W. and Duggan, A.W., Persistence of
immunoreactive neurokinins in the dorsal horn of barbiturate
anaesthetized and spinal cats, following release by tibial nerve
stimulation, Neurosci. Lett., 118 (1990c) p25-28.
246 Hope, P.J., Lang, C.W., Grubb, B.D. and Duggan, A.W., Release of
immunoreactive galanin in the spinal cord of rats with ankle
inflammation: studies with antibody microprobes, Neuroscience, 60
(1994) p801-807.
247 Howe, J.R., Wang, J.-Y. and Yaksh, T.L., Selective antagonism of
the antinociceptive effect of intrathecally applied alpha adrenergic
agonists by intrathecal prazosin and intrathecal yohimbine, J.
Pharmacol. Exp. Therap., 224 (1983) p552-558.
248 Hua, X.-Y., Boublick, J.H., Spicer, M.A., Rivier, J.E., Brown,
M.R. and Yaksh, T.L., The antinociceptive effects of spinally
administered neuropeptide Y in the rat: systematic studies on the
structure-activity relationship, J. Pharmacol. Exp. Therap., 258
(1991) p243-248.
249 Hua, X.Y., Saria, A., Gamse, R., Theodorsson-Norheim, E., Brodin,
E. and Lundberg, J.M., Capsaicin induced release of multiple
tachykinins ( substance P, neurokinin A and eledoisin-like material )
from guinea-pig spinal cord and ureter, Neuroscience, 19 (1986) p313-
319.
250 Hunt, S.P., Kelly, J.S., Emson, P.C., Kimmel, J.R., Miller, R.J.
and Wu, J.-Y., An immunohistochemical study of neuronal populations
containing neuropeptides or gamma-aminobutyrate within the
superficial layers of the rat dorsal horn, Neuroscience, 6 (1981)
pl883-1898.
251 Hunter, J.C., Birchmore,B., Woodruff, R. , Hughes, J., Kappa
opioid binding sites in the dog cerebral cortex and spinal cord,
Neuroscience, 31 (1989) p735-743.
252 Hunter, J.C., Kilpatrick, G.J. and Brown, J.R., Pharmacological
analysis of 1251-Bolton and Hunter labelled eledoisin binding sites
in rat spinal cord by quantitative autoradiography, Neurosci. Lett.,
78 (1987) pl2-16.
253 Hunter, J.C. and Maggio, J.E., A pharmacological study with
substance K: evidence for multiple types of tachykinin receptors,
Eur. J. Pharmacol., 105 (1984) pl49-153.
215
254 Hylden, J.L., Thomas, D.A., Iadarola, M.J., Nahin, R.L. and
Dubner, R. , Spinal opioid analgesic effects are enhanced in a model
of unilateral inflammation/hyperalgesia: possible involvement of
noradrenergic mechanisms, Eur. J. Pharmacol., 194 (1991) pl35-143.
255 Hylden, J.L. and Wilcox, G.L., Pharmacological characterization
of substance P-induced nociception in mice: modulation by opioid and
noradrenergic agonists at the spinal level, J. Pharmacol. Exp.
Therap., 226 (1983) p398-404.
256 Hylden, J.L.K., Nahin, R.L., Traub, R.J. and Dubner, R.,
Expansion of receptive fields of spinal lamina I projection neurons
in rats with unilateral adjuvant-induced inflammation; the
contribution of dorsal horn mechanisms, Pain, 37 (1989) p229-243.
257 Ichikawa, H., Matsuo, S., Wakisaka, S., Itotagawa, T., Kato, J.
and Akai, M. , Leucine-enkephalin-, neurokinin A- and cholecystokinin-
like immunoreactivities in the guinea pig tongue, Archs. Oral Biol.,
35 (1990) pl81-188.
258 Jalanka, H.H., Medetomidine- and medetomidine-ketamine-induced
immobilization in blue foxes (Alopex lagopus) and its reversal by
atipamezole, Acta. Vet. Scand., 31 (1990) p63-71.
259 Jeftinija, S., Semba, K. and Randic, M. , Norepinephrine reduces
excitability of single cutaneous afferent C-fibers in the cat spinal
cord, Brain Res., 219 (1981) p456-463.
260 Jessell, T.M. and Iversen, L.L., Opiate analgesics inhibit
substance P release from rat trigeminal nucleus, Nature, 268 (1977)
p54 9-551.
261 Johnson, S.M. and Duggan, A.W., Evidence that the opiate
receptors of the substantia gelatinosa contribute to the depression,
by intravenous morphine, of impulses in unmyelinated primary
afferents, Brain Res., 207 (1981) p223-228.
262 Johnston, G.A.R., Transmitter inactivating processes, Proc. Aust.
Physiol. Pharmacol. Soc., 9 (1978) p94-98.
263 Jones, D.J., Kendall, D.E. and Enna, S.J., Adrenergic receptors
in rat spinal cord, Neuropharmacology, 21 (1982) pl91-195.
264 Jones, E.G. and Hendry, S.H.C., Co-localization of GABA and
neuropeptides in neocortical neurons, T. I. N. S., 9 (1986) p71-76.
265 Jurna, I. and Grossmann, W., The effect of morphine on mammalian
nerve fibres, Eur. J. Pharmacol., 44 (1977) p339-348.
266 Jurna, I. and Heinz, G., Differential effects of morphine and
opioid analgesics on A and C fibre-evoked activity in ascending axons
of the rat spinal cord, Brain Res., 171 (1979) p573-576.
267 Kage, R. , McGregor, G.P., Thim, L. and Conlon, J.M., Neuropeptide
gamma, a peptide isolated from rabbit intestine that is derived from
gamma preprotachykinin, J. Neurochem., 50 (1988) pl412-1417.
216
268 Kalso, E.A., Sullivan, A.F., McQuay, H.J., Dickenson, A.H. and
Roques, B.P., Cross-tolerance between mu opioid and alpha-2
adrenergic receptors, but not between mu and delta opioid receptors
in the spinal cord of the rat, J. Pharmacol. Exp. Therap., 265 (1993)
p551-558 .
269 Kamisaki, Y., Ishikawa, T., Takao, Y. , Omodani, H., Kuno, N. and
Itoh, T., Binding of [3H]p-aminoclonidine to two sites, alpha2-
adrenoceptors and imidazoline binding sites: distribution of
imidazoline binding sites in rat brain, Brain Res., 514 (1990) pl5-
21.
270 Kanazawa, I. and Jessell, T., Post mortem changes and regional
distribution of substance P in the rat and mouse nervous system,
Brain Res., 117 (1976) p362-367.
271 Kanazawa, I., Ogawa, T., Kimura, S. and Munekata,E., Regional
distribution of substance P, neurokinin alpha and neurokinin beta in
rat central nervous system, Neurosci. Res., 2 (1984) plll-120.
272 Kangawa, K., Minamino, N., Fukuda, A. and Matsuo, H., Neuromedin
K: a novel mammalian tachykinin identified in porcine spinal cord,
Biochem. Biophys. Res. Comm., 14 (1983) p533-540.
273 Kangrga, I. and Randic, M., Tachykinins and calcitonin gene-
related peptide enhance release of endogenous glutamate and aspartate
from the rat spinal dorsal horn slice, J. Neurosci., 10 (1990) p2026-
2038.
274 Karhuvaara, S., Kallio, A., Salonen, M., Tuominen, J. and
Scheinin, M. , Rapid reversal of a2-adrenoceptor agonist effects by
atipamezole in human volunteers, Br. J. Clin. Pharmacol., 31 (1991)
pl60-165.
275 Katayama, Y., North, R.A. and Williams, J.T., The action of
substance P on neurons of the myenteric plexus of the guinea-pig
small intestine, Proc. Royal Soc. London, 206(1163) (1979) pl91-208.
276 Katoh, K., Murai, K. and Nonoyama, T., Effects of substance P on
fluid and amylase secretion in exocrine pancreas of rat and mouse,
Res. Vet. Sci., 36 (1984) pl47-152.
277 Kaumann, A.J., Opiate receptors for behavioral analgesia resemble
those related to the depression of spinal nociceptive neurons,
Science, 199 (1978) pl231-1233.
278 Kawatani, M., Erdman, S.L. and de Groat, W.C., Vasoactive
intestinal polypeptide and substance P in primary afferent pathways
to the sacral spinal cord of the cat, J. Comp. Neurol., 241 (1985)
p327-347.
279 Kayser, V., Guilbaud, G. and Besson, J.M., Potent antinociceptive
effects of clonidine systemically administered in an experimental
model of clinical pain, the arthritic rat, Brain Res., 593 (1992) p7-
13.
280 Kelley, A.E., Stinus, L. and Iversen, S.D., Behavioural
activation induced in the rat by substance P infusion into ventral
tegmental area: implication of dopaminergic A10 neurones, Neurosci.
Lett., 11 (1979) p335-339.
217
281 Khoury, G.F., Stein, C. and Garland, D.E., Intra-articular
morphine for pain after knee arthroscopy, Lancet, 336 (1990) p874.
282 Kilborn, M.J., Potter, E.K. and McCloskey, D.I., Neuromodulation
of the cardiac vagus: comparison of neuropeptide Y and related
peptides, Regul. Pept., 12 (1985) pl55-161.
283 Kimura, S., Goto, K., Ogawa, T., Sugita, Y. and Kanazawa, I.,
Pharmacological characterization of novel mammalian tachykinins
neurokinin alpha and neurokinin beta, Neurosci. Res., 2 (1984) p97-
104 .
284 Kosterlitz, H.W., Corbett, A.D., Gillan, M.G.C., McKnight, A.T.,
Paterson, S.J. and Robson, L.E., Recent developments in the bioassay
of opioids, Regul. Pept., [Suppl] 4 (1985) pl-7.
285 Kotani, H., Hoshimaru, M., Nawa, H. and Nakanishi, S., Structure
and gene organization of bovine neuromedin K precursor, Proc. Natl.
Acad. Sci. (USA), 83 (1986) p7074-7078.
286 Krause, J.E., Chirgwin, J.M., Carter, M.S., Xu, Z.S. and Hershey,
A.D., Three rat preprotachykinin mRNAs encode the neuropeptides
substance P and neurokinin A, Proc. Natl. Acad. Sci. (USA), 84 (1987)
p881-885.
287 Kream, R.M., Schonfeld, T.A., Mancuso, R. , Clancy, A.N., El-
Bermani, W. and Macrides, F., Precursor forms of substance P in
nervous tissue: detection with antisera to SP, Sp-Gly and SP-Gly-Lys,
Proc. Natl. Acad. Sci. (USA), 82 (1985) p4832-4836.
288 Krukoff, T.L., Neuropeptide Y-like immunoreactivity in cat spinal
cord with special reference to autonomic areas, Brain Res., 415
(1987) p300-308.
289 Kuo, D.C. and de Groat, W.C., Primary afferent projections of the
major splanchnic nerve to the spinal cord and gracile nucleus of the
cat, J. Comp. Neurol., 231 (1985) p421-434.
290 Kuo, D.C., Nadelhaft, I., Hisamitso, T. and de Groat, W.C.,
Segmental distribution and central projections of renal afferent
fibers in the cat studied by transganglionic transport of horseradish
peroxidase, J. Comp. Neurol., 216 (1983) pl62-174.
291 Kuraishi, Y., Hirota, N., Sato, Y., Kaneko, S., Satoh, M. and
Takagi, H., Noradrenergic inhibition of the release of substance P
from primary afferents in the rabbit spinal dorsal horn, Brain Res.,
359 (1985a) pl77-182.
292 Kuraishi, Y., Hirota, N., Satoh, M. and Takagi, H.,
Antinociceptive effects of intrathecal opioids, noradrenaline and
serotonin in rats: mechanical and thermal algesic tests, Brain Res.,
326 (1985b) pl68-171.
293 Kuraishi, Y., Hirota, N., Sugimoto, M., Satoh, M. and Takagi, H.,
Effects of morphine on noxious stimuli-induced release of substance P
from rabbit dorsal horn in vivo, Life Sci., 33 si (1983) p693-696.
294 Kuwahara, A. and Yanaihara, N., Action of the newly discovered
mammalian tachykinins, substance K and neuromedin K, on
gastroduodenal motility of anaesthetised dogs, Regul. Pept., 17
(1987) p221-228 .
218
295 Kwiat, G.C. and Basbaum, A.I., The origin of brainstem
noradrenergic and serotonergic projections to the spinal dorsal horn
in the rat, Somatosensory and Motor Research, 9 (1992) pl57-173.
296 Lackner, K.J., Mapping of monoamine neurons and fibres in the cat
lower brainstem and spinal cord, Anat. Embryol., 161 (1980) pl69-195.
297 Lam, F.Y. and Ferrell, W.R., Specific neurokinin receptors
mediate plasma extravasation in the rat knee joint, Br. J.
Pharmacol., 103 (1991) pl263-1267.
298 Lam, F.Y. and Ferrell, W.R., Effects of interactions of
naturally-occurring neuropeptides on blood flow in the rat knee
joint, Br. J. Pharmacol., 108 (1993) p694-699.
299 Lamotte, C., Pert, C.B. and Snyder, S.H., Opiate receptor binding
in primate spinal cord: distribution and changes after dorsal root
section, Brain Res., 112 (1976) p407-412.
300 Lamotte, C.C. and Shapiro, C.M., Ultrastructural localization of
substance P, met-enkephalin, and somatostatin immunoreactivity in
lamina X of the primate spinal cord, J. Comp. Neurol., 306 (1991)
p290-306.
301 Laneuville, O., Dorais, J. and Couture, R., Characterization of
the effects produced by neurokinins and three agonists selective for
neurokinin receptor subtypes in a spinal nociceptive reflex of the
rat, Life Sci., 42 (1988) pl295-1305.
302 Lang, C.W., Duggan, A.W. and Hope, P.J., Analgesic doses of
morphine do not reduce noxious stimulus-evoked release of
immunoreactive neurokinins in the dorsal horn of the cat spinal cord,
Br. J. Pharmacol., 103 (1991) pl871-1876.
303 Lang, C.W. and Hope, P.J., Evidence for localized release of
substance P within rat spinal cord evoked by physiological and
electrical stimuli, Neuropeptides, 26 (1994) p413-419.
304 Lang, C.W., Hope, P.J., Grubb, B.D. and Duggan, A.W.,
Microinjection of noradrenaline or medetomidine does not alter the
pattern of nerve stimulus-evoked release of substance P in the spinal
cord of the anaesthetised cat: a study with antibody microprobes, Br.
J. Pharmacol., 112 (1994) p951-957.
305 Laufer, R., Gilon, C., Chorev, M. and Selinger, Z., [p-
Glu6,Pro9]SP6-11, a selective agonist for the substance P-receptor
subtype, J. Med. Chem., 29 (1986) pl284-1288.
306 Laufer, R. , Wormser, U., Friedman, Z.Y., Gilon, C., Chorev, M.
and Selinger, Z., Neurokinin B is a preferred agonist for a neuronal
substance P receptor and its action is antagonized by enkephalin,
Proc. Natl. Acad. Sci. (USA), 82 (1985) p7444-7448.
307 Le Bars, D., Guilbaud, G., Jurna, I. and Besson, J.M.,
Differential effects of morphine on responses of dorsal horn lamina V
type cells elicited by A and C fibre stimulation in the spinal cat,
Brain Res., 115 (1976a) p518-524.
308 Le Bars, D., Menetrey, D., Conseiller, C. and Besson, J.M.,
Effects of morphine upon the lamina V cells activities in the dorsal
horn of the decerebrate cat, Brain Res., 113 (1976b) p293-310.
219
309 Leah, J.D., Cameron, A. A. and Snow, P.J., Neuropeptides in
physiologically identified mammalian sensory neurones, Neurosci.
Lett., 56 (1985) p257-264.
310 Lee, C.-M., Campbell, N.J., Williams, B.J. and Iversen, L.L.,
Multiple tachykinin binding sites in peripheral tissues and in brain,
Eur. J. Pharmacol., 130 (1986) p209-217.
311 Lee, C.-M., Iversen, L.L., Hanley, M.R. and Sandberg, B.E.B., The
possible existence of multiple receptors for substance P, Naunyn
Schmeid. Arch. Pharmacol., 318 (1982) p281-287.
312 Lee, J.-M., McLean, S., Maggio, J.E., Zamir, N., Roth, R.H.,
Eskay, R.L. and Bannon, M.J., The localization and characterization
of substance P and substance K in striatonigral neurons, Brain Res.,
371 (1986) pl52-154.
313 Leeman, S.E. and Hammerschlag, R. , Stimulation of salivary
secretion by a factor extracted from hypothalamic tissue,
Endocrinology, 81 (1967) p803-809.
314 Lembeck, F. and Donnerer, J., Opioid control of the function of
primary afferent substance P fibres, Eur. J. Pharmacol., 114 (1985)
p241-246.
315 Light, A.R. and Perl, E.R., Differential termination of large
diameter and small diameter primary afferent fibres in the spinal
dorsal gray as indicated by labelling with horseradish peroxidase,
Neurosci. Lett., 6 (1977) p59-63.
316 Lilja, M., Juustila, H., Sarna, S. and Jounela, A.J., Transdermal
and oral clonidine, Ann. Med., 23 (1991) p265-269.
317 Lindberg, L.-A., Sedative and analgesic effects of detomidine in
horses and cattle, Acta. Vet. Scand., 82 Suppl. (1986) pl-208.
318 Lindefors, N., Brodin, E., Theodorsson-Norheim, E. and
Ungerstedt, U., Calcium-dependent potassium-stimulated release of
neurokinin A and neurokinin B from rat brain regions in vitro,
Neuropeptides, 6 (1985) p453-461.
319 Lindefors, N., Brodin, E. and Ungerstedt, U., Subchronic
haloperidol decreases substance P, substance K and preprotachykinin
mRNAs in rat striatonigral neurons, Eur. J. Pharmacol., 161 (1989)
p95-98.
320 Linderoth, B. and Brodin, E., Tachykinin release from rat spinal
cord in vitro and in vivo in response to various stimuli, Regul.
Pept., 21 (1988) pl29-140.
321 Lindsay, R.M., Lockett, C., Sternberg, J. and Winter, J.,
Neuropeptide expression in cultures of adult sensory neurons:
Modulation of substance P and calcitonin gene-related peptide levels
by nerve growth factor, Neuroscience, 33 (1989) p53-65.
322 Littlewood, G.M., Iversen, L.L. and Turner, A.J., Neuropeptides
and their peptidases, Neurochem. Int., 12 (1988) p383-389.
220
323 Ljungdhal, A., Hokfelt, T. and Nilsson, G., Distribution of
substance P-like immunoreactivity in the central nervous system of
the rat. I. Cell bodies and nerve terminals, Neuroscience, 3 (1978)
p861-943.
324 Lombard, M.-C. and Besson, J.M., Attempts to gauge the relative
importance of pre- and post-synaptic effects of morphine on the
transmission of noxious messages in the dorsal horn of the rat spinal
cord, Pain, 37 (1987) p335-345.
325 Lovick, T.A. and Hunt, S.P., Substance P immunoreactivity and
serotonin containing neurons in the ventral brainstem of the cat,
Neurosci. Lett., 36 (1983) p223-228.
326 Lundberg, J.M., Hokfelt, T., Martling, C.R., Saria, A. and
Cuello, A.C., Substance P immunoreactive sensory nerves in the lower
respiratory tract of various mammals including man, Cell Tissue Res.,
235 (1984) p251-261.
327 Lundberg, J.M., Hokfelt, T., Nilsson, G., Terenius, L., Rehfeld,
J., Elde, R. and Said, S., Peptide neurons in the vagus, splanchnic
and sciatic nerves, Acta. Physiol. Scand., 104 (1978) p499-501.
328 MacDonald, E., Scheinin, H. and Scheinin, M., Behavioural and
neurochemical effects of medetomidine, a novel veterinary sedative,
Eur. J. Pharmacol., 158 (1988) pll9-127.
329 MacDonald, M.R., Takeda, J., Rice, C.M. and Krause, J.E.,
Multiple tachykinins are produced and secreted upon post-
translational processing of the three substance P precursor proteins,
alpha, beta and gamma-preprotachykinin, J. Biol. Chem., 264(26)
(1989) pl5578-15592 .
330 Maggi, C.A., Santicioli, P., Giuliani, S., Regoli, D. and Meli,
A. , Activation of micturition reflex by substance P and substance K:
indirect evidence for the existence of multiple tachykinin receptors
in the rat urinary bladder, J. Pharmacol. Exp. Therap., 238(1) (1986)
p259-266.
331 Maggio, J.E., Tachykinins, Ann. Rev. Neurosci., 11 (1988) pl3-28.
332 Maggio, J.E. and Hunter, J.C., Regional distribution of kassinin-
like immunoreactivity in rat central and peripheral tissues and the
effect of capsaicin, Brain Res., 307 (1984) p370-373.
333 Maggio, J.E., Sandberg, B.E.B., Bradley, C.V., Iversen, L.L.,
Santikarn, S., Williams, B.H., Hunter, J.C. and Hanley, M.R.,
Substance K: a novel tachykinin in mammalian spinal cord. In P.
Skrabenek (Ed.), Substance P - Dublin 1983, Boole, Dublin, 1983, p20-
21.
334 Malmfors, G., Leander, S., Brodin, E., Hakansson, R. , Holmin, T.
and Sundler, F. , Peptide-containing neurons intrinsic to the gut
wall. An experimental study in the pig, Cell Tissue Res., 214 (1981)
p225-238.
335 Mantyh, P.W., Gates, T., Mantyh, C.R. and Maggio, J.E.,
Autoradiographic localization and characterization of tachykinin
receptor binding sites in the rat brain and peripheral tissues, J.
Neuroscience, 9 (1989) p258-279.
221
336 Mantyh, P.W., Hunt, S.P. and Maggio, J.E., Substance P receptors:
localization by light microscopic autoradiography in rat brain using
[3H]SP as the radioligand, Brain Res., 307 (1984a) pl47-165.
337 Mantyh, P.W., Maggio, J.E. and Hunt, S.P., The autoradiographic
distribution of kassinin and substance K binding sites is different
from the distribution of substance P binding sites in rat brain, Eur.
J. Pharmacol., 102 (1984b) p361-364.
338 Mantyh, P.W., Mantyh, C.R., Gates, T., Vigna, S.R. and Maggio,
J.E., Receptor binding sites for substance P and substance K in the
canine gastrointestinal tract and their possible role in inflammatory
bowel disease, Neuroscience, 25 (1988) p817-837.
339 Markle, R.A., Boyd, M.L. and Coryell, V.H., Substance P increases
rat aortic vascular permeability, Life Sci., 46 (1990) p965-969.
340 Marshal, K.W., Chiu, B. and Inman, R.D., Substance P and
arthritis: analysis of plasma and synovial fluid levels, Arthritis
Rheum., 33 (1990) p87-90.
341 Mauborgne, A., Bourgoin, S., Benoliel, B.-B., Hirsch, M.,
Berthier, J.-L., Hamon, M. and Cesselin, F., Enkephalinase is
involved in the degradation of endogenous substance P released from
slices of rat substantia nigra, J. Pharmacol. Exp. Therap., 243
(1987a) p674-680.
342 Mauborgne, A., Javoy-Agid, F., Legrand, J.C., Agid, Y. and
Cesselin, F. , Decrease of substance P-like immunoreactivity in the
substantia nigra and pallidum of Parkinsonian brains, Brain Res., 268
(1983) pl67-17 0.
343 Mauborgne, A., Lutz, O., Legrand, J.C., Hamon, N. and Cesselin,
F., Opposite effects of delta and mu opioid receptor agonists on the
in vitro release of substance P-like material from the rat spinal
cord, J. Neurochem., 48 (1987b) p529-537.
344 Mayer, D.J. and Liebeskind, J.C., Pain reduction by focal
electrical stimulation of the brain: an anatomical and behavioural
analysis, Brain Res., 68 (1974) p73-94.
345 Mayer, E.A., Lao, D.D.F., Snape, W.J. and Sachs, G., The
activation of calcium and calcium-activated potassium channels in
mammalian colonic smooth muscle by substance P, J. Physiol., 420
(1990) p47-71.
346 Mayer, N., Lembeck, F., Goedert, M. and Otten, U., Effects of
antibodies against nerve growth factor on the postnatal development
of substance P-containing sensory neurons, Neurosci. Lett., 29 (1982)
p47-52.
347 Maynard, F.M., Early clinical experience with clonidine in spinal
spasticity, Paraplegia, 24 (1986) pl75-182.
348 McCreery, D.B., Bloedel, J.R. and Hames, E.G., Effects of
stimulating in raphe nuclei and in reticular formation on response of
spinothalamic neurons to mechanical stimuli, J. Neurophysiol., 42
(1979) p!66-182.
222
349 McElroy, A.B., Clegg, S.P., Deal, M.J., Ewan, G.B., Hagan, R.M.,
Ireland, S.J., Jordan, C.C., Porter, B., Ross, B.C., Ward, P. and
Whittington, A.R., Highly potent and selective heptapeptide
antagonists of the neurokinin NK-2 receptor, J. Med. Chem., 35 (1992)
p2582-2591.
350 McKelvey, J.F. and Blumberg, S., Inactivation and metabolism of
neuropeptides, Ann. Rev. Neurosci., 9 (1986) p415-434.
351 McQuay, H.J. and Dickenson, A.H., Implications of nervous system
plasticity for pain management, Anaesthesia, 45 (1990) pl01-102.
352 Melzack, R. and Wall, P.D., Pain Mechanisms: A New Theory,
Science, 150 (1965) p973-979.
353 Merighi, A., Polak, J.M., Fumagalli, G. and Theodosis, G.T.,
Ultrastructural localization of neuropeptides and GABA in rat dorsal
horn: a comparison of different immunogold labelling techniques, J.
Histochem. Cytochem., 37 (1989) p529-540.
354 Michel, M.C., Brodde, O.-E., Schnepel, B., Behrendt, J., Tschada,
R. , Motulsky, H.J. and Insel, P.A., [3H] idazoxan and some other
alpha-2 adrenergic drugs also bind with high affinity to a
nonadrenergic site, Molec. Pharmacol., 35 (1989) p324-330.
355 Michel, M.C. and Insel, P.A., Are there multiple imidazoline
binding sites? T. I. P. S., 10 (1989) p342-244.
356 Minami, M. , Kuraishi, Y., Kawamura, M. , Yamaguchi, T., Masu, Y.,
Nakanishi, S. and Satoh, M. , Enhancement of preprotachykinin A gene
expression by adjuvant-induced inflammation in the rat spinal cord:
possible involvement of substance P-containing spinal neurons in
nociception, Neurosci. Lett., 98 (1989) pl05-110.
357 Minamino, N., Kangawa, K., Fukuda, A. and Matsuo, H., Neuromedin
L: a novel mammalian tachykinin identified in porcine spinal cord,
Neuropeptides, 4 (1984) pl57-166.
358 Minota, S., Dun, N.J. and Karczmar, A.G., Substance P-induced
depolarization in sympathetic neurons: not simple K-inactivation,
Brain Res., 216 (1981) p224-228.
359 Mizrahi, J., D'Orleans-Juste, P., Drapeau, G., Escher, E. and
Regoli, D., Partial agonists and antagonists for substance P, Eur. J.
Pharmacol., 91 (1983) pl39-140.
360 Moncada, S., Ferreira, S.H. and Vane, J.R., Inhibition of
prostaglandin biosynthesis as the mechanism of analgesia of aspirin¬
like drugs in the dog knee joint, Eur. J. Pharmacol., 31 (1975) p250-
160.
361 Moore, A.K., Vilderman, S., Lubenskyi, W., McCans, J. and Fox,
G.S., Differences in epidural morphine requirements between elderly
and young patients after abdominal surgery, Anesth. Analg., 70 (1990)
p316-320.
362 Morimoto, H., Murai, M., Maeda, Y., Yamaoka, M. , Nishikawa, M. ,
Kiyotoh, S. and Fujii, T., FK 224, a novel cyclopeptide substance P
antagonist with NK^ and NK2 receptor selectivity, J. Pharmacol. Exp.
Therap., 262 (1992) p398-402.
223
363 Morris, B.R., Herz, A., Distinct distribution of opioid receptor
types in rat lumbar spinal cord, Naunyn Scmeidebergs Arch.
Pharmacol., 336 (1987) p240-243.
364 Morton, C.R., Duggan, A.W. and Zhao, Z.Q., Kelatorphan
potentiates the effect of [met5]enkephalin in the substantia
gelatinosa of the cat spinal cord, Eur. J. Pharmacol., 140 (1987)
pl95-201.
365 Morton, C.R. and Hutchison, W.D., Morphine does not reduce the
intraspinal release of calcitonin gene-related peptide in the cat,
Neurosci. Lett., 117 (1990) p319-324.
366 Morton, C.R., Hutchison, W.D., Duggan, A.W. and Hendry, I.A.,
Morphine and substance P release in the spinal cord, Exp. Brain Res.,
82 (1990) p89-96.
367 Morton, C.R., Hutchison, W.D. and Hendry, I.A., Release of
immunoreactive somatostatin in the spinal dorsal horn of the cat,
Neuropeptides, 12 (1988) pl89-197.
368 Mudge, A.W., Leeman, S.E. and Fishbach, G.D., Enkephalin inhibits
release of substance P from sensory neurons in culture and decreases
action potential duration, Proc. Natl. Acad. Sci. (USA), 76 (1979)
p52 6-530.
369 Murase, K., Ryu, P.D. and Randic, M., Tachykinins modulate
multiple ionic conductances in voltage-clamped rat spinal dorsal horn
neurons, J. Neurophysiol., 61 (1989) p854-865.
370 Nagahisa, A., Kanai, Y., Suga, O., Taniguchi, K., Tsuchiya, M. ,
Lowe, J.A.,Ill and Hess, H.-J., Anti inflammatory and analgesic
activity of a non-peptide substance P receptor antagonist, Eur. J.
Pharmacol., 217 (1992) pl91-195.
371 Nagashima, A., Takano, Y., Tateishi, K. , Matsuoka, Y. , Hamaoka,
T. and Kamiya, H., Central pressor actions of neurokinin B: increases
in neurokinin B contents in discrete nuclei in spontaneously
hypertensive rats, Brain Res., 499 (1989) pl98-203.
372 Nakagawa, I., Omote, K. , Kitahata, L.M., Collins, J.G. and
Murata, K., Serotonergic mediation of spinal analgesia and its
interaction with noradrenergic systems, Anesthesiology, 73 (1990)
p474-478.
373 Nakajima, T., Yashima, Y. and Nakamura, K. , Quantitative
autoradiographic localization of neuropeptide Y receptors in the rat
lower brainstem, Brain Res., 300 (1986) pl44-150.
374 Nakamura-Craig, M. and Smith, T.W., Substance P and peripheral
inflammatory hyperalgesia, Pain, 38 (1989) p91-98.
375 Nakanishi, S., Mammalian tachykinin receptors, Ann. Rev.
Neurosci., 14 (1991) pl23-136.
376 Nakata, Y., Kusaka, Y., Yajima, H. and Segawa, T., Active
reuptake of substance P carboxy-terminal heptapeptide (5-11) into rat
brain and rabbit spinal cord slices, J. Neurochem., 37 (1981) pl529-
1534.
224
377 Nance, P.W., Shears, A.H. and Nance, D.M., Reflex changes induced
by clonidine in spinal cord injured patients, Paraplegia, 27 (1989)
p296-301.
378 Nawa, H., Hirokuazu, K. and Nakanishi, S., Tissue-specific
generation of two preprotachykinin mRNAs from one gene by alternative
RNA splicing, Nature, 312 (1984) p729-734.
379 Nawa, H., Hirose, T., Takashima, H., Inayama, S. and Nakanishi,
S., Nucleotide sequences of cloned cDNAs for two types of bovine
brain substance P precursor, Nature, 306 (1983) p32-36.
380 Neugebauer, V. and Schaible, H.-G., Peripheral and spinal
components of the sensitization of spinal neurons during an acute
experimental arthritis, Agents Actions, 25 (1988) p234-236.
381 Nicoll, R.A. , Schenker, C. and Leeman, S.E., Substance P as a
transmitter candidate, Ann. Rev. Neurosci., 3 (1980) p227-268.
382 Nilsson, G., Hokfelt, T. and Pernow, B., Distribution of
substance P-like immunoreactivity in the rat central nervous system
as revealed by immunohistochemistry, Med. Biol., 52 (1974) p424-427.
383 Nilsson, G., Larsson, L.-I., Hakansson, R. , Brodin, E., Pernow,
B. and Sundler, F., Localization of substance P-like immunoreactivity
in mouse gut, Histochemistry, 43 (1975a) p97-99.
384 Nilsson, G. , Pernow, B., Fisher, G.H. and Folkers, K., Presence
of substance P-like immunoreactivity in plasma from man and dog,
Acta. Physiol. Scand., 94 (1975b) p542-544.
385 Nishikawa, T. and Shimizu, S.-I., Inhibition of noradrenaline
release from cerebrocortical synaptosomes and stimulation of
synaptosomal Na/K ATPase activity by morphine in rats, J. Pharm.
Pharmacol., 42 (1990) p68-71.
386 Nishikawa, T., Teramoto, T. and Shimizu, S.-I., Effect of
morphine on Na/K ATPase from homogenate of synaptosomes and of
synaptic membrane of rat cerebral cortex, Brain Res., 510 (1990) p92-
96.
387 Noguchi, K. and Ruda, M.A. , Gene regulation in an ascending
nociceptive pathway: Inflammation- induced increase in
preprotachykinin mRNA in rat lamina I spinal projection neurons, J.
Neurosci., 12 (1992) p2563-2572.
388 Nolan, A. , Livingstone, A. and Waterman, A. , Antinociceptive
actions of intravenous alpha2-adrenoceptor agonists in sheep, J. Vet.
Pharmacol. Therap., 10 (1987) p202-209.
389 Nolan, A.M. and Erhardt, W., The cardiorespiratory effects of
intrathecal xylazine in the conscious rabbit, J. Vet. Pharmacol.
Therap., 13 (1990) p29-35.
390 North, R.A. and Yoshimura, M., The actions of noradrenaline on
neurones of the rat substantia gelatinosa in vitro, J. Physiol., 349
(1984) p43-56.
391 Nowak, I.M. and MacDonald, R.L., Substance P: ionic basis for
depolarizing responses of mouse spinal cord neurons in cell culture,
J. Neurosci., 2 (1982) plll9-1128.
225
392 Nussbaumer, J.C., Yanagisawa, M. and Otsuka, M. , Pharmacological
properties of a C-fibre response evoked by saphenous nerve
stimulation in as isolated spinal cord-nerve preparation of the
newborn rat, Br. J. Pharmacol., 98 (1989) p373-382.
393 Nyberg, F., Le Greves, P., Sundqvist, C. and Terenius, L.,
Characterization of substance P(l-7) and (1-8) generating enzyme in
human CSF, Biochem. Biophys. Res. Comm., 125 (1984) p244-250.
394 Ogawa, T., Kanazawa, I. and Kimura, S., Regional distribution of
substance P, neurokinin alpha and neurokinin beta in rat spinal cord,
nerve roots and dorsal root ganglia, and the effects of dorsal root
section or spinal transection, Brain Res., 359 (1985) pl52-157.
395 Ohlen, A., Lindbom, L., Staines, W., Hokfelt, T., Cuello, A.C.,
Fischer, J. A. and Hedqvist, P., Substance P and calcitonin gene-
related peptide: immunohistochemical localisation and microvascular
effects in rabbit skeletal muscle, Naunyn Schmeid. Arch. Pharmacol.,
336 (1987) p87-93.
396 Oku, R. , Satoh, M. , Fujii, N., Otaka, A., Yajima, H. and Takagi,
H., Calcitonin gene-related peptide promotes mechanical nociception
by potentiating release of substance P from the spinal dorsal horn in
rats, Brain Res., 403 (1987) p350-354.
397 Olgart, L., Hokfelt, T., Nilsson, G. and Pernow, B., Localization
of substance P-like immunoreactivity in nerves in the tooth pulp,
Pain, 4 (1977) pl53-159.
398 Oliveras, J.L., Besson, J.M., Guilbaud, G. and Liebeskind, J.C.,
Behavioural and electrophysiological evidence of pain inhibition from
midbrain stimulation in the cat, Exp. Brain Res., 20 (1974) p32-44.
399 Omote, K., Kitahata, L.M., Collins, J.G., Nakatani, K. and
Nakagawa, I., Interaction between opiate subtype and alpha-2
adrenergic agonists in suppression of noxiously evoked activity of
WDR neurons in the spinal dorsal horn, Anesthesiology, 74 (1991)
p737-743.
400 Ono, H., Mishima, A., Ono, S., Fukuda, H. and Vasko, M.R.,
Inhibitory effects of clonidine and tizanidine on release of
substance P from slices of rat spinal cord and antagonism by alpha-
adrenergic receptor antagonists, Neuropharmacology, 30 (1991) p585-
589.
401 Onofrio, B.M. and Yaksh, T.L., Intrathecal delta-receptor ligand
produces analgesia in man, Lancet, (1983) pl386-1387.
402 Ossipov, M.H., Harris, S., Lloyd, P. and Messineo, E., An
isobolographic analysis of the antinociceptive effect of systemically
and intrathecally administered combinations of clonidine and opiates,
J. Pharmacol. Exp. Therap., 255 (1990a) pll07-1116.
403 Ossipov, M.H., Harris, S., Lloyd, P., Messineo, E., Lin, B.S. and
Bagley, J., Antinociceptive interaction between opioids and
medetomidine: systemic additivity and spinal synergy, Anesthesiology,
73 (1990b) pl227-1235.
226
404 Ossipov, M.H., Lozito, R. , Messineo, E., Green, J., Harris, S.
and Lloyd, P., Spinal antinociceptive synergy between clonidine and
morphine, U69593, and DPDPE: isobolographic analysis, Life. Sci., 47
(1990c) p71-7 6.
405 Ossipov, M.V., Suarez, L.J. and Spaulding, T.C., Antinociceptive
interactions between alpha 2-adrenergic and opiate agonists at the
spinal level in rodents, Anesth. Analg., 68 (1989) pl94-200.
406 Ota, K., Namiki, A., Ujike, Y. and Takahashi, I., Prolongation of
tetracaine spinal anesthesia by oral clonidine, Anesth. Analg., 75
(1992) p262-264.
407 Otsuka, M. and Konishi, S., Release of substance P-like
immunoreactivity from isolated spinal cord of newborn rat, Nature,
264 (1976) p83-84.
408 Otsuka, M. and Yanagisawa, M. , Effect of a tachykinin antagonist
on a nociceptive reflex in the isolated spinal cord-tail preparation
of the newborn rat, J. Physiol., 395 (1988) p255-270.
409 Otsuka, M. and Yoshioka, K., Neurotransmitter functions of
mammalian tachykinins, Physiological Reviews, 73 (1993) p229-308.
410 Otten, U., Goedert, M., Mayer, N. and Lembeck, F., Requirement of
nerve growth factor for development of substance P-containing sensory
neurones, Nature, 287 (1980) pl58-159.
411 Pang, I.-H. and Vasko, M.R., Morphine and norepinephrine but not
5-hydroxytryptamine and gamma-aminobutyric acid inhibit the
potassium-stimulated release of substance P from rat spinal cord
slices, Brain Res., 376 (1986) p268-279.
412 Parker, R.M.C., Fleetwood-Walker, S.M., Rosie, R. , Munro, F.E.
and Mitchell, R. , Inhibition by NK2 but not NKi antagonists of
carrageenan-induced preprodynorphin mRNA expression in rat dorsal
horn lamina I neurons, Neuropeptides, 25 (1993) p213-222.
413 Parris, W.C., Kambam, J.R., Naukaum, J.R. and Rama Sastry, B.V.,
Immunoreactive substance P is decreased in saliva of patients with
chronic back pain syndromes, Anesth. Analg., 70 (1990) p63-67.
414 Parsons, C.G., Czlonkowski, A., Stein, C. and Herz, A.,
Peripheral opioid receptors mediating antinociception in
inflammation. Activation by endogenous opioids and role of the
pituitary-adrenal axis, Pain, 41 (1990) p81-93.
415 Pearse, A.G.E. and Polak, J.M., Immunocytochemical localization
of substance P in mammalian intestine, Histochemistry, 41 (1975)
p373-375.
416 Pelletier, G., Leclerc, R. and Dupont, A., Electron microscope
immunohistochemical localization of substance P in the central
nervous system of the rat, J. Histochem. Cytochem., 25 (1977) pl373-
1375.
417 Pereira da Silva, J.A. and Carmo-Fonseca, M. , Peptide containing
nerves in human synovium: Immunohistochemical evidence for decreased
innervation in rheumatoid arthritis, J. Rheumatol., 17 (1990) pl592-
1599.
227
418 Pernow, B., Studies on substance P: purification, occurrence and
biological actions, Acta. Physiol. Scand. Suppl., 29(sl05) (1953) pl-
90.
419 Pernow, B., Substance P, Pharmacol. Rev., 35 (1983) p85-141.
420 Pert, C.B., Kuhar, M.J. and Snyder, S.H., Autoradiographic
localization of the opiate receptor in rat brain, Life Sci., 16
(1975) pl849-1854.
421 Pertovaara, A., Kauppila, T., Jyvasjarvi, E. and Kalso, E.,
Involvement of supraspinal and spinal segmental alpha-2-adrenergic
mechanisms in the medetomidine-induced antinociception, Neuroscience,
44 (1991) p705-714.
422 Picard, P., Boucher, S., Regoli, D., Gitter, B.D., Howbert, J.J.
and Couture, R. , Use of non-peptide tachykinin receptor antagonists
to substantiate the involvement of NKq and NK2 receptors in a spinal
nociceptive reflex in the rat, Eur. J. Pharmacol., 232 (1993) p255-
261.
423 Pickel, V.M., Reis, D.J. and Leeman, S.E., Ultrastructural
localization of substance P in neurons of rat spinal cord, Brain
Res., 122 (1977) p534-540.
424 Piercey, M.F., Dobry-Schreur, P.J.K., Masiques, N. and Schroeder,
L.A., Stereospecificity of SP1 and SP2 receptors, Life Sci., 36
(1985) p777-780.
425 Pohl, M. , Mauborgne, A., Bourgoin, S., Benoliel, J.J., Hamon, M.
and Cesselin, F. , Neonatal capsaicin treatment abolishes the
modulations by opioids of substance P release from rat spinal cord
slices, Neurosci. Lett., 96 (1989) pl02-107.
426 Pollard, H., Bouthenet, M.L., Moreau, J., Souil, E., Verroust,
P., Ronco, P. and Schwartz, J.C., Detailed immunoautoradiographic
mapping of enkephalinase (EC 3.4.24.11) in rat central nervous
system: comparison with enkephalins and substance P, Neuroscience, 30
(1989) p339-37 6.
427 Poncelet, M. , Gueudet, C., Emonds-Alt, X., Breliere, J.-C., Le
Fur, G. and Soubrie, P., Turning behavior induced in mice by a
neurokinin A receptor agonist: Stereoselective blockade by SR 48968,
a non-peptide receptor antagonist, Neurosci. Lett., 149 (1993) p40-
42.
428 Potter, E.K. and McCloskey, M.J.D., [Leu^, Pro^] NPY, a
selective functional postjunctional agonist at neuropeptide-Y
receptors in anaesthetised rats, Neurosci. Lett., 134 (1992) pl83-
186.
429 Rajaofetra, N., Ridet, J.-L., Poulat, P., Marlier, L., Sandillon,
F., Geffard, M. and Privat, A., Immunocytochemical mapping of
noradrenergic projections to the rat spinal cord with an antiserum
against noradrenaline, J. Neurocytol., 21 (1992) p481-494.
430 Randic, M. and Miletic, V. , Effect of substance P in cat dorsal
horn neurones activated by noxious stimuli, Brain Res., 128 (1977)
pl64-169.
228
431 Reddy, S.V.R., Maderdrut, J.L. and Yaksh, T.L., Spinal cord
pharmacology of adrenergic agonist-mediated antinociception, J.
Pharmacol. Exp. Therap., 213 (1980) p525-533.
432 Reddy, S.V.R. and Yaksh, T.L., Spinal noradrenergic terminal
system mediates antinociception, Brain Res., 189 (1980) p391-402.
433 Regoli, D., Drapeau, G., Dion, S. and Couture, R., New selective
agonists for neurokinin receptors: pharmacological tools for receptor
characterization, T. I. P. S., 9 (1989) p290-295.
434 Regoli, D., Drapeau, G., Dion, S. and D' Orleans-Juste, P.,
Receptors for neurokinins in peripheral organs. In J.L. Henry, A.C.
Couture, G. Cuello, G. Pelletier, R. Quirion and D. Regoli (Eds.),
Substance P and neurokinins, Springer-Verlag, (1987), p99-107.
435 Regoli, D., Rhaleb, N.-E., Dion, S., Tousignant, C., Noureddine,
R., Jukic, D. and Drapeau, G., Neurokinin A. A pharmacological study,
Pharmacol. Res., 22 (1990) pl-15.
436 Reid, M. , Herrera-Marschitz, M. , Hokfelt, T., Terenius, L. and
Ungerstedt, U., Differential modulation of striatal dopamine release
by intranigral injection of gamma-amino butyric acid (GABA),
dynorphin A and substance P, Eur. J. Pharmacol., 147 (1988) p411-420.
437 Reiser, G., Folkers, K. and Hamprecht, B., Substance P enhances
cation permeabilty of neuronal cell lines, Regul. Pept., 5 (1982)
p85-93.
438 Rethelyi, M. , Trevino, D.L. and Perl, E.R., Distribution of
primary afferent fibres within the sacrococcygeal dorsal horn; An
autoradiographic study, J. Comp. Neurol., 185 (1979) p603-622.
439 Reynolds, D.V., Surgery in the rat during electrical analgesia
induced by focal brain stimulation, Science, 164 (1969) p444-445.
440 Robertson, J.T. and Muir, W.W., A new analgesic drug combination
in the horse, Am. J. Vet. Res., 44 (1983) pl667-1669.
441 Roerig, S.C., Lei, S., Kitto, K. , Hylden, J.K.L. and Wilcox,
G.L., Spinal interactions between opioid and noradrenergic agonists
in mice: Multiplicativity involves delta and alpha- 2 receptors, J.
Pharmacol. Exp. Therap., 262 (1992) p365-374.
442 Rosell, S., Bjorkroth, U., Xu, J.-C. and Folkers, K., The
pharmacological profile of s substance P (SP) antagonist. Evidence
for the existence of subpopulations of SP receptors, Acta. Physiol.
Scand., 117 (1983) p445-449.
443 Rosell, S., Olgart, L., Gazelius, B., Panopoulos, P., Folker, K.
and Horig, J., Inhibition of antidromic and substance P-induced
vasodilation by a substance P antagonist, Acta. Physiol. Scand., Ill
(1981) p381-382 .
444 Rostaing, S., Bonnet, F., Levron, J.C., Vodinh, J., Pluskwa, F.
and Saada, M. , Effect of epidural clonidine on analgesia and
pharmacokinetics of epidural fentanyl in postoperative patients,
Anesthesiology, 75 (1991) p420-425.
229
445 Rovero, P., Pestellini, V. , Maggi, C.A., Patacchini, R. , Regoli,
D. and Giachetti, A., A highly selective tachykinin NK-2 receptor
antagonist containing D-tryptophan, Eur. J. Pharmacol., 175 (1990)
pll3-115.
446 Rovero, P., Pestellini, V., Patacchini, R., Santicioli, P.,
Maggi, C.A. and Meli, A., Conformationally constrained tachykinins:
N-methylated analogues of neurokinin A, Biopolymers, 28 (1989) p65-
67 .
447 Rowan, S., Todd, A.J. and Spike, R.C., Evidence that neuropeptide
Y is present in GABAergic neurons in the superficial dorsal horn of
the rat spinal cord, Neuroscience, 53 (1993) p537-545.
448 Ruffolo, R.R., Alpha2-adrenoceptor agonists and antagonists,
Neurotransmissions, 6 (1990) pl-8.
449 Russell, N.J.W., Schaible, H.-G. and Schmidt, R.F., Opiates
inhibit the discharges of fine afferent units from inflamed knee
joint of the cat, Neurosci. Lett., 76 (1987) pl07-112.
450 Sagen, J. and Proudfit, H.K., Effects of intrathecally
administered noradrenergic antagonists on nociception in the rat,
Brain Res., 310 (1984) p295-301.
451 Sakamoto, H. and Atsumi, S., Substance P-immunoreactive elements
in laminae I and II of the chicken spinal cord: a light- and
electron-microscopic study, Neurosci. Res., 7 (1989) pl03-116.
452 Sakurada, T., Manome, Y., Tan-No, K., Sakurada, S., Kisara, K.,
Ohba, M. and Terenius, L., A selective and extremely potent
antagonist of the neurokinin- 1 receptor, Brain Res., 593 (1992)
p319-322.
453 Salonen, J.S. and Eloranta, M., Biotransformation of medetomidine
in the rat, Xenobiotica, 20 (1990) p471-480.
454 Saria, A., Gamse, R., Petermann, J., Fischer, J.A., Theodorsson-
Norheim, E. and Lundberg, J.M., Simultaneous release of several
tachykinins and calcitonin gene-related peptide from rat spinal cord
slices, Neurosci. Lett., 63 (1986) p310-314.
455 Saria, A., Martling, C.R., Yan, Z., Theodorsson-Norheim, E.,
Gamse, R. and Lundberg, J.M., Release of multiple tachykinins from
capsaicin-sensitive sensory nerves in the lung by bradykinin,
histamine, DMPP and vagal nerve stimulation, Am. Rev. Resp. Dis., 137
(1988) pl330-1335.
456 Sasai, Y. and Nakanishi, S., Molecular characterization of rat
substance K receptor and its mRNAs, Biochem. Biophys. Res. Comm., 165
(1989) p695-7 02 .
457 Sasek, C.A. and Elde, R.P., Distribution of neuropeptide Y-like
immunoreactivity and its relationship to FMRF-amide-like
immunoreactivity in the sixth lumbar and first sacral spinal cord
segments of the rat, J. Neurosci., 5 (1985) pl729-1739.
458 Sastry, B.R., Gamma-aminobutyric acid and primary afferent
depolarization in feline spinal cord, Can. J. Physiol. Pharmacol., 57
(1979a) pll57-1167.
230
459 Sastry, B.R., Substance P effects on spinal nociceptive neurones,
Life Sci., 24 (1979b) p2169-2170.
460 Sastry, B.R., Potentiation of presynaptic inhibition of
nociceptive pathways as a mechanism for analgesia, Can. J. Physiol.
Pharmacol., 58 (1980) p97-100.
461 Sastry, B.R. and Goh, J.W., Actions of morphine and met-
enkephalin amide on nociceptor driven neurons in the substantia
gelatinosa and deeper dorsal horn, Neuropharmacology, 22 (1983) pll9-
122.
462 Savola, J.M., Ruskoaho, H., Puurunen, J. and Salonen, J.S.,
Evidence for medetomidine as a selective and potent agonist at alpha-
2 adrenoceptors, J. Auton. Pharmacol., 6 (1986) p275-284.
463 Savola, M.K.T. and Savola, J.M., [3H] dexmedetomidine, an alpha-2
adrenergic receptor agonist, binds to a non-adrenergic imidazole-
preferring site in rat CNS, Proceedings, Neuroscience 1992, Finland,
P53 (1992) p97.
464 Schaffer, D.D., Hsu, W.H. and Hopper, D.L., Antagonism of
xylazine-induced depression of shuttle avoidance responses in dogs by
administration of 4-aminopyridine, doxapram, or yohimbine, Am. J.
Vet. Res., 47 (1986) p2116-2121.
465 Schaible, H-G., Hope, P.J., Lang, C.W. and Duggan, A.W.,
Calcitonin gene-related peptide causes intraspinal spreading of
substance P released by peripheral stimulation, Eur. J. Neurosci., 4
(1992) p750-757.
466 Schaible, H.-G., Duggan, A.W., Lang, C.W. and Hope, P.J.,
Neurophysiological and neuropharmacological studies on arthritic
pain. In L. Vecchiet, D. Albe-Fessard, V. Lindblom and M.A.
Giamberardino (Eds.), 'New Trends in Referred Pain and Hyperalgesia',
Elsevier Science Publishers B.V., Amsterdam, (1993) ppl89-203.
467 Schaible, H.-G., Jarrott, B., Hope, P.J. and Duggan, A.W.,
Release of immunoreactive substance P in the spinal cord during
development of acute arthritis in the knee joint of the cat: a study
with antibody microprobes, Brain Res., 529 (1990) p214-223.
468 Scheinin, H., Karhuvaara, S., Olkkola, K.T., Kallio, A., Anttila,
M. , Vuorilehto, L. and Scheinin, M. , Pharmacodynamics and
pharmacokinetics of intramuscular dexmedetomidine, Clin. Pharmacol.
Ther., 52 (1992) p537-546.
469 Schmauss, C. and Yaksh, T.L., In vivo studies on spinal opiate
receptors mediating antinociception. II. Pharmacological profiles
suggesting a differential association of mu, delta and kappa
receptors with visceral chemical and cutaneous thermal stimuli in the
rat, J. Pharmacol. Exp. Therap., 228 (1984) pl-12.
470 Schroder, H.D. and Skagerberg, G., Catecholamine innervation of
the caudal spinal cord in the rat, J. Comp. Neurol., 242 (1985) p358-
368.
471 Schultzberg, M., Ebendal, T., Hokfelt, T., Nilsson, G. and
Pfenninger, K. , Substance P-like immunoreactivity in cultured spinal
ganglia from chick embryos, J. Neurocytol., 7 (1978) pl07-117.
231
472 Segal, I.S., Jarvis, D.J., Duncan, S.R., White, P.F. and Maze,
M., Clinical efficacy of oral-transdermal clonidine combinations
during the perioperative period, Anesthesiology, 74 (1991) p220-225.
473 Segawa, T., Nakata, Y. , Yajima, H. and Kitagawa, K., Further
observation on the lack of active uptake system for substance P in
the central nervous system, Jpn. J. Pharmacol., 27 (1977) p573-580.
474 Sekizawa, K., Tamaoki, T., Graf, P.D., Basbaum, C.B., Borson,
D.B. and Nadel, J. A, Enkephalinase inhibitor potentiates mammalian
tachykinin-induced contraction in ferret trachea, J. Pharmacol. Exp.
Therap., 243 (1987) pl211-1217.
475 Senba, E., Yanaihara, C., Yanaihara, N. and Tohyama, M.,
Proenkephalin opioid peptide product in the sensory ganglia of the
rat: a developmental immunohistochemical study, Dev. Brain Res., 48
(1989) p263-271.
476 Sharkey, K.A., Sobrino, J.A., Cervero, F., Varros, A. and
Dockray, G.J., Visceral and somatic origin of calcitonin gene-related
peptide immunoreactivity in the lower thoracic spinal cord of the
rat, Neuroscience, 32 (1989) pl69-179.
477 Shen, K. and Crain, S.M., Dual opioid modulation of the action
potential duration of mouse dorsal root ganglion neurons in culture,
Brain Res., 491 (1989) p227-242.
478 Shen, K.F. and Crain, S.M., Cholera toxin-A subunit blocks opioid
excitatory effects on sensory neuron action potentials indicating
mediation by G-protein linked receptors, Brain Res., 525 (1990) 225-
231.
479 Sherman, T.G., Akil, H. and Watson, S.J., The molecular biology
of neuropeptides, Elsevier Science Publishers B.V., (1989).
480 Shigemoto, R., Yokota, Y., Tsuchida, K. and Nakanishi, S.,
Cloning and expression of a rat neuromedin K receptor cDNA, J. Biol.
Chem., 265 (1990) p623-628.
481 Solomon, R.E. and Gebhart, G.F., Intrathecal morphine and
clonidine: antinociceptive tolerance and cross-tolerance and effects
on blood pressure, J. Pharmacol. Exp. Therap., 245 (1988a) p444-454.
482 Solomon, R.E. and Gebhart, G.F., Mechanisms of effects of
intrathecal serotonin on nociception and blood pressure in rats, J.
Pharmacol. Exp. Therap., 245 (1988b) p905-912.
483 Stanfa, L.C., Sullivan, A.F. and Dickenson, A.H., Alterations in
neuronal excitability and the potency of spinal mu, delta and kappa
opioids after carrageenan-induced inflammation, Pain, 50 (1992) p345-
354 .
484 Stein, C., Peripheral mechanisms of opioid analgesia, Anesth.
Analg., 76 (1993) pl82-191.
485 Stein, C., Gramsch, C. and Herz, A., Intrinsic mechanisms of
antinociception in inflammation: local opioid receptors and beta-
endorphin, J. Neurosci., 10 (1990a) pl292-1298.
232
486 Stein, C., Hassan, A.H.S., Przewlocki, R., Gramsch, C., Peter, K.
and Herz, A. , Opioids from immunocytes interact with receptors on
sensory nerves to inhibit nociception in inflammation, Proc. Natl.
Acad. Sci. (USA), 87 (1990b) p5935-5939.
487 Stevens, C. and Yaksh, T.L., Opioid and adrenergic spinal
receptor systems and pain control, NIDA Res. Monograph, 81 (1988)
p343-352.
488 Stevens, R.T., Hodge, C.J. and Apkarian, A.V., Kolliker-Fuse
nucleus; the principal source of pontine cathecholaminergic cells
projecting to the lumbar spinal cord of cat, Brain Res., 239 (1982)
p589-594 .
489 Stjarne, L. and Lundberg, J.M., On the possible roles of
noradrenaline, adenosine 5-triphosphate and neuropeptide Y as
sympathetic cotransmitters in the mouse vas deferens. In T. Hokfelt,
K. Fuxe and B. Pernow (Eds.), Progress in Brain Research, Vol. 68th ,
Elsevier, Amsterdam, (1986), p263-278.
490 Stjarne, P., Lundblad, L., Anggard, A., Hokfelt, T. and Lundberg,
J.M., Tachykinins and calcitonin gene-related peptide: co-existence
in sensory nerves of the nasal mucosa and effects on blood flow, Cell
Tissue Res., 256 (1989) p439-446.
491 Suarez-Roca, H., Abdullah, L., Zuniga, J., Madison, S. and
Maixner, W., Multiphasic effect of morphine on the release of
substance P from rat trigeminal nucleus slices, Brain Res., 579
(1992) pl87-194.
492 Suh, H.H. and Tseng, L.L.-F., Intrathecal administration of
thiorphan, bestatin, desipramine and fluoxetine differentially
potentiate the antinociceptive effects induced by beta-endorphin and
morphine, administered intracerebroventricularly, Neuropharmacology,
29 (1990) p2 07-214.
493 Sullivan, A.F., Dashwood, M.R. and Dickenson, A.H., Alpha 2-
adrenoceptor modulation of nociception in rat spinal cord: location,
effects and interactions with morphine, Eur J Pharmacol., 138 (1987)
pl69-177.
494 Sullivan, A.F., Dickenson, A.H. and Roques, B.P., Delta-opioid
mediated inhibitions of acute and prolonged noxious-evoked responses
in rat dorsal horn neurones, Br. J. Pharmacol., 98 (1989) pl039-1049.
495 Sullivan, A.F., Kalso, E.A., McQuay, H.J. and Dickenson, A.H.,
The antinociceptive actions of dexmedetomidine on dorsal horn
neuronal responses in the anaesthetized rat, Eur. J. Pharmacol., 215
(1992) pl27-133.
496 Szeli, J., Molina, E., Zappia, L. and Bertaccini, G., Action of
some natural polypeptides on the longitudinal muscle of the guinea
pig ileum, Eur. J. Pharmacol., 43 (1977) p285-287.
497 Taiwo, Y.O., Fabian, A., Pazoles, C.J. and Fields, H.L.,
Potentiation of morphine antinociception by monoamine reuptake
inhibitors in the rat spinal cord, Pain, 21 (1985) p329-337.
233
498 Takahashi, T., Konishi, S., Powell, D., Leeman, S.E. and Otsuka,
M. , Identification of the motoneuron-depolarizing peptide in bovine
dorsal root as hypothalamic substance P, Brain Res., 73 (1974) p59-
69.
499 Takano, Y., Nagashima, A., Masui, H., Kuromizu, K. and Kamiya,
H., Distribution of substance K (Neurokinin A) in the brain and
peripheral tissues of rats, Brain Res., 369 (1986) p400-404.
500 Takano, Y. and Yaksh, T.L., Relative efficacy of spinal alpha-2
agonists, dexmedetomidine, clonidine and ST-91, determined in vivo by
using N-ethoxycarbonyl-2-ethoxy-l, 2-dihydroquinoline, an irreversible
antagonist, J. Pharmacol. Exp. Therap., 258 (1991) p438-446.
501 Tamsen, A. and Gordh, T., Epidural clonidine produces analgesia,
Lancet, (1984) p231-232.
502 Tamsen, A., Sakurada, T., Wahlstrom, A., Terenius, L. and
Hartvig, P., Postoperative demand for analgesics in relation to
individual levels of endorphins and substance P in cerebrospinal
fluid, Pain, 13 (1982) pl71-183.
503 Tateishi, K., Kishimoto, S., Kobayashi, H., Kobuke, K. and
Matsuoka, Y., Distribution and localization of neurokinin A-like
immunoreactivity and neurokinin B-like immunoreactivity in rat
peripheral tissue, Regul. Pept., 30 (1990) pl93-200.
504 Tateishi, K., Matsuoka, Y. and Hamaoka, T., Establishment of
highly specific radioimmunoassays for neurokinin A and neurokinin B
and determination of tissue distribution of these peptides in rat
central nervous system, Regul. Pept., 24 (1989) p245-257.
505 Tatemoto, K., Lundberg, J.M., Jornvall, H. and Mutt, V.,
Neuropeptide K: isolation, structure and biological activities of a
novel brain tachykinin, Biochem. Biophys. Res. Comm., 128 (1985)
p947-953.
506 Theodorsson-Norheim, E., Hemsen, A., Brodin, E. and Lundberg,
J.M., Sample handling techniques when analyzing regulatory peptides,
Life Sci., 41 (1987) p845-848.
507 Theriault, E., Otsuka, M. and Jessell, T., Capsaicin-evoked
release of substance P from primary sensory neurons, Brain Res., 170
(1979) p209-213.
508 Thompson, S.W.N., Urban, L. and Dray, A., Contribution of NKq and
NK2 receptor activation to high threshold afferent fibre evoked
ventral root responses in the rat spinal cord in vitro, Brain Res.,
625 (1993) pl00-108.
509 Thor, K.B. and Helke, C.J., Serotonin- and substance P-containing
projections to the nucleus tractus solitarii of the rat, J. Comp.
Neurol., 265 (1987) p275-293.
510 Tiseo, P.J., Adler, M.W. and Liu-Chen, L.-Y., Differential
release of substance P and somatostatin in the rat spinal cord in
response to noxious cold and heat; effect of dynorphin A(l-17), J.
Pharmacol. Exp. Therap., 252 (1990) p539-545.
234
511 Tjolsen, A., Lund, A. and Hole, K., The role of descending
noradrenergic systems in regulation of nociception: the effects of
intrathecally administered alpha-adrenoceptor antagonists and
clonidine, Pain, 43 (1990) pll3-120.
512 Too, H.P., Cordova, J.L. and Maggio, J.E., Heterogeneity of
tachykinin-like immunoreactive peptides in rat spinal cord and dorsal
root ganglia, Peptides, 10 (1989a) p25-30.
513 Too, H.P., Cordova, J.L. and Maggio, J.E., A novel
radioimmunoassay for neuromedin K-like immunoreactivity in guinea pig
ileum and urinary bladder. II. Heterogeneity of tachykinins in guinea
pig tissues, Regul. Pept., 26 (1989b) p93-105.
514 Toth, P.T., Bindokas, V.P., Bleakman, D., Colmers, W.F. and
Miller, R.J., Mechanism of presynaptic inhibition by neuropeptide Y
at sympathetic nerve terminals, Nature, 364 (1993) p635-637.
515 Traynor, J.R., Hunter, J.C., Rodriguez, R.E., Hill, R.G. and
Hughes, J., Delta-opioid receptor binding sites in rodent spinal
cord, Br. J. Pharmacol., 100 (1990) p319-323.
516 Tregear, G.W., Niall, H.D., Potts, J.T., Leeman, S.E. and Chang,
M.M., Synthesis of substance P, Nature New Biol., 232 (1971) p87-89.
517 Tseng, L.L. and Tang, R., Differential actions of the blockade of
spinal opioid, adrenergic and serotonergic receptors on the tail-
flick inhibition induced by morphine microinjected into the dorsal
raphe and central gray in rats, Neuroscience, 33 (1989) p93-100.
518 Tsuchida, K., Shigemoto, R. , Yokota, Y. and Nakanishi, S., Tissue
distribution and quantitation of the mRNAs for three rat tachykinin
receptors, Eur. J. Biochem., 193 (1990) p751-757.
519 Tulloch, I.F. and Zieglgansberger, W., Substance P-induced
excitation of spinal cord neurones, J. Physiol., 280 (1978) 12P-13P.
520 Tung, A.S. and Yaksh, T.L., In vivo evidence for multiple opiate
receptors mediating analgesia in the rat spinal cord, Brain Res., 247
(1982) p75-83.
521 Turner, A.J. and Hooper, N.M., Metabolism of tachykinins by cell-
surface peptides. In J.L Henry, A.C. Couture, G. Cuello, G.
Pelletier, R. Quirion and D. Regoli (Eds.), Substance P and
neurokinins, Springer-Verlag, 1987.
522 Uhlen, S., Persson, M.L., Alari, L., Post, C., Axelsson, K.L. and
Wikberg, J.E., Antinociceptive actions of alpha 2-adrenoceptor
agonists in the rat spinal cord: evidence for antinociceptive alpha
2-adrenoceptor subtypes and dissociation of antinociceptive alpha 2-
adrenoceptors from cyclic AMP, J. Neurochem., 55 (1990) pl905-1914.
523 Unnerstall, J.R., Kopajtic, T.A. and Kuhar, M.J., Distribution of
alpha 2 agonist binding sites in the rat and human central nervous
system: analysis of some functional, anatomical correlates of the
pharmacological effects of clonidine and related adrenergic agents,
Brain Res., 319 (1984) p69-101.
524 Vaha-Vahe, A.T., The clinical effectiveness of atipamezole as a
medetomidine antagonist in the dog, J. Vet. Pharmacol. Therap., 13
(1990) pl98-205.
235
525 Vainio, 0. and Vaha-Vahe, T., Reversal of medetomidine sedation
by atipamezole in dogs, J. Vet. Pharmacol. Therap., 13 (1990) pl5-22.
526 Valentino, K.L., Tatemoto, K., Hunter, J. and Barchas, J.D.,
Distribution of neuropeptide K-immunoreactivity in the rat central
nervous system, Peptides, 7 (1986) pl043-1059.
527 Van den Bos, R. , Cools, A.R. and Ogren, S.O., Neurokinin A
enhances the stimulatory effects of d-amphetamine on motor activity
in the nucleus accumbens of the rat, Acta. Physiol. Scand., 138
(1990) p423-424.
528 Van Dongen, P.A., Theodorsson-Norheim, E., Brodin, E., Hokfelt,
T., Grillner, S., Peters, A., Cuello, A.C., Forssman, W.G., Reinecke,
M. and Singer, E.A., Immunohistochemical and chromatographic studies
of peptides with tachykinin-like immunoreactivity in the central
nervous system of the lamprey, Peptides, 7 (1986) p297-313.
529 Van Essen, E.J., Bovill, J.G. and Ploeger, E.J., Extradural
clonidine does not potentiate analgesia produced by extradural
morphine after menisectomy, Br. J. Anaes., 66 (1991) p237-241.
530 Vaught, J.L., Scott, R.W. and Jacoby, H.I., A differentiation
between peripheral and central neurokinin receptors using
phenoxybenzamine, Eur. J. Pharmacol., 125 (1986) p325-331.
531 Villar, M.J., Wiesenfeld-Hallin, Z., Xu, X.-J., Theosdorsson, E.,
Emson, P.C. and Hokfelt, T., Further studies on galanin-, substance
P-, and CGRP-like immunoreactivities in primary sensory neurons and
spinal cord: effects of dorsal rhizectomies and sciatic nerve
lesions, Exp. Neurol., 112 (1991) p29-39.
532 Vincent, S.R., Satoh, K., Armstrong, D.M. and Fibiger, H.C.,
Substance P in the ascending cholinergic reticular formation, Nature,
306 (1983) p688-691.
533 Virtanen, R. , Savola, J.M., Saano, V. and Nyman, L.,
Characterization of the selectivity, specificity and potency of
medetomidine as an alpha-2 adrenoceptor agonist, Eur. J. Pharmacol.,
150 (1988) p9-14 .
534 von Euler, U.S. and Gaddum, J.H., An unidentified depressor
substance in certain tissue extracts, J. Physiol., 72 (1931) p74-87.
535 Wahlestedt, C., Yanaihara, N. and Hakanson, R. , Evidence for
different pre- and post-junctional receptors for neuropeptide Y and
related peptides, Regul. Pept., 13 (1986) p307-318.
536 Wakisaka, S., Kajander, K.C. and Bennett, G.J., Increased
neuropeptide Y (NPY)-like immunoreactivity in rat sensory neurons
following peripheral axotomy, Neurosci. Lett., 124 (1991) p200-203.
537 Wakisaka, S., Kajander, K.C. and Bennett, G.J., Effects of
peripheral nerve injuries and tissue inflammation on the levels of
neuropeptide Y-like immunoreactivity in rat primary afferent neurons,
Brain Res., 598 (1992) p349-352.
538 Walker, M.W., Ewald, D.A., Perney, T.M. and Miller, R.J.,
Neuropeptide Y modulates neurotransmitter release and Ca2+ currents
in rat sensory neurons, J. Neurosci., 8 (1988) p2438-2446.
236
539 Wang, L., Ahmad, S., Benter, I.F., Chow, A., Mizutani, S. and
Ward, P.E., Differential processing of substance P and neurokinin A
by plasma dipeptidyl(amino)peptidase IV, aminopeptidase M and
angiotensin converting enzyme, Peptides, 12 (1991) pl357-1364.
540 Warden, M.K. and Young, W.S.III., Distribution of cells
containing mRNAs encoding substance P and neurokinin B in the rat
central nervous system, J. Comp. Neurol., 272 (1988) p90-113.
541 Waterfall, A.H., Clarke, R.W. and Bennett, G.W., Detection of
thyrotrophin releasing hormone in rat brain in vivo using novel
antibody microprobes: effects of amphetamine, Neurosci. Lett., 151
(1993) pp97-100.
542 Waterman, A., Livingstone, A. and Bouchenafa, O., Analgesic
effects of intrathecally-applied alpha 2-adrenoceptor agonists in
conscious, unrestrained sheep, Neuropharmacology, 27 (1988) p213-216.
543 Watson, S.P., The action of substance P on contraction, inositol
phospholipids and adenylate cyclase in rat small intestine,
Biochemical Pharmacology, 33 (1984) p3733-3737.
544 Watson, S.P., Sandberg, B.E.B., Hanley, M.R. and Iversen, L.L.,
Tissue selectivity of substance P alkyl esters suggesting multiple
receptors, Eur. J. Pharmacol., 87 (1983) p77-84.
545 Weihe, E., Reinecke, M., Opherk, D. and Forssman, W.G.,
Peptidergic innervation (substance P) in the human heart, J. Mol.
Cell. Cardiol., 13 (1981) p331-333.
546 Werz, M.A. and MacDonald, R.L., Heterogenous sensitivity of
cultured dorsal root ganglion neurones to opioid peptides selective
for mu and delta-opiate receptors, Nature, 299 (1982) p730-733.
547 Westfall, T.C., Martin, J., Chen, X.L., Ciarleglio, A.,
Carpentier, S., Henderson, K., Knuepfer, M. , Beinfeld, M. and Naes,
L., Cardiovascular effects and modulation of noradrenergic
neurotransmission following central and peripheral administration of
neuropeptide Y, Synapse, 2 (1988) p299-307.
548 Westlund, K.N., Bowker, R.M., Ziegler, M.G. and Coulter, J.D.,
Origins of spinal noradrenergic pathways demonstrated by retrograde
transport of antibody to dopamine-beta-hydroxylase, Neurosci. Lett.,
25 (1981) p243-249.
549 Westlund, K.N., Bowker, R.M., Ziegler, M.G. and Coulter, J.D.,
Noradrenergic projections to the spinal cord of the rat, Brain Res.,
263 (1983) pl5-31.
550 Westlund, K.N., Bowker, R.M., Ziegler, M.G. and Coulter, J.D.,
Organization of descending noradrenergic systems. In M.G. Ziegler and
C.R. Lake (Eds.), Frontiers of Clinical Neuroscience. Volume 2:
Norepinephrine, Williams and Wilkins, Baltimore, (1984), p55-73.
551 Whittle, B.J.R., Lopez-Belmonte, J. and Rees, D.D., Modulation of
the vasodepressor actions of acetylcholine, bradykinin, substance P
and endothelin in the rat by a specific inhibitor of nitric oxide
formation, Br. J. Pharmacol., 98 (1989) p646-652.
237
552 Wienrich, M. , Reuss, K. and Harting, J., Effects of receptor-
selective neurokinin agonists and a neurokinin antagonist on the
electrical activity of spinal cord neurones in culture, Br. J.
Pharmacol., 98 (1989) p914-920.
553 Wiesenfeld-Hallin, Z., Hokfelt, T., Lundberg, J.M., Forssman,
W.G., Reinecke, M. , Tschopp, F. and Fischer, J., Immunoreactive
calcitonin gene-related peptide and substance P co-exist in sensory
neurons and interact in spinal behavioral responses of the rat,
Neurosci. Lett., 52 (1984) pl99-204.
554 Wiesenfeld-Hallin, Z., Xu, X.-J., Hakanson, R. , Feng, D.-M. and
Folkers, K. , Tachykinins mediate changes in spinal reflexes after
activation of unmyelinated muscle afferents in the rat, Acta Physiol.
Scand., 141 (1991) p57-61.
555 Wikberg, J.E. and Hajos, M. , Spinal cord alpha 2-adrenoceptors
may be located postsynaptically with respect to primary sensory
neurons: destruction of primary C-afferents with neonatal capsaicin
does not affect the number of 3Hclonidine binding sites in mice,
Neurosci. Lett., 76 (1987) p63-68.
556 Wikberg, J.E.S., Uhlen, S. and Chhajilani, V. , Medetomidine
stereoisomers delineate two closely related subtypes of idazoxan
(imidazoline) I-receptors in the guinea pig, Eur. J. Pharmacol., 193
(1991) p335-340.
557 Wilcox, G.L., Pharmacological studies of scratching behavior
elicited by spinal substance P and excitatory amino acids, Ann. N. Y.
Acad. Sci., 525(3) (1988) 228-236.
558 Wilcox, G.L., Excitatory neurotransmitters and pain. In M.R.
Bond, J.E. Charlton and C.J. Woolf (Eds.), Proceedings of the Vlth
World Congress on Pain, Elsevier Science Publishers B.V., (1991),
p97-117.
559 Wilcox, G.L., Carlsson, K.-H., Jochim, A. and Jurna, I., Mutual
potentiation of antinociceptive effects of morphine and clonidine on
motor and sensory responses in rat spinal cord, Brain Res., 405
(1987) p84-93.
560 Wilier, J.C. and Bussel, B., Evidence for a direct spinal
mechanism in morphine-induced inhibition of nociceptive reflexes in
humans, Brain Res., 187 (1980) p212-215.
561 Williams, C.A., Brien, P.L,, Nichols, P.L. and Gopalan, R. ,
Detection of substance P-like substances from cat brainstem sites
during fatiguing isometric contractions, Neuropeptides, 26 (1994)
p319-328.
562 Williams, C.A., Holtsclaw, L.I. and Chiverton, J.A., Release of
immunoreactive enkephalinergic substances in the periaquaductal grey
of the cat during fatiguing isometric contractions, Neurosci. Lett.,
139 (1992) pl9-23.
563 Williams, C.A., Holtsclaw, L.I. and Chiverton, J.A., Release of
immunoreactive neuropeptide Y from brainstem sites in the cat during
isometric contractions. Neuropeptides, 24 (1993) p53-61.
564 Woolf, C.J., Evidence for a central component of post-injury pain
hypersensitivity, Nature, 306 (1983) p686-687.
238
565 Woolf, C.J. and Wall, P.D., Relative effectiveness of C primary
afferent fibres of different origins in evoking a prolonged
facilitation of the flexor reflex in the rat, J. Neurosci., 6 (1986a)
pl433-1442.
566 Woolf, C.J. and Wall, P.D., Morphine-sensitive and morphine-
insensitive actions of C-fibre input in the rat spinal cord,
Neurosci. Lett., 64 (1986b) p221-225.
567 Woolf, C.J. and Wiesenfeld-Hallin, Z., Substance P and calcitonin
gene-related peptide synergistically modulate the gain of the flexor
withdrawal reflex in the rat, Neurosci. Lett., 66 (1986) p226-230.
568 Wormser, U., Laufer, R. , Hart, Y. , Chorev, M. , Gilon, C. and
Selinger, Z., Highly selective agonists for substance P receptor
subtypes, EMBO J., 5 (1986) p2805-2808.
569 Wright, P.M.C., Carabine, U.A., McClune, S., Orr, D.A. and Moore,
J., Preanaesthetic medication with clonidine, Br. J. Anaes., 65
(1990) p628-632 .
570 Yaksh, T.L., In vivo studies on spinal opiate receptor systems
mediating antinociception. I. Mu and delta receptor profiles in the
primate, J. Pharmacol. Exp. Therap., 226 (1983) p303-316.
571 Yaksh, T.L., Pharmacology of spinal adrenergic systems which
modulate spinal nociceptive processing, Pharmacol. Biochem. Behav.,
22 (1985) p845-858.
572 Yaksh, T.L., Tolerance: factors invoked in changes in the dose-
effect relationship with chronic drug-exposure. In A.I. Basbaum and
J.M. Besson (Eds.), Towards a New Pharmacotherapy of Pain, John
Wiley, New York, (1990), pl57-180.
573 Yaksh, T.L., Farb, D.H., Leeman, S.E. and Jessell, T.M.,
Intrathecal capsaicin depletes substance P in the rat spinal cord and
produces prolonged thermal analgesia, Science, 206 (1979) p481-483.
574 Yaksh, T.L., Jessell, T.M., Gamse, R. , Mudge, A.W. and Leeman,
S.E., Intrathecal morphine inhibits substance P release from
mammalian spinal cord in vivo, Nature, 286 (1980) pl55-157.
575 Yaksh, T.L. and Noueihed, R., The physiology and pharmacology of
spinal opiates, Ann. Rev. Pharmacol. Toxicol., 25 (1985) p433-462.
576 Yanagisawa, M. and Otsuka, M. , Pharmacological profile of a
tachykinin antagonist, spantide, as examined on rat spinal
motoneurones, Br. J. Pharmacol., 100 (1990) p711-716.
577 Yanaihara, C., Sato, H., Hirohashi, M. , Sakagami, M. , Yamamoto,
K., Hashimoto, T., Yanaihara, N., Abe, K. and Kaneko, T., Substance P
radioimmunoassay using N-alpha-tyrosyl-substance P and demonstration
of substance P-like immunoreactivity in human blood and porcine
tissue extracts, Endocrinol. Jap., 23 (1976) p457-463.
578 Yashpal, K., Dam, T.-V. and Quirion, R. , Quantitative
autoradiographic distribution of multiple neurokinin binding sites in
rat spinal cord, Brain Res., 506 (1990) p259-266.
239
579 Yashpal, K., Dam, T.-V. and Quirion, R., Effects of dorsal
rhizotomy on neurokinin receptor sub-types in the rat spinal cord: A
quantitative autoradiographic study, Brain Res., 552 (1991) p240-247.
580 Yasuhara, T., Nakajima, T., Falconieri, G. and Erspamer, V. , New
tachykinins Glu-2-Pro-5-kassinin (Hyalambates kassinin) and
hyalambatin in the skin of the African rhacophorid frog Hyalambates
maculatus, Biomed. Res., 2 (1981) p613-617.
581 Yeung, J.C. and Rudy, T.A., Multiplicative interaction between
narcotic agonisms expressed at spinal and supraspinal sites of
antinociceptive action as revealed by concurrent intrathecal and
intracerebroventricular injections of morphine, J. Pharmacol. Exp.
Therap., 215 (1980) p633-642.
582 Yonehara, N., Shibutani, T. and Inoki, R., Contribution of
substance P to heat-induced edema in rat paw, J. Pharmacol. Exp.
Therap., 242 (1987) pl071-1076.
583 Yoshimura, M. and North, R.A., Substantia gelatinosa neurones
hyperpolarized in vitro by enkephalin, Nature, 305 (1983) p529-533.
584 Young, W.S.III. and Kuhar, M.J., Noradrenergic alpha 1 and alpha
2 receptors: light microscopic autoradiographic localization, Proc.
Natl. Acad. Sci. (USA), 77 (1980) pl696-1700.
585 Zhao, Z.-Q. and Duggan, A.W., Idazoxan blocks the action of
noradrenaline but not spinal inhibition from electrical stimulation
of locus coeruleus and nucleus Kolliker-Fuse of the cat, Neurosci.,
25 (1988) p997-1005.
586 Zhao, Z.Q., Morton, C.R., Hall, J.G. and Duggan, A.W., The
selective effects of metorphamide on dorsal horn neurones of the cat
spinal cord, Neuropeptides, 8 (1986) p327-334.
240
NEUROPEPTIDES
Neuropeptides (1994) 26, 413-419
©) Longman Group Ltd 1994
Evidence for Localized Release of Substance PWithin
Rat Spinal Cord Evoked by Physiological and
Electrical Stimuli
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Abstract—Antibodies immobilized onto the outer surface of glass microelectrodes were used
to measure and localize substance P (SP) release in the spinal cords of anaesthetized rats.
Utilizing a C-terminally directed antibody, significant levels of SP were not found in the lumbar
spinal cord in the absence of peripheral noxious stimulation. Following noxious heating or
pinch of the ipsilateral hind paw or electrical stimulation of the ipsilateral tibial nerve at C-fibre
strength, significant amounts of released SP were detected. This noxious stimulus-evoked
release of SP was primarily in the region of the substantia gelatinosa. In conclusion, the antibody
microprobe technique can be employed to focally detect the release of neuropeptide in vivo,
even in structures as small as rat spinal cord. The technique reveals that SP release in the rat
follows broadly the same pattern as that previously reported in the cat.
Introduction
Substance P (SP) is known to be involved in the
spinal processing and transmission of nociceptive
afferent inputs.' 6 Many of the studies seeking to
elucidate the functions of SP, whether behavioural,
histological, pharmacological or physiological in
nature, employ the rat as an experimental model.
To date, the release of SP within rat spinal cord in
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vivo has been assessed by perfusion techniques,7-9
but such techniques suffer from poor spatial reso¬
lution. The smaller amounts of peptide contained
in rat spinal cords, as compared to those of larger
mammalian species such as the cat or rabbit, may
also present a problem in the in vivo measurement
of peptide release. Techniques involving the col¬
lection of peptide in a perfusate will dilute it to even
smaller concentrations, and the possibility exists
that release will be undetected following mild stim¬
uli. Thus, to date, both in vivo and in vitro studies
on rat spinal cord have described only 40 mM pot¬
assium or 10 M capsaicin application, or repeated
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flexion of a polyarthritic limb as being adequate
stimuli to evoke SP release.
In recent years the antibody microprobe tech¬
nique of Duggan et al10 " has been used to study
the distribution of release of various neuropeptides
in the cat spinal cord, and also to determine the
adequate stimuli required to evoke that release.12
Antibody microprobes have several advantages
over other methods of in vivo neuropeptide
measurement: 1) they are physically much smaller
than push-pull cannulae or microdialysis tubing,
and cause little apparent physiological or ana¬
tomical disruption in their utilization; 2) they are
capable of detecting even very small amounts of
peptide, estimated as low as 10"17 moles pep-
tide/nricroprobe; 3) they offer a much better spatial
resolution than other methods (in the order of 100
m), and are consequentially better suited for the
localization of peptide release within small struc¬
tures or within discrete areas such as the substantia
gelatinosa of the rat.
Antibody microprobes showed that immu-
noreactive SP (irSP) is released in the cat lumbar
spinal cord, in vivo, in response to noxious mech¬
anical and thermal stimulation of the hind paws
and also in response to electrical stimulation of
the tibial nerves at C-fibre strength.12 Whichever
stimulus type was employed, the evoked release of
irSP was predominantly centered in the region of
the substantia gelatinosa, with a smaller amount of
release in the region of lamina V of the grey matter.
Basal presence of irSP in the absence of peripheral
noxious stimulation was not a consistent finding,
but when present, basal irSP was detected only in
the region of the substantia gelatinosa, and in much
smaller amounts than that evoked by subsequent
noxious stimulation.
The rat is, as previously described, a much more
common model for the study of SP function and
nociceptive processing than the cat: in recent years,
for example, the development of new models for
neuropathic pain have all involved the rat.13-15 The
aim of the current study was to determine the dis¬
tribution of stimulus evoked irSP release in rat spi¬
nal cord in vivo in comparison to that previously
described in the cat, and additionally to examine
whether or not the adequate stimuli for irSP release




Antibody microprobes were prepared as previously
described.10 " Briefly, fine glass micropipettes were
heat sealed at both ends and incubated in a 10%
solution of aminopropyltriethoxysilane in toluene.
This produced a siloxane polymer on the outer sur¬
face of the glass to which protein A (Sigma) was
immobilized with glutaraldehyde coupling. The *
protein A was then utilized to bind immu¬
noglobulins present in a polyclonal antiserum
raised against the C-terminal of SP (Peninsula Lab¬
oratories). Manufacturers data for this antiserum
stated no cross-reactivity for neurokinin A, neu¬
rokinin B or neuropeptide K. The sensitivity of
the prepared antibody microprobes was assessed by
incubating a small number of the probes in 10"7M
SP in vitro at 37°C for 30 min. prior to susequent
incubation in a solution of Bolton-Hunter '^-lab¬
elled SP (Amersham) diluted to 2000 cpm 1This
in vitro incubation in unlabelled SP was, in all tests,
sufficient to reduce subsequent 125I binding by at
least 50%. All incubations, whether during probe
preparation, in vitro testing, or following in vivo
use were carried out in 51 capillaries of the relevant
solution, with the exception of antibody to protein
A binding which used 12.51 capillaries. Incubations
in these capillaries were, except for the unlabelled
SP in vitro mentioned above, for 24-48 h at
4°C.
Animal preparation
Experiments were performed on 13 rats (male and
female, 220-270 g). Anaesthesia was induced with
sodium thiopentone (120 mg kg'1, 45 rng ml"1 i.p.)
and maintained with periodic top-up doses of the
same drug (15 mg kg"1, 15 mg ml"1 i.p.). Blood
pressure was monitored via carotid cannulation,
and the trachea was also cannulated. The lower
thoracic/upper lumbar spinal cord was exposed by
dorsal laminectomy and a solution of 3% agar in
sterile saline was injected under the rostral end of
the dissection and caudally to cover the exposed
surface of the cord. In all experiments the tibial
nerve in one hindlimb was exposed to allow elec¬
trical stimulation.
To allow microprobe insertion an opening was
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made in the agar covering the cord to form a pool
which was then irrigated with warmed, sterile
Ringer solution. Within this pool the dura mater
was cut longitudinally and reflected laterally. Pairs
ofmicroprobes, placed 3 mm apart rostrocaudally,
were inserted 2.25 mm into the spinal cord with a
stepping motor micromanipulator. By filling the
first microprobes with saline, or by using a silver
ball electrode placed on the cord surface, elec¬
trophysiological recordings were made to determine
the best area for microprobe insertion with regard
to the field potentials evoked by stimulation of the
ipsilateral hind limb. The last microprobes inserted
into the spinal cord were used to ionophorese pon-
tamine sky blue dye to allow subsequent his¬
tological verification of microprobe placement.
Peripheral stimulation was by either electrical
stimulation of the ipsilateral tibial nerve at C-fibre
strength (10-20 V, 20 Hz, 0.5 ms pulse width) or by
heating, in water at 48°C, or noxious pinching of
the ipsilateral hindpaw. Noxious heating of the paw
involved placing the paw in a beaker of water pre¬
heated to the desired temperature and insulated to
prevent loss of heat during the period of the test.
Noxious pinch was by the application of a single
crocodile clip dorso-ventrally across all digits of the
ipsilateral paw. Noxious stimuli were, when
applied, of 2 min duration, and followed placement
ofmicroprobes within the spinal cord. Microprobes
were left in situ for 8 min following cessation of
noxious stimulation or, where no peripheral stimu¬
lus was applied, for 10 min.
Following removal from the spinal cord micro¬
probes were washed for 15 min in cold phosphate-
buffered saline (PBS) containing 0.1% Tween and
incubated for 24 h at 4°C in 125I Bolton Hunter
labelled SP. Probes were then washed for a further
15 min in cold PBS and the tips were broken off
and fixed to a sheet of cartridge paper. This sheet
was placed in an X-ray film cassette loaded with
Kodak, NMB monoemulsion film.
X-ray film images of antibody microprobes were
analysed with a computer based image analysis sys¬
tem employing an Image Technology PC frame
grabber board operating in a DCS 286e (AT) com¬
puter. A CCD camera scanned each image, and as
previously described,16 following background sub¬
traction, a transverse integration of optical density
was performed for each microprobe at defined
intervals. With the resolution of the analysis system
used, this corresponded to a 10 m interval between
each integration. The resultant plot of optical
density, or grey scale, for each individual probe
image was then stored as a file on hard disk along
with 37 coded values representing the experimental
parameters applying to that particular microprobe.
Any reduction in grey scale value along the length
of the microprobe equates to binding of endogen¬
ous irSP and susequent failure to bind the otherwise
expected amount of l25I-labelled tracer. An analysis
program was used to group together individual
plots for microprobes meeting stated experimental
criteria, and produce for each group a plot ofmean
grey scale value with respect to depth within the
spinal cord. For the purposes of further analysis
(standard error ofmeans and statistical significance
of differences between means), integration points
were grouped in threes, bringing the spatial reso¬
lution of the analysis to 30 m. Mean image analy¬
ses could then be compared, both visually, and stat¬
istically by the Student's t-test. This method of
analysis thus samples release at many sites within
the spinal cord, with a resolution of 30 sites mm"1.
Results
A total of 94 microprobes coated with antibodies
to SP were inserted into the spinal cord and a fur¬
ther 48 microprobes were used for concurrent in
vitro testing as described.
Controls
35 microprobes were inserted 2.25 mm into the
spinal cord for a period of 10 min and in the absence
of any prior or concurrent noxious peripheral
stimulation. In the spinal lumbar enlargement this
places the tips of the microprobes just below or at
the base of the ventral grey matter. The Student's
t-test was used to compare the mean grey scale
image of the control group with one derived from
in vitro microprobes not exposed to SP prior to
incubation in labelling peptide. No statistically sig¬
nificant differences were seen at any point in the
dorsal spinal cord, thus a basal presence of irSP
was not detected.
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Electrical stimulation of ipsilateral tibial nerve
Figure 1A shows the mean image analysis of a
group of 13 microprobes inserted into the spinal
cord for 10 min with a concurrent 2 min period of
electrical stimulation of the ipsilateral tibial nerve
above C-fibre threshold (10-20 V, 20 Hz, 0.5 ms
pulse width). The mean image of the control group
of 35 microprobes, inserted for 10 min in the
absence of any peripheral stimulation is also illus¬
trated. Figure IB shows a plot of the t-statistics for
the differences between these 2 image analyses with
a diagram of cord structure for reference. The
shaded area on this t-plot represents the sites of
significant differences (t > 2, p < 0.05) between the
2 mean images. Electrical stimulation of the ipsi¬
lateral tibial nerve in this manner resulted in stat¬
istically increased amounts of irSP being detected
over an area approximately 0.5 mm wide, extending
from the cord surface to within the dorsal horn of
the spinal grey matter, with the area of maximal
release being centered on the superficial laminae of
Depth within the spinal cord (mm)
Fig. 1 Ipsilateral tibial nerve stimulation (above C-fibre thr¬
eshold) resulted in detection of irSP in the superficial dorsal
horn. (A) The mean image analyses of controls (no applied
peripheral stimulation, 10 min microprobe insertion, n = 35)
and nerve stimulus microprobes (nerve stim.) (20 Hz, 10-20 V,
0.5 ms pulse width, applied for 2 min out of 10 min microprobe
insertion period, n = 13) are shown. (B) The significant increase
in detected irSP following electrical stimulation of the ipsilateral
tibial nerve is confirmed in the plot of the t-test values derived
from the 2 groups shown in Figure 1A. The shaded area rep¬
resents points where the t-value exceeds 2.0 (p < 0.05), indi¬
cating detection of increased irSP at this level of significance.
This plot of t-values is related to a diagram of rat lumbar spinal
cord.
the dorsal horn. A much smaller zone of significant
release was seen approximately 0.75 mm below cord
surface. This smaller, deep zone of release was not
evident when noxious mechanical or noxious ther¬
mal stimuli were employed.
Noxious mechanical stimulation
Figure 2A shows the mean image analysis of a
group of 15 microprobes inserted 2.25 mm into the
spinal cord for 10 min with a concurrent 2 min
period of noxious pinching of the ipsilateral hind
paw by means of application of a crocodile clip
across the phalanges, placed dorso-ventrally. As in
Figure 1A, the mean image analysis of the control
group is also illustrated. Figure 2B shows a t-plot
for the significance of the differences between these
2 groups. The stimulus-evoked release of irSP in
the dorsal spinal cord is similar in spread to that
seen with tibial nerve stimulation, although the
small, deeper zone of release is absent.
At the end of each experiment it was observed
that repeated application of the alligator clip (to a
Fig. 2 Noxious mechanical stimulation of the ipsilateral hind-
paw resulted in detection of irSP in the superficial dorsal horn.
(A) The mean image analyses of controls (no applied peripheral
stimulation. 10 min microprobe insertion, n = 35) and pinch
(crocodile clip applied to ipsilateral hindpaw for 2 min out of 10
min microprobe insertion period, n = 15) antibody microprobe
groups are illustrated. (B) The significant increase in detected
irSP following pinching of the ipsilateral hindpaw is confirmed
in the plot of the t-test values derived from the 2 groups shown
in Figure 1A. The shaded area represents points where the t-
value exceeds 2.0 (p < 0.05), indicating detection of increased
irSP at this level of significance. This plot of t-values is related
to a diagram of rat lumbar spinal cord.
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maximum of 8 min total) had not caused obvious
bruising or oedema in the soft tissues of the paw.
Noxious thermal stimulation
The mean image analysis of 29 microprobes
inserted 2.25 mm into the spinal cord for 10 min.
during which time the ipsilateral hind paw was
placed in water at 48°C for 2 min. together with the
control group mean image analysis is illustrated in
Figure 3A. A plot of t-statistics derived from the
differences between these 2 groups is shown in Fig¬
ure 3B. Noxious thermal stimulation evoked sig¬
nificant irSP release over a similar area in the dorsal
horn to that seen with the other types of noxious
peripheral stimulation. The small deep zone of
release seen following tibial nerve stimulation was,
however, absent. This stimulus-evoked release of
irSP following noxious thermal stimulation was less
marked than that obtained with the other types of
stimulus, but it was more obviously centered within
the superficial dorsal horn.
Depth within the spinal cord (mm)
Fig. 3 Noxious thermal stimulation of the ipsilateral hindpaw
resulted in detection of irSP in the superficial dorsal horn. (A)
The mean image analyses of controls (no applied peripheral
stimulation, 10 min microprobe insertion, n = 35) and heat
(immersion of ipsilateral hindpaw in water at 48°C, for 2 min
out of 10 min microprobe insertion period, n = 29) antibody
microprobe groups are illustrated. (B) The significant increase
in detected irSP following heating of the ipsilateral hindpaw is
confirmed in the plot of the t-test values derived from the 2
groups shown in Figure 1A. The shaded area represents points
where the t-value exceeds 2.0 (p < 0.05), indicating detection of
increased irSP at this level of significance. This plot of t-values
is related to a diagram of rat lumbar spinal cord.
Discussion
The detection of noxious stimulus-evoked release
of irSP in the superficial dorsal horn is consistent
with the hypothesis that, in the rat, SP is released
from the central terminals of nociceptive afferent
fibres.17-21 The major location of such terminals
derived from the skin of the rat is the superficial
dorsal horn; laminae I—11 of the dorsal grey
matter.22 The absence of basal levels of irSP in the
dorsal spinal cord in the present study is in agree¬
ment with earlier work in cat spinal cord where
either no irSP or very small basal amounts were
found in the area of the substantia gelatinosa in the
absence of prior noxious stimulation.12,23'24
Although the rat spinal cord is anatomically much
smaller than that of the cat, and hence the absolute
amounts of a given neuropeptide, whether basal or
stimulus-evoked, will also be smaller by compari¬
son, concentrations at sites of release are probably
similar. The small, discrete zones of irSP detection
in the deep dorsal horn seen following nerve stimu¬
lation (Fig. IB) indicate that microprobes are sen¬
sitive enough to detect such limited release even
over a very small area. Given this high sensitivity
(each individual antibody microprobe is capable of
detecting as little as an estimated 10"17 moles of
peptide),10 it is unlikely that a basal release of irSP
in the rat superficial dorsal horn went undetected
in the present study.
In the rat, as in the cat, noxious stimulus evoked
release of irSP was centered on the superficial dorsal
horn which includes the substantia gelatinosa (lam¬
inae 1 and II) of the spinal grey matter. The area of
significant increases in irSP detection seen following
peripheral stimulation in the present study (Figs
IB, 2B and 3B) appears at first to be more diffuse
than the distribution of irSP revealed in immu-
nocytochemical studies.17"21-25 There are several
possible explanations for this. SP, and also the other
members of the tachykinin neuropeptide family, are
probably not subject to any rapid reuptake mech¬
anisms but rather are inactivated by peptidase
metabolism. In plasma or cerebrospinal fluid, in
vitro, SP has a half life in the order of 2 min,
which would be long enough if applied to in vivo
conditions to allow some spread away from the
initial sites of release.26 This may explain our finding
of irSP in the dorsal columns. In cat studies such
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dorsal spread into the white matter has been
observed with antibody microprobes, resulting in
a typical zone of stimulus-evoked irSP detection
approximately 1 mm wide, although like the present
findings in the rat, maximal in and centered on the
superficial dorsal horn. The typical zone of stimulus
evoked irSP detection reported in this study is
approximately 0.5 mm wide, which given the
different sizes of the spinal cords of the 2 species is
comparable to the 1 mm wide zone seen in the cat.
The increases in irSP following noxious thermal
stimulation (Fig. 3B), whilst lower than those seen
following pinch (Fig. 2B) or nerve stimulation (Fig.
IB) do appear to be better demarcated in terms
of localization within the spinal cord. This would
support the hypothesis that the relatively broad
zone of stimulus-evoked irSP detection seen in all
cases in the rat might be due simply to spread away
from sites of release as a consequence of the limit
of the rate of peptide breakdown in vivo. Fur¬
thermore, the distance of the substantia gelatinosa
from the dorsal surface of the spinal cord varies
more greatly in the rat than in the cat with respect
to laterality. Pooling of microprobes inserted at
varying distances from the cord midline may then
result in a greater 'blurring' of localization in the
rat, making the resultant zone of irSP detection
seem disproportionately wide. Small errors in probe
placement, or breathing movements transferred to
the cord will also be relatively more significant when
studying smaller structures, thus adding to the
above effect. Indeed individual microprobe images,
as opposed to the pooled mean images, did fre¬
quently show a much more restricted zone of irSP
detection, although this was still centred in the
superficial dorsal horn.
Previous studies of SP release in the rat in vivo
have employed models of inflammatory disease to
evoke release, such as flexion of an arthritic joint
or pinching of a formalin injected paw.8,27 We have
shown in the present study that noxious stimuli
applied to undamaged tissues; pinch and heat to
normal paw, and also electrical stimulation at C-
fibre strength of peripheral nerve, were adequate in
evoking irSP release in the rat. There is one impor¬
tant difference, however, between the present
results and those previously obtained in the cat. In
the cat immersion of the hind paw in water at 48°C
was ineffective in producing significant increases in
detected irSP; water temperatures of 50 or 52°C
were required. The rat foot is different in structure
from that of the cat. The skin is thinner and there
is less hair and subcutaneous soft tissue in the rat.
The surface area to volume ratio of the rat foot is
also much higher. Water at 48°C may then be more
effective at raising the temperature of subdermal
tissues in the rat, such that the noxious stimulus at
such sites is equivocal to that achieved with water
at higher temperatures in the cat. As 48°C was
an adequate stimulus in the present study, higher
temperatures were not employed to avoid causing
actual tissue damage. Thus the conclusion that
potentially severe or damaging noxious stimuli were
needed to produce spinal release of irSP in the cat
does not appear to be a cross-species generalisation,
since such severe stimuli were not needed in the
rat.
The small zones of irSP detection in the deep
dorsal horn seen following nerve stimulation in the
present study were not a consistent finding in the
earlier cat studies. Although irSP containing ter¬
minals predominate in the superficial dorsal horn
of both species, they are also seen in deeper laminae
of the spinal cord. At these deeper sites the network
of irSP terminals is less continuous, forming iso¬
lated populations of irSP containing terminals.
Individual microprobe images from cat studies
occasionally identified small zones of irSP release in
the deep dorsal horn, but this was never consistent
enough to reach significance in pooled data (per¬
sonal observation). Deep irSP release in the rat was
seen only with tibial nerve stimulation, not with
noxious heat or pinch. This may reflect the spinal
distribution of nerve terminals from joint afferents
or 'silent' nociceptors in this species, i.e. those
receptors not activated by noxious stimuli applied
to normal skin.
In conclusion, the release ofirSP following noxi¬
ous afferent stimulation in the rat is limited to the
superficial dorsal horn, and adequate stimuli to
evoke such release are in the same range as those
employed in cat studies, although lower grade ther¬
mal stimuli were adequate in evoking release in
the rat. Additionally, the pattern of irSP release
following such stimuli in the rat is comparable with
that previously reported in the cat. By revealing this
focal release with the antibody microprobe tech¬
nique, we have demonstrated that microprobes are
STIMULATED RELEASE OF SUBSTANCE P WITHIN RAT SPINAL CORD 419
a suitable experimental tool for use in smaller, as
well as larger, laboratory species.
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MICROINJECTION OF NEUROPEPTIDE Y INTO THE
SUPERFICIAL DORSAL HORN REDUCES
STIMULUS-EVOKED RELEASE OF IMMUNOREACTIVE
SUBSTANCE P IN THE ANAESTHETIZED CAT
A. W. Duggan,* P. J. Hope and C. W. Lang
Department of Preclinical Veterinary Science, University of Edinburgh, Summerhall,
Edinburgh EH9 1QH, U.K.
Abstract—In barbiturate anaesthetized spinal cats, antibody microprobes were used to measure release
of immunoreactive substance P in the superficial dorsal horn following electrical stimulation of
unmyelinated primary afferents of the ipsilateral tibial nerve. Prior microinjection of neuropeptide Y
(0.2--0.6 n\ of 10~5mol/l solution) in the region of the substantia gelatinosa reduced the evoked release
of immunoreactive substance P for up to 40 min. Microinjection of similar volumes of phosphate-buffered
saline at similar sites was without effect.
This action of neuropeptide Y could contribute to analgesia, particularly if this neuropeptide is
co-released with noradrenaline from axon terminals in the superficial dorsal horn.
The superficial dorsal horn of the spinal cord of
several species contains a dense network of neuro¬
peptide Y (NPY)-containing fibres, mainly of
supraspinal origin.'-4-6-7'23-27 Many such fibres prob¬
ably contain both NPY and noradrenaline since these
substances extensively co-exist in brainstem neur¬
ons.15-24 The superficial dorsal horn of the spinal cord
is a site of potential interaction of many neuroactive
compounds. The substantia gelatinosa is the major
site of termination of cutaneous unmyelinated pri¬
mary afferents,30 many of which are nociceptors, and
these fibres contain excitant amino acids and neuro¬
peptides either singly or in a complex series of
combinations.14 In addition, both intrinsic neurons
of the substantia gelatinosa as well the terminals of
propriospinal and supraspinally derived fibres con¬
tain amino acids, monoamines and neuropeptides. To
understand the interactions between such a wealth of
compounds is clearly a complex task. One aspect
which can be investigated experimentally is whether
any of the substances contained within the substantia
gelatinosa act to reduce the release of compounds
from the central terminals of primary afferent fibres.
Both in the peripheral and central nervous systems
there are several instances where NPY has been
shown to have effects on nerve terminals consistent
with an impairment of transmitter release.8-18-20-26-38 If
NPY had such an action in the superficial dorsal
horn, and if the relevant receptors were located near
the terminals of nociceptive afferents, then such a
mechanism could contribute to analgesia both of
segmental and supraspinal origin. An inhibition
*To whom correspondence should be addressed.
Abbreviations: IR SP, immunoreactive substance P; NPY,
neuropeptide Y; PBS, phosphate-buffered saline.
of transmitter release from the central terminals of
nociceptors has been suggested as important in
several mechanisms of analgesia. Thus, Melzack and
Wall32 proposed a segmental presynaptic inhibition of
nociceptive transmission which could be activated by
impulses in large diameter (non-nociceptive) primary
afferent fibres. Presynaptic inhibition, either directly
by supraspinal fibres or indirectly through activation
of segmental inhibition, has been proposed as a
mechanism important in supraspinal control of spinal
transmission of nociceptive information.2-10 NPY
requires consideration in both contexts since anal¬
gesia has been demonstrated following its intrathecal
administration to the rat.41
The antibody microprobe has shown that, in the
anaesthetized cat, peripheral noxious cutaneous stim¬
uli produce a release of immunoreactive substance P
(IR SP) localized mainly to the region of the substan¬
tia gelatinosa.11,13 The present experiments have
examined whether NPY modifies such release.
Because the antibody microprobe can detect release
from relatively small areas of the central nervous
system,13 it was appropriate to administer NPY also
to restricted areas. This was done by microinjecting
NPY in approximately 0.2 /z 1 volumes from micro-
pipettes positioned with their tips in the region of the
superficial dorsal horn in which microprobes have
localized evoked release of IR SP.
EXPERIMENTAL PROCEDURES
Antibody microprobes were prepared as previously
described.12 Briefly, fine glass micropipettes, heat sealed
at both ends, were incubated in a 10% solution of
aminopropyltriethoxysilane in toluene. This produced a
siloxane polymer layer on the outer surface of microprobes
and glutaraldehyde was then used to immobilize protein
733
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A (Porton) to this polymer. Protein A then bound im¬
munoglobulins present in a polyclonal antiserum containing
antibodies directed at the carboxy terminus of SP (Peninsula
Laboratories). These antibodies bind substance P and frag¬
ments of substance P containing the last five amino acids:
there is negligible cross-reactivity with neurokinin A and
neurokinin B (information supplied by the manufacturer).
Experiments were performed on seven cats anaesthetized
initially by the intraperitoneal injection of pentobarbitone
sodium (35 mg/kg) and anaesthesia was maintained by the
continuous infusion of pentobarbitone, 3 mg/kg/h. All ani¬
mals were artificially ventilated following neuromuscular
paralysis with 4 mg/kg/h gallamine. Blood pressure was
monitored via a cannula in a carotid artery and end tidal
CO, levels were continually measured and maintained at
4%. The lumbar spinal cord was exposed by removal of the
relevant laminae and the spinal cord was then transected at
the thoracolumbar junction following injection of 0.1 ml of
2% lignocaine at the site of transection. The lumbar dura
mater was cut longitudinally and retracted laterally. A thin
layer of Ringer/agar was then placed over the dorsal surface
of the exposed spinal cord. At sites of proposed microprobe
insertion an area of agar was removed and a small part of
the pia-arachnoid was removed with sterile fine forceps. The
exposed dorsal area of the spinal cord was continuously
irrigated with sterile Ringer solution held at 37°C by a heat
exchanger jacket around the delivery tube. Cats received
two intramuscular injections of ampicillin, 25 mg/kg, at
approximately 10 h intervals.
Although IR SP release in the superficial dorsal horn is
evoked by a variety of noxious peripheral stimuli,13-36 it is
difficult to deliver such stimuli repeatedly without damaging
peripheral tissues and hence the firing of nociceptors to
successive stimuli may alter. For such a reason electrical
stimulation of the tibial nerve was used to elicit spinal
release of IR SP in the present experiments. Previous
experiments have shown that low amplitude stimuli exciting
mainly myelinated afferents of this nerve in the cat do not
evoke a spinal release of IR SP but that stimuli also exciting
unmyelinated afferents do produce release localized pre¬
dominantly to the region of the substantia gelatinosa. The
right and left tibial nerves were exposed in the calf, im¬
mersed in liquid paraffin and mounted on platinum stimu¬
lating electrodes. Stimulation employed square wave pulses,
0.3 ms duration, and an amplitude of at least 80 times the
threshold stimulus needed to produce a short latency field
potential, recorded with a microelectrode placed in the
upper dorsal horn. Stimulus frequency varied from 10 to 30
Hz but was constant for each experiment and stimulus
durations were all 20 min.
Microprobes were inserted into the spinal cord (two at a
time) with stepping motor micromanipulators. With the first
probe introduced into a particular area of the spinal cord,
it was usual to obtain extracellular recordings during intro¬
duction to determine the areas of the skin of the hind limb
which activated adjacent neurons during brushing. All
microprobes were inserted to a depth of 3 mm which, in the
lumbar dorsal horn of the adult cat, places the tips in the
upper ventral horn. In a typical experiment four to eight
microprobes were left in the left side of the spinal cord in
the absence of peripheral nerve stimulation and then sub¬
sequent microprobes were associated with left tibial nerve
stimulation. The stimulus was not delivered in the time
required to remove one pair of microprobes and insert a
fresh pair and this period lasted 5-10 min. After about 20
microprobes had been inserted into the left side of the spinal
cord, the sequence was repeated on the right side.
The antibody microprobe technique detects bound en¬
dogenous ligand by the failure of binding of exogenous
radiolabelled ligand. Thus, following removal from the
spinal cord, microprobes were washed for 15 min in cold
phosphate-buffered saline (PBS) containing Tween (0.1%)
and then incubated for 24 h at 6°C in a PBS-azide solution
of l2!I-radiolabelled SP (Amersham) containing 0.5%
bovine serum albumin. The final dilution resulted in ap¬
proximately 2000 d.p.m. per /d. After this incubation,
microprobes were washed for 15 min in PBS-Tween while
continually drawing the solution through the patent tips to
remove any radiolabelled SP from within. The tips were then
broken off and glued to a sheet of paper, which was placed
in an X-ray film cassette with a sheet of monoemulsion film
(Kodak, NMC).
Images of microprobes were analysed with an image
analysis system employing an Image Technology PC Vision
frame grabber board operating in a Data Control Systems
286e (AT based) computer. A charge coupled device camera
scanned each image and, as described previously,22 after
background subtraction, a transverse integration of
the optical density of the image of each microprobe was
executed at defined intervals. With the magnification of the
system used and the resolution of the image analysis system
(512 x 512 locations per frame) this corresponds to a 10 /im
interval for transverse integrations. The resultant integrals
were stored on a hard disk record which included 40 coded
values which described the experimental conditions relevant
to that particular image. An analysis program subsequently
obtained groups of microprobes which met stated criteria
and obtained the mean image analysis of each group, which
was plotted with respect to the distance within the spinal
cord (see Fig 1-5). The spatial resolution of microprobe
images is dependent on radiation scattering and hence on
the distance between sources and film emulsion. At 3 mm
from the tip, a microprobe has a diameter of approximately
30 nm and hence it is improbable that a biological resol¬
ution of 10 /rm can be attained. Hence in subsequent
mathematical treatments, the resolution was reduced to
approximately 33 sites per mm by calculating means for
three successive values. Each site is treated independently
and hence, for a selected group of microprobes, a mean
optical density (grey scale) can be calculated for each site
and, when comparing two groups of microprobes, statistical
significance can be assigned to differences between mean
optical densities at each site.
Microinjection of NPY was performed in two ways. In
two experiments the tip of an antibody microprobe and a
micropipette containing 0.5 /r 1 of NPY were positioned just
above the dorsal surface of the spinal cord. The microprobe
was held vertically in a micromanipulator; the NPY-
containing micropipette was at an angle of 10°C to the
vertical in an anteroposterior plane. After the micro¬
manipulator positional readings had been recorded, the
NPY-containing pipette was retracted and the microprobe
introduced 3 mm into the spinal cord. A simple trigono¬
metric calculation then determined the distance the NPY-
containing pipette needed to be moved rostrally so that
when introduced into the spinal cord, with its tip positioned
1.1 mm from the dorsal surface (this approximates to the
middle of the substantia gelatinosa), the tip would be
100/rm from the shaft of the previously introduced anti¬
body microprobe. NPY (0.2 /rl) was then microinjected
slowly approximately over the whole period the microprobe
was in the spinal cord.
In the remaining five experiments a serious of two to three
microinjections, each of 0.2/rl and 1.0-1.2 mm from the
spinal cord surface, were made with a micropipette succes¬
sively introduced at the margins of an area denuded of pia
mater. Microprobes were then inserted in the central part of
such an area after the microinjections were complete.
The NPY-containing micropipettes had tip sizes of
15-20/rm and were calibrated by filling the shanks with
volumes of firstly 0.2 and then 0.4/rl of water. These
volumes were expelled from a Hamilton microlitre syringe
onto a small piece of Parafilm and rapidly sucked up into
a micropipette under microscopic control. Calibration
marks were then placed on the micropipette with a fine pen
and the water subsequently expelled and replaced by
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Fig. 1. Stimulus-evoked release of immunoreactive sub¬
stance P. (A) The mean image analysis of 16 microprobes
present in the spinal cord of the spinal cat for 20min,
without any peripheral nerve stimulation, is compared with
that of 33 microprobes also in the spinal cord for 20 min,
but throughout that time the ipsilateral tibial nerve was
electrically stimulated at a strength adequate to excite both
myelinated and unmyelinated fibres. Ordinate: integrals
obtained during analysis of microprobe images. Optical
density was measured in 30 pm squares on a grey scale of
0-255 and transverse integrations then performed over each
microprobe image. Abscissa: depth within the spinal cord
with the surface being at 0. The lines join the mean grey scale
values for the two groups of microprobes. For microprobes
present in the spinal cord during nerve stimulation the ( + )
standard error of the mean grey scale value at each analysis
point is plotted and for the no-stimulus microprobes the
( — ) standard error is plotted at each point. (B) A represen¬
tation of the sites in the spinal cord where nerve stimulation
produced significant increases in levels of immunoreactive
substance P. The diagram was obtained from a transverse
section of the seventh lumbar spinal segment. Roman
numerals indicate the approximate positions of spinal lami¬
nae. At each analysis point in the mean image analyses
shown in A the t statistic derived from the standard error
of the difference of means has been calculated and plotted
in relationship to position in the spinal cord (see text). The
hatched area indicates the sites where the difference pro¬
duced by nerve stimulation is significant at the P < 0.05
level.
an NPY-containing solution. In the spinal cord, NPY
was microinjected by pressure applied to the interior of
the micropipette by a hand-held syringe and tubing. The
volumes injected were approximate in the sense that a
graticule in a binocular microscope served to monitor the
distance travelled by the upper level of the NPY-containing
solution. It was possible to restrict the movement of this
meniscus to one-tenth of the distance between the 0.2 and
0.4 p\ calibration marks, although the taper in the micro¬
pipette shank complicates simple estimates of the volume
ejected. The concentration of NPY in the microinjected
solution was 10~7M in one experiment and 10~5M in six
experiments.
A series of experiments was also performed in which
PBS-azide was microinjected into the spinal cord using
depths, volumes and injection times similar to those em¬
ployed with microinjection of NPY. The injections of PBS
were performed in the same animals used for microinjection
of NPY. Such control injections were needed for two
reasons. Firstly, a decline in the effectiveness of nerve
stimulation in releasing IR SP could simply result from a
relative exhaustion of levels of SP in nerve terminals.
Secondly, although the volumes of NPY microinjected were
small, microprobes measure release of a neuropeptide from
very small areas of the central nervous system and hence any
microinjection must be viewed as a distortion potentially
altering release either by disrupting fibres and/or neurons, or
causing some neurons to fire by mechanical deformation.
RESULTS
Stimulus-evoked release of immunoreactive sub¬
stance P
The mean image analyses of 16 microprobes in¬
serted 3 mm into the spinal cord and left for 20 min
in the absence of peripheral nerve stimulation and 33
microprobes inserted for the same times and depths
but during electrical stimulation of myelinated and
unmyelinated primary afferents of the ipsilateral
tibial nerve are compared in Fig. 1A. These micro¬
probes are derived from all seven experiments. Sig¬
nificant differences between these mean image
analyses occur from 0.6 to 1.4 mm from the dorsal
surface of the spinal cord with the maximal increase
occurring at 1.0 mm (Fig. IB). This site of maximal
release approximates to the region of the substantia
gelatinosa and lamina I and agree with previously
reported findings.13 It needs to be pointed out that
when dye is ejected from the tip of a single micro¬
probe, and the resultant deposit is subsequently
located in a spinal cord section, then the sites of
presence of a neuropeptide can be inferred with some
accuracy. With mean image analyses as presented
here, however, the location of sites of release is less
precise. Thus with microprobes placed a fixed dis¬
tance in the spinal cord (3 mm in the present exper¬
iments), the relationship of spinal laminae to distance
from the tip will vary between animals and, in a given
experiment, with distance from the midline. When
encoding the information describing the position of
each microprobe, a correction factor is included when
appropriate, but nevertheless the referring of spinal
laminae to a mean image analysis should be regarded
as approximate.
Microprobes present in the spinal cord during micro¬
injection of neuropeptide Y
The mean image analyses of 12 microprobes in¬
serted 3 mm into the spinal cord for 20 min and with
electrical stimulation ofmyelinated and unmyelinated
afferents of the ipsilateral tibial nerve (stimulus con¬
trols) and 13 microprobes inserted under the same
conditions but with NPY (10~7 M in one experiment,
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Fig. 2. Reduced evoked release of IR SP during microinjec¬
tion of NPY in the superficial dorsal horn. The mean image
analyses of two groups of microprobes are shown. All were
inserted 3 mm into the spinal cord and remained there for
20 min while the tibial nerve was electrically stimulated. The
upper trace is the mean image analysis of 12 microprobes
inserted prior to microinjection of NPY; the lower trace is
the mean image analysis of 13 microprobes present while
NPY (0.2/d) was slowly microinjected over the 20 min
that microprobes were in the superficial dorsal horn. Both
groups of microprobes are derived from the same exper¬
iments. A plot of the t statistics devised from the differences
of the means of the two image analyses is shown with respect
to distance from the surface of the spinal cord.
10 5 M in the other) being microinjected 1.1mm
from the cord dorsum and 100 /tm from the micro-
probe shaft are compared in Fig. 2. Although the
mean image analysis of microprobes inserted during
NPY microinjection is displaced below that of con¬
trol microprobes (indicating reduced stimulus-evoked
release of IR SP), this only attains significance at
about 1.5 mm from the dorsal surface. In the first
20 min period after microinjection, the inhibition of
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Fig. 3. Reduced evoked release of IR SP in the period
0-20 min after microinjection of NPY into the superficial
dorsal horn. This figure compares the mean image analysis
of 33 microprobes inserted during peripheral nerve stimu¬
lation, but prior to microinjection ofNPY (these are derived
from all experiments), and that of 22 microprobes present
in the spinal cord in the period 0-20 min after microinjection
of NPY in the superficial dorsal horn, and also with
peripheral nerve stimulation (these probes are also derived
from all experiments). All were inserted 3 mm into the spinal
cord. The t statistics derived from the differences of the
means of the two illustrated mean image analyses are plotted
below.
microprobes and those inserted into the spinal cord
in the second 20 min period after microinjection are
analysed below.
Microprobes inserted into the spinal cord after micro¬
injection of neuropeptide Y
The effectiveness of peripheral nerve stimulation in
evoking release of IR SP prior to and in the 20 min
period following microinjection of NPY (10~5M) is
compared in Fig. 3. The mean image analysis for
microprobes inserted following NPY is significantly
displaced below that of stimulus control microprobes
beginning at 0.8 mm and extending to 2.0 mm from
the dorsal surface. This is virtually over the whole of
the dorsal horn. In the second 20 min period after
microinjection of NPY the evoked release of IR SP
was still reduced but over a more restricted area of
the spinal cord. Figure 4 compares the mean image
analyses of the microprobes inserted in this period
with those inserted prior to NPY microinjection.
The tibial nerve was stimulated with both groups.
The post-NPY (second 20 min period) analysis is
displaced below that of preinjection microprobes
indicating inhibition of release but the plot of signifi¬
cances of differences between these analyses indicates
that the significant differences were restricted to a
zone approximating to laminae I and II. Five micro¬
probes were inserted in the third ensuing 20 min
postinjection period and no impairment of nerve-
evoked release of IR SP was observed.
Release of immunoreactive substance P following
microinjection of phosphate -buffered saline containing
sodium azide
No inhibition of stimulus-evoked release of IR SP
occurred following microinjection of PBS-azide in
the region of the substantia gelatinosa. Figure 5A
illustrates the mean image analyses of microprobes
inserted during peripheral nerve stimulation but prior
to microinjection of PBS-azide and microprobes
inserted into the spinal cord in the first 20 min after
microinjection. There is a small zone at the surface of
the spinal cord with the latter group indicating
enhanced release of IR SP, but within the spinal cord
the two analyses are virtually identical. Figure 5B
compares preinjection microprobes with those in¬
serted in the second 20 min period after PBS-azide
microinjection and again the image analyses of the
two groups are virtually identical.
DISCUSSION
The present experiments have shown that micro¬
injection of 0.2-0.6 p\ ofNPY (10 s M), in the region
of the substantia gelatinosa of the dorsal horn,
reduces nerve stimulus-evoked release of IR SP.
Interpretation of these results requires consideration
of the constraints imposed by microinjection. It was
unknown in the present experiments whether NPY
would be inactivated quickly or slowly within the
Neuropeptide Y and substance P release 737
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Fig. 4. Reduced evoked release of IR SP in the period
2M0 min after microinjection of NPY into the superficial
dorsal horn. The nerve stimulus control analysis is for the
same group of 33 microprobes shown in Fig. 3. The lower
mean image analysis is for 20 microprobes present in the
spinal cord with similar conditions to those of the control
group but in the period 2 MO min after microinjection of
NPY into the superficial dorsal horn. The t statistics derived
from the differences of the means plotted in the two analyses
are plotted below.
spinal cord and hence the initial experiments micro-
injected the peptide continuously while microprobes
were in the spinal cord. This technique had the
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Fig. 5. Failure of microinjection of PBS in the superficial
dorsal horn to reduce evoked release of IR SP. In both A
and B the nerve stimulus controls comprise 25 microprobes
present for 20 min in the spinal cord during electrical
stimulation of the ipsilateral tibial nerve. In A, the mean
image analysis of this group is compared with that of 12
microprobes inserted under similar conditions in the same
experiments but 0-20 min after microinjection of PBS in the
superficial dorsal horn; in B the comparison is with the mean
image analysis of seven microprobes inserted 21-40 min
after PBS microinjection.
disadvantage that the neuropeptide was administered
at one site only (although relatively close to part of
the microprobe shaft) and the time for diffusion was
restricted when compared with the method of intro¬
ducing microprobes after microinjection. The find¬
ings that greater inhibition of the evoked release of
IR SP was produced by the latter method indicate
its suitability for a compound such as NPY. Micro¬
injection probably introduces relatively large
amounts of a compound when compared with synap¬
tic release, and hence local inactivation processes
are likely to be saturated for some time after micro¬
injection. Hence, even with a rapidly degraded
compound, introduction of microprobes after micro¬
injection is probably the preferred method. Thus
persistence of the effect of NPY up to 1 h after
microinjection does not necessarily represent the per¬
sistence of effect of this compound after synaptic
release.
It is probable that most of the increases in IR
SP produced by peripheral nerve stimulation in
the present experiments came from release from
the central terminals of peripheral nociceptors."'13
Significant inhibition of IR SP release following NPY
microinjection occurred over nearly the whole of
the dorsal gray matter in the first 20 min after micro¬
injection but was restricted to the region of laminae
I-II in the ensuing 20 min. This suggests that control
(no stimulus) microprobes were detecting a basal
presence of IR SP in the deeper layers of the dorsal
horn, that this was increased by nerve stimulation
and that microinjection of NPY reduced both basal
and stimulus-evoked release.
An inhibition.of SP release from the central termi¬
nals of unmyelinated primary afferents can explain
the present results. There are no fine structural
studies of the relationship between NPY-containing
fibres and the neural elements of the superficial dorsal
horn of mammals, but one study in the lamprey5
found close apposition of IR NPY-containing vari¬
cosities and the ascending and descending branches
of primary sensory neurons.
In the periphery several actions of NPY on nerve
terminals have been described. There is evidence that
NPY released from the sympathetic nerve terminals
to blood vessels acts as a negative feedback to inhibit
both its own release and that of noradrenaline.37'38
High intensity stimulation of the cardiac sympathetic
nerves results in prolonged inhibition of the ability of
the vagus to slow the heart. This effect, which is
mimicked by NPY, is believed to result from an
inhibition of acetylcholine release from vagal end¬
ings.26 Guiliani et a/.18 obtained evidence for an
inhibition, by NPY, of tachykinin release from the
peripheral terminals of sensory nerves to the airways
of the guinea-pig.
There is also electrophysiological data supporting
presynaptic actions of NPY in the central nervous
system. In the hippocampus of the rat both Colmers
et al.s,9 and Haas et al.20 obtained evidence for an
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inhibition of release of an excitatory transmitter,
believed to be l-glutamate, by NPY (10~6M), added
to the perfusate of a slice preparation. It is important
to emphasize that these latter effects were obtained in
slice preparations (which lack a blood supply), since
vascular effects need to be considered when any
compound is injected into or superfused onto the
brain or spinal cord under in vivo conditions. NPY
does contract blood vessels39 and hence a contri¬
bution of such an effect to the present results cannot
be excluded. It is unknown whether small intrinsic
vessels of the spinal cord bear receptors to NPY.
The dense plexus of NPY-containing fibres in the
superficial dorsal horn of several species1'4'6'7,23'27
probably mainly represents an extensive co-existence
of NPY with catecholamines. NPY co-exists with
noradrenaline in many neurons of the locus
coeruleus15'24 and hence it is probable that it is
co-released with noradrenaline in the superficial
dorsal horn. There is a dense network of noradrena-
line-containing fibres319'31'40 in the dorsal horn. In
addition, a small number of intrinsic spinal neurons
contain NPY.27'35
The effects of NPY in the present experiments
could act synergistically to noradrenaline in con¬
trolling spinal transmission of nociceptive infor¬
mation. Thus, intrathecal administration of
noradrenaline inhibits spinal reflexes to peripheral
noxious stimuli25'28,34 and microiontophoretic admin¬
istration of noradrenaline in the substantia gelatinosa
suppresses the transmission of nociceptive infor¬
mation to deeper neurons.16'21,44 Noradrenaline has
been shown to hyperpolarize neurons of the rat
substantia gelatinosa43 and hence a co-release of
noradrenaline and NPY from the spinal terminations
of supraspinally derived fibres could inhibit spinal
transmission of nociceptive information by both pre-
and postsynaptic mechanisms. Noradrenaline prob¬
ably also acts presynaptically since studies in the
spinal cord of the rabbit using push-pull cannulae
have shown a reduction of noxious stimulus-evoked
release of IR SP following superfusion of the spinal
cord with noradrenaline.29
Much of the work on noradrenaline and spinal
transmission of nociceptive information was done in
the absence of knowledge of the co-existence of
noradrenaline and NPY. There is some evidence that
spinal inhibition from activity in coerulospinal fibres
cannot be fully accounted for by release of nor¬
adrenaline. In both the rat and cat, inhibition of
spinal neurons by noradrenaline is blocked by a-2
adrenoceptor antagonists such as idazoxan and not
by a or /I adrenoceptor antagonists.16,44 In the cat,
however, iontophoretic administration of idazoxan in
amounts adequate to block inhibition by noradrena¬
line failed to block spinal inhibition from electrical
stimulation in the region of the locus coeruleus or
nucleus Kolliker-Fuse.44 Intravenous idazoxan also
did not block this inhibition. One explanation for
such a result is that the action of NPY was sufficient
to effect inhibition despite blockade of the action of
co-released noradrenaline.
Fuxe et al,17 have recently suggested differing func¬
tional roles for high and low affinity receptors for
NPY. Low affinity receptors are proposed as being
localized to subsynaptic areas where high concen¬
trations of non-degraded peptide are encountered.
High affinity NPY (possibly Y2 receptors) are pro¬
posed as occurring remotely from sites of release and
dependent on diffusion of released NPY. They term
the process "volume transmission". A proportion of
released molecules could be degraded by peptidases
and hence Y2 receptors are the likely candidates for
mediating the remote effects of released NPY because
of their activation by carboxy-terminus fragments 13-
36 ofNPY. High affinity sites for NPY have been dem¬
onstrated in the trigeminal nucleus substantia gelati¬
nosa33 and, hence, if the hypothesis of Fuxe et al}1 is
correct, a somatopically diffuse inhibition of sub¬
stance P release may follow synaptic release of NPY.
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Note added in proof:
A recent study [Bleakman D., Colmers W. F., Fournier A. and Miller R. J. (1991) Br. J. Pharmac. 103, 1781-1789]
found that NPY (10~7 M) inhibited calcium entry into cultured rat dorsal root ganglion cells and a Y2 receptor was
involved. This was proposed as underlying a previous report [Walker M. W., Ewald D. A., Perney T. M. and Miller
R. J. (1988) J. Neurosci. 8, 2438-2446] that NPY reduced high potassium evoked release of substance P from cultured
rat dorsal root ganglion cells. Both of these studies are in accord with the present findings in the cat.
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RELEASE OF IMMUNOREACTIVE GALANIN IN THE
SPINAL CORD OF RATS WITH ANKLE INFLAMMATION:
STUDIES WITH ANTIBODY MICROPROBES
P. J. Hope,* C. W. Lang,+ B. D. GrubbJ and A. W. Duggan§
Department of Preclinical Veterinary Sciences, Royal (Dick) School of Veterinary Studies,
University of Edinburgh, Summerhall, Edinburgh EH9 1QH, Scotland, U.K.
I Abstract—Antibody microprobes bearing antibodies to the carboxy-terminus of rat galanin were inserted
into the spinal cords of anaesthetized normal rats and those in which ankle inflammation had been induced
by the unilateral subcutaneous injection of Freund's adjuvant four to six days previously. In normal rats,
a basal presence of immunoreactive galanin was detected in the dorsal horn. Similar levels of immuno-
' reactive galanin were found in the dorsal horn of both sides of the spinal cord in animals with unilateral
ankle inflammation. Flexing the ankle or compressing the foot in normal rats failed to alter levels of
immunoreactive galanin detected by microprobes. In animals with ankle inflammation, prolonged periods
of ankle flexion did release immunoreactive galanin in the ipsilateral dorsal horn. Subsequent noxious
ankle compression in these animals did not increase but rather decreased immunoreactive galanin in the
dorsal horn to below basal levels.
The reason for this decrease is unknown but it may represent an inhibition of release or a depletion
of spinal stores of galanin.
In the rat spinal cord, galanin occurs in dorsal
root ganglion neurons, intrinsic neurons of the spinal
cord and in fibres of supraspinal origin.I-9,12-15-20
In most studies of the possible functions of galanin
in the spinal cord, this neuropeptide has been applied
topically to the spinal cord surface.
When galanin has been administered in this way
the effects have not been uniform. Following intra¬
thecal administration in relatively low doses, galanin
has been variously found to produce hyperalgesia
to mechanical but not thermal noxious stimuli,2
to result in vocalization to innocuous mechanical
peripheral stimuli2 and to enhance reflexes to per¬
ipheral noxious thermal but not mechanical stimuli.23
In contrast to these enhanced responses, a number of
depressant actions of intrathecal galanin have also
been observed, although following the administration
of larger amounts than those producing increased
responses. These depressant actions include decreased
responses in hot plate and tail flick tests17 and
decreased flexor reflexes produced by peripheral
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nerve stimulation.24 In addition, galanin has been
found to reduce the potentiation of flexor reflexes
produced by conditioning stimulation of a peripheral
nerve24 and to markedly potentiate the depression of
these reflexes by intrathecal morphine.25
Following nerve crush in the rat, galanin levels
in dorsal root ganglion cells (along with those of
vasoactive intestinal polypeptide and neuropeptide
Y) increase markedly8-21-22 and this is associated with
altered effects of topical galanin. Thus, in normal rats,
galanin reduced the facilitation of hindlimb flexor
reflexes produced by substance P applied topically
to the spinal cord, but this effect disappeared within
11-14 days of peripheral nerve section. Moreover,
at this stage, galanin reduced facilitation of the
flexor reflex by vasoactive intestinal polypeptide.
Such experiments led Xu et al.16 to propose that
galanin released from primary afferents has a func¬
tion during nerve regeneration to suppress spinal
transmission of ectopic impulses arising from regen¬
erating nerve endings.
Compounds released from the central endings of
primary afferent fibres are normally thought of as
important in excitatory transmission. These depress¬
ant actions of galanin do not appear compatible with
such a role, although galanin could be co-released
with an excitant amino acid and/or tachykinin, and
have independent inhibitory actions. Alternatively,
these depressant effects could represent the action of
galanin released from intrinsic neurons of the spinal
cord or from extrinsic fibres such as those descending
from the brain stem.
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Experiments in this laboratory have had a con¬
tinued interest in changes in the central release
of neuropeptides with developing inflammation in
peripheral tissues.1019 We have extended this series to
include galanin. Little is known of the role of galanin
in inflammation, but Kuraishi et al.n found that
intrathecal administration of an antiserum to galanin
induced hypoalgesia to mechanical stimulation of an
inflamed but not a normal hind paw of the rat.
EXPERIMENTAL PROCEDURES
Experiments were performed on anaesthetized rats
(female and male, 220-320 g). Both normal (untreated)
rats (« = 11) and rats with a unilateral inflammation
(n = 16) of the ankle were used.
Induction of peripheral inflammation
Under diethyl ether anaesthesia, rats (270-330 g) received
four subdermal injections of Freund's complete adjuvant
(Sigma, l.Omg/ml, total volume of 0.15ml) around the
ankle joint to induce a unilateral inflammation. This injec¬
tion results in a unilateral swelling of the ankle region, and
previous studies618 have shown that this involves both the
joint and periarticular tissues, e.g. connective tissue, tendons
and overlying skin. For the purposes of this paper, we shall
describe this lesion as unilateral inflammation of the ankle.
Four to six days after the induction of inflammatory lesions,
the animals were used for neuropeptide release studies.
Microprobe preparation
Antibody microprobes were prepared as described previ¬
ously.3'4 Fine glass micropipettes were heat sealed at
both ends and incubated in a 10% solution of aminopropyl-
triethoxysilane in toluene. This produced a siloxane polymer
on the outer surface of the microprobes, to which protein A
(Sigma) was immobilized using glutaraldehyde coupling.
Protein A then bound immunoglobulins present in an
antiserum to rat galanin purchased from Peninsula Labor¬
atories. Data from the manufacturer indicate negligible
cross-reactivity with porcine galanin. neuropeptide Y
and substance P. With microprobes bearing anti-galanin
antibodies, however, preincubation in porcine galanin
(10 7 M) for 30min at 37"JC resulted in greater than
60% suppression of [l:M]rat galanin. Preincubation with
rat galanin (10 7 M) under the same conditions resulted
in approximately 90% suppression of [l25I]rat galanin
binding. Because antibody microprobes have to work within
the constraint of antibody specificity, what is detected under
in vivo conditions will be termed immunoreactive (IR)
galanin. In contrast, no significant suppression of binding of
[125I]galanin was caused by preincubation of microprobes
with 10"7M endothelin, neuropeptide Y, substance P or
neurokinin A. All incubations were carried out in 5 p\
capillaries previously treated with Sigmacote to prevent
binding of peptides to glass.
Surgical preparation and experimental protocols
Anaesthesia was induced with intraperitoneal (i.p.)
sodium thiopentone (I20mg/kg initially, maintained as
required with 15 mg/kg i.p.). Blood pressure was monitored
via a cannula in a carotid artery. Cannulae were also
inserted into the trachea and jugular vein. Animals were
mounted in a frame by means of three pairs of lateral bars
applied to the vertebral bodies adjacent to the exposed
segments of the spinal cord. A controlled heating blanket
maintained body temperature at 36-38°C. Humidified oxy¬
gen was delivered to the region of the tracheal cannulae
external opening with all animals. The lower laminae of
the thoracic/upper lumbar vertebrae were removed and the
exposed spinal cord then covered with 3% agar in saline.
To facilitate microprobe insertion, an opening was made in
the agar forming a pool which was irrigated with warm
sterile Ringer's solution. Within this pool, the dura mater
was cut and retracted laterally. Unlike experiments on the
cat,5-1019 it was not necessary to remove the pia arachnoid
in the rat to allow microprobes to be inserted into the spinal
cord. In each experiment a proportion of microprobes was
filled with Pontamine Sky Blue after breaking the tips to
5-10 fim diameter. Pairs of microprobes aligned in the same
rostrocaudal line and separated by 3 mm were inserted into
the spinal cord with a stepping motor micromanipulator to
a depth of 2.25 mm. They remained in the spinal cord for
10, 15 or 20min. In the results as presented, microprobe
images from all time periods have been pooled. More than
20 microprobes were inserted into the spinal cord in each
experiment.
Peripheral stimuli used
Because the most likely stimulus producing pain from
inflamed skin, joints or tendons is mechanical, resulting
either from direct physical contact or movement of the
damaged tissues, the present experiments employed a series
of repeated mechanical stimuli of increasing intensity. These
consisted of flexing the inflamed joint area and then mechan¬
ically compressing the inflamed tissues. Comparable stimuli
were also applied to the uninflamed hind limbs or normal
animals. Flexion of the ankle was applied by holding the
hind paw gently and pulling the limb out to its full extent,
then pushing the paw gently until it was in close apposition
to the knee. This flexion of the ankle joint was repeated
10 times per minute throughout the period that microprobes
remained in the spinal cord. The second (more severe)
stimulus consisted of laterally compressing the ankle with a
modified spring clip for 10 s each minute for the period that
microprobes were present in the spinal cord.
Following removal from the spinal cord, microprobes
were washed for 15min in cold phosphate-buffered saline
(PBS) containing 0.1% Tween and then incubated for 24 h
at 4'C in a solution of [l25I]galanin (rat, 2000 c.p.m.//il).
After this incubation, microprobes were washed for 15 min
in cold PBS. The distal portions (8-12 mm) were then
broken off and placed in an X-ray film cassettee with a sheet
of monoemulsion film (Kodak, NMB).
Details of the analysis of microprobe images have been
published previously.3-7 Briefly, X-ray film images of micro¬
probes were analysed with an image analysis system employ¬
ing an Imaging Technology PC Vision Plus frame grabber
board operating in a DCS 286e (AT-based) computer. A
CCD camera scanned each image and. after background
subtraction, a transverse integration of the grain density of
the image of each microprobe was executed at defined
intervals. With the magnification of the system used and
the resolution of the image analysis system (512 x 512
locations/frame), this corresponds to a 10/im interval for
transverse integrations. The resultant integrals were stored
on a hard disk with 37 coded values which described the
experimental conditions relevant to that particular micro¬
probe image. An analysis program subsequently obtained
groups of microprobes which met defined criteria and
determined the mean image analysis of each group, which
was plotted with respect to depth within the spinal cord. In
addition, differences between two defined groups of micro¬
probes were assigned statistical significance by determining
the r-statistics derived from the differences of means at each
analysis point (see Figs 2 and 3). It is important to empha¬
size the spatial resolution of the method. Microprobe images
were analysed at 100 sites/mm, but in the data of the present
work this has been reduced to 33 sites/mm by obtaining
the mean of three consecutive values. At the end of each
experiment, Pontamine Sky Blue (contained in some micro¬
probes) was ejected electrophoretically at defined depths
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from the dorsal surface of the spinal cord. The cords were
removed, processed and sectioned for determination of the
location of the resultant dye spots.
RESULTS
Basal levels of immunoreactive galanin in normal rats
and those with unilateral ankle inflammation
Comparisons between the mean image analyses
of in vitro microprobes not exposed to galanin and
those inserted into the spinal cord in the absence of
any active peripheral stimulus (no stim.) showed
a basal presence of IR-galanin in both sides of
the spinal cords of normal rats and those with
unilateral ankle inflammation. Further analysis
showed that there were no significant differences
in basal extracellular levels of IR-galanin in the
dorsal horns and dorsal columns of normal (n = 39)
and arthritic (« = 58) animals, and the ipsilateral
(n = 29) and contralateral (n = 29) sides of the
spinal cord of animals with peripheral ankle
inflammation also showed no significant differences
in basal levels of IR-galanin. Thus, comparable basal
levels of IR-galanin were found in normal rats and
animals with unilateral peripheral inflammation.
Figure IA compares the mean image analysis of
microprobes inserted into the side of the spinal cord
ipsilateral to peripheral inflammation, but in the
absence of any added stimulation with that of in vitro
microprobes. Figure IB plots, in 30 /im intervals, the
differences between the mean image analyses of the
two groups and the hatched area indicates where
these differences are significant at the P < 0.05
level. This shows that there was a basal presence of
IR-galanin at significant levels throughout the whole
of the dorsal horn and dorsal columns, but not within
the ventral horn.
Mechanical stimulation of normal and inflamed ankle
joints and adjacent tissues
Animals with unilateral ankle inflammation. As
described in Experimental Procedures, it was usual
to insert two microprobes into the sides of the spinal
cord ipsilateral to the peripheral ankle inflammation
and flex the inflamed ankle for a defined period and,
following their removal, to insert two microprobes
into the opposite side of the spinal cord and flex the
normal ankle in a similar manner. This sequence was
repeated three or more times.
When the inflamed ankle was flexed, extracellular
levels of IR-galanin were not increased above pre-
stimulus levels during the first two periods of ankle
flexion, but were increased by the third period. In
Fig. 2A, it can be seen that the mean image analysis
of microprobes inserted into the side of the spinal
cord ipsilateral to the peripheral inflammation, but
prior to ankle flexion, is virtually identical to that
of microprobes present in the spinal cord during
the first period of ankle flexion. Such a result also
occurred during the second period of ankle flexion
(not illustrated). Figure 2B and C, however, shows
that during the third period of ankle flexion, extra¬
cellular levels of IR-galanin were significantly elev¬
ated in the superficial and deep dorsal horn when
compared with those present in the absence of added
stimulation.
Increasing the intensity of mechanical stimulation
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Fig. 1. Basal presence of IR-galanin in the side of the spinal cord ipsilateral to ankle inflammation.
(A) The mean image analyses of two groups of microprobes are plotted with respect to length: those which
were not inserted into the spinal cord but simply incubated in [i:5I]galanin (in vitro, n = 25) and those
remaining in the spinal cord in the absence of added peripheral stimulation (No stim., ipsilateral ankle
inflammation, n =29). With each mean image analysis, the mean grey scale was determined in 30/im
intervals and a line joins these points. At each point +S.E.M. is also plotted. (B) A plot of the t statistics
derived from the differences between the two mean image analyses of A is related to an outline of the
spinal cord at the area sampled. The hatched areas indicate where these differences are significant at
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Fig. 2. Flexion of the inflamed ankle and spinal release of IR-galanin. (A) The mean image analysis of
29 microprobes present in the spinal cord in the absence of any added stimulus (No stim.) is compared
with those in the spinal cord during the first period of flexion of the inflamed ankle (n = 20, flexion 1).
(B) Microprobes from the third (n = 13, flexion 3) period of ankle flexion are compared with those present
prior to ankle flexion (No stim., n = 29). (C) The differences between the No stim. and third flexion groups
are plotted with respect to a diagram of the spinal cord. The hatched areas indicate where these differences
are significant at the P < 0.5 level.
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inflamed ankle gave the unexpected result of decreas¬
ing extracellular levels of IR-galanin. This decrease
was not significant during the first period of noxious
ankle compression, but was very evident during the
second application of this stimulus. Thus, Fig. 3A
compares the mean image analysis of microprobes
present in the spinal cord during the second period of
ankle flexion and that of microprobes present in the
absence of active peripheral stimulation. Figure 3B
shows that significant differences occurred between
these groups at several sites in the nucleus proprius
of the dorsal horn.
Limited data were obtained on the effects of ankle
compression on the normal side of animals with
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Fig. 3. Noxious lateral compression of the inflamed ankle
region and spinal release of IR-galanin. (A) The mean
image analysis of 29 microprobes present in the spinal cord
in the absence of any added stimulus (No stim.) is compared
with those present during the second (n = 12) period
of noxious lateral ankle compression. (B) The differences
between the two groups of microprobes in A are plotted
with respect to depth in the spinal cord. Because only
isolated points attain significance at the P < 0.05 level, there
is no hatching as in Figs 1 and 2.
unilateral inflammation. Thus, the mean image
analysis of seven microprobes present in the side of
the spinal cord contralateral to the inflamed ankle
and during compression of the normal ankle failed to
show significant differences from that ofmicroprobes
present in the same side of the spinal cord and during
flexion of the normal ankle (not illustrated).
Normal animals. Flexing the ankle of normal rats
failed to increase extracellular levels of IR-galanin in
the ipsilateral spinal cord (five microprobes). Severe
compression of the foot of the normal rat also failed
to alter basal levels of IR-galanin in the ipsilateral
spinal cord (33 microprobes).
DISCUSSION
The present experiments found comparable
basal levels of IR-galanin in both normal animals
and in those with peripheral inflammation, but in
both groups release of this neuropeptide was not
easily produced by peripheral stimuli and, indeed,
decreased extracellular levels followed noxious
stimulation of inflamed tissues.
The source and stimulus for a basal extracellular
presence of IR-galanin can only be conjectured, since
this peptide is present in primary afferent fibres,
intrinsic neurons and supraspinally derived fibres of
the rat.1-9'11-12'15-20 There is dispute among investigators
on the abundance of galanin-containing neurons in
dorsal root ganglia of the rat with estimates varying
from rare (<5%)21 to more common than neurons
containing calcitonin gene-related peptide." In the
present experiments, release of galanin by peripheral
stimuli was not readily detected. Thus, in rats with
peripheral inflammation, repeated flexion of the
involved ankle was needed to increase extracellular
levels of IR-galanin and in normal rats noxious foot
compression did not produce a spinal release of the
neuropeptide. We do not believe this is the release
pattern of a compound present in many primary
afferent fibres. Release from intrinsic neurons of
the cord and/or supraspinally derived fibres may
be significant with galanin. The study of Morton
and Hutchison,16 using antibody microprobes in the
spinal cat, may be interpreted as showing a basal
presence of galanin derived from intrinsic neurons
of the spinal cord. In this work, a basal presence of
IR-galanin was detected in the region of lamina II
and at the spinal cord surface. Electrical stimulation
of both A and C fibres of the tibial nerve (10 Hz)
failed to produce a spinal release of IR-galanin.
Similarly ineffective were peripheral noxious thermal
and mechanical stimuli.
Using immunocytochemical techniques, galanin-
containing neural structures in the spinal cord have
been shown to be relatively heavily concentrated in
laminae I and II of the dorsal horn, but not in
the deeper laminae IV and V nor in the dorsal
columns.20 In the present experiments, this differ¬
ence was not observed and IR-galanin was present
relatively diffusely in the dorsal columns and dorsal
horn, although peak levels were in the super¬
ficial dorsal horn. This may represent a diffusion of
galanin away from sites of release, which implies a
relative resistance to degradation at sites of release.
Relevant to this is the report that, when incubated
with membrane preparations of rat hypothalami,
the half-lives of galanin 1-29 and galanin 1-16 were
100 and 28 min, respectively.14 If this reflects the rate
of degradation of galanin under in vivo conditions,
then diffusion away from sites of release is to be
expected.
The results of noxious lateral ankle compression
are unlike any we have observed with other neu-
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ropeptides. It is possible that the decreased levels
produced by this stimulus represent an inhibition
of both basal and evoked release of galanin by the
activity of afferents brought into play by such stimuli.
An alternative explanation is that repeated stimuli
deplete the stores of releasable galanin to the extent
that basal levels decline below those present prior to
any active stimulus. The report of Klein et al." that
30 min of peripheral nerve stimulation in the rat
resulted in reduced levels of IR-galanin, measured by
immunocytochemistry of the dorsal horn, supports
such a proposal. Both an inhibition of release or a
depletion of stores as explanations for the present
results require that previously released galanin be
degraded approximately within the interval between
insertion of successive microprobes.
CONCLUSIONS
The results of the present experiments are support¬
ive of those of Kuraishi et al.'3 in suggesting that
galanin has a functional role in the spinal cord,
with the development of peripheral inflammation.
Release studies alone cannot determine function and,
in the present instance, whether released galanin
facilitates or inhibits transfer of information from
nociceptive primary afferents. The relative difficulty
with which galanin was released by peripheral stimu¬
lation argues against this neuropeptide being a simple
transmitter released by a particular population of
afferent fibres. If galanin has an inhibitory role
in spinal processing of nociceptive information, then
its apparent depletion or inhibition of release by
prolonged severe stimuli may have implications for
the perception of pain with persistent inflammatory
states.
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Antibody microprobes bearing antibodies to the C-terminus of substance P (SP) were used to measure release of immunoreactive (ir) SP
in the dorsal horn of barbiturate anaesthetized spinal cats. Electrical stimulation of unmyelinated primary afferents of the ipsilateral tibial
nerve produced a relatively localised release of ir SP in the superficial dorsal horn. Prior microinjection of the peptidase inhibitors kelator-
phan and enalaprilat in the dorsal horn resulted in ir SP being detected over the whole of the dorsal horn and the overlying dorsal column.
This pattern had previously been observed with evoked release of ir neurokinin A and supports the proposal that a slow degradation results
in a neuropeptide accessing many sites remote from sites of release.
INTRODUCTION
The encoding of the onset and offset of a burst of af¬
ferent information to a neurone requires that released
neurotransmitters should be rapidly inactivated. If the
inactivating mechanism is a component of the pre- and/or
postsynaptic elements of a synapse, such an arrangement
favours rapid inactivation and also minimises the prob¬
ability that significant amounts of released transmitter
will diffuse to adjacent areas. Thus active uptake into
both the releasing terminal and adjacent glial processes,
such as occurs with the inhibitory amino acid y-aminobu-
tyric acid, GABA10'20, probably ensures that GABA has
little direct effect on sites outside a synapse at which re¬
lease has occurred. With neuropeptides the situation is
less clear. High affinity uptake systems for neuropeptides
have not been demonstrated in nervous tissue25. Al¬
though enzymes are assumed to be important in limiting
the actions of synaptically released neuropeptides, some
reviewers have drawn attention to difficulties inherent in
such an assumption and in particular to the failure of
peptidases to be located adjacent to some sites of pep¬
tide release2-25. Thus there is reason to believe that some
neuroactive compounds released in the central nervous
system will not be degraded rapidly and thus could ac¬
cess receptors remote from sites of release. The process
whereby this widespread presence of discretely released
compounds results in alterations in excitability of many
neurones has been termed volume transmission by Fuxe
et al.11.
Our interest in such a process comes from studies of
the release of substance P (SP) and neurokinin A (NKA)
in the spinal cord using antibody microprobes. These
two compounds extensively coexist in primary afferent
fibres3 and it was anticipated that their release would
occur at similar sites in the spinal cord and in response
to similar peripheral stimuli. Peripheral noxious cutane¬
ous stimuli did evoke release of both neuropeptides, but
whereas that of immunoreactive (ir) SP was centred on
the substantia gelatinosa7 ir NKA was detected diffusely
over the dorsal horn8. Because in vitro data indicate a
relative resistance of NKA to enzymic degradation14'27'30
it was proposed that the ability of NKA to access sites
remote from those of release resulted from a slow rate
of degradation under physiological conditions. Such a
finding has important implications for the possible func¬
tions of substance P and neurokinin A in the spinal cord
and for the volume transmission proposal of Fuxe and
Agnati11.
One test of such a hypothesis is whether protecting SP
from enzymic degradation results in the release pattern
of this neuropeptide becoming similar to that of NKA
with widespread diffusion in the spinal cord. Under in
vitro conditions SP is degraded by a number of enzymes
including aminopeptidases, endopeptidases and carboxy-
peptidases12'21'23'34, but it is uncertain which of these are
Correspondence: A.W. Duggan, Department of Preclinical Veterinary Sciences, University of Edinburgh Summerhall, Edinburgh. EH9 1QH.
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important under physiological conditions and, in partic¬
ular, in the central nervous system. The present exper¬
iments have used the antibody microprobe technique to
examine the distribution of stimulus-evoked release of ir
SP in the spinal cord of the cat following the adminis¬
tration of peptidase inhibitors.
It was decided that the combination of kelatorphan
and enalaprilat should be used initially, since the former
compound is an inhibitor of aminopeptidases, dipeptidyl-
aminopeptidases and the neutral metallo-endopeptidase
enkephalinase, EC 3.4.24.II32 and the latter inhibits
peptidyl dipeptidase A (angiotensin-converting enzyme
EC 3.4.15.1)28'31. Since the antibody microprobe tech¬
nique permits measurements of release at discrete sites
in the central nervous system, it is appropriate that drugs
attempting to modify release should also be administered
at discrete sites of release. In the present experiments,
therefore, kelatorphan and enalaprilat were microin-
jected from glass micropipettes with tips positioned in
the substantia gelatinosa of the dorsal horn of the spinal
cord and adjacent to sites of penetration by microprobes.
The results indicate a remarkable diffusion of ir SP
within the spinal cord following peptidase inhibition.
MATERIALS AND METHODS
Microprobe preparation
Antibody microprobes were prepared following the technique
recently described6. Conventional glass micropipettes were heat
sealed at both ends, incubated in a 10% solution of aminopropyl-
triethoxysilane in toluene and then heat cured. This procedure pro¬
duced a siloxane polymer on the outer surface of each micropipette
to which protein A was immobilised using glutaraldehyde. Protein
A then bound antibodies to substance P during incubation of the
micropipettes in a substance P antiserum. The antiserum used was
polyclonal and directed against the C-terminus of SP. The manu¬
facturer (Peninsula) indicated for this antibody significant cross-re-
activity with SP 3-11, little for SP 4-11 and no cross-reactivity with
NKA, neuropeptide K or neurokinin B. In vitro tests showed uni¬
form binding of 125I-SP (Bolton-Hunter) to the probes and an ap¬
proximately 50% suppression of such binding after preincubation in
a 1(T7 M SP solution for 30 min at 37°C. The binding was not sup¬
pressed by preincubation in a Ringer solution with kelatorphan
(10~3 M) or kelatorphan and enalaprilat (10~3 M each).
Animal preparation
The experiments were performed on anaesthetised, spinalised
cats. Anaesthesia was induced with 35 mg/kg sodium pentobarbi¬
tone i.p. and. after cannulation of a cephalic vein, maintained by
continuous infusion at 3 mg/kg/h. Blood pressure was measured
with a cannula in a carotid artery. A tracheostomy was made for
artificial respiration which was started after the dissection and fol¬
lowing neuromuscular paralysis with gallamine administered inter¬
mittently at a dose of 4 mg/kg/h. End tidal CO, levels and body
temperature were controlled throughout the experiment.
An extended laminectomy exposed the caudal lumbar spinal seg¬
ments. The spinal cord was transected at the thoracolumbar junc¬
tion following injection of 0.1 ml of 2% lignocaine. The cats were
fixed in a metal frame. After cutting the dura, a layer of sterile
Ringer-agar was placed over the dorsal surface of the spinal cord.
At proposed insertion sites of the probes, the agar was removed
and the pia-arachnoid was opened with fine forceps. A perfusion
pump delivered sterile Ringer solution continuously to the exposed
areas. A heat exchanger jacket around the delivery tubing main¬
tained this solution at 38°C. For electrical stimulation the tibial
nerve of the left hindlimb was dissected after incision of the skin
and separating the two heads of the gastrocnemius-soleus muscle.
A small pool was formed with the skin flaps and filled with mineral
oil and a stimulation electrode was placed under the nerve for en
passant stimulation.
Experimental protocol
Before microprobes were inserted into the spinal cord, extracel¬
lular recordings were obtained in spinal laminae IV-VI to deter¬
mine the distribution of afferent input from the tibial nerve and
the hind paw to select sites for the study of ir SP release by mi¬
croprobes. Pairs of microprobes were introduced to a depth of 4
mm using two stepping motor micromanipulators and kept in the
cord for 10 min. During these periods either no stimulus was ap¬
plied or electrical or noxious mechanical stimulation was performed.
For nerve stimulation, electrical pulses of 0.5 ms duration and 50
V amplitude were applied with a frequency of 20 Hz to the ipsi-
lateral tibial nerve. This stimulation was considered supramaximal
for all afferent fibres in the tibial nerve. For noxious mechanical
stimulation five crocodile clips were applied to the toes of the ip-
silateral hind paw for periods of 3 min and this stimulus repeated
once within the 10 min microprobes were in the spinal cord. First
the left side of the cord and electrical nerve stimulation were used
and then we switched to the right side of the cord and noxious me¬
chanical stimulation was employed.
Prior to injecting peptidase inhibitors (control period) several
probes were inserted in the absence of stimulation or during elec¬
trical nerve stimulation or noxious mechanical stimulation of the
toes. Peptidase inhibitors were then microinjected into the grey
matter using a micropipette connected to a syringe. Ringer solu¬
tion containing peptidase inhibitors (up to 1CT3 M) was injected at
depths of 2.5, 2, 1.5 and 1 mm from the dorsal surface and around
the region where the microprobes had been introduced. The vol¬
ume of each injection was approximately 0.05-0.1 p\ with total
volumes of 0.2-0.5 p\. The solution contained either kelatorphan
(a gift of Dr B.P. Roques) or a mixture of kelatorphan and enal¬
aprilat. In some experiments only Ringer solution was microin¬
jected. Following the microinjections, further probes were inserted
at defined intervals (starting 15 min after the microinjections were
complete) and the electrical or mechanical stimuli were repeated.
At the end of each experiment pontamine Sky blue (contained
in microprobes) was ejected electrophoretically at depths of 1 and
4 mm from the dorsal surface of the spinal cord. The cords were
removed, processed and sectioned for determination of the loca¬
tion of the resultant dye spots. These data were used to relate lo¬
cations on the probes to the laminae of Rexed (see next para¬
graph).
Treatment of probes and data analysis
After removal from the spinal cord, microprobes were washed
for 15 min in cold phosphate-buffered saline (PBS) containing
Tween (0.1%) and then incubated for 24 h at 6°C in a PBS-azide
solution of 125I-Bolton-Hunter SP containing bovine serum albu¬
min. The final dilution of the radiolabelled peptide was approxi¬
mately 2000 dpm per /A. Following incubation in labelled peptide,
the probes were washed for 15 min in PBS-Tween (0.1%), the tips
were broken off, glued to a sheet of paper and placed in an X-ray
cassette with a sheet of monoemulsion film for up to 7 days.
The resulting X-ray images were scanned in 10 pm intervals us¬
ing a charge-coupled device camera and an image analysis system
employing an Imaging Technology PC Vision Plus frame grabber
board operating in a DCS 286e (AT based) computer13. This pro¬
cedure produced an image of each probe showing the grey density
(on a scale of 0 to 255) along 5 mm of the tip. Transverse integra¬
tions were then performed along each analysed image to give a plot
of total optical density (grey scale) with respect to length. Although
the image analysis system produced a plot with a longitudinal res-
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olution of 10 /im, this was reduced to 30 /xm by calculating the av¬
erage of three successive integrals. This is more in line with the
biological resolution of the microprobe method (see ref. 5). Inhi¬
bition of binding of radioactive SP on these probes (reduced grey
density) indicates previous binding of ir SP in the cord. These ar¬
eas of reduced binding were then related to sites within the cord
(see above). Groups of probes were pooled and then means (±
S.E.M. in 30 pm steps) were displayed in graphs which showed the
averaged grey densities along the probes in relationship to the
depth within the cord. Comparisons were made between different
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Fig. 1. Release of immunoreactive substance P in the dorsal horn
following peripheral nerve stimulation and the failure of microin¬
jection of Ringer solution to alter such release. A: images of 2
groups of microprobes present in the cord prior to nerve stimula¬
tion ('No stim.', n = 19) and during electrical stimulation of the
tibial nerve ('Nerve stim.', n = 42). Each continuous line repre¬
sents the mean densitometric analysis of a group of microprobes
which have bound [125I]substance P and produced autoradiographic
images. The analysis was performed in 30 /tm intervals and the dots
represent the standard errors of the mean at each analysis point.
Prior to incubation in [l2SI]SP the probes were inserted 4 mm into
the cord for periods of 10 min. Abcissa: depth in the spinal cord,
0 corresponds to the surface of the cord, 4 mm to the ventral bor¬
der of the ventral horn and 1 mm approximates to lamina II. Or¬
dinate: grey scale integrals obtained by transverse analysis of mi¬
croprobe images in 30 pm steps. The slope of the 'No stim.' probes
reflects the shape of the microprobes with an increasing number of
binding sites along the shaft progressing away from the tips. Inhi¬
bition of binding of [125I]SP (reduced grey density) is equated with
previous binding of (unlabelled) endogenous ir SP in the cord. B:
the mean image analyses of two groups: the 'Nerve stim.' group
shown in A and microprobes present in the spinal cord during
electrical stimulation of the tibial nerve, but post-microinjection of
Ringer solution at depths 1.0, 1.5, 2.0 and 2.5 mm from the dorsal
surface ('Nerve stim. post-Ringer microinjection', n - 14).
RESULTS
As previously reported7, electrical stimulation of the
tibial nerve evoked a focal release of ir SP in the super¬
ficial dorsal horn of all cats. This is demonstrated in Fig.
1A. The 'No stim.'group displays the averaged image of
19 microprobes which were in the cord for periods of 10
min prior to electrical nerve stimulation. There is regu¬
lar binding of 125I-SP along the probe and the slope of
the grey density curve was similar to that of probes in¬
cubated in labelled SP without previous exposure to the
non-labelled neuropeptide. By contrast the averaged im¬
age of 42 probes present in the cord during electrical
nerve stimulation (the 'Nerve stim.' group in Fig. 1A)
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Nerve stim. 60 - 70 min
post peptidase inhibitors
No stim.
Depth within spinal cord (mm)
Fig. 2. Effect of peptidase inhibitors on the pattern of release of ir
SP. The peptidase inhibitors kelatorphan or kelatorphan and enal-
aprilat were microinjected at depths of 2.5, 2.0, 1.5 and 1.0 mm
prior to insertion of the microprobes displayed. Each graph shows
the averaged image analysis of the 'No stim.' probes (n = 19, same
group in all graphs) and the averaged image analysis of a group of
microprobes present in the cord during electrical nerve stimulation
in a specific period post-microinjection (n = 15 probes in A; n =
15 probes in B; n = 13 probes in C).
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exhibited inhibition of binding of 125I-SP from 0.5 mm
to 2.0 mm from the dorsal surface with a peak at 0.8-
1.2 mm (see also Fig. 3A). This deficit indicates prior
binding of ir SP to the probes in this area of the spinal
cord.
In confirmation of previous results9, microinjection of
Ringer solution in volumes similar to those used with
peptidase inhibitors did not alter stimulus-evoked release
of ir SP in the dorsal horn. Fig. IB compares the mean
image analysis of 14 microprobes inserted in the spinal
cord in the periods 15-25 and 35-45 min after microin¬
jection of Ringer solution into the dorsal horn and dur¬
ing peripheral nerve stimulation with the corresponding
pre-injection microprobes. There are no significant dif¬
ferences between these groups.
Microinjection of peptidase inhibitors
When peptidase inhibitors were microinjected into the
grey matter the probes present in the cord during nerve
stimulation showed a significantly different pattern of
123I-SP binding which progressed with time after injec¬
tion. Fig. 2A displays the averaged image of 15 micro¬
probes which were in the spinal cord in the period 15-25
min post-microinjection of peptidase inhibitors, either
kelatorphan alone or kelatorphan and enalaprilat, at
depths of 2.5, 2, 1.5 and 1 mm. Peripheral nerve stim¬
ulation was used with all. These probes show a zone of
reduced grey density extending from the surface of the
cord down to 2.0 mm, again with a peak at about 1 mm.
At 35-45 min after microinjection of the peptidase in¬
hibitors the zone of reduced binding of 125I-SP had ex¬
tended even further (Fig. 2B) down to 3.5 mm from the
dorsal surface of the spinal cord. Fig. 2C shows a partial
recovery from the effects of the peptidase inhibitors at
the period 60-70 min after their microinjection.
The relation of such reduced binding of [125I]SP to the
anatomy of the spinal cord is shown in Fig. 3. In Fig.
3A a plot of f-values (30 pm separation) derived from
Fig. 3. The spinal laminar distribution of nerve stimulus-evoked release of ir SP before and after microinjection of peptidase inhibitors. A:
a plot of the f-statistics derived from the differences between the averaged image of the "No stim.' microprobes and the averaged image of
the 'Nerve stim.' microprobes shown in Fig. 1A. B: a corresponding plot of the differences between the images of the 'No stim.' microprobes
and the 'Nerve stim. post-peptidase inhibitors' microprobes shown in Fig. 2B. The significances were calculated in 30 pm intervals. 2T cor¬
responds to P < 0.05 and 4T to P < 0.01. The shaded areas indicate sites in the cord in which the 'stimulus curves' were significantly
different from the non-stimulation baseline, with P < 0.05. The ordinate in each plot is distance along microprobes in mm and this has been






the differences of the means of the two image analyses
of Fig. 1 are related to spinal laminae. In Fig. 3B the
t-values derived from the differences of means of the
image analyses of Fig. 2B are similarly plotted. These
figures compare the effects of nerve stimulation before
and after injection of peptidase inhibitors. They show
that the zone of nerve stimulus-evoked presence of ir SP
expanded both dorsally and ventrally following microin¬
jection of peptidase inhibitors. Fig. 3B shows that the
greatest effect of the stimulus was to elevate levels of ir
SP in the dorsal columns. The no-stimulus group of Figs.
1A and 2B, however, has a small but non-significant
zone of inhibition of binding of 125I SP in laminae I and
II and it is this which results in the greatest change pro¬
duced by nerve stimulation post-peptidase inhibition to
be seen in the dorsal column.
This shift is further apparent in Fig. 4 which plots the
/■-values derived by subtracting the mean image analysis
Fig. 4. The spinal distribution of the changes in nerve stimulus-
evoked release of ir SP produced by microinjection of peptidase
inhibitors. This is a plot of the t-statistics derived from the differ¬
ences of means of the two mean image analyses shown in Fig. 2B
(/! = 15, 35-35 min after peptidase inhibitors and during nerve
stimulation) and Fig. IB (n = 14, after Ringer solution microin¬
jection and during nerve stimulation). The hatched area highlights
where t > 2 and where significance occurs at P < 0.05. The Ro¬
man numerals indicate the laminae of Rexed.
of microprobes inserted after microinjection of Ringer
solution from those of microprobes present 35-45 min
after microinjection of peptidase inhibitors. With both
groups the ipsilateral tibial nerve was electrically stimu¬
lated. Although the peptidase inhibitors did produce a
significant increase of the stimulus-evoked release of ir
SP in the region of lamina II (at about 1 mm), the
change in the levels of ir SP was significantly higher in
the adjacent dorsal column and lamina IV. This results
from the normal low levels in these latter areas follow¬
ing peripheral nerve stimulation.
Kelatorphan vs. kelatorphan and enalaprilat
Separate analysis of the probes present in the cord
post-microinjection of kelatorphan and those inserted
post-microinjection of both peptidase inhibitors showed
that the groups were essentially similar at all periods.
Fig. 5 shows the overlap of the averaged images of the
two groups of probes both of which were in the cord from
35-45 min post-microinjection (n = 7 probes post-kela-
torphan and n = 8 probes post-kelatorphan plus enala¬
prilat). The values derived from the differences between
these two analyses do not show significant differences.
Effects of microinjection of peptidase inhibitors restricted
to laminae I and II
In the experiments described above peptidase inhibi¬
tors had been microinjected at depths of 2.5, 2.0, 1.5 and
1.0 mm, in order to inhibit peptidases throughout the
grey substance over a wide area of the dorsal horn. In a
smaller number of experiments the microinjection was
restricted to the region of laminae I and II, i.e. to a
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Depth within spinal cord (mm)
Fig. 5. A comparison of groups of microprobes inserted during
electrical stimulation of the tibial nerve, 35-45 min post-microin¬
jection of kelatorphan {n = 7 probes) and of kelatorphan plus
enalaprilat (n = 8 probes), at depths of 2.5, 2.0, 1.5 and 1.0 mm
from the dorsal surface of the spinal cord. A plot of the t-statistics
derived from the differences of the means of the two groups is
shown below.
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depth of 1 mm. In these experiments the protocol was
different in that the probes were kept in the cord for
periods of 20 min and the stimuli were applied for longer
times (electrical nerve stimulation) or repeated more of¬
ten (noxious pinch). Fig. 6 shows that the restricted mi¬
croinjection of peptidase inhibitors at a depth of 1 mm
was followed by an expansion of the region in which
stimulus-associated ir SP was detected.
Effect of peptidase inhibitors on the pattern of ir-SP
evoked by noxious mechanical stimulation
Since electrical nerve stimulation is a quantitatively
well-defined but unphysiological stimulus, we investi¬
gated whether the effect of peptidase inhibitors could
also be demonstrated with ir SP released by natural stim¬
uli. Fig. 7 displays the result of these experiments. The
stimulus was noxious pinch to the toes of the ipsilateral
hind paw, using crocodile clips, applied twice for 3 min
in a 10 min test period.















Depth within spinal cord (mm)
Fig. 6. Effect of the microinjection of peptidase inhibitors in the
region of laminae I and II on the pattern of release of ir SP. All
probes were in the spinal cord for 20 min. A: release of ir SP by
electrical stimulation of the tibial nerve (20 Hz. 50 V, 0.5 ms pulse
duration). 'No stim.' group: n = 5 probes; 'Nerve stim.' group: n
= 13 probes. These control microprobes are restricted to those ex¬
periments in which peptidase inhibitors were only microinjected in
the region of laminae I and II. B: nerve stimulus-evoked release of
ir SP 55-75 min following microinjection of kelatorphan and enal-
aprilat at 1.0 mm from the dorsal surface of the spinal cord. 'Nerve
stim. post-peptidase inhibitors (laminae I & II)' group: n = 4. The
'No stim.' group is the same as that shown in A.
prior to injection of peptidase inhibitors. The mean im¬
age analysis of 21 probes present in the cord in the ab¬
sence of peripheral stimulation is compared with that of
46 probes present in the cord during the application of
noxious pinch. The stimulus produced increased levels of
ir SP in a restricted area of the superficial dorsal horn.
Following microinjection of peptidase inhibitors at depths
of 1.0 to 2.5 mm from the dorsal surface, this zone pro¬
gressively expanded with peripheral nerve stimulation
(Fig. 7B and C). At 50-60 min after peptidase inhibitor
microinjection, noxious pinch produced significantly in¬
























Noxious pinch 50 - 60 min
post peptidase inhibitors
No stim.
4 3 2 1 0
Depth within spinal cord (mm)
Fig. 7. Effect of the microinjection of peptidase inhibitors at 2.5,
2.0, 1.5 and 1.0 mm from the dorsal surface of the spinal cord on
the pattern of release of ir SP evoked by noxious mechanical stim¬
ulation. Each graph shows the averaged image of the 'No stim.'-
probes of the control period (n = 21) and the averaged image of
probes present in the cord during noxious pinch under the condi¬
tions indicated (n = 46, 15 and 11 from top to bottom). Each probe
was in the cord for 10 min: noxious pinch of the toes was applied




(laminae I & II)
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DISCUSSION
The present results have shown that microinjection of
peptidase inhibitors into the dorsal horn of the spinal
cord results in a remarkably diffuse pattern of inhibition
of binding of 125I-SP to the immobilised antibodies of
microprobes. Prior to discussing the physiological signif¬
icance of this finding, some technical considerations re¬
quire examination.
In vitro tests showed that high concentrations of ke-
latorphan and enalaprilat did not inhibit the binding of
125I-SP to microprobes. Hence, the present results can¬
not have resulted from a diffuse binding of these com¬
pounds to microprobes following microinjection into the
spinal cord. The simplest explanation of the altered
binding curves produced by the peptidase inhibitors is
that this resulted from increased binding of ir SP to mi¬
croprobes associated with increased levels at many sites
in the dorsal horn. As previously discussed"''6 a localised
inhibition of binding of an exogenous ligand could also
result from damage to antibodies from proteases either
present in the extracellular fluid of the spinal cord or
liberated from damaged cells. Such a proposal also re¬
quires, however, that proteases be released centrally fol¬
lowing certain peripheral stimuli to explain the increased
inhibition of binding shown on microprobes following
such stimuli. The different patterns of inhibition of bind¬
ing produced by identical peripheral stimuli on micro¬
probes bearing different antibodies, however, is very dif¬
ficult to reconcile with such a hypothesis. It is equally
difficult to explain wide-spread inhibition of the binding
of 125I-SP to microprobes as resulting from enhanced ac¬
tivity of proteases following microinjection of compounds
which inhibit peptidases. Thus the present experiments
provide important support for the validity of results ob¬
tained with the antibody microprobe technique.
Within the spinal grey matter a pattern of widespread
presence could represent diffusion of ir SP away from
sites of release or simply a revealing of minimally re¬
leased ir SP protected from degradation at sites of re¬
lease. The greatest change in the levels of ir SP detected
following peptidase inhibition, however, occurred in the
dorsal column white matter (Fig. 4) where there are vir¬
tually no nerve endings and, hence, no sites of release.
This change must have resulted from diffusion of pro¬
tected ir SP from sites of release in the superficial dorsal
horn. It is probable, therefore, that the pattern of re¬
lease of ir SP observed in the spinal grey matter follow¬
ing peptidase inhibition predominantly results from dif¬
fusion away from the sites of release detected in the
normal spinal cord.
The present experiments indicate that enzymic degra¬
dation is an important determinant of the degradation of
substance P under physiological conditions in the spinal
cord. Since kelatorphan inhibits aminopeptidases, de-
peptidylaminopeptidases and endopeptidase 24:11 (ref.
32) it is not possible to state which is the more impor¬
tant physiologically. Kelatorphan alone produced effects
similar to the combined adminstration of kelatorphan
and enalaprilat and, hence, it is probable that angioten-
sin-converting enzyme does not contribute significantly
to the degradation of substance P at least in the spinal
cord in vivo. In slice preparations from the substantia
nigra of the rat22 and the dorsal spinal cord of the guinea
pig12 the converting enzyme inhibitor captopril failed to
modify the levels of ir SP released in response to either
high external K+ (substantia nigra) or capsaicin added
to the perfusate (spinal cord) supporting the conclusion
of the present study. Both of these studies found that
inhibitors of endopeptidase 24.11 (enkephalinase) such
as phosphoramidon, thiorphan and kelatorphan caused
increased release from the slice preparation following
either high external K+ or capsaicin.
One difficulty in the interpretation of such experi¬
ments is that the enzymes inhibited may be important in
metabolising a number of neuropeptides in addition to
substance P. Kelatorphan potentiates the actions of met-
enkephalin administered microiontophoretically in the
substantia gelatinosa of the cat26 and applied to the sur¬
face of the rat spinal cord4. It also increases high K+
evoked release of metenkephalin from spinal cord
slices24. All of these actions probably result from inhibi¬
tion of endopeptidase 24:11. Opioids have been shown
to reduced high K+-evoked release of SP from a slice
preparation17 and, as a result, proposed as exerting a
presynaptic inhibitory control of the release of SP from
the central terminals of nociceptors17. Mauborgne et
al.24 proposed that a potentiation of such a control was
reponsible for their failure to observe an enhancement,
by kelatorphan, of high K+-evoked release of SP from a
rat spinal cord slice. Such a result was anticipated in the
design of the present experiments, since a potentiated
block of SP release by protected opioid peptides could
effectively prevent the detection of any impaired degra¬
dation of released SP. That the present experiments
readily found evidence of enhanced levels of ir SP fol¬
lowing the microinjection of peptidase inhibitors does
suggest, however, that tonic control of SP release from
the central terminals of nociceptors is not a significant
factor in the anaesthetized cat. It needs to be pointed
out moreover that experiments suggesting such a control
have come from experiments on slice preparations, where
elevated K+ was used as a stimulus for release of SP and
these have the problem of not knowing the source of SP.
High K+ will depolarize virtually all neural elements in
a slice and it is just as likely that the depression of such
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release by opioids is exerted postsynaptically on intrinsic
neurons of the slice as on the severed central terminals
of nociceptors.
The most significant result of the present experiments
is the demonstration that enzyme inhibition not only de¬
termines the levels of substance P sustained at sites of
release but also the sites accessed following release. The
microprobe method is particularly suited to study spread
following release, since it samples continuously along its
length. In essence, the present experiments have shown
that peptidase inhibition causes the pattern of presence
of ir SP following stimulus-evoked release to resemble
that of ir NKA8'15.
In vitro, NKA is relatively resistant to degradation by
plasma enzymes30 and by an endopeptidase degrading
SP isolated by Nyberg et al27. Indeed it has been em¬
phasised that the potency of tachykinins in some in vitro
preparations is not only determined by the relative abun¬
dance of NKX, NK2 and NK3 receptors but also by the
activity of degrading enzymes29.
The first convincing demonstration that a synaptically
released neuropeptide could act at a distance was that
of Jan and Jan16 on neurones of bull frog sympathetic
ganglia. Thus, electrical stimulation of a preganglionic
nerve produced a depolarisation (mimicked by applica¬
tion of a luteinising hormone releasing hormone, LHRH)
in neurones not receiving an innervation by LHRH con¬
taining nerve endings. Within the central nervous system
this concept of an action distant from a site of release
has been termed volume transmission111. It has been
proposed11 that transmission at a synaptic site of release
is characterised by low-affinity receptors (concentrations
are high) whereas effects distally are mediated by high-
affinity receptors which may also be activated by degra¬
dation products as well as the original neuropeptide. The
present results are supportive of these proposals, since
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Antibody-coated microprobes were used to study the time course of release and disappearance of immunoreactive neurokinins in the dorsal spinal
cord, in response to electrical stimulation of unmyelinated fibres of the tibial nerve of the cat. Noxious cutaneous stimuli were not used thereby
avoiding potentially uncontrolled tissue damage and inflammation. Microprobes, inserted into the spinal cords of barbiturated anaesthetized spinal
cats prior to nerve stimulation, detected a basal level of immunoreactive neurokinins. During nerve stimulation immunoreactive neurokinins were
released significantly in the upper dorsal horn and dorsal columns and required at least 1 h to return to prestimulus levels. The persistence of immuno¬
reactive neurokinins in the dorsal horn may underlie the prolonged hyperexcitability of some spinal neurons following brief noxious stimuli.
The antibody microprobe is a device well suited to
localize sites of release of neuropeptides within the cen¬
tral nervous system [5, 6], Thus in experiments employ¬
ing microprobes coated with antibodies to substance P
(SP), spinal immunoreactive (ir) SP release evoked by
noxious cutaneous stimuli, was centered on the substan¬
tia gelatinosa of the dorsal horn with a second, deeper,
area approximating to laminae V and VI [6]. Such re¬
stricted areas of release were not seen in experiments
using similar noxious cutaneous stimuli, but employing
microprobes bearing antibodies to neurokinin A (NKA).
Noxious stimulus-evoked release of irNKA was detected
widely in the dorsal spinal cord of the cat, including the
overlying dorsal columns [7]. This was an unexpected re¬
sult since immunohistochemical studies indicate that
these neuropeptides have a similar distribution within
the upper dorsal horn of the rat [4],
In addition there was evidence that irNKA persisted
beyond the duration of a noxious stimulus. Since there
is evidence that NKA is resistant to degradation by pro¬
cesses which rapidly inactivate SP [16, 18] it was pro¬
posed that the apparent persistence and diffusion of
irNKA away from sites of release from nerve terminals,
most probably resulted from a natural slow inactivation
of this compound. This conclusion has important impli-
Correspondence: A.W. Duggan, Department of Preclinical, Veterinary
Sciences, University of Edinburgh, Summerhall, Edinburgh, EH9
1QH, U.K.
cations for the possible functions of NKA in the spinal
cord, particularly in view of the several reports that pro¬
longed hyperexcitability of spinal neurones can follow a
relatively brief input from nociceptors [2,3,9, 11, 15, 19,
20],
When using noxious stimuli applied to the skin, there
is always the possibility that tissue damage is produced
by a particular stimulus and hence that nociceptors will
continue to fire, at a reduced rate, after the period of sti¬
mulus application. Thus the persistence of irNKA in the
experiments cited could have resulted from irNKA being
released from a subset of nociceptors activated by mini¬
mal tissue damage. This possibility can be investigated
by employing electrical stimulation of a peripheral nerve
as the stimulus to evoke neuropeptide release, since there
is no evidence that afferent fibres fire for periods beyond
the application of an electrical stimulus. Thus the pre¬
sent experiments have used antibody microprobes to
study spinal release of ir neurokinins produced by elec¬
trical stimulation of the tibial nerve in the anaesthetized
spinal cat.
Experiments were performed on 8 cats anaesthetized
with sodium pentobarbitone (35mg/kg, i.p. initially and
maintained with an intravenous infusion of 3-6 mg/kg/
h). Blood pressure and end tidal C02 levels were moni¬
tored continuously. Five cats were paralysed with inter¬
mittent (90 min) injections of gallamine triethiodide (4
mg/kg) and artificially ventilated. The spinal cord was
exposed by removal of the lumbar laminae and tran-
0304-3940/90/$ 03.50 © 1990 Elsevier Scientific Publishers Ireland Ltd.
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sected at the thoraco-lumbar junction after injection of
local anaesthetic at the site of section. The dura was
opened with sterile scissors and then covered with sterile
agar. The agar was removed locally to allow microprobe
penetration and small areas of pia-arachnoid were
removed with sterile fine forceps. These exposed areas
were irrigated continuously with a sterile Ringer solution
at 37°C and removed by suction. It is important to pre¬
vent contamination and infection of the spinal cord, in
experiments which measure neuropeptide release, since
the latter are contained in inflammatory exudates. The
animal also received two subcutaneous injections of an
ampicillin suspension (25 mg/kg). The left and right
tibial nerves were exposed in the hind limbs, mounted on
stimulating electrodes and immersed in liquid paraffin
pools to prevent dehydration.
Antibodies were immobilized onto the outer surface of
glass micropipettes as previously described by Duggan et
al. [5]. The antisera used were from two sources - Penin¬
sula Laboratories and Milab. Both have complete cross-
reactivity with neuropeptide K, an N-terminal extended
neurokinin A, 70-80% cross-reactivity with neurokinin
B, but negligible cross-reactivity with substance P. For
the purposes of the present experiments microprobes are
described as detecting immunoreactive neurokinins (ir
NK).
Microprobes were filled with 2% Pontamine sky blue
in 0.2 M sodium acetate and then introduced 3 mm into
the spinal cord, in pairs, via independently controlled
stepping-motor micromanipulators. Initially, field
potentials in response to electrical stimulation of the
ipsilateral tibial nerve (A fibre strength) were recorded
and an optimal distance from the mid-line was chosen
(on the basis of these recordings) for the subsequent in¬
troduction of microprobes. The threshold stimulus for
production of field potentials using pulses 0.3 ms
duration were determined at this time. A typical proto¬
col consisted of 3-4 pairs of microprobes remaining in
the spinal cord for 15-30 min in the absence of any sti¬
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Fig. 1. Comparisons of the levels of immunoreactive neurokinins in the dorsal horn before, during and at various times after peripheral nerve stimula¬
tion. The mean image analyses ( + S.E.M.) of 5 groups of microprobes bearing antibodies to neurokinins are shown. All microprobes were inserted
in the spinal cord to a depth of 3 mm, for a duration of 30 min. A, B, and C (upper panels): in each section a graph described as stimulus is the
mean image analysis of microprobes (n= 11) inserted in the spinal cord whilst the ipsilateral tibial nerve was stimulated at an intensity sufficient
to excite C-fibres (continuous tetanus of 0.3 ms pulses, at 10 Hz, x 100 threshold). In each of the upper panels this graph is compared with another
described as: A: controls. Microprobes inserted into the cord immediately prior to any nerve stimulation (n= 18). B: first recovery. Microprobes
inserted into the cord immediately after cessation of nerve stimulation (« = 7). C: second recovery. Microprobes inserted into the cord for the period
31-60 min after cessation of nerve stimulation («= 11). D: third recovery. Microprobes inserted into the cord for the period 61-90 min after cessation
of nerve stimulation (n = 12). A, B. C and D (lower panels): plots of the T values (IT= P< 0.05) derived from the differences between the two graphs
of each upper panel.
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electrical nerve stimulation (2 pairs of microprobes). A
further 4 pairs ofmicroprobes were then introduced over
the next 2 h, each remaining 15-30 min in the spinal
cord. After an interval of 1-2 h, this sequence was
repeated on the other side of the spinal cord whilst sti¬
mulating the opposite tibial nerve. The electrical stimu¬
lus was a continuous tetanus (10 Hz) of 0.3 ms pulses,
the stimulus strength being x 100 threshold for produc¬
tion of a spinal cord field potential.
As previously described [5, 7], after withdrawal from
the spinal cord, microprobes were washed and incubated
in i25I-NKA. Autoradiographic images of the micro¬
probes were then obtained by placing their tips on
monoemulsion X-ray film (Kodak, NMC) [5]. These im¬
ages were analysed using the method of Hendry et al. [8]
using a computerized image analysis system to measure
optical density in 10 //m steps along the length of each
autoradiographic image. For clarity, in the illustration
of this paper the means of 3 successive sites (30 ^m) are
shown.
The experiments employed 94 microprobes inserted
into the spinal cord. In addition, in each experiment 4-6
microprobes were also used for concurrent in vitro tests
ofmicroprobe sensitivity.
As found previously ["/], microprobes inserted into the
spinal cord in the absence of any peripheral stimulus,
and prior to any noxious stimulus, showed a widespread
basal inhibition of binding of 125I-NKA when compared
with in vitro microprobes, not exposed to NKA, but
simply incubated in the labelled peptide.
The basal levels of ir NK were increased by electrical
stimulation of A and C fibres of the ipsilateral tibial
nerve. This effect is shown for microprobes remaining in
the spinal cord for 30 min in Fig. 1 A.
As observed previously [7] this increase in ir NK oc¬
curred relatively diffusely over the upper dorsal horn
including the dorsal columns. Within the first 30 min af¬
ter cessation of nerve stimulation the levels of ir NK
detected in the dorsal horn did not significantly decline
(Fig. 1B). Indeed in the deep dorsal horn the mean image
analysis of microprobes in this first recovery period is
displaced above that of microprobes present during the
stimulus, suggesting diffusion away from the sites of re¬
lease, but these differences are not significant. In the pe¬
riod 31-60 min after nerve stimulation (second recovery)
the mean image analysis of microprobes (Fig. 1C) is
uniformly below that of those within the spinal cord dur¬
ing nerve stimulation, but the differences attain signifi¬
cance only in limited areas. At 61-90 min after nerve sti¬
mulation (third recovery) however (Fig. ID) recovery is
virtually complete, as shown by the plot of the signifi¬
cance of differences between these microprobes and
those in the spinal cord during nerve stimulation (Fig.
ID, lower panel).
The present experiments have shown ir NK released
by peripheral nerve stimulation persists in the dorsal
horn in elevated amounts for at least an hour beyond the
cessation of the stimulus. This persistence probably ac¬
counts for the diffuse presence of ir NK detected by mic¬
roprobes when compared with the localized presence of
substance P [6] calcitonin gene-related peptide [13] and
somatostatin [14] in the region of the substantia gelati-
nosa.
Neuropeptides appear to be degraded mainly by
enzymes but there are often difficulties in determining
which enzymes are responsible for the major part of
degradation of a particular peptide under physiological
conditions and whether these enzymes are located adja¬
cent to sites of release. Whilst a number of enzymes de¬
grade SP [1, 16], of these only endopeptidase 24.11 signi¬
ficantly degrades NKA, and at a slower rate [10, 18],
Thus there are reasonable biochemical grounds to sup¬
port the conclusion of the present experiments that neur¬
okinins, particularly NKA, may be slowly degraded
when released in the spinal cord.
Although some reviews have drawn attention to the
failure of peptidases to be located adjacent to presumed
sites of release of neuropeptides [1, 12], there is little in¬
formation on this question when considering tachykinins
in the spinal cord. In an autoradiographic study of the
distribution of endopeptidase 24:11, relatively high levels
of this enzyme were found in the substantia gelatinosa
of the spinal cord, but there were much higher levels in
the overlying pia and dura in both the rat and man [21].
It was suggested that meningeal enzymes protect the
brain and spinal cord from neuropeptides in the cerebro¬
spinal fluid (CSP) but the present studies suggest the re¬
verse: meningeal enzymes may prevent the escape of spi-
nally released neuropeptides into the subdural space.
In the present study the immunoreactivity detected by
microprobes cannot be identified in exact molecular
terms but is most likely neurokinin A or neuropeptide K.
A contribution by neurokinin B cannot be excluded.
Although this latter compound is not present in signifi¬
cant amounts in dorsal roots [17] it is within neurones
of the upper dorsal horn which could have been acti¬
vated by the stimuli used the present experiments. Dif¬
ferentiation between these compounds requires the use
of antibodies directed at non-homologous regions of
these peptides.
The persistence and diffusion of ir NK suggests a role
different from that of a transmitter conveying informa¬
tion about the onset, location and duration of a peri¬
pheral noxious stimulus. As cited previously, however,
several laboratories have found prolonged hyperexcita-
bility of some spinal neurones following a brief input
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from nociceptors [2, 3, 9, 11, 15, 19, 20] and neurokinins
warrant consideration as being involved in these
changes.
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Sustained isometric contraction of skeletal muscle results in release of
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Antibody microprobes were used to study release of immunoreactive neurokinins in the dorsal horn of the anaesthetized spinal cat following
sustained isometric contraction of ipsilateral hindlimb muscles. Microprobes had immobilized antibodies to neurokinin A (NKA) on their outer
surfaces and bound a proportion of released molecules when inserted in the central nervous system. Bound molecules were detected in autoradio-
graphs as zones of reduced binding of 125I-NKA in which microprobes were incubated after withdrawal from the spinal cord. The left hindlimb
was immobilized using an epoxy bandage splint and isometric contraction of muscles induced by intermittent tetanic stimulation of a ventral root.
A basal presence of immunoreactive neurokinins was detected and this was increased by sustained isometric muscle contraction. It is probable that
ergoreceptors contain and release neurokinins.
A variety of spinal processes are activated by an input
from skeletal muscle afferents. In addition to the fast
transmission from Group I and II afferents to motoneu-
rones and cells of origin of ascending tracts, there is evi¬
dence for longer lasting events. Thus electrical stimula¬
tion of small diameter myelinated and unmyelinated
afferents of the nerve to the gastrocnemius-soleus muscle
of the rat has been shown to produce long lasting facili¬
tation of a flexor reflex elicited by intermittent stimula¬
tion of the sural nerve [14], In addition, isometric con¬
traction of skeletal muscle is associated with circulatory
and respiratory changes believed to be important in exer¬
cise [2, 11, 12]. These latter changes are dependent on im¬
pulses in muscle afferents, since they are abolished by
section of the dorsal roots containing afferents from the
muscle being stimulated. Experiments using anodal
block of impulse propagation in large fibres and also lo¬
cal anaesthetic injections into dorsal roots suggested that
small diameter afferents were important [12]. The rele¬
vant afferents which are activated by muscle stretch,
pressure or metabolites have been termed ergoreceptors
and they include both small myelinated and unmyeli¬
nated fibres. Ergoreceptors have been differentiated
Correspondence: A.W. Duggan, Department of Preclinical Veterinary
Sciences, University of Edinburgh, R.(D.)S.V.S.. Summerhall, Edin¬
burgh EH9 1QH, U.K.
from nociceptors, although a small proportion of the lat¬
ter can fire with muscle contraction under ischaemic con¬
ditions [10].
Our interest in this area derives from experiments
using antibody microprobes to localize sites of release of
tachykinins within the spinal cord following either elec¬
trical stimulation of peripheral nerves or natural stimuli
applied to skin or joints [5, 6, 8]. Both immunoreactive
substance P (irSP) and ir neurokinin A (irNKA) were
released in the spinal cord by electrical stimulation of
unmyelinated primary afferents. When using natural sti¬
muli however it appeared that spinal release of irSP was
best seen with damaging stimuli to the skin or when
inflammation was well developed in a joint. Release of
irNKA was observed with noxious but not necessarily
damaging skin stimuli and immediately when a joint was
injected with kaolin and carrageenan. In addition ir
NKA persisted in the spinal cord for in excess of 30 min
after a period of adequate stimulation [8].
It is of importance to determine if activation of ergore¬
ceptors results in a spinal release of tachykinins. Since
previous results indicated that irNKA rather than irSP
was better associated with subdamaging stimuli, the pre¬
sent experiments have studied the spinal release of
irNKA during sustained isometric contraction of hind¬
limb muscles of barbiturate-anaesthetized cats.
Experiments were performed on 6 cats anaesthetized
with pentobarbitone (35 mg/kg, i.p., initially and main-
0304-3940/91/$ 03.50 © 1991 Elsevier Scientific Publishers Ireland Ltd.
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tained with an intravenous infusion of 3-6 mg/kg/h).
Arterial blood pressure and end tidal C02 levels were
monitored continuously. All animals were artificially
ventilated with air. The spinal cord was exposed by re¬
moval of the lumbar laminae. The dura was opened with
sterile scissors and then covered with sterile agar. The
agar was removed locally at proposed sites of micro-
probe penetration and within the exposed areas, small
areas of pia-arachnoid were removed with sterile fine
forceps for microprobe entry. These exposed areas were
irrigated continuously with a sterile Ringer solution
which was removed by suction. The fine polyethylene
tubing delivering and removing the perfusate had also
been sterilized. It is important to prevent contamination
and infection of the spinal cord in experiments which
measure the release of neuropeptides since the latter are
contained in inflammatory exudates. The animal also
received two injections of an ampicillin suspension, each
of 25 mg/kg.
Sustained isometric contraction of lower leg muscles
can be achieved by immobilizing the limb with pins driv¬
en through the joints and stimulating the appropriate
nerves electrically [12]. For the present experiments it
was felt that limb immobilization produced surgically
could result in a large release of irNKA which might ob¬
scure any possible release evoked by sustained muscle
contraction. Surgery to the hindlimb was therefore
avoided by immobilizing the knee joint (leg extended)
and ankle joint (held at approximately 90°) in an epoxy
bandage splint (Vetcast 3M). A clamp then immobilized
the bandage splint. Prior to covering the spinal cord with
agar, the L6, L7 and Si ventral roots were exposed and
sectioned close to their junction with the spinal cord.
The ventral root giving a consistent maintained rise in
blood pressure (see Fig. 1) when stimulated at 4 x thres¬
hold to elicit a muscle twitch (just visible above the prox¬
imal edge of the epoxy bandage) was used for subse¬
quent test stimuli. Stimulus pulses were 0.1 ms in
duration and a continuous tetanus was induced with
repetitive stimulation of the central root at 40 Hz for 1
min and repeated at 5 min intervals while microprobes
were in the spinal cord for 30 min (Fig. 1). Antibodies
to NKA were immobilized to glass micropipettes
through coating the latter successively with a polymer
derived from aminopropyltriethoxysilane, glutaralde-
hyde, protein A and finally, antibodies [4], The latter
were derived from antisera purchased from Peninsula
Labs, and Milab. Both had complete cross-reactivity
with neuropeptide K, an N-terminal extended form of
neurokinin A, 70-80% cross reactivity with neurokinin
B but negligible cross-reactivity with substance P. For
the purposes of the present experiments microprobes are
described as detecting immunoreactive neurokinins
(irNK). Prior to use in the spinal cord, the tips of micro¬
probes were broken back to 5-10 /<m in diameter and all
were filled with a 1 % (w/v) solution of Pontamine sky
blue in 0.2 M sodium acetate. This enabled extracellular
recordings to be obtained with microprobes as well as
dye to be deposited from their tips for subsequent histo¬
logical examination. All of the sites chosen for micro-
probe penetration were in the same spinal segment as
that of the ventral root stimulated to produce isometric
muscle contraction. Microprobes were introduced inde¬
pendently, two at a time, using stepping-motor micro¬
manipulators.
After withdrawal from the spinal cord, microprobes
were washed for 15 min in cold PBS Tween and then
incubated in 125I-NKA for 24 h at 4°C. The concentra¬
tion of labelled peptides for these incubations was 1.0
/<Ci/ml. After this incubation, microprobes were washed
for 15 min in cold PBS Tween with suction applied to
each microprobe to remove any contained labelled neu¬
ropeptide. The tips were then broken off and fixed to a
sheet of paper and placed in a cassette with a sheet of
monoemulsion X-ray film (Kodak NMC). The images of
microprobes were analysed using the method of Hendry
et al. [7], Simply, this estimated optical density in 10 /(m
squares on a grey scale of 0-255. Transverse integrations
were performed across each microprobe image to give a
plot of optical density against length along a microprobe
and hence of depth within the spinal cord. A search pro¬
gram subsequently computed a mean image analysis for
defined groups of microprobes together with the stand¬
ard errors ofmeans. The method treats sites in the spinal
cord progressively 10 /zm from the dorsal surface, as in¬
dependent. For clarity in the illustrations of this paper
the means of 3 successive sites are shown.
Results were obtained using 79 microprobes. In addi¬
tion in each experiment 4 to 6 microprobes were used for
in vitro sensitivity tests. These showed that incubation in
a solution containing 10~8 M NKA for 30 min at 37°C
significantly reduced the binding of l25I-NKA. Stimula¬
tion of a ventral root produced rises in systolic blood
pressure of 20-40 mmHg as shown in Fig. IB. This
figure also shows that the effect was repeatable within
the period (usually 30 min) microprobes were in the spi¬
nal cord. In the experiment illustrated the dorsal roots
of segments L5 to S2 inclusive were subsequently sec¬
tioned and ventral root stimulation then failed to elicit
a pressor response.
Previous experiments with microprobes bearing anti¬
bodies to NKA have found a remarkable persistence of
irNKA beyond the duration of an effective peripheral
noxious cutaneous stimulus [6, 8]. Thus when examining
microprobes inserted into the spinal cord without any
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Fig. 1. Isometric muscle contraction and spinal release of irNK. A:
Upper records. Mean image analyses of microprobes inserted for 30
minutes into the spinal cord in the absence of any stimulus and prior
to periods of isometric muscle contraction («= 15) and those inserted
for the same time but during isometric muscle contraction (n = 24). The
image analysis was performed in 30 pm steps. At each step the stan¬
dard error of the mean image density is plotted below the mean for
controls and above the mean for isometric muscle contraction. Lower
record. A plot of the /-values for the differences between means in the
upper records. B: an example of the rises in arterial blood pressure
associated with the isometric muscle contraction following ventral root
stimulation. Ordinate: mmHg.
ate between those inserted prior to any active stimulus
and those inserted after a period of stimulation. Figure
1A illustrates the mean image analyses of control micro-
probes inserted for 30 minutes prior to ventral root sti¬
mulation («= 15) and, those inserted for the same time
during ventral root stimulation (77 = 24, Fig. IB).
Ventral root stimulation increased levels of irNK sig¬
nificantly in the superficial dorsal horn and adjacent dor¬
sal columns, as shown by the plot of /-values for the dif¬
ferences between the two mean image analyses. As in
previous experiments the effective stimulus resulted in
detection of irNK over a relatively broad area. The mean
image analysis of 32 microprobes inserted 0-30 min after
a period of ventral root stimulation showed persistence
of increased levels relative to microprobes inserted prior
to the stimulus. This persistence has also been observed
with cutaneous stimuli and peripheral nerve stimulation.
In the one experiment in which the dorsal roots were
sectioned, this procedure produced a large release of
irNK in the spinal cord.
The present experiments have shown spinal release of
irNK following impulses in muscle afiferents activated by
isometric contraction. Although it is not possible to
exclude the firing of some nociceptors under those condi¬
tions [10], it is probable that activity in ergoreceptors
was responsible for the release of irNK. It is improbable
that cutaneous nociceptors produced the observed re¬
lease of irNK since the epoxy bandage immobilizing the
limb was broadly applied and the fur of the cat acts as
a natural padding. As in previous experiments, irNK
was detected over a relatively broad area and extended
into the dorsal columns [6, 8]. It has been previously pro¬
posed that this broad distribution resulted from a slow
degradation of released molecules [6],
Small-diameter afferents from hindlimb muscles pro¬
ject mainly to the lamina I of the spinal cord [3] and re¬
lease at this superficial site is probably responsible for
the prominence of the diffusion of irNK into the dorsal
columns. This location also favours the contention that
release occurred mainly from the central terminals of
primary afiferents although the contribution from intrin¬
sic spinal neurones cannot be assessed in experiments of
this type.
Spinal release of a neurokinin may be a factor in the
blood pressor response to isometric muscle contraction
but previous experiments [6, 8] suggest that ir neuroki¬
nins persist beyond the duration of the blood pressor re¬
sponse as induced in the present experiments. Intrathecal
administration of the tachykinin antagonist [n>-Pro2,D-
Phe7,D-Tryp9]-SP has attenuated the pressor response to
isometric muscle contraction [9] but this compound does
not readily differentiate between NK1 and NK2 recep¬
tors and hence between the actions of substance P and
NKA [1],
The interest of the present experiments is that ir neu¬
rokinins can be released centrally from a fibre type other
than nociceptors. Thus these fibres need consideration as
being involved in the prolonged increases in some spinal
reflexes following electrical stimulation of small dia¬
meter muscle afferents [14],
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Noxious mechanical stimulation of the hind paws of the anaesthetized rat
fails to elicit release of immunoreactive /^-endorphin in the periaqueductal
grey matter
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As a test of the hypothesis that an animal responds to a severe peripheral painful stimulus by a central release of //-endorphin, antibody micro-
probes were inserted stereotactically into the midbrain of urethane anesthetized rats. These microprobes bore antibodies to //-endorphin immobilized
to their outer surfaces. While microprobes were in the brain for periods of 10 to 30 min either no stimulus was delivered or alligator clamps were
applied to both hind paws. Microprobes were then incubated with l25I-//-endorphin. Quantitative image analysis of microprobe autoradiographs
showed no differences between the no-stimulus and noxious-stimulus groups. Thus these experiments found no evidence for //-endorphin release
following a severe peripheral painful stimulus.
Acute noxious foot shock to rats produces a naloxone
reversible analgesia [14, 15] and elevated circulating lev¬
els of immunoreactive (ir) /(-endorphin [10, 17]. Elevated
levels of circulating /(-endorphin however, do not appear
to produce analgesia [17] and a central release of opioids
including /(-endorphin has been proposed as responsible
for opioid analgesia produced by a variety of procedures.
The sites where such release could occur are many in¬
cluding areas within the brain but also in the superficial
dorsal horn of the spinal cord from activity in descending
fibres [19],
The opioid /(-endorphin has a relatively restricted dis¬
tribution within the brain. The cell bodies synthesizing
/(-endorphin are found predominantly in the hypotha¬
lamic arcuate nuclei [12] and the axons arborize mainly
in the hypothalamus, midbrain and medulla. Prominent
among these are fibres coursing through and terminating
in the periaqueductal gray matter (PAG). These PAG-
terminating fibres have been implicated in mechanisms
of analgesia. Thus electrical stimulation in the ventral
PAG of the rat produces naloxone reversible analgesia
Correspondence: A.W. Duggan, Department of Preclinical Veterinary
Sciences, University of Edinburgh. Summerhall, Edinburgh EH9 1QH,
UK.
[1, 14]. The site of release of an opioid peptide produced
by such stimulation is not known with certainty but Herz
and Millan [10] have suggested that the resultant analge¬
sia derives from a release of /(-endorphin within the PAG
from direct stimulation of nerve terminals adjacent to the
stimulating electrodes.
One recent study [7] measured /(-endorphin levels in
the PAG of rats following subcutaneous injection of for¬
malin into the forepaws and found elevated amounts at
60 and 120 minutes post injection. Elevated levels of any
compound in an area of the brain when measured by
homogenization and extraction probably mainly repre¬
sents that present within neurones. Thus elevated levels
could equally result from a phase of inhibition of release
just prior to extraction or from increased synthesis fol¬
lowing a previous period of release. Difficulties have
arisen from measuring /(-endorphin in cerebrospinal
fluid (CSF). Early reports found that electrical stimula¬
tion in the region of the periaqueductal grey matter of
humans, adequate to produce pain relief, was associated
with elevated levels of /(-endorphin in CSF. A subse¬
quent study however found that the contrast media used
as aids to ventricular cannulation interfered with the
radioimmunoassay for /(-endorphin and that increased
levels could not be linked to pain relief [2], Another pro¬
cedure used for pain relief, transcutaneous vibratory
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stimulation, has been recently shown not to produce
changes in CSF levels of /^-endorphin [8]. These difficul¬
ties associated with indirect measures of release indicate
the need for a more direct approach.
Although many of the experiments cited have used
electrical stimulation, and this is relevant to clinical prac¬
tice. the present experiments have examined a question
fundamental to an understanding of the physiology of
/1-endorphin: does a severe peripheral noxious stimulus
evoke release of /(-endorphin in the region of the
periaqueductal grey?
This has been studied in anaesthetised rats by using
antibody microprobes inserted through the cerebral cor¬
tex into the PAG and delivering a severe noxious me¬
chanical stimulus to the hind paws. Although these ex¬
periments have had to be conducted with the constraint
of anaesthesia, ethical considerations prevent the con¬
duct of release experiments in conscious animals by any
method when repeated noxious stimuli are used.
Experiments were performed on 6 rats anaesthetised
with intraperitoneal urethane (1.5 g/kg initially and sup¬
plemented when necessary). The trachea was cannulated
and blood pressure measured with a cannula in a femoral
artery. Animals were mounted in a stereotaxic head
frame after 2% lidocaine had been sprayed into the ears,
and bilateral bone flaps were removed over the sites of
proposed microprobe entry. The dura mater was re¬
moved at these sites. The exposed areas of cerebral cor¬
tex were intermittently irrigated with warm Ringer's so¬
lution. When microprobes had been introduced, small
pieces of plastic film were placed over the adjacent cere¬
bral cortex to minimize drying. A controlled electric
blanket was used to maintain body temperature in the
range 36-38°C. The area chosen for penetration of the
PAG was A.P. +2.2 mm using the stereotaxic atlas of
Paxinos and Watson.
Microprobes were prepared by immobilizing antibod¬
ies to /(-endorphin to the outer surfaces of glass
micropipettes [4], Briefly the micropipettes were coated
successively with: a polymer derived from gamma amino
propyltriethoxysilane, glutaraldehyde, protein A and fi¬
nally antibodies. In vitro tests showed that incubation of
microprobes in /(-endorphin, 10-8 M, for 30 minutes at
37°C resulted in near complete suppression of the bind¬
ing of l25I-/(-endorphin (Amersham). With such sensitiv¬
ity microprobes are estimated to detect 10"17 mol of li-
gand bound over 100 //m of length [3] and this is one
order ofmagnitude better than that of microprobes used
to detect release of substance P [5].
Microprobes were inserted into the brain two at a time
using stepping motor microdrives. In 5 experiments the
microprobes were inserted 7 mm from the brain surface
at approximately the same anterior-posterior level, but
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Fig. 1. A: the mean image scan of 38 microprobes inserted 7 mm into
the brain along the track indicated in B, and no peripheral stimulus was
applied, is plotted together with the mean scan of 31 microprobes pres¬
ent in the brain while a severe noxious mechanical stimulus was applied
to both hind paws. The image analysis was performed at 30 //m inter¬
vals and for both groups a line has joined the mean density obtained at
each point. For the no stimulus group the +S.E.M. has been plotted at
each analysis point and the -S.E.M. plotted for the noxious stimulus
group. Ordinate— Grey scale: integrals obtained by transverse integra¬
tion of optical density of microprobe images in 30 /tm intervals. Ab¬
scissa — Depth within the brain of analysis points. B: The ^-statistics
derived from the differences ofmean density (grey scale) at each analy¬
sis point for the no stimulus and the noxious stimulus groups have been
plotted along the line of introduction of microprobes into the midbrain.
As the r-values are all less than 2, the observed differences are not
significant at the P< 0.05 level.
from opposite sides, at an angle of 15° to the vertical.
Such a track is illustrated in Fig. 1. In one experiment
microprobes were introduced 10 mm into the brain. Mi¬
croprobes remained in the brain for periods of 10 to 30
minutes, and either no peripheral stimulus was applied,
or alligator clamps were applied to all of the digits of
both hind paws and to the central pads with a sequence
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of 3 min on, 2 min off. This stimulus was experienced as
very painful by the experimenters when applied to the
fingers. Approximately twenty microprobes were in¬
serted into the brain in each experiment and animals
were killed by an intravenous injection of pentobar¬
bitone sodium.
Following removal from the brain, microprobes were
first washed in cold phosphate buffered saline (PBS) and
then inserted into a solution of l25I-/?-endorphin in PBS
containing bovine serum albumin 2%. After 24 h incuba¬
tion at 60°C, microprobes were again washed and the
tips were then carefully broken off and glued to a sheet of
paper and placed in an X-ray film cassette with a sheet of
monoemulsion film (Kodak NMC). Exposures varied
from 3 to 10 days.
Autoradiographs of microprobes were scanned with
an image analysis system using an Imaging Technology
PC Visionplus frame grabber board operating within an
AT based computer [6, 9], This performed microden-
sitometric estimates ofmicroprobe images and compiled
integrals derived by transverse integrations across each
microprobc in 30 jum intervals. These integrals were
stored on hard disc and a sorting program subsequently
selected microprobes meeting designated criteria and
plotted the mean integrals (± S.E.M.) for each group, in
30 //m intervals, and determined the significance of dif¬
ferences between defined groups of microprobes at each
interval (see Fig. 1).
Fig. 1A illustrates the mean image analysis of 38 mi¬
croprobes inserted 7 mm into the midbrain in the ab¬
sence of any active peripheral stimulus and that of 31
microprobes present in the same area during noxious
pinching of the skin. The two group analyses are virtu¬
ally identical at all sites in the brain examined including
the PAG. This is further shown in Fig. 1B which plots the
statistics derived from the means of these two analyses in
30 jum intervals and these are placed along a microprobc
track. This shows that at each site sampled, noxious
stimulation of the hind limbs failed to produce elevated
levels of ir-/?-endorphin and hence failed to release this
neuropeptide. In one experiment microprobes were in¬
serted 10 mm into the midbrain and hence the areas con¬
tacted at points along such microprobes differed from
those inserted 7 mm, preventing addition of these results.
In this experiment the mean image analysis of 12 micro¬
probes inserted in the absence of stimulation, showed no
significant differences from that of 14 microprobes in¬
serted while alligator clips were applied bilaterally to the
hind paws.
The mechanical stimulus used in the present experi¬
ment was more severe than that which produces a release
of ir substance P in the spinal cord of the anaesthetised
cat [5] and rat (Hope and Lang, unpublished) and yet
failed to produce a detectable release of ir-/?-endorphin in
the PAG. Anaesthesia may have reduced the responses
of /^-endorphin releasing neurones but many naloxone
sensitive events have been described in anaesthetised ani¬
mals [11, 13, 18]. The results do not favour the response
of an animal to a severe painful peripheral stimulus [16]
being mediated in part by a release of/^-endorphin within
the PAG.
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Abstract
Experiments were performed in barbiturate-anaesthetized, spinalized cats to investigate the effect of
calcitonin gene-related peptide (CGRP) on the spatial distribution of immunoreactive substance P (ir-SP) in
the spinal cord released by electrical nerve stimulation and noxious mechanical stimuli. The presence of ir-
SP was assessed with microprobes bearing C-terminus-directed antibodies to SP. CGRP was microinjected
into the grey matter of the spinal cord near microprobe insertion sites at depths of 2500, 2000, 1500 and
1000 jam using minute amounts (in total 0.2- 0.5 p\) of Ringer solution containing CGRP at a concentration of
10~5 or 10~3 M. In the untreated cord electrical stimulation of the tibial nerve (suprathreshold for all C fibres)
elicited release of ir-SP which was centred in and around the lamina II. After microinjection of CGRP,
stimulation-associated ir-SP was detected in a region extending from the cord surface down to the ventral
horn. This pattern was similar to that observed after the microinjection of synthetic peptidase inhibitors
(Duggan et al., Brain Res., 579, 261 -269, 1992). The large expansion of sites accessed by ir-SP was time-
dependent, reaching a maximal effect within 10-40 min after microinjection of CGRP, and reversal was
observed in subsequent probes. A similar expansion of the regions accessed by ir-SP after microinjection of
CGRP was also observed when release of ir-SP was evoked by noxious mechanical stimulation of the toes.
These results indicate that one important function of CGRP in the spinal cord may be the control of the
intraspinal sites and neuronal circuits accessed by released substance P, possibly by inhibition of
endopeptidases responsible for peptide degradation.
Introduction
Recently we have shown in the cat that inhibition of peptidases in the
spinal cord by synthetic peptidase inhibitors causes substance P (SP),
which is normally focally released in the superficial dorsal horn by
electrical nerve stimulation and noxious mechanical stimulation of the
foot, to spread widely away from sites of release (Duggan et al. 1992).
This was demonstrated by using antibody-bearing microprobes which
allow a spatial analysis of the distribution of a neuropeptide within
the spinal cord (Duggan et al., 1988a; Hendry et al., 1988). In the
untreated spinal cord the release of immunoreactive SP (ir-SP) evoked
by electrical nerve stimulation is mainly centred in and around the
substantia gelatinosa, which is the major projection site of afferent fibres
containing SP (Duggan et al., 1988b). After the microinjection of
synthetic endopeptidase inhibitors, ir-SP was detected in an area which
extended from the surface of the cord down to the ventral horn, at
the time of the maximal peptidase inhibitor effect (Duggan et al., 1992).
These results imply that the access of tachykinin receptor sites by the
ligand SP may be controlled dynamically by the activity level of
endopeptidases. They support experimentally the proposal that peptides,
after release, may diffuse to reach receptors in remote areas (Agnati
et al., 1986; Fuxe and Agnati, 1991).
Although protecting a synaptically released compound from
degradation is usually considered in terms of enhancing and prolonging
the event occurring at the releasing synapse, our experiments with
peptidase inhibitors suggest that access to remote areas is an important
physiological consequence of inhibition of degradation for compounds
released in the central nervous system. Whereas the synthetic peptidase
inhibitors allowed the demonstration of spreading following synaptic
release in principle, a more important task is to identify endogenous
compounds which influence the effect of endopeptidases and thus could
act as determinants of the sites accessed by a neuropeptide. It was
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suggested by Le Greves etal. (1985) that calcitonin gene-related peptide
(CGRP) may act as a physiological peptidase inhibitor. CGRP is
contained in a proportion of somatic and visceral afferent fibres , with
significant CGRP immunoreactivity in laminae I, II and V of the spinal
cord, and a significant depletion of ir-CGRP in these laminae occurs
after dorsal rhizotomy (Rosenfeld et al., 1983; Gibson et at., 1984;
Wiesenfeld-Hallin et at., 1984; Lee et at., 1985; Skofitsch and
Jacobowitz, 1985; Franco-Cereceda et at., 1987; Ju et at., 1987;
Cameron et at., 1988; Carlton et at., 1988; Chung et at., 1988;
Harmann et at., 1988; McNeill et at., 1988; Mulderry et at., 1988;
Kruger etal., 1989; Sharkey etal., 1989; Nahin et at., 1991). CGRP
is often colocalized with SP in unmyelinated afferent neurons (Gibson
etal., 1984; Wiesenfeld-Hallin et at., 1984; Gibbins et at., 1985; Lee
etal., 1985; Matsuyama etal., 1986). CGRP has been shown to cause
a small depolarization of spinal cord neurons (Miletic and Tan, 1988;
Ryu et at., 1988). When applied topically to the spinal cord, however,
CGRP has prolonged the facilitation of a flexor reflex of the rat by
SP (Wiesenfeld-Hallin et al., 1984; Woolf and Wiesenfeld-Hallin,
1986). One possible mechanism of interaction could be by prolonging
the life of substance P by control of endopeptidase activity. On the
basis of our recent findings with the synthetic peptidase inhibitors we
examined in the present experiments whether microinjection of CGRP
into the spinal cord would mimic the effect of synthetic peptidase
inhibitors, i.e. lead to an expansion of the intraspinal area which is
accessed by SP focally released in the superficial dorsal horn. The
occurrence of such an action has important implications for the receptors
accessed by, and hence the function of, SP in the spinal cord.
Materials and methods
Microprobe preparation
Conventional glass micropipettes were used to prepare microprobes
as recently described (Duggan et al.. 1988a). Micropipettes, heat-sealed
at both ends, were incubated in a 10% solution of
aminopropyltriethoxysilane in toluene. Subsequent heat curing produced
a siloxane polymer on the outer surface. Using glutaraldehyde, protein
A was immobilized to the siloxane polymer in order to bind antibodies
to SP during incubation of the micropipettes in a SP antiserum. We
used a polyclonal antiserum which was directed against the C-terminus.
The manufacturer (Peninsula) indicated for this antibody significant
cross-reactivity with SP 3-11, little for SP 4-11 and no cross-reactivity
for neurokinin A, neurokinin B and neuropeptide K. In in vitro tests
(Bolton-Hunter) [l25I]SP was bound to the probes and —50%
suppression of the binding of radioactive SP was achieved by
preincubation in a 10~7 M SP solution for 30 min at 37°C. The
binding was not suppressed by preincubation in Ringer solution
containing CGRP up to a concentration of 10~3 M.
Animal preparation
Anaesthetized, spinalized cats were used to perform the experiments.
The anaesthesia was started by 35 mg/kg sodium pentobarbitone i.p.
and, after cannulation of a cephalic vein, maintained by continuous
infusion at 3.0 ntg/kg/h. Blood pressure was measured using a cannula
in a carotid artery. A tracheotomy was made for artificial respiration,
which was started after the dissection following neuromuscular paralysis
with gallamine, 4 mg/kg/h. End-tidal CO, levels and body
temperature were monitored throughout the experiment. The animals
were kept at 36—38°C by a controlled heating pad.
A laminectomy exposed the caudal lumbar segments. The cord was
transected at the thoracolumbar junction following injection of 0.1 ml
of 2 % lignocaine. The cats were fixed in a metal frame. After cutting
the dura a layer of agar in Ringer was placed over the dorsal surface
of the spinal cord. At the insertion sites of the probes the agar was
removed and the pia-arachnoid was opened with sterile fine forceps.
These exposed areas were continuously irrigated with sterile Ringer
solution maintained at 38°C by a heat exchanger around the tubing
interposed between the infusion pump and the spinal cord. For electrical
stimulation the tibial nerve of the left hindlimb was dissected after
incision of the skin and separating the two gastrocnemius muscles. A
small pool was formed with the skin flaps and filled with mineral oil,
and a stimulation electrode was placed under the nerve for en passant
stimulation.
Experimental protocol
Sites were selected for the study of release of SP which showed, in
extracellular recordings, strong afferent input from the electrical
stimulation of the tibial nerve and from pinching the ipsilateral paw.
Pairs of microprobes were introduced to a depth of 4 mm using two
stepping motor micromanipulators and kept in the cord for 10 min.
During these periods either no stimulus was applied, or electrical or
noxious mechanical stimulation was performed. With nerve stimulation,
electrical pulses of 0.5 ms duration and 50 V amplitude were applied
with a frequency of 20 Hz either for 10 min (in initial experiments)
or for 2 min. Since the stimulus threshold for the largest fibres was
100— 200 mV, this stimulation was considered supramaximal for all
afferent fibres. For noxious mechanical stimulation, five crocodile clips
were applied to the toes for 3 min, and this was repeated once within
the 10 min during which the microprobes were in the spinal cord. First
the left side of the cord and electrical nerve stimulation were used,
and then we switched to the right side of the cord and noxious
mechanical stimulation was employed.
After having inserted several probes in the control period, in periods
of no stimulation, electrical nerve stimulation or noxious mechanical
stimulation of the toes, CGRP was microinjected into the grey matter
using a micropipette connected to a syringe. Minute amounts (in total
0.2—0.5 /d) of Ringer solution containing CGRP at 10^5 or 10^3 M
were injected at depths of 2500, 2000, 1500 and 1000 ^m, around the
region where the microprobes were introduced. In some experiments
only Ringer solution was microinjected. Following the microinjections
further probes were inserted at defined intervals after injection (starting
5 min after the microinjections were finished) and the electrical or
mechanical stimuli were repeated.
At the end of the experiments pontamine sky blue was ejected at
depths of 1 and 4 mm from the dorsal surface of the cord. The cords
were removed, processed and cut for determination of the location of
the resultant dye spots. These data were used to relate the position of
the probes to the laminae of the grey matter.
Treatment of probes and data analysis
After removal from the spinal cord, the microprobes were washed for
15 min in cold phosphate-buffered saline (PBS) containing Tween
(0.1%) and then incubated for 24 h at 6°C in a PBS—azide solution
of [l25I]SP containing bovine serum albumin. The final dilution of the
radiolabelled peptide was —2000 dpm per p\. Following incubation
in labelled peptide the probes were washed for 15 min in Tween, and
the tips were broken off and placed in an X-ray cassette on a
monoemulsion film (Kodak NMC) for up to 7 days.
The resulting X-ray images were scanned at 10-/rm intervals using
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a CCD camera and an image analysis system employing an Imaging
Technology PC Vision Plus frame grabber board operating in a DCS
286e (AT-based) computer. This procedure produced an image of each
probe showing the grey density along 5 mm of the tip. Transverse
integrations were then performed along each analysed image to give
a plot of the total optical density (grey scale) with respect to length.
Although the image analysis system produced a plot with a longitudinal
resolution of 10 ^m, this was reduced to 30 /rm by calculating the
average of three successive integrals. This is more in line with the
biological resolution of the microprobe method (Duggan, 1991).
Inhibition of binding of radioactive SP on these probes (reduced grey
density) indicates previous binding of ir-SP in the cord. These sites
of deficits were then related to sites within the cord (see above). Groups
of probes were pooled and the means ±SEM were displayed in graphs
which showed the averaged grey densities along the probes in relation
to the depth within the cord. Comparisons were made between different
groups of probes using the Student's r-test at intervals of 30 /tin.
Results
Pattern of the intraspinal release of immunoreactive
substance P evoked by electrical nerve stimulation
Control conditions
In each experiment the first pair of probes was inserted into the spinal
cord prior to electrical nerve stimulation ('No stim.' probes), and the
subsequent two pairs of probes were introduced whilst the tibial nerve
was stimulated electrically ('Nerve stim. control' probes). All No stim.
and Nerve stim. probes were kept in the spinal cord for periods of
10 min and the intervals between the insertion of subsequent pairs of
probes were 10—15 min.
Prior to electrical stimulation there was no substantial release of ir-
SP. By contrast, significant release of ir-SP in the dorsal horn was
evoked by electrical stimulation of the tibial nerve in all cats. Figure
1A shows the averaged images of the No stim. probes (n = 19) and
of Nerve stim. control probes (n = 23). The image of the No stim.
probes shows a small zone of reduced binding of [l25I]SP at ~ 1 mm
from the dorsal surface which did not, however, differ significantly
from that of probes incubated in a solution of [l25I]SP without
previous exposure to the non-labelled neuropeptide. During the presence
of the Nerve stim. control probes in the cord the tibial nerve was
stimulated electrically for 2 min with pulses of 0.5 ms duration and
an amplitude of 50 V delivered at a frequency of 20 Hz. These probes
show an inhibition of binding [125I]SP from —0.5 mm to —2.0 mm
from the dorsal surface with a peak at 1 mm. This deficit of radioactive
binding is equated with previous binding to the probe of SP which was
released in the cord by nerve stimulation. The statistical analysis of
the differences between the No stim. and the Nerve stim. control curves
is displayed in Figure 2A (see below).
Microinjection of CGRP
After having examined the release of ir-SP under control conditions,
CGRP (10^5 M solution) was microinjected into the grey matter
around the insertion sites of the probes at depths of 2500, 2000, 1500
and 1000 ftm (four tracks). The total volume injected was 0.5 /d and
the injection procedure took — 10 min. At defined intervals after the
last microinjection, further pairs of probes were inserted and the tibial
nerve was stimulated electrically with the same parameters as in the
control period (for 2 min with pulses of 0.5 ms duration and an
amplitude of 50 V delivered at a frequency of 20 Hz). Again the
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Fig. 1. Pattern of the stimulus-evoked release of ir-SP in the untreated cord
(A) and after CGRP (10~5 M) microinjected at depths of 2500, 2000, 1500
and 1000 /mi (B and C). Each curve represents the averaged densitometric plot
of a sample of probes which have bound [1251]SP and produced
autoradiographic images. The lines are the connected mean values at 30-jun
intervals and the dots represent the standard errors at these intervals. Prior to
incubation in [125I]SP the probes were inserted 4 mm into the cord for periods
of 10 min either prior to nerve stimulation ('No stim.', n = 19) or during
electrical stimulation of the tibial nerve ('Nerve stim.' probes; stimulus duration
2 min, impulses of 50 V, 0.5 ms duration, delivered at a frequency of 20 Hz).
In all graphs 0 mm corresponds to the surface of the cord, 4 mm corresponds
approximately to the ventral border of the ventral horn, and 1 mm corresponds
approximately to lamina II. The slope of the No stim. probes reflects the shape
of the microprobes with an increasing diameter, and hence the number of binding
sites along the shaft. Inhibition of binding of [l25I]SP (reduced grey density)
is equated with previous binding of (unlabelled) endogenous ir-SP in the cord.
intervals between the introduction of pairs of probes were
—10- 15 min.
When CGRP was previously microinjected into the grey matter, the
microprobes present in the spinal cord during nerve stimulation showed
a different pattern of [l25I]SP binding. Figure IB shows the combined
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Fig. 2. Statistical analysis of the data shown in Figure 1 superimposed on schematic drawings of transverse sections of the spinal cord. The graphs show the
significance of the differences between the averaged images of the No stim. probes and the Nerve stim. probes (in A) and the significances of the differences
between the images of the No stim. probes and the 'Nerve stim. 5— 15 and 25-35 min post CGRP' probes (in B). The significances were calculated at 30
intervals and plotted along the probe. 21 corresponds to P < 0.05 and 4t to P < 0.01. The shaded areas indicate sites in the cord in which the stimulus curves
were significantly different from the non-stimulation baseline, with P < 0.05. The numerals correspond to the laminae of Rexed.
averaged images of two groups of probes. They were in the cord either
5 —15 or 25 —35 min after microinjection of CGRP. Compared to the
No stim. image the grey density on these probes (n = 12) was reduced
over a zone extending from the dorsal surface to —3.3 mm ventrally.
This pattern indicates previous binding of endogenous ir-SP to the
probes in a large area of the cord during peripheral nerve stimulation.
Probes in the cord 45 — 55 min after microinjection of CGRP (n = 5)
showed a considerable reversal of the effect of CGRP. The image of
the 'Nerve stim. 45—55 min post CGRP' probes (Fig. 1C) shows a
partial return to the image of the Nerve stim. probes displayed in Figure
1 A. There was a difference from the No stim. baseline only in an area
from 0.3 to 1.7 mm.
Figure 2 illustrates the changes in the area over which ir-SP was
detected following microinjection of CGRP in relation to spinal laminae.
Figure 2A is derived from the probes shown in Figure 1A (electrical
stimulation prior to CGRP) and Figure 2B was compiled from the
probes displayed in Figure IB (effect of CGRP on stimulus-evoked
ir-SP.) In both cases the statistics derived from the differences between
No stim. probes and Nerve stim. probes are plotted at 30-/im intervals.
The shaded areas in both graphs show the areas in which significance
of the differences was at least P < 0.05 (21). In the untreated cord
the area of significant stimulus-evoked ir-SP release was extended from
the white matter adjacent to the superficial dorsal horn to lamina V
with a peak in the region of lamina II (Fig. 2A). After microinjection
of CGRP the area of significant stimulus-associated ir-SP reached the
dorsal surface of the cord and even lamina VII (Fig. 2B).
Microinjection of CGRP versus Ringer solution
In further experiments the effect of microinjection of Ringer solution
was compared to that of microinjection of CGRP. After having tested
the release of ir-SP in the control period, Ringer solution was
microinjected using the same protocol as with CGRP and then pairs
of probes were inserted and the tibial nerve was stimulated electrically.
Finally, CGRP (10~3 M) was microinjected at the same site and the
stimulation was repeated using further pairs of probes for the detection
of ir-SP. In all of these experiments the tibial nerve was stimulated
with pulses of 50 V, 0.5 ms at a frequency of 20 Hz for periods of
10 min.
Whereas the microinjection of CGRP caused an expansion of the
area in which stimulus-evoked ir-SP was detected, the microinjection
of Ringer did not produce this effect. This is displayed in Figure 3A.
It shows the averaged images of No stim. probes (n = 19, the same
groups as in Fig. 1),'Nerve stim. post Ringer' probes (n = 14) and
'Nerve stim. 25 — 35 min post CGRP' probes (n = 13), all of which
were present in the cord for periods of 10 min. After the microinjection
of Ringer the pattern of stimulus-evoked ir-SP was similar (and
statistically not different) to that found when the cord was left untreated
prior to stimulation. The effect of CGRP was similar to that obtained
with a solution of 10~5 M (see Fig. 1). Figure 3B shows the statistical
differences between the Nerve stim. post Ringer and the Nerve stim.
post CGRP probes. Although levels of ir-SP were increased at the site
of maximal release (1 mm from the dorsal surface) following CGRP,
the greatest and most significant changes occurred both dorsally and
ventrally to this area.
Microinjection of CGRP versus peptidase inhibitors
In a previous study we examined the effect of microinjection of the
peptidase inhibitors kelatorphan and enalaprilat (inhibitors of
endopeptidase 3.4.24.11 and angiotensin-converting enzyme
respectively) on the pattern of ir-SP evoked by electrical stimulation
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Fig. 3. Effect of microinjection of Ringer and of CGRP (10 3 M) on the
pattern of stimulus-evoked ir-SP. (A) Averaged images of the 'No stim.' probes
0n = 19), 'Nerve stim. post Ringer' probes (n = 14) and 'Nerve stim.
25—35 min post CGRP' probes (n = 13). Electrical stimulation of the tibial
nerve for 10 min with pulses of 50 V, 0.5 ms duration, at a frequency of 20 Hz.
(B) Statistical analysis between the Nerve stim. 25 — 35 min post CGRP probes
and the Nerve stim. post Ringer probe shown in A. The same analysis was
used as in Figure 2.
of the tibial nerve (Duggan et at., 1992). Since the experimental
protocol in the previous and the present study was similar, the images
of microprobes sampled during comparable resting and stimulus
conditions can be related to each other. For this comparison the groups
of probes with the maximum effects of the compounds were chosen,
i.e. for peptidase inhibitors (ICG3 M) the probes present in the cord
35—45 min after microinjection, and for CGRP (10~3 M) the probes
inserted in the cord 25—35 min after application of CGRP. During
exposure of all probes the tibial nerve was stimulated electrically for
10 min. Figure 4 shows that the average image of probes present in
the cord after peptidase and after CGRP were very similar. Except
for a small area in the dorsal columns there was no statistically
significant difference between these groups of probes. This result
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Fig. 4. Effect of microinjection of CGRP and of the peptidase inhibitors
kelatorphan and enalaprilat on the stimulus-evoked release of ir-SP. The release
of ir-SP was evoked by electrical stimulation of the tibial nerve for 10 min with
pulses of 50 V, 0.5 ms pulse duration, at 20 Hz. The plots represent the averaged
images of probes present in the cord under the conditions indicated. For both
compounds the subgroup of probes was selected which showed the maximal
effect after the injection of the compound(s). For the 'Nerve stim. post CGRP'
group the number of probes was 13 and for the 'Nerve stim. post peptidase
inhibitors' group it was 15. The dots over the x-axis show the statistical analysis.
suggests that the effects of CGRP and synthetic peptidase inhibitors
on the pattern of stimulus-evoked ir-SP were similar, i.e. possibly
involving similar mechanisms.
Pattern of the intraspinal release of ir-SP evoked by noxious
mechanical stimulation
In another series of probes we examined whether CGRP also had an
effect on the release of ir-SP evoked by noxious pinch applied to
restricted areas, thus activating a smaller number of afferents than
electrical nerve stimulation. After having studied in the left side of
the lumbar cord the release of ir-SP evoked by electrical stimulation
of the tibial nerve, further probes were inserted into the right side of
the cord and noxious pinch was used as a stimulus. Five crocodile clips
were applied to the ipsilateral toes and the foot pad, twice for 3 min
in a 10-min test period. The experimental protocol was similar to that
used with electrical nerve stimulation.
Figure 5 shows the result of this series of experiments. In all graphs
the averaged image of Nox. pinch probes is related to the averaged
image of No stim. probes, i.e. the image of 21 probes which were
in the cord prior to any noxious mechanical stimulation. Figure 5A
shows the release of ir-SP during pinch whilst the cord was left untreated
(n = 46 probes). There was a small zone of release at about 1 mm.
Figure 5B, C shows the release of ir-SP following the microinjection
of CGRP (lO"3 M) at depths of 2500, 2000, 1500 and 1000 /un (total
volume —0.5 /d). Again there was an increase in the difference between
the Nox. pinch and the No stim. curves, and the zone of stimulus-
evoked ir-SP showed an expansion which developed with time after
the injection.
Discussion
These results show that the presence of CGRP in the spinal cord may
alter the pattern of distribution of ir-SP evoked by electrical nerve and
noxious mechanical stimulation. Whilst the release of ir-SP is usually
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Fig. 5. Effect of microinjection of CGRP at 2500, 2000, 1500 and 1000 ftm
on the pattern of release of ir-SP evoked by noxious mechanical stimulation.
Each graph shows the averaged image of the 'No stim.' probes of the control
period (n = 21) and the averaged image of probes present in the cord during
noxious pinch under the conditions indicated (n = 46 in A, 7 in B, and 6 in
C). Each probe was in the cord for 10 min; noxious pinch of the toes was applied
twice for 3 min in the 10-min periods.
more focal and centred in and around lamina II, this neuropeptide can
be detected in a large area of the cord after microinjection of CGRP.
It was essential to show that the decreased binding of [l25I]SP to
microprobes was not due to binding by the microinjected CGRP.
In vitro tests indicated that CGRP did not suppress the binding of
[,25I]SP to the probes. It was also important to examine whether the
microinjection itself could alter the pattern of binding of ir-SP. Probes
which were present in the cord during electrical nerve stimulation, after
microinjection of Ringer solution, showed a pattern which almost
overlapped that found on probes present in the untreated cord during
nerve stimulation. Collectively, therefore, the pattern of decreased
binding of [125I]SP after CGRP most likely resulted from the
widespread presence of ir-SP in the dorsal horn as a conseqence of
some action of CGRP. This result indicates, therefore, (1) that the
presence of ir-SP in a defined area of the cord is dependent on factors
additional to the site of release, and (2) that CGRP is an endogenous
compound with the capacity to alter the sites accessed by ir-SP.
Increased levels of ir-SP in the spinal cord following the
administration of CGRP could result either from an enhanced release
mechanism or by an inhibition of the degradation of SP. Oku et al.
(1987) proposed an enhancement of release when they found that CGRP
increased the levels of ir-SP released into the perfusate of a rat spinal
cord slice preparation by capsaicin, although CGRP alone did not alter
the basal (unstimulated) release of ir-SP. As mentioned above, under
in vitro conditions CGRP inhibits an endopeptidase degrading SP
(LeGreves et al., 1985). If degradation is prevented, ir-SP could achieve
higher concentrations at site(s) of release and hence could diffuse to
remote areas. We favour the second mechanism since in our previous
study the pattern of ir-SP was altered in the same way after CGRP
as by the microinjection of synthetic peptidase inhibitors.
The effect of CGRP on the spatial distribution of ir-SP could be
demonstrated using either electrical nerve stimulation or application
of noxious pinch. The development and the size of the effect of CGRP
differed to some extent with the two types of stimulation. With electrical
nerve stimulation the effect of CGRP was much more pronounced,
probably as a result of the activation of a much larger number of afferent
fibres. Furthermore, the expansion of ir-SP developed rapidly and
showed reversibility during the time period studied (Fig. 1). With
noxious pinch the expansion of released ir-SP seemed to be slower.
The reasons for these differences in the time course are not known
but the findings suggest that several factors, such as the amount of
released ir-SP and the local presence of CGRP, may interact.
CGRP is released from slices of the spinal cord and cultured dorsal
root ganglion cells in vitro by solutions with a high extracellular
potassium concentration and/or capsaicin (Mason et al., 1984; Saria
et al., 1986; Pohl et al., 1989). Intraspinal release in vivo has been
shown with application of electrical stimulation of unmyelinated afferent
fibres and noxious mechanical stimuli (Morton and Hutchison, 1989).
Co-release of CGRP and SP was demonstrated from the peripheral
branches of capsaicin-sensitive afferents (Geppetti et al., 1989; Maggi
et al., 1991) as well as from spinal cord slices (Saria et al., 1986).
It is very likely, therefore, that many stimuli, especially noxious ones,
lead to co-release of ir-CGRP and ir-SP from the central terminals of
afferent neurons. The normal stimulus-evoked release of ir-SP in our
experiments may therefore represent a process of release and partial
persistence of ir-SP resulting from peptidase inhibition by co-released
CGRP. This effect could explain why the zone of stimulus-evoked
release in the control conditions was apparently larger than the region
in which SP-positive neurons are mainly found.
The functional significance of the present results may be related to
the spatial distribution of receptors for SP. Although the location of
NK1 receptors in the spinal cord matches in general the location of
SP-positive neurons and fibres, the density of receptors and SP-
immunoreactive neurons may differ (Ljungdahl et al., 1978; Gibson
et al., 1984; Charlton and Helke, 1985; Lee et al., 1985; Helke et al.,
1986; Yashpal et al. 1990). Some of the receptors are located in regions
remote from the areas in which the SP-containing neurons are located
preferentially and in which ir-SP is released under normal conditions.
If SP diffuses after stimulation it could reach and activate these binding
sites. The presence of other factors, including the release of CGRP,
therefore, may determine when receptors for SP will be activated.
Previous experiments with antibody microprobes showed that the
normal release pattern for neurokinin A (NKA) in the spinal cord
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resembled that of SP following CGRP in the present experiments
(Duggan et al., 1990; Hope et al., 1990). It was proposed that this
resulted from a slow degradation of synaptically released NKA. In vitro
experiments have shown a rapid degradation of SP but not NKA by
plasma (Theodorsson-Norheim et al., 1987), angiotensin-converting
enzyme (Hooper et al., 1985) and an endopeptidase isolated from
human cerebrospinal fluid (Nyberg et al., 1984). With the isolated rat
urinary bladder the proposed action ofNKA relative to that of SP has
been attributed to a slow degradation of NKA by peptidases (Maggi
et al., 1991). It is a fascinating possibility that the central terminals
of nociceptors release a focally acting compound (such as L-glutamate),
a relatively non-focal compound (SP) and a diffusely acting substance
(NKA), but that the degree of diffuseness of the action of SP is under
the control of another co-released peptide, CGRP. This concept of non-
focal action of synaptically released compounds has recently been
summarized by Fuxe and his colleagues and termed volume
transmission (Agnati et al., 1986; Fuxe and Agnati, 1991).
A synergistic action of SP and CGRP at the spinal level has been
described in some situations. These peptides act synergistically on the
gain of the flexor withdrawal reflex in the rat which is elicited by
stimulation of unmyelinated primary afferent fibres (Woolf and
Wiesenfeld-Hallin, 1986). Ionophoretic application of both SP and
CGRP onto dorsal horn neurons in the spinal cord of the rat showed
that CGRP enhanced the excitatory effect of SP. but did not elevate
resting discharges on its own; it also enhanced the SP-mediated
facilitation of responses to cutaneous noxious stimuli (Biella et al.,
1991). In behavioural experiments the intrathecal application of SP
and CGRP together has a longer effect on the mechanical pain threshold
than SP alone, although the amount of facilitation by SP is not changed
by CGRP (Oku et al., 1987). Such effects may result from postsynaptic
receptor-mediated action of both neuropeptides, but they are also
consistent with a prolonged life of SP through endopeptidase inhibition
by CGRP.
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Analgesic doses of morphine do not reduce noxious
stimulus-evoked release of immunoreactive neurokinins in the
dorsal horn of the spinal cat
C.W. Lang, ^.W. Duggan & P.J. Hope
Department of Preclinical Veterinary Sciences, University of Edinburgh, Summerhall, Edinburgh EH9 1QH
1 Antibody microprobes were used to detect immunoreactive neurokinin A release in the dorsal spinal
cord of barbiturate-anaesthetized spinal cats.
2 Noxious mechanical stimulation of the ipsilateral hind paw and electrical stimulation (suprathreshold
for unmyelinated primary afferent fibres) of the ipsilateral tibial nerve evoked immunoreactive neurokinin
A release.
3 Systemic morphine, 5mgkg_1, i.v., did not block immunoreactive neurokinin A release in response to
these stimuli.
4 Subsequent naloxone administration, 0.5mgkg"', i.v., did not alter this stimulus-evoked release.
5 Basal levels of immunoreactive neurokinin A were unaltered by morphine or naloxone.
6 These results suggest that the analgesic effects of morphine at the spinal cord level are not brought
about by activation of presynaptic opiate receptors on neurokinin A containing afferent terminals.
Keywords: Neurokinins; morphine; naloxone; antibody microprobes; cat spinal cord.
Introduction
Substance P and neurokinin A, two members of the tachy¬
kinin family of neuropeptides, extensively coexist in the small
diameter dorsal root ganglion cells of the rat (Dalsgaard et al,
1985). Both tachykinins have been proposed as important in
the transmission of information from nociceptive afferents to
spinal or brainstem neurones (Otsuka & Yanagisawa, 1988;
Fleetwood-Walker et al., 1990). Studies of the release of these
compounds in the spinal cord by use of antibody microprobes
have shown both tachykinins to be released in response to a
similar range of peripheral noxious stimuli (Duggan et al.,
1988b; 1990; Hope et al., 1990a; Schaible et al., 1990)
although important differences in noxious stimuli release pat¬
terns have also been identified. Noxious stimuli producing
detectable tissue damage caused greater release of immuno¬
reactive substance P in the dorsal horn, than noxious, non-
damaging stimuli. Noxious cutaneous stimuli also released
immunoreactive neurokinin A, but potentiation by tissue
damage was not seen. Immunoreactive neurokinin A exhibited
a remarkable spread beyond sites of release and persisted fol¬
lowing an effective stimulus. In contrast a focal, non-persistent
pattern was observed with immunoreactive substance P.
These findings suggest that neurokinin A, unlike the relatively
short-lived substance P, may not function as a conventional
neurotransmitter, but might rather have a long term modula¬
tory role on spinal cord systems.
Iontophoretic administration of morphine (Duggan et al.,
1977) and the p opioid agonist [D-Ala2 Me-Phe4, Gly-ol5]
enkephalin (DAMGO) (Fleetwood-Walker et al., 1988) in the
region of the substantia gelatinosa selectively suppressed the
transmission of impulses from nociceptive afferents to deeper
neurones of the dorsal horn. The substantia gelatinosa is the
major site of termination of unmyelinated cutaneous afferent
fibres (Light & Perl, 1977). Since administration of naloxone
in the substantia gelatinosa completely blocked the effects of
analgesic doses of systemic morphine on deep neurones of the
dorsal horn of the cat (Johnson & Duggan, 1981) it is likely
that opiate receptors in the substantia gelatinosa are the
major ones mediating the analgesic actions of morphine at the
spinal level, whether administered systemically or intrathe¬
cal^. One mechanism by which morphine could produce
analgesia is by presynaptic inhibition of neurotransmitter
release from nociceptive primary afferent terminals. In support
of this hypothesis, morphine in high concentrations, when
added to the superfusate of either a slice of the upper dorsal
horn (Jessel & Iversen, 1977; Mauborgne et al., 1987) or of the
spinal cord in vivo (Yaksh et al., 1980; Go & Yaksh, 1987) has
been shown to reduce stimulus evoked release of immunoreac¬
tive substance P. However, systemically administered morp¬
hine at analgesic doses has failed to reduce release of immuno¬
reactive substance P evoked by noxious stimulation (Kuraishi
et al., 1983; Morton et al., 1990).
With the recognition that a peripheral noxious stimulus
results in the central release of a number of neuroactive com¬
pounds including amino acids (Kangrga & Randic, 1990) and
peptides (Duggan et al., 1988b; 1990), a complete study of
opiates and release from primary afferents is clearly a complex
task. There is evidence that the arrival of impulses in nocicep¬
tive afferents produces not only fast transmission to fibres
ascending to the brain but also long lasting events such as
prolonged facilitation of flexor reflexes (Woolf, 1983; Woolf &
Wall, 1986a; Cook et al., 1987; Cervero et al., 1988; Neuge-
bauer & Schaible, 1988; Hoheisel & Mense, 1989; Hylden et
al., 1989). It has been proposed that neurokinin A (rather than
substance P) is more important in these prolonged spinal
events since, following release of immunoreactive neurokinin
A, this peptide (or an extended form such as neuropeptide K)
diffuses widely and persists in the spinal cord (Hope et al.,
1990a). Of note is the finding that in the rat, low doses of
morphine suppressed the prolonged facilitation of spinal
reflexes produced by nociceptive input, whereas higher doses
were required to suppress fast transmission as measured by an
unfacilitated nociceptive reflex (Woolf & Wall, 1986b). Such
considerations indicate the need for a study of opiates and the
central release of neurokinin A. In the present study therefore,
the effects of analgesic doses of systemically administered
morphine were examined on the noxious stimulus-evoked
release of immunoreactive neurokinin A in the dorsal horn of
the spinal cord in barbiturate-anaesthetized cats.
Methods
Preparation ofantibody microprobes
1 Author for correspondence.
Antibody microprobes were prepared as previously described
(Duggan et al., 1988a). Fine glass micropipettes, heat sealed at
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base and tip, were incubated in a 10% solution of amino-
propyltriethoxysilane producing an even layer of a siloxane
polymer bearing free amino-groups on the outer surface of the
probes. Glutaraidehyde was then used to immobilize protein
A (Sigma) onto this polymer; protein A then bound immuno¬
globulins present in an antiserum raised against the carboxyl
terminus of neurokinin A (Peninsula). Although this anti¬
serum is described as anti-neurokinin A, information from the
manufacturer indicates it has 100% cross reactivity with
neuropeptide K (an N-terminal extended form of neurokinin
A), 70t-80% cross-reactivity with neurokinin B, but negligible
cross-reactivity with substance P. For purposes of the present
experiments microprobes are described as detecting immuno-
reactive neurokinins.
The antiserum lyophylate contained salts from the suspend¬
ing buffer which limited the possible concentration of
resuspended antibody. A dilution of approximately 1:3000
was used. All protein binding outside the spinal cord took
place in 5 pi glass capillaries containing the relevant solutions.
Animal preparation/recording/microprobe analysis
Experiments were performed on 8 cats anaesthetized initially
with intraperitoneal sodium pentobarbitone 35mgkg_1, and
maintained by continuous intravenous infusion of sodium
pentobarbitone, 3mgkg_1h_1. All animals were artificially
ventilated with air and when necessary paralysed with galla-
mine triethiodide, 4mgkg~1h"1. Blood pressure was mea¬
sured continuously via a cannula in the left carotid artery and
end tidal C02 levels were also monitored and maintained at
4%.
The lumbar spinal cord was exposed by dorsal laminectomy
and the spinal cord transected at the level of T13/L1 following
injection of 0.1 ml of 2% lignocaine (Astra). The lumbar dura
mater was cut longitudinally at the level of L7-S1 and
retracted laterally. The exposed cord was then covered with a
thin layer of Ringer/agar. At sites of proposed microprobe
insertion a small area of agar was removed to form a pool and
the underlying pia-arachnoid removed with fine sterile forceps.
Such areas were then continuously irrigated with sterile
Ringer solution at 37°C. Microprobes were inserted into the
spinal cord with stepping motor micromanipulators. The first
probe in each new area was used to obtain extracellular
recordings to identify the receptive fields, to light brushing of
the skin, of neurones encountered along a microprobe track.
Peripheral noxious stimulation was provided either by
applying 'crocodile' clips to the pads and interdigital skin of
the ipsilateral hind paw in a cycle of 3 min on, 2min off, for
the duration of the stimulus or by electrical stimulation of the
ipsilateral tibial nerve (groups of three 0.5 ms square wave
pulses at 330 Hz, repeated at 10 Hz, amplitude 20 V). All
microprobes were inserted 3 mm into the dorsal spinal cord
which, in an adult cat, places the tips in the upper ventral
horn. All probes remained in the spinal cord for 30min fol¬
lowing insertion.
Antibody microprobes demonstrate localized binding of an
endogenous ligand by their subsequent failure to bind exoge¬
nous radiolabeled ligand. Following removal from the spinal
cord, microprobes were washed for 15min in cold phosphate
buffered saline containing Tween-80 (0.1%) and then incu¬
bated for 24 h at 4°C in a phosphate buffered saline/azide sol¬
ution of [125I]-neurokinin A containing 0.5% bovine serum
albumin diluted to give approximately 2000c.p.m./d"1. Fol¬
lowing this incubation, microprobes were again washed for
15 min in PBS-Tween with suction applied to the base of the
microprobes to draw any labelled neurokinin A out of the
tips. The tips were then broken off and fixed to a sheet of
paper which was placed in an X-ray film cassette with a sheet
of monoemulsion X-ray film (NMB-Kodak). Exposure times
were typically in the order of 3—4 weeks reflecting the limited
amounts of this antibody which could be bound to the probe
surfaces. In each experiment 8 microprobes were used for in
vitro tests of sensitivity. Four of these were incubated with
10"7 moll"1 neurokinin A for 30min at 37°C prior to incu¬
bation in [125I]-neurokinin A. The other 4 were simply incu¬
bated with the radiolabeled neuropeptide.
The resulting X-ray film images were analysed with an
image analysis system employing an Imaging Technology PC
Vision Plus frame grabber board operating in a DCS 286e
(AT-based) computer. A television (CCD) camera was used as
described previously (Hendry et al., 1988) to produce a trans¬
verse integration of optical density, with a resolution of 10/rm,
along the length of each microprobe. These integrals were
stored on a hard disk together with 32 coded values assigned
to various experimental parameters for each microprobe.
These codings allowed sorting of microprobes into groups
meeting stated criteria. Images from these groups could then
be averaged and the differences between control and test
groups calculated and assigned levels of statistical significance.
It should be emphasized that the spatial resolution of this
method is 100 sites (each of 10/rm) per mm, and that events at
each site are considered independently of others in the averag¬
ing of images and the calculation of group differences and
their significances.
Drug dosage and experimental regimes
The drugs used were administered via an intravenous catheter
into the right cephalic vein. Morphine was administered as a
lOmgml"1 solution in physiological saline, naloxone as
1 mgml"1 in physiological saline.
As previously demonstrated (Duggan et al., 1990; Hope et
al., 1990a) the elevation of immunoreactive neurokinin levels
in the dorsal spinal cord, following a discrete stimulus, persists
for up to 1 h beyond stimulation. This persistence creates diffi¬
culties when testing a compound which may block release,
since a series of pre-drug measurements of stimulus-evoked
release may result in a build up of immunoreactive neuro¬
kinins in the dorsal horn such that any subsequent reduction
in release brought about by the drug may not be detectable.
Consequently, these experiments examined the basal levels of
immunoreactive neurokinins in the absence of any stimulus
and then administered morphine prior to measuring stimulus-
evoked release of these compounds. Several groups have
shown that in the spinal cat, doses of morphine of 0.3 to
4.0mgkg_1 i.v. reduced the synaptic activation of dorsal horn
neurones by peripheral noxious stimuli (Le Bars et al.,
1976a,b; Duggan et al., 1980; Johnson & Duggan, 1981). The
present experiments used morphine at levels just above the
upper limit of this range (5.0mgkg_1, i.v.) since, with the pro¬
tocol used, lack of effectiveness of the stimulus would be more
readily detected than a partial reduction. A more significant
test of the effect of morphine on immunoreactive neurokinin
release came from the effects of subsequent naloxone adminis¬
tration. If stimulus evoked release of immunoreactive neuro¬
kinins is increased when naloxone is administered after
morphine, this indicates that morphine had reduced release of
these compounds. The above protocol is not optimal if morp¬
hine increases release of immunoreactive neurokinins. A series
of experiments was therefore included in this study in which
naloxone was administered prior to morphine in an attempt
to block such an increase. Comparisons were also made with
earlier studies on the effects of stimulus-evoked release of
immunoreactive neurokinins in the absence of morphine
(Hope et al., 1990a,b).
Results
A total of 97 microprobes coated with antibodies to neuro¬
kinin A were inserted into the spinal cord. Additionally, 64
microprobes were used for concurrent in vitro tests. These
consistently demonstrated suppression of the binding of
[125I]-neurokinin A by greater than 50% following incu¬
bation with neurokinin A 10"7moll"1.
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Figure 1 The effects of systemic morphine administration on resting
levels of immunoreactive neurokinins in the dorsal horn. Controls:
the mean image analysis of microprobes (n = 11) inserted into the
dorsal spinal cord with no prior or concurrent drug administration
and no prior to concurrent peripheral stimulation. Morphine: the
mean image analysis of microprobes (n = 7) inserted into the dorsal
spinal cord immediately following morphine (5mgkg_1, i.v.) adminis¬
tration and in the absence of prior or concurrent peripheral stimu¬
lation. The analysis was performed with a resolution of 33 points per
millimetre and with each group the continuous line has joined these
points. The ( + ) s.e.mean at each point is plotted for the morphine
group and the ( —) s.e.mean at each point is plotted for the control
group. The t values (21 = P < 0.05) derived from the differences
between the means of the two groups are also shown.
Thirty-five probes were inserted 3 mm into the cord and left
for 30min without stimulation of either hind paw or the con¬
current administration of any drug. These microprobes
formed the basis for assessing possible effects of morphine or
naloxone on the basal levels of immunoreactive neurokinins.
The remaining 62 probes were inserted into the spinal cord
in the presence of peripheral noxious stimuli and/or drug
administration.
Effects ofmorphine and naloxone on basal levels of
immunoreactive neurokinins
In four experiments, morphine was the first drug administered
and in the remaining experiments naloxone was the first drug
administered. Seven probes were inserted into the spinal cord
in the absence of prior or concurrent noxious stimuli, and
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Figure 2 The effects of systemic naloxone administration on resting
levels of immunoreactive neurokinins in the dorsal horn. Controls:
the mean image analysis of microprobes (n = 23) inserted into the
dorsal spinal cord with no prior or concurrent drug administration
and no prior or concurrent peripheral stimulation. Naloxone: the
mean image analysis of microprobes (n = 13) inserted into the dorsal
spinal cord immediately following naloxone (0.5mgkg~\ i.v.) admin¬
istration and in the absence of prior or concurrent peripheral stimu¬
lation. S.e.means for the two groups and t values (21 = P < 0.05)
derived from the differences of the means are shown as in Figure 1.
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Figure 3 The effects of noxious stimulation of the ipsilateral hind
paw, following systemic morphine administration on immunoreactive
neurokinin levels in the dorsal horn. Controls: the mean image
analysis of microprobes (n = 11) inserted into the dorsal spinal cord
with no prior or concurrent drug administration and no prior or con¬
current peripheral stimulation. Morphine (stim): the mean image
analysis of microprobes (n = 17) inserted into the dorsal spinal cord
following morphine (5mgkg_1, i.v.) administration and during
noxious stimulation of the ipsilateral hind paw. S.e.means for the two
groups and r values (2t = P < 0.05) derived from the differences of the
means are shown as in Figure 1.
within 1 min of morphine administration (5mgkg_1, i.v.). In
all cases, this dose of morphine was the first drug adminis¬
tered. The mean image analysis of these probes is illustrated in
the upper trace of Figure 1. When this group is compared to
the mean image analysis of microprobes inserted in the
absence of prior peripheral stimulation in the same experi¬
ments (lower trace, 'controls', Figure 1), no significant differ¬
ences are present as shown in the plot of the t statistics for the
differences between these groups of microprobes.
Thirteen probes were inserted into the spinal cord in the
absence of prior or concurrent noxious stimulation and within
1 min of naloxone administration (0.5mgkg_1, i.v.). No prior
morphine administration had occurred. The mean image
analysis of this group of microprobes and the relevant (no
stimulus) controls are shown in Figure 2. The plot of the t
statistics derived from the differences between these groups
shows that no significant differences are present.
■2 f
3 2 1 0 -1
Depth within spinal cord (mm)
Figure 4 Effect of naloxone following morphine on noxious stimulus
evoked immunoreactive neurokinin release. Morphine (stim): the
mean image analysis of microprobes (n = 17) as described in Figure 3.
Naloxone following morphine (stim): the mean image analysis of
microprobes (n = 10) inserted into the dorsal spinal cord immediately
following those illustrated in the morphine (stim) group, and after nal¬
oxone (0.5mgkg~\ i.v.) administration during noxious stimulation of
the ipsilateral hind paw. S.e.means for the two groups and f values
(21 = P < 0.05) derived from the differences of the means are shown as
in Figure 1.
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An additional 10 probes were inserted into the spinal cord
in the absence of prior or concurrent noxious stimulation and
within 1 min of morphine administration (5mgkg"\ i.v.) but
in this case morphine immediately followed naloxone
(0.5mgkg_1, i.v.) administration. Again, when compared with
the relevant control group no significant differences were
found.
In summary, neither morphine nor naloxone, administered
in the absence of peripheral noxious stimulation, produced
significant changes in detectable levels of immunoreactive
neurokinins in the dorsal spinal cord. A combination of these
two drugs also failed to alter significantly basal levels of
immunoreactive neurokinins.
Effect ofmorphine on stimulus-evoked immunoreactive
neurokinin release
Seventeen microprobes were inserted into the dorsal spinal
cord within 90min of morphine administration (5mgkg"\
i.v.) and with concurrent noxious stimulation of the ipsilateral
hind paw. Noxious pinch and electrical stimulation of unmy¬
elinated primary aflferents have previously been shown to be
adequate stimuli for evoking immunoreactive neurokinin
release in the dorsal spinal cord (Duggan et al., 1990; Hope et
al., 1990a). Following morphine administration, noxious
stimulus dependent immunoreactive neurokinin release was
seen in the present experiments in a zone extending from the
spinal cord surface to approximately 1.3 mm into the dorsal
grey matter as shown in Figure 3. Although the increases in
the levels of immunoreactive neurokinins in the dorsal horn
produced by the stimulus appeared comparable to those pro¬
duced by comparable stimuli in previous studies in which
morphine had not been administered (Duggan et al., 1990;
Hope et al., 1990a) a small inhibition of release by morphine
could only be assessed by the subsequent administration of
naloxone.
Eleven probes were inserted into the dorsal spinal cord
within lmin of naloxone (0.5mgkg"', i.v.) given after morp¬
hine and during peripheral noxious stimulation. These probes
were inserted after those represented in Figure 3, i.e. imme¬
diately after the period of stimulation which followed morp¬
hine administration. Figure 4 shows that naloxone had no
effect on the stimulus-evoked levels of immunoreactive neuro¬
kinins in the dorsal horn which were observed following
morphine. This lack of effect of naloxone suggests that the
dosage of morphine used prior to naloxone had not altered
the release of immunoreactive neurokinins.
Discussion
When the results of the present experiments are considered
with those of Kuraishi et al. (1983) and Morton et al. (1990),
there is little evidence that analgesic doses of opiates adminis¬
tered systemically reduce tachykinin release (either neurokinin
A or substance P) from the central terminals of nociceptors.
Since such results are at variance with the conclusions of
experiments which have examined the effect on substance P
release of topically applied opiates, these differences require
comment.
Inhibition of substance P release by opiates was first shown
by Jessell & Iversen (1977) in a slice preparation of rat tri¬
geminal nucleus. The stimulus used, however, was 47 mm pot¬
assium in the perfusate. This will depolarize virtually all
neural structures in the slice, and hence the source of sub¬
stance P is uncertain. Furthermore, the concentration of
morphine used was high (10"5m). Using the push-pull
cannula technique on rabbit spinal cord in vivo, Hirota et al.
(1985), demonstrated a reduction in the release of substance P
following noxious cutaneous stimulation with morphine
(10"5m) in the perfusate. Further support for the proposal
that opiates impair substance P release from the central ter¬
minals of nociceptors came from the experiments of Yaksh et
al. (1980) and Go & Yaksh (1987), in which morphine (10~4m)
added to a superfusate of intact cat spinal cord in vivo reduced
the release of substance P into the perfusate following electri¬
cal stimulation of unmyelinated primary afferents.
Mauborgne et al. (1987), however, found that while the p-
receptor agonist DAMGO (10~5 m) increased both high pot¬
assium and capsaicin induced release of substance P from
dorsal horn slices, the <5-receptor agonist [d-Thr2]-Leu-
enkephalin-Thr (DTLET) (3 x 10"6 m) reduced release in the
same preparation. The K-agonist, U50488H (0.5-50 x 10"6m),
did not affect release of substance P (Hamon et al., 1988; Pohl
et al., 1989).
It should be noted that the concentrations 'of drugs used in
all of the above studies were high and that no group has
found that systemic analgesic doses of morphine reduce sub¬
stance P release in the dorsal horn of spinal animals. Thus,
Kuraishi et al. (1983), using push pull canulae in the dorsal
horn of the spinal rabbit observed that systemic morphine
(lOmgkg-1) failed to reduce immunoreactive substance P
release from noxious mechanical stimulation. Using antibody
microprobes, Morton et al. (1990) failed to observe any effect
of morphine given in two dose ranges (l-6mgkg"' and 10-
20mgkg_1) on immunoreactive substance P release in the
dorsal horn of the spinal cat following noxious mechanical or
thermal cutaneous stimulation.
Since studies which have observed effects on tachykinin
release have used relatively high concentrations of opiates, is
the same true of experiments which have administered opiates
microiontophoretically in the substantia gelatinosa and hence
may have over-emphasized the importance of effects near the
first central synapse of nociceptors? Although concentrations
in microiontophoretic experiments are unknown, the finding
that naloxone administered in the substantia gelatinosa
decreased the effects of systemic morphine, 4mgkg_1, on
deeper neurones (Johnson & Duggan, 1981) does support the
importance of opiate receptors in the substantia gelatinosa in
mediating the action of systemic morphine on spinal neurones.
When y-aminobutyric acid acts presynaptically on the
central terminals of large diameter muscle afferents, the result¬
ant depolarization is associated with reduced transmitter
release and an increased excitability when tested with an
adjacent stimulating microelectrode (Curtis et al., 1980).
Administering opioids near the central terminals of nocicep¬
tors in the substantia gelatinosa however, has resulted in
decreased electrical excitability (Sastry, 1980; Carstens et al.,
1987), a result not consistent with the well-established mecha¬
nism of presynaptic inhibition in the spinal cord. A different
mechanism of reducing transmitter release might be if calcium
entry with each invading impulse were to be reduced through
a shortening of action potential duration. Such a shortening
has been observed with micromolar concentrations of opioids
acting on cultured dorsal root ganglion neurones (Werz &
Macdonald, 1982; Shen & Crain, 1989) but lower (nanomolar)
concentrations had the opposite effect (Shen & Crain, 1989).
Support for a postsynaptic effect of opioids on intrinsic neu¬
rones of the substantia gelatinosa has come from Yoshimura
& North (1983) who observed a hyperpolarization of such
cells in a slice preparation, and Sastry & Goh (1983) who
found many to be excited in vivo by iontophoretically admin¬
istered morphine. The inconsistency in these reports however
has not been explained.
Recently Lombard & Besson (1989) have tried to assess the
relative importance of pre- and postsynaptic actions of morp¬
hine by recording the firing of dorsal horn neurones in decere¬
brate spinal rats with intact dorsal roots (and an induced
peripheral arthritis) and comparable cells in non-arthritic
animals with sectioned dorsal roots. Morphine (2mgkg~\
i.v.) depressed the spontaneous firing of neurones in both
preparations but a greater effect was observed in the arthritic
animals with intact dorsal roots. Such a result indicates an
action by opiates on the pathway from primary afferent ter¬
minals to the neurones studied but cannot distinguish between
effects on terminals and effects on interneurones interposed
between such terminals and the neurones studied.
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It has been the conclusion of studies which have observed
reductions in tachykinin release with high concentrations of
opiates that a presynaptic action on the central terminals of
nociceptors is an important component of opiate analgesia
(Yaksh & Noueihed, 1985). The present experiments con¬
sidered with those of Kuraishi et al. (1983) and Morton et al.
(1990) suggest that such an action does not occur significantly
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Lack of effect of microinjection of noradrenaline or
medetomidine on stimulus-evoked release of substance P in the
spinal cord of the cat: a study with antibody microprobes
'C.W. Lang, 2P.J. Hope, 3B.D. Grubb & 4A.W. Duggan
Department of Preclinical Veterinary Sciences, Royal (Dick) School of Veterinary Studies, University of Edinburgh,
Summerhall, Edinburgh EEI9 1QH
1 Experiments were performed on barbiturate anaesthetized, spinalized cats to investigate the effect of
microinjected noradrenaline or medetomidine on the release of immunoreactive substance P in the dorsal
spinal cord following peripheral nerve stimulation. The presence of immunoreactive substance P was
assessed with microprobes bearing C-terminus-directed antibodies to substance P.
2 Noradrenaline or medetomidine were microinjected into the grey matter of the spinal cord, near
microprobe insertion sites, at depths of 2.5, 2.0, 1.5 and 1.0 mm below the spinal cord surface with
volumes of approximately 0.125 pi and a concentration of 10~3m.
3 In the untreated spinal cord, electrical stimulation of the ipsilateral tibial nerve (suprathreshold for
C-fibres) elicited release of immunoreactive substance P which was centred in and around lamina II.
Neither noradrenaline nor medetomidine administration in the manner described produced significant
alterations in this pattern of nerve stimulus-evoked release.
4 In agreement with recent ultrastructural studies these results do not support a control of substance P
release by catecholamines released from sites near to the central terminals of small diameter primary
afferent fibres.
Keywords: Antibody microprobes; substance P release; spinal cord; peripheral nerve stimulation; microinjection; noradrenaline;
medetomidine
Introduction
Although there is considerable information on the brainstem
sites of origin of descending pathways controlling spinal
transmission of nociceptive information, comparatively little
is known about the mechanisms operating at the spinal ter¬
mination of these pathways. A wealth of evidence suggests
that release of the monoamines, noradrenaline (NA) and
5-hydroxytryptamine (5-HT), mediates, in part, brainstem
control of spinal nociceptive transmission. This evidence
includes the effects of agonists applied either topically to the
spinal cord (mouse: (Hylden & Wilcox, 1983) rat: (Camarata
& Yaksh, 1985; Sullivan et al., 1987; Solomon & Gebhart,
1988; Gordh et al., 1989; Tseng & Tang, 1989; Danzebrink &
Gebhart, 1990; Tjolsen et al., 1990; Uhlen et al., 1990; Fisher
et al., 1991; Hylden et al., 1991; Takano & Yaksh, 1991) cat:
(Collins et al., 1984; Nakagawa et al., 1990) sheep (Water¬
man et al., 1988)) or near to single neurones in the dorsal
spinal cord (Headley et al., 1978; Jeftinija et al., 1981; Nagy
& Hunt, 1982; Curtis el al., 1983; Davies & Quinlan, 1985;
Fleetwood-Walker et al., 1985; Zhao & Duggan, 1987) and
the behavioural effects of electrical stimulation of brain stem
areas exhibiting monamine containing cell bodies (rat:
(Reynolds, 1969), and man (Meyerson et al., 1979)). In addi¬
tion there is a dense plexus of catecholamine containing
nerve terminals (rat: (Schroder & Skagerberg, 1985; Rajao-
fetra et al., 1992), cat: (Lackner, 1980; Doyle & Maxwell,
1991a), primate (Westlund et al., 1984)), and a marked den¬
sity of catecholamine bindings sites (rat: (Young & Kuhar,
1980), Jones et al., 1982; Unnerstall et al., 1984; Giron et al..
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1985), sheep: (Bouchenafa & Livingston, 1987) and man:
(Unnerstall et al., 1984)), in the superficial dorsal spinal cord,
the main area of termination of small diameter primary
afferent fibres.
One hypothesis for a mechanism of selective analgesia at
the spinal level is a presynaptic reduction in transmitter
release from primary afferent terminals of nociceptive origin.
This has been investigated by a number of methods for
several compounds including NA. These methods include
both in vivo and in vitro transmitter release studies (Kuraishi
et al., 1985; Pang & Vasko, 1986; Ono et al., 1991) and
electrophysiological assessments of changes in the excitability
of the spinal terminations of primary afferent fibres in res¬
ponse to compounds administered microionophoretically
(Jeftinija et al., 1981; Nagy & Hunt, 1982; Curtis et al.,
1983). Such studies however, have produced controversial
results and the spinal mechanisms underlying supraspinal
controls involving monoamines remain unresolved.
The most direct method of investigating a possible pre¬
synaptic control by monoamines of transmission of inform¬
ation conveyed by nociceptors is to measure transmitter
release in the dorsal spinal cord, in response to defined
peripheral noxious stimuli, before and after monoamine app¬
lication close to the releasing terminals. The tachykinin
neuropeptide substance P (SP) has been shown, by a variety
of techniques, to be released in the spinal dorsal horn follow¬
ing peripheral noxious stimuli. With the antibody microprobe
technique, such release in spinal cats has been shown to be
centered on laminae I and II, the major sites of termination
of cutaneous small diameter primary afferents (Duggan et al.,
1988b; 1991; 1992; Schaible et al., 1992). Controls of trans¬
mitter release from the central terminals of peripheral
nociceptors might, therefore, be reasonably expected to
influence the stimulus-evoked release of SP in laminae I and
II of spinal cats. In the present series of experiments
antibody microprobes have been used to measure the release
of immunoreactive SP (irSP) in the superficial dorsal horn in
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response to electrical stimulation of unmyelinated primary
afferent fibres. The effects of NA microinjection from a
micropipette with its tip positioned in the region of the
substantia gelatinosa have been evaluated in terms of any
change in the subsequent pattern of stimulus evoked irSP
detection. Because of existing evidence that the relevant
receptors mediating the antinociceptive action of spinal NA
are of the <x2-adrenoceptor type (Fleetwood-Walker et al.,
1985), the effects of the highly selective a2-adrenoceptor
agonist, medetomidine hydrochloride, were also studied.
Methods
Animal preparation
Experiments were carried out on 7 barbiturate-anaesthetized
cats. These were skeletally mature animals, males and
females, bred specifically for research purposes and with
body weights in the range of 2.5-3 kg. Induction of anaes¬
thesia was by intraperitoneal injection of pentobarbitone
sodium (35mgkg"') and maintenance was by a continuous
intravenous infusion of the same compound (3mg kg"'h"').
All animals were artificially ventilated following neuromus¬
cular paralysis with gallamine (4 mg kg"1 h"1). Gallamine
was subsequently administered intermittently to allow ade¬
quate checks on the level of anaesthesia. Blood pressure was
monitored via a cannulated carotid artery and end-tidal C02
levels were continually monitored and maintained at 4%.
The lumbar spinal cord was exposed by removal of the
overlying bony laminae and the spinal cord was then
transected at the thoraco-lumbar junction following intra¬
spinal injection of 0.1 ml of a 2% lignocaine solution. The
lumbar dura mater was cut longitudinally and retracted
laterally. A thin layer of Ringer/agar was then placed over
the dorsal surface of the exposed spinal cord. At sites of
proposed microprobe insertion an area of agar and a small
part of the underlying pia-arachnoid were removed with
sterile fine forceps. The area of the spinal cord exposed in
this way was then irrigated with a sterile Ringer solution held
at 37°C by a heat exchanger jacket around the delivery tube.
Following the induction of anaesthesia, cats received two
intramuscular injection of ampicillin, 25 mg kg-1, 10 h apart.
When measuring neuropeptide release by any method it is
important to have near sterile conditions (Duggan. 1992).
Although irSP release in the superficial dorsal horn is
evoked by a variety of noxious peripheral stimuli (Duggan et
al., 1988b), it is difficult to deliver such stimuli repeatedly
without damaging peripheral tissues and thus altering the
firing of peripheral nociceptors to successive stimuli. For this
reason, electrical stimulation of unmyelinated primary affer¬
ent fibres in the tibial nerve was used to elicit spinal release
of irSP in the present series of experiments. The right and left
tibial nerves were exposed in the lower limb, immersed in
liquid paraffin and mounted on platinum stimulating elec¬
trodes. Stimulation was with square wave pulses, 0.3 ms
duration, with an amplitude of at least 80 times the threshold
stimulus needed to produce a short latency field potential as
measured with a recording electrode placed in the upper
dorsal horn. Stimulus frequency was 20 FIz and stimulation
duration was lOmin in every case.
Microprobe preparation
Antibody microprobes were prepared as previously described
(Duggan et al., 1988a; Duggan, 1992). Briefly, fine glass
micropipettes, heat sealed at both ends, were incubated in a
10% solution of aminopropyltriethoxysilane in toluene. This
produced a siloxane polymer layer on the outer surfaces of
the microprobes and glutaraldehyde was then used to im¬
mobilize protein A (Sigma) to this polymer. Protein A then
bound immunoglobulins present in a polyclonal antiserum
containing antibodies directed at the C-terminus of SP
(Peninsula Laboratories). These antibodies bind SP and
fragments of SP containing at least the last five amino acid
residues; data from the manufacturer indicates negligible
cross-reactivity with either neurokinin A or neurokinin B.
Microprobes were inserted into the spinal cord, in pairs,
with stepping motor micromanipulators. Prior to insertion,
microprobes had both ends removed to allow filling with a
solution of pontamine sky blue to aid visualization of the
tips. With the first probe introduced into a particular area of
the spinal cord, it was usual to obtain extracellular recor¬
dings during introduction into the spinal cord in order to
confirm that fibres in the ipsilateral tibial nerve did project to
that area. All microprobes were inserted to a depth of 4 mm
which, in the lumbar spinal cord of the adult cat, places the
tip in the ventral horn. Microprobes were left in situ for
lOmin following insertion into the cord, during which time
either (a) no peripheral stimulus was applied to allow detec¬
tion of basal irSP levels or (b) the ipsilateral tibial nerve was
stimulated as previously described, with or without prior
drug application (see results). Insertions of consecutive pairs
of antibody microprobes, in the same area of the spinal cord,
were at intervals of at least 25 min.
The antibody microprobe technique detects bound endog¬
enous ligand by the subsequent failure of binding of exo¬
genous radiolabelled ligand. Thus, following removal from
the spinal cord, microprobes were washed for 15 min in a
cold solution of phosphate-buffered saline (PBS) containing
Tween (0.1%) and then incubated for 24 h at 6°C in a
PBS-azide solution of (Bolton-Hunter) l25I-radiolabelled SP
(Amersham) containing 0.5% bovine serum albumin. This
solution was diluted to give approximately 2000 counts
min"1 pi"1. After this incubation, microprobes were again
washed for 15 min in cold PBS-Tween, while continually
drawing the solution through the tips to remove any radio-
labelled SP from the inside. The tips were then carefully
broken off about 1 cm back and glued to a sheet of paper
which was placed in an X-ray film cassette with a sheet of
monoemulsion film (Kodak NMB).
The resulting X-ray film images of microprobes were
analysed with an image analysis system employing an Imag¬
ing Technology PC Vision Plus frame grabber board
operating in a Data Control Systems 286e (AT based) com¬
puter. A CCD camera scanned each image and, as described
previously (Hendry et al., 1988), after background subtrac¬
tion in a transverse integration of the optical density of the
image of each microprobe was executed at defined intervals.
With the magnification used and the resolution of the image
analysis system (512 by 512 locations per frame) this corres¬
ponds to a 10 pm interval for transverse integrations. The
resultant integrals were stored on a hard disk record which
included 40 coded values for each individual image relevant
to the experimental conditions surrounding it. An analysis
programme subsequently obtained groups of microprobes
which met stated criteria and obtained the mean image
analysis of each group. This mean image analysis was plotted
with respect to distance from spinal cord surface (see Figures
la, 2 and 3a). In addition, differences between the mean
image analyses of control and experimental groups were
obtained, t statistics were then calculated and a probability
of significance assigned to the difference in the mean grey
scale values at each analysis point (see Figures lb and 3b). It
is important to emphasize the spatial resolution of this tech¬
nique. For microprobes inserted into the spinal cord events
are examined optically at 100 sites per mm. Since such a
resolution exceeds the biological resolution of the microprobe
technique, the mean of 3 successive sites was calculated and
stored giving an approximate resolution of 33 sites per mm.
During in vitro tests of antibody microprobes, [l25I]-SP was
bound to a representative group of probes. At least 50%
suppression of this binding of radioactive SP was achieved by
prior incubation of the microprobes in a solution of 10"7m
unlabelled SP for 30 min at 37°C.
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Microinjection of drug solutions
NA and medetomidine (a gift from Farmos) solutions
(10~3m in sterile Ringer) were microinjected into the dorsal
horn from micropipettes (tip diameter 20-40 pm) positioned
with a micromanipulator to the appropriate regions and at
depths of 1.0, 1.5, 2.0, and 2.5 mm below the dorsal spinal
cord surface. Although in the cat, the peak release of irSP
evoked by tibial nerve stimulation is in the superficial dorsal
horn, 1.1 mm below the cord surface, (Duggan et al., 1988b;
1991; 1992; Schaible et al., 1992), there is significant release
from approximately 0.5 to 1.0 mm deep in this area. Hence
the microinjections were performed at sites deep in the region
of the substantia gelatinosa. The total drug volume was
0.5 pi, i.e. 0.125 pi at each site. Previous experiments (Dug¬
gan et al., 1991; 1992; Schaible et al., 1992) have shown that
microinjections of Ringer solution (or of PBS), in compar¬
able or larger volumes to those used in the present study,
have no effect on the stimulus-evoked release of irSP in this
region of the spinal cord.
The timing of microinjections in relation to the application
of stimuli evoking release of irSP is important in experiments
of this type for several reasons. Firstly, if a compound is
inactivated quickly, the microinjection may need to be per¬
formed whilst a microprobe is already in situ and a stimulus
being delivered. Previous experiments with neuropeptide
(NPY) microinjection (Duggan et al., 1991), inhibitors of
endopeptidase 24.11 (Duggan et al., 1992) and calcitonin
gene-related peptide (CGRP) (Schaible et al., 1992) showed
that this was not necessary with these compounds. Secondly,
the injected compound may need to diffuse within the spinal
cord for an effect of irSP release to be detected; this implies a
need to inject some time prior to testing for inhibition of
release. In the present experiments injections of NA or
medetomidine were performed after control microprobes
(either no stimulus or nerve stimulus controls) had been
removed from the cord and these microinjections were then
given gradually over a 5 min period. Subsequent pairs of
microprobes were then inserted as rapidly as possible into the
cord and were typically in situ 1-2 min after cessation of
drug microinjection. Drug microinjections and subsequent
microprobe insertions during nerve stimulation were always
at least 25 min after the preceding period of ipsilateral tibial
nerve stimulation.
Both NA and medetomidine were microinjected using
10~3 M solutions and in volumes of approximately 0.125 pi at
each site. These volumes correspond to spheres with a radius
of approximately 340 pm and in the absence of a removal
mechanism, such as neuronal uptake, a 10 fold reduction in
concentration (to 10~4m) will occur with an expansion of
this sphere, by diffusion, to a radius of 736 pm. Drug absorp¬
tion into local blood vessels will reduce the concentration still
further, but as the starting concentrations for both NA and
medetomidine were relatively high and the drugs were also
administered close to the major zone of primary afferent fibre
termination, the concentrations of drug used should have
been sufficient to reveal any action at such sites. This
methodology has successfully altered the pattern of release of
SP following microinjection of NPY or CGRP (Duggan et
al., 1991; Schaible et al., 1992).
Results
Stimulus-evoked release of immunoreactive substance P
The mean image analyses of 13 microprobes inserted 4 mm
into the spinal cord and left for 10 min in the absence of
peripheral nerve stimulation, and 24 microprobes inserted for
the same time and to the same depth but during electrical
stimulation of myelinated and unmyelinated primary affer-
ents of the ipsilateral tibial nerve are illustrated in Figure la.
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Figure 1 Nerve stimulus-evoked release of immunoreactive-sub-
stance P in the superficial dorsal horn, (a) The mean image analysis
of two groups of microprobes are plotted: those which remained in
the spinal cord for 10 min and no peripheral stimulus was applied
(air controls, n= 13) and those present in the spinal cord during
electrical stimulation of myelinated and unmyelinated afferents of the
ipsilateral tibial nerve (skin controls, n = 24). The mean grey scale of
microprobes was calculated in 30 pm intervals and a line joins these
points. At each point the s.e.mean (+ for Stim controls, - for air
controls) is plotted, (b) A plot of the t statistics derived from the
differences of the means from the two groups of microprobes shown
in (a). This plot is superimposed on a diagram of a cross section of
the lumbar spinal cord of the cat and the hatched area indicates
where these differences are significant with a probability of <0.05.
Significant differences between these mean image analyses
occur from 0.7 to 1.2 mm from the dorsal surface of the
spinal cord, and there is also a smaller zone of significance
approximately 1.5 mm below the cord surface. The distribu¬
tion of significant differences between the two groups is
illustrated in Figure lb. The maximal difference occurs at a
depth of 1.0 mm below the spinal cord surface. This site of
maximal release approximates to the substantia gelatinosa
and lamina I of the dorsal grey matter and agrees with the
findings of previous studies (Duggan el al., 1988b; 1991;
1992; Schaible et al., 1992). When dye is ejected from the tip
of a single microprobe and its position in the spinal cord
subsequently determined in a spinal cord section, then sites
of neuropeptide release can be inferred with great accuracy.
With mean image analyses, as presented here, the location of
sites of release is less precise. With microprobes inserted a
fixed distance into the spinal cord (4 mm in this series of
experiments) the relationship of spinal laminae to distance
from the tip will vary between individual animals, and also
with distance from the midline. When encoding the infor¬
mation describing the position of a microprobe, a correction
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factor is included when appropriate, but the relative broad¬
ness of the sites of release of irSP results in part from these
anatomical differences.
Microprobes present in the spinal cord following
microinjection of noradrenaline
The mean image analyses of 38 microprobes inserted 4 mm
into the spinal cord for lOmin with concurrent electrical
stimulation of myelinated and unmyelinated afferents of the
ipsilateral tibial nerve (stim. controls) and 35 microprobes
inserted under the same conditions but following the injec¬
tion of 10~3m NA at depths of 1.0, 1.5, 2.0 and 2.5 mm
below cord surface in the area of subsequent microprobe
insertions (post NA) are illustrated in Figure 2. The two
groups of microprobes are derived from the same experi¬
ments. The two mean image analyses are virtually identical
and at no points do the differences between them approach
statistical significance (at P<0.05).
Microprobes present in the spinal cord following
microinjection ofmedetomidine
The mean image analyses of 31 microprobes inserted 4 mm
into the spinal cord for lOmin with concurrent electrical
stimulation of the myelinated and unmyelinated afiferents of
the ipsilateral tibial nerve (stim. controls) and 20 microprobes
inserted under the same conditions but following the microin¬
jection of 10""3 m medetomidine at depths of 1.0, 1.5, 2.0 and
2.5 mm below the spinal cord surface in the area of subse¬
quent microprobe insertion (post Med) are illustrated in
Figure 3a. These two groups are again derived from the same
experiments, i.e. the 'Stim control' groups illustrated in
Figures 2 and 3a do not represent the same microprobes.
Although the post medetomidine group is displaced above
the control group at sites deep to the superficial dorsal horn,
(suggestive of increased release) there are no statistically
significant differences between the two groups within the
spinal cord at shown in Figure 3b. A small area of increased
irSP detection following medetomidine microinjection is evi¬
dent at the cord surface. This has been an observation in
previous studies with microprobes and has been related to
the late development of inflammation at the sites of removal
of pia mater at the cord surface (Duggan el al., 1988b) in
some experiments. Hence it is more likely to be seen in the
post injection than pre injection microprobes.
Thus, neither 10~3m NA nor 10-3M medetomidine, mic-
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Figure 3 Lack of effect of microinjection of medetomidine into the
dorsal horn on the nerve stimulus-evoked release of immunoreactive-
substance P. (a) The mean image analysis of microprobes present in
the spinal cord for 10 min during electrical stimulation of myelinated
and unmyelinated primary afferents of the ipsilateral tibial nerve
(Stim controls, « = 31) and those with comparable stimulation but
inserted after microinjection of medetomidine (10~3m) into the dor¬
sal horn (post Med, n = 20). (b) A plot of the r-statistics derived
from the differences of means of the two groups shown in (a) is
superimposed on a diagram of the lumbar spinal cord of the cat. The
hatched area indicates significant differences with a probability of
<0.05.
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Figure 2 Lack of effect of microinjection of noradrenaline (NA)
into the dorsal horn on the nerve-stimulus-evoked release of
immunoreactive-substance P. The mean image analysis of two groups
of microprobes are plotted: those present in the spinal cord for
10 min during electrical stimulation of myelinated and unmyelinated
afferents of the ipsilateral tibial nerve (Stim controls, n = 38) and
those with comparable stimulation but inserted after microinjection
of noradrenaline (10"3m) into the dorsal horn (post NA, n = 35).
The format of plotting is similar to that of Figure la.
Discussion
The present results are part of an extended study of possible
presynaptic controls of tachykinin release from the central
terminals of nociceptors. Presynaptic inhibition of transmitter
release from such terminals has been proposed as important
in several mechanisms of analgesia, including that resulting
from impulses arriving in large diameter afferents (Melzack &
Wall, 1965) and that produced by electrical stimulation of
certain brainstem regions (Reynolds, 1969; Meyerson et al.,
1979).
There is evidence that, in acutely spinalized cats, the irSP
detected by microprobes and localized to the region of the
substantia gelatinosa following peripheral nerve stimulation,
is largely released from the central terminals of primary
afferent fibres. The substantia gelatinosa is the major site of
termination of cutaneous unmyelinated primary afferent
fibres (Sugiura et al., 1986), and a proportion of these are
known to contain substance P (Nagy & Hunt, 1982; Price,
1985). A contribution from intrinsic substance P-containing
spinal neurones is possible, but in the spinalized animal
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release from fibres of supraspinal origin cannot have occur¬
red. Thus physiological controls acting on the terminals of
unmyelinated primary afferents should be revealed by this
methodology, provided the compounds are administered in a
relevant manner.
Although microinjection of NA directly into the substantia
gelatinosa had no effect on the stimulus-evoked release of
irSP, administration of drugs in this manner has previously
been shown to be an effective way of modulating stimulus-
evoked irSP release. Microinjection of NPY was shown to
reduce irSP detection following peripheral nerve stimulation
(Duggan et al., 1991). Conversely, microinjection of CGRP
or of a mixture of the peptidase inhibitor drugs, kelatorphan
and enalaprilat, enhanced post-stimulus detection of irSP by
antibody microprobes (Duggan et al., 1992; Schaible et al.,
1992). Microinjections of comparable volumes of Ringer or
PBS solutions in these studies were without effect. NA may,
following microinjection, have been subject to rapid re¬
uptake and degradation in the spinal cord. Medetomidine, a
synthetic compound, does not appear to be subject to any
re-uptake mechanism (R. Virtanen, Farmos, personal com¬
munication). Following systemic administration, medeto¬
midine is metabolized by hydroxylation in the liver (Salonen
& Eloranta, 1990) but little is known of its elimination from
the central nervous system.
The current observation that NA was ineffective in reduc¬
ing noxious stimulus-evoked irSP release disagrees with ear¬
lier studies of catecholamines and SP release from the spinal
cord. Ono et al. (1991) demonstrated that clonidine (10~5 m)
and tizanidine (10"'M), both a2-adrenoceptor agonist drugs,
reduced the veratridine-induced release of SP from slices of
rat spinal cord in vitro. This effect was blocked by yohimbine
(10"5m) and also by prazosin (10"5m), suggesting the
involvement of a2B-adrenoceptors. Pang & Vasko (1986),
reported that NA (10"5m) inhibited the high potassium-
evoked release of SP from a rat spinal cord slice. Veratridine
application or simple elevation of extracellular potassium
levels do not selectively activate primary afferent fibres and
perfusion of cord slices allows no spatial resolution of the
source of neurotransmitter release. Thus SP will probably be
released from a host of structures in these experiments, in¬
cluding fibres of supraspinal/propriospinal origin and intrin¬
sic neurones of the slice as well as primary afferent terminals.
Thus the action of a2-agonists cannot necessarily be related
to an action on primary afferent terminals.
More directly comparable to th'e present study are the
experiments of Kuraishi et al. (1985) who reported that NA
(10"5m) added to the perfusate of a push-pull cannula
inserted into the upper dorsal horn of rabbit spinal cord in
vivo reduced the release of irSP in response to a peripheral
noxious mechanical stimulus. The cannulae used were of
600 pm outer diameter and the flow rate was 50plmin"'
(0.83 pis"1). Although it is uncertain how much of the per¬
fusate passing through a push-pull cannula escapes into the
surrounding tissue, 0.83 pi s~' is a relatively large flow rate in
relationship to the dimensions of the dorsal horn of the
rabbit. The distance from the dorsal surface of the spinal
cord to lamina I of the grey matter is approximately 1 mm
and as 1 pi represents 1 mm3, it is probable that administra¬
tion of NA in this way results in activation of adrenoceptors
over a very wide area of the spinal grey and white matter.
Indeed, an important distinction between the present study
and those in which effects on SP release have been observed
is the method of drug administration. In our experiments,
NA and medetomidine microinjections were restricted to the
dorsal horn and the volumes were relatively small.
Experiments in which large volumes of drug containing
solutions are administered will access the intraspinal preter¬
minal regions of primary afferents running rostally and
caudally in the white matter and this could be a cause of
reduced stimulus-evoked release of SP which is not related to
a physiological mechanism. There is good evidence for 5-HT
receptors on the peripheral branches of unmyelinated pri¬
mary afferents (Neto, 1978) and for y-aminobutyric acid
(GABA) receptors on undefined peripheral nerve fibres
(Sakatani et al., 1991). A recent study (Sakatani et al., 1993)
found that GABA, 10~4m, applied to the hemisected spinal
cord of the neonatal rat, reduced the amplitude of the com¬
pound action potential resulting from propagation of impul¬
ses along dorsal column fibres. This was a receptor-mediated
and not a local anaesthetic type of effect since it was reversed
by bicuculline. Such a block of conduction in some fibres
would reduce transmitter release at the relevant terminals.
Thus caution is needed in interpreting the results of
experiments in which adrenoceptor agonists are administered
either diffusely to a slice preparation or intraspinally in large
volumes as necessarily revealing a physiological control of SP
released from the central terminals of nociceptors. Although
we do not know the precise areas at which pharmacologically
active doses of these compounds were present in our experi¬
ments, it is probable that restricting administration to areas
near the central terminals of nociceptors is more likely to
study controls acting at those terminals.
Ultrastructural studies have also failed to find evidence for
a synaptic control by catecholamines of transmitter release
from the central terminals of nociceptors. In both the rat
(Sugiura et al., 1986) and cat (Doyle & Maxwell, 1991a,b;
1993a) axo-axonic contacts containing dopamine-fl-hydroxy-
lase or tyrosine hydroxylase in the presynaptic element were
not identified in the region of the substantia gelatinosa, the
major site of termination of small diameter primary afferent
fibres. Axo-dendritic and axo-somatic contacts were readily
identified in the same area. These contacts have also been
observed with identified lamina I spinothalamic tract cells of
the monkey (Price, 1985). It is interesting to note that
previous results from our laboratory which provided evidence
for a control by NPY of the spinal release of SP following
activation of peripheral nociceptors (Duggan et al., 1991)
have been supported by recent ultrastructural studies (Doyle
& Maxwell, 1993b).
Electrophysiological studies of the effects of NA and 5-HT
on the electrical excitability of the central terminals of small
diameter primary afferents have given results allowing for
more than one interpretation, and have not helped resolve
the issue of whether presynaptic a2-adrenoceptors are
involved in physiological controls at such sites. With large
diameter primary afferents, presynaptic inhibition by GABA
is mediated by a terminal depolarization detected as an in¬
creased excitability to stimulation by an adjacent microelec-
trode (Curtis et al., 1977). Both Carstens et al. (1982) and
Jeftinija et al. (1981) found that microiontophoretically
administered monoamines increased the electrical threshold
of the central terminals of small diameter afferents. Curtis et
al. (1983) suggested that this was an artifact due to an altered
current distribution during electrical stimulation as a result of
glial uptake of administered NA or 5-HT, rather than a
novel mechanism of presynaptic inhibition.
The present results do not support the proposal that there
is a physiological control of SP release from the central
terminals of nociceptors mediated by ^-adrenoceptors. This
is in accord with ultrastructural and electrophysiological
observations. It is more probable that the potent effects of
a2-adrenoceptor agonists in suppressing spinal transmission
of nociceptive information result from postsynaptic actions
on neurones of the spinal cord. We believe that experiments
purporting to support presynaptic control mechanisms are
difficult to interpret both in terms of the source of the
released SP by the stimuli used, and/or the sites accessed by
the method of drug administration.
Assistance with this work was provided by M. Arnott, E. Rogers, C.
Warwick and E.J. Chalmers. Animals were cared for in the Well¬
come Animal Unit of the Faculty of Veterinary Medicine. Support
was provided by the Wellcome Trust and the Agricultural Food
Research Council.
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